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ABSTRACT
The ability of the luteinising hormone-releasing hormone (LHRH) receptor to activate
multiple signal transduction pathways (additional to its conventional activation of
phospholipase C, PLC) was investigated. In particular the potential activation of the
mitogen-activated protein (MAP) kinases was explored using an in vitro kinase
activity assay, establishing that LHRH induces a marked and sustained increase in
MAP kinase activity. Experiments with the Ca2+ ionophore, ionomycin and the
phorbol ester, phorbol 12,13-dibutyrate (PDBu) were performed to assess whether
the consequences of phosphoinositide hydrolysis evoked by the LHRH receptor such
as Ca2+ mobilisation or PKC activation could mimic the LHRH-induced activation.
This effect could be partially mimicked by PDBu, but not by, ionomycin. The role of
PKC in LHRH-induced MAP kinase activity was further examined. The PKC
inhibitors GF109203X, Ro-31 8220 and H7 or the downregulation of phorbol ester-
sensitive PKC isoforms prevented the LHRH- and PDBu-induced responses. The
LHRH-induced response was relatively resistant to H7, consistent with the possibility
that the LHRH receptor may differentially activate one or more PKC species in
gonadotrophs. The LHRH-induced response was additionally prevented by the
tyrosine kinase (TK) inhibitors genistein and MDC or the tyrosine phosphatase
inhibitor pervanadate. Phosphorylation of p42 and p44 MAP kinase was
independently determined by anti-ERK 1 + 2 immunoblots of the electrophoretic
mobility shift after SDS-PAGE separation of samples.
Pertussis toxin (PTx) also prevented the majority of the LHRH-induced MAP kinase
activation, providing the first indication for Gaj/0-mediated signal transduction by the
LHRH-receptor. Mastoparan (which activates Gai/0 proteins) partially mimicked the
effect of LHRH and was also sensitive to PTx. Further support for a role of Gocj/0 in
the LHRH action was provided by the demonstration that LHRH can inhibit in a dose-
dependent manner the forskolin- and PACAP-stimulated cAMP formation in aT3-1
cells, an effect which was largely reversed by PTx and appears to be independent of
PKC action or Ca2+ mobilisation.
The ability of the LHRH receptor to activate MAP kinase was compared to that of the
5-hydroxytryptamine (5-HT)2c and the type 1 a metabotropic giutamate (mGlu1a)
receptors when transiently expressed in COS 7 cells. The LHRH receptor alone
elicited a marked MAP kinase response whilst each receptor caused a large
activation of [3H]inositol phosphate production and translocation of [3H]PDBu binding
sites, suggesting that a component additional to PLC was necessary for MAP kinase
activation. This was not attributable to the LHRH receptor containing an atypical
motif for rhodopsin family members Asp instead of Asn at position 318 as a mutant
LHRH receptor containing Asn 318 was still capable of yielding a MAP kinase
response.
In anterior pituitary tissue from pro-oestrous rats, LHRH caused time- and
concentration-dependent activation of MAP kinase. The magnitude of this response
on various days of the oestrous cycle correlated with that of LHRH priming (the
unique ability of LHRH to increase pituitary responsiveness to itself). The response
to LHRH was mimicked by a phorbol ester but not by ionomycin and was blocked
with high potency by GF109203X but not by H7 (in a similar manner to the PKC
species that mediates LHRH priming). The functional significance of MAP kinase
activation in gonadotrophs is considered with respect to LHRH priming. Possible
steroidal influences on LHRH-induced MAP kinase activation in ocT3-1 cells were
also investigated, showing a facilitatory influence of oestrogen.
Finally LHRH-induced activation of the putative downstream target of MAP kinases,
phospholipase A2 (PLA2) was assessed in aT3-1 cells. This response appeared to
be mediated by a G-protein, probably Ga-|2, and was unaffected by inhibitors of PKC
or tyrosine kinases or by pertussis toxin. PLA2 therefore does not appear to be a
downstream target of the MAP kinases activated here in response to LHRH, despite
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Chapter 1
INTRODUCTION
The transduction of signals from ceil surface receptors to their effector systems in the
cytoplasm and nucleus is most frequently mediated by a cascade of protein
phosphorylation and dephosphorylation. This being achieved by the sequential
activation of protein kinases and an array of adaptor proteins and guanyl-nucleotide
exchange proteins. Most cellular phosphorylations occur at serine/threonine
residues and since such events are initiated by growth factors via receptors which
are tyrosine kinases they must in some way regulate serine/threonine-specific
kinases or phosphatases. At the onset of the present study a wealth of evidence
was emerging about a family of serine/threonine kinases known as the mitogen-
activated protein (MAP) kinases or extracellular-regulated kinases (ERKs), which are
rapidly activated in response to growth factor stimulation [Pelech & Sanghera, 1992;
Sturgill, 1992; Thomas, 1992], These agonist-dependent kinases which require to be
phosphorylated on both a tyrosine and threonine residue for full activity [Anderson et
al, 1990; Boulton et al, 1991], thus appeared to represent a crucial link between cell
surface receptors and changes in a number of cellular responses, particularly gene
expression. At this time the literature on MAP kinase signal transduction pathways
essentially concerned growth factor regulation of these enzymes. However phorbol
esters [reviewed in Cobb et al, 1991] and a G-protein activator fluoroaluminate
[Anderson et al, 1991] had also been reported to activate MAP kinases, presenting
the intriguing possibility that other agonists perhaps including those acting through
G-protein coupled receptors might additionally activate MAP kinases.
1.1 AIMS OF THIS STUDY
The primary aim of this research project has been to determine if activation of the
luteinising hormone-releasing hormone (LHRH) receptor, a seven transmembrane-
spanning domain, G-protein-coupled receptor with no intrinsic tyrosine kinase
activity, might result in the phosphorylation and activation of MAP kinase in a clonal
gonadotroph cell line, aT3-1, which intrinsically expresses a large number of high
2
affinity LHRH receptors. Having established the occurrence of an LHRH-mediated
MAP kinase activation the main questions addressed were:
(1) what are the main intermediary signalling components leading to LHRH-
induced MAP kinase activation?
(2) is marked activation of MAP kinase an unusual property of the LHRH
receptor, or is it common to all G-protein linked receptors?
(3) does activation of MAP kinase by LHRH occur in native gonadotrophs of the
anterior pituitary gland and if so, is this an important regulatory event in the
unique phenomenon of LHRH "self priming", (an effect observed in pro-
oestrous rat anterior pituitary tissue which is crucial to coordinating the
luteinising hormone surge prior to ovulation; see section 1.3)?
(4) is phospholipase A2 (PLA2) a cellular target for MAP kinase in aT3-1 cells?
3
1.2 THE aT3-1 CELL LINE
Studies of the molecular and cellular biology of anterior pituitary cells has depended
for many years on primary cultures of pituitary cells or pituitary pieces in vitro, both
which have limited viability and gradually lose their function over time. Furthermore,
the anterior pituitary gland is composed of a number of different cell types including:
gonadotrophs, which release luteinising hormone (LH) and follicle-stimulating
hormone (FSH); thyrotrophs, which release thyroid-stimulating hormone (TSH);
lactotrophs, which release prolactin (PRL); somatotrophs, which release growth
hormone (GH); corticotropins, which release adrenocorticotrophic hormone (ACTH)
as well as non-endocrine endothelial cells, folliculo-stellate cells and stromal cells
[Farquhar et al, 1975]. The cellular heterogeneity of the anterior pituitary gland
therefore complicates any investigations regarding specific cell types, for example,
gonadotrophs represent only approximately 10% of the anterior pituitary cell
population. Consequently, unless a specific response such as LH or FSH release is
measured, interpretation of results is problematic. An alternative approach to the
use of pituitary pieces or primary cultures is to use clonal cell lines like the GH3 and
AtT-20 cell lines derived from pituitary tumours [Tashijan et al, 1968]. However until
recently there was no clonal cell line of gonadotrophs. Accordingly an established
cell line of gonadotroph lineage was developed to study regulation and expression of
the gonadotrophins [Windle et al, 1990].
It is now possible to target expression of oncogenes to specific cell types in
transgenic mice thus providing a method for immortalising rare cell types by directing
expression of the simian virus-40 T-antigen (SV40 Tag) with the promoter and
associated regulatory domains of a gene of interest [Jenkins & Copeland, 1989].
Expression of LH and FSH is a specialised function of gonadotrophs, therefore the
genes encoding LH and FSH represented good candidate genes for this approach.
LH and FSH are members of a larger family, the glycoprotein hormones. Each of
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these hormones is a heterodimer sharing a common a-subunit, with a unique (3-
subunit [Pierce & Parsons, 1981]. A fusion gene containing - 1.8 kilobases of 5'
flanking sequences of the human glycoprotein hormone a-subunit linked to the
protein-coding sequences of SV40 T-antigen oncogene was used for Tag-driven
tumorigenesis. Transgenic mice bearing this fusion gene heritably developed
pituitary tumours, which were found to be anterior pituitary specific [Windle et ai,
1990]. Tumour cells were dispersed then cultured and after serial dilution of the
resulting stable cultures, several clonal cell lines were established. The aT3-1 cell
line was maintained for two years without any change in phenotype and remained
stably diploid when tested. This cell line was found to be expressing LH and FSH a-
subunit, but not the specific p-subunits, consistent with these cells being precursors
of gonadotrophs and/or thyrotrophs. Further characterisation of these cells revealed
synthesis and secretion of mRNA for the a-subunit in response to an LHRH analog,
nafarelin, in both a time- and concentration-dependent manner (consistent with the
analog acting through specific LHRH receptors), whereas aT3-1 cells did not
respond to TRH. Therefore these cells appear to be gonadotrophs due to the
presence of LHRH (but not TRH) receptors. The lack of the p-subunit for LH or FSH
may be explained if the transformed cells were not yet fully differentiated into
gonadotrophs or thyrotrophs and were arrested at this stage.
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1.3 LUTEINISING HORMONE-RELEASING HORMONE AND THE
GONADOTROPHINS
Luteinising hormone-releasing hormone actions on gonadotrophin release
Hormones secreted (in a pulsatile manner) from the basophilic cells of the anterior
pituitary gland, are responsible for regulating the function of many target tissues
around the body including the gonads (luteinising hormone; LH and follicle-
stimulating hormone; FSH), the thyroid (through thyroid-stimulating hormone; TSH)
and the adrenals (through adrenocorticotrophic hormone). Other functions such as
lactation (through prolactin; PRL) and growth (through the actions of growth
hormone; GH) are also regulated by anterior pituitary hormones. Most of the
hormones of the anterior pituitary are regulated by releasing hormones or factors
secreted (again in a pulsatile manner), from the hypothalamus into the
adenohypophyseal portal vasculature. Luteinising hormone-releasing hormone
(LHRH, pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), also widely known as
gonadotrophin-releasing hormone (GnRH) because it can stimulate the release of
FSH as well, is the hypothalamic decapeptide, which is chiefly responsible for the
production and secretion of the gonadotrophins LH and FSH. In brief, LH acts in
females to induce ovulation and then maintain the secretory functions of the corpus
luteum, whilst in males LH stimulates the Leydig cells in the testis to produce
testosterone. FSH stimulates the development of ovarian follicles in the female and
spermatogenesis and the production of androgen-binding protein in males. The
actions of LHRH are therefore important for maintenance of the reproductive cycle in
mammals. In addition to regulating the synthesis and secretion of LH and FSH,
LHRH additionally regulates LHRH receptor numbers and significantly, it can
increase gonadotroph responsiveness to itself, an effect known as LHRH self priming
[Aiyer et al, 1974; Edwardson & Gilbert, 1976; Pickering & Fink, 1976; Pickering &
Fink, 1979],
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The LHRH self-priming effect and its role in the pre-ovulatory luteinising
hormone surge
In the majority of mammals (including humans, sheep, monkeys and rats), ovulation
is triggered by a spontaneous surge in LH which is triggered by a neural signal and
mediated by a surge in LHRH, which in turn is evoked by a surge of oestradiol-17(3
(E2) acting on the central nervous system [Everett, 1987; Fink, 1979; Fink, 1988a;
Fink, 1988b]. However, the LHRH surge is too small on its own to cause the
ovulatory LH surge and is dependent upon the LHRH self-priming effect, a property
of LHRH that by direct action, massively increases (20-50 fold) the responsiveness
of the gonadotroph to itself [Fink, 1979; Fink, 1988a; Fink, 1988b; Fink et al, 1976;
Nett et al, 1984]. LHRH self-priming acts in co-ordination with the cyclic surge of
LHRH in the hypophysial portal blood so that both events reach this peak capacity
simultaneously, producing a massive and coherent peak of LH release, on a day of
the cycle known as pro-oestrous.
A number of major differences have been detected between the priming and
releasing action of LHRH (see Table 1.1). Notably in contrast to the releasing action
of LHRH, priming: (1) cannot be mimicked by K+ depolarisation or Ca2+ ionophores,
(2) is independent on normal extracellular Ca2+ concentrations, (3) involves an
elongation and change in the orientation of the microfilaments, (4) involves the
movement of secretory granules towards a "marginal" zone close to the plasma
membrane of immunoidentified gonadotrophs, (5) involves the synthesis of a new
protein (other than additional hormone) with a relative molecular mass of 70 kDa,
whose exact function in priming has yet to be determined, (6) involves post receptor
changes which result in the potentiation of the IP3 and Ca2+ mechanisms and may
involve activation of an H7-resistant form of protein kinase C (PKC) or PKC-like
kinase [briefly reviewed in Fink, 1995]. Although pulses of LHRH do increase LHRH
receptor mRNA in pituitary cells [Kaiser et al, 1992], the LHRH priming effect is
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unlikely to be attributed to an increase in LHRH receptors because over the time
scale corresponding to the onset of priming (~1 h) the increase would be insignificant
[Fink, 1995]. Furthermore in studies of LHRH priming carried out on pituitary slices
in vitro, no detectable increase was observed in LHRH binding sites after a 60 min
exposure to LHRH [Mitchell et al, 1988]. Whilst E2 appears to be required to
maintain the LH surge (in part due to an indirect effect on the LHRH-releasing
neurones facilitating LHRH release [Fink, 1988c]), and whilst E2 enhances the
magnitude of the priming effect, steroids do not mediate the effect [Aiyer et al, 1974;
Meiden et al, 1981]. Progesterone can also enhance LHRH responses, this effect is
also dependent on a prior exposure to E2 [Aiyer & Fink, 1974; Fink, 1988b; Turgeon
& Waring, 1981]. Although the exact mechanisms of this effect are as yet
unresolved, it is possible that some mechanisms of LHRH, E2 and progesterone-




Differences between the "releasing" and "priming" actions of LHRH in female
pituitary gonadotrophs.
Comparison between the releasing and priming actions of LHRH in the
pro-oesrtrous rat
(based on Fink 1986 and Thomson 1992)
Releasing Priming
Can be repeated frequently yes only once every 3h
Enhanced by oestrogen yes yes
Dependent on extracellular Ca2+ yes no
Mimicked by high K+ yes no
Mimicked by Ca2+ ionophores yes no
Dependent on protein synthesis no yes
Dependent on integrity of
microfilaments
no yes
Elicited in dispersed cells yes not for rat pituitary
glands
Cyclic AMP acts as a mediator no no
lns(1,4,5)P3 acts as a mediator yes yes





AA acts as a mediator no yes
1.4 THE LHRH RECEPTOR
Cloning of the LHRH receptor
Luteinising hormone-releasing hormone (LHRH) exerts its effect on gonadotrophs
synthesis and release via plasma membrane-bound receptors primarily found in the
anterior pituitary gland [Clayton & Catt, 1981]. A number of studies demonstrated
that anterior pituitary tissue was a potential source of mRNA for construction of
cDNA libraries from which the LHRH receptor could be subsequently cloned [Eidne
et al, 1981; Sealfon et al, 1990a; Sealfon et al, 1990b; Yoshida et al, 1989].
However the use of pituitary tissue had limited success as gonadotrophs account for
-10 % of the anterior pituitary cell population, therefore LHRH receptor mRNA as a
percentage of the total anterior pituitary mRNA is also likely to be low. The
development of the aT3-1 cell line provided a richer source of mRNA which greatly
improved subsequent cloning attempts. This cell line has been shown to abundantly
express the LHRH receptor [Windle et al, 1990], indeed when aT3-1 mRNA was
injected into oocytes, these oocytes were shown to be twice as responsive to LHRH
as those injected with anterior pituitary mRNA [Sealfon et al, 1990a]
The first cloning of the LHRH receptor was achieved by a homology screening
strategy [Tsutsumi et al, 1992]. Sets of degenerate oligonucleotides to conserved
transmembrane domains of G protein-coupled receptors were used to generate
polymerase chain reaction (PCR) products using cDNA templates from the aT3-1
cell line. The products were cloned and sequenced. Complementary (antisense)
oligonucleotides of promising sequences were co-injected with aT3-1 mRNA into
oocytes and monitored for the hybrid arrest of receptor-mediated electrophysiological
responses to LHRH [Tsutsumi et al, 1992]. The mouse LHRH receptor sequence
was also identified by another group using a similar approach; RNA transcribed from
aT3-1 cDNA clone pools (was also expressed in oocytes) and LHRH responses
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were measured with a Ca2+-sensitive photoprotein, aequorin [Reinhart et al, 1992].
This mouse sequence was identical to that reported by Tsutsumi and co-workers
except for one single nucleotide, the methionine at residue position 250 is converted
to a leucine. In another approach a mouse LHRH receptor cDNA clone was isolated
by expression of a pool of cDNA clones in transformed COSM6 cells that were
subsequently screened with an iodinated LHRH analogue [Perrin et al, 1993]. The
cloned murine receptor exhibited appropriate ligand binding characteristics and
LHRH-stimulated inositol phosphate (IP) production when expressed in COS 1 cells
[Miller, 1993]. The cloning and sequencing of the mouse LHRH receptor was closely
followed by the human [Chi et al, 1993; Kakar et al, 1992], rat [Eidne et al, 1992;
Kaiser et al, 1992; Perrin et al, 1993] and sheep receptors [Brooks et al, 1993; llling
et al, 1993]. These were obtained by hybridisation with random-primed cDNA,
labelled oligonucleotides or labelled PCR-generated probes, all based on the mouse
sequence. Southern blot analyses with mouse and rat genomic DNA are consistent
with the presence of a single gene for the LHRH receptor [Zhou et al, 1994],
Although several alternative transcripts have been identified, these appear only to
encode truncated proteins [Stojilkovic et al, 1994].
Alignment of the mammalian LHRH receptors cloned to date has demonstrated a
high degree of homology between species and has highlighted subtle amino acid
changes which may account for the small differences in pharmacology observed
between the species [llling et al, 1993]. At the amino acid level any two of the LHRH
receptors share greater than 85% amino acid sequence. The mouse and rat
receptors share 97% identity, the human and sheep LHRH receptors have 89%
identity with each other and both contain an additional (to the mouse and rat
receptors) lysine residue in the second intracellular loop. The degree of homology
rises to >90% in the transmembrane (TM) domains with TM2, TM3, TM5, TM6 and
TM7 being most highly conserved. Extracellular (EC) loop EC1 is also well
conserved.
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Molecular structure of the LHRH receptor
The hydropathy plot of the amino acid sequence of the LHRH receptor has a
predicted structure which is characteristic of the superfamily of G protein-coupled
receptors (apart from a truncated carboxyl-terminus), consisting of a single
polypeptide chain with seven hydrophobic transmembrane domains. Based on
structural similarities to the extensively characterised proteins bacteriorhodopsin and
rhodopsin, which included electron diffraction data [Henderson, 1990], TM domains
1-7 are predicted to be a-helical and to be arranged in a bundle with a central
hydrophilic ligand binding pocket [Baldwin, 1993]. The TM domains are connected
by hydrophilic extracellular and intracellular (IC) loops or domains (EC1-3 and IC1-3;
Figure 1.1). In all species the cloned LHRH receptor has three consensus
sequences for N-linked glycosylation sites located in EC1 and EC2. Previous
studies on SDS-PAGE gel electrophoresis of solubilised native LHRH receptors
reported an approximate molecular weight of 50,000-60,000 [Clayton, 1989]. The
calculated molecular weight of the cloned mouse LHRH receptor sequence protein is
37, 684 [Reinhart et al, 1992; Tsutsumi et al, 1992], indicating that the LHRH
receptor is indeed glycosylated. The LHRH receptor, in common with other G
protein-coupled receptors, has many conserved residues within the transmembrane
domains, including a number of proline residues in TM2, TM4, TM5, TM6 and TM7
[Baldwin, 1993]. These residues probably face inwards to the hydrophilic pocket of
the receptor and are proposed to induce the kinks in the a-helices, and may also
have a role in ligand-induced signal transduction [Davidson et al, 1994a] A pair of
cysteine residues are found in EC1 and EC2 which are presumed to form a
disulphide bridge, as in many G protein-coupled receptors. An alternative site for a
disulphide bridge is additionally found in the LHRH receptor between a cysteine
residue in EC2 and in the N-terminus. In TM6 there is a highly conserved Phe-X-X-
Cys-Trp-X-Pro-Tyr motif [reviewed in [Davidson et al, 1994a]. Potential sites for
phosphorylation by cAMP-dependent kinase and protein kinase C (PKC) have been
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identified in IC1, for casein kinase II in IC2 and for PKC in IC3 [Tsutsumi, 1993).
Additionally, there is a tyrosine residue at position 238 but the surrounding residues
do not match the consensus phosphorylation sequence for any known kinase. Other
striking features of the LHRH receptor structure include an unusually long third
intracellular loop which has a high content of basic amino acids and TMD 7 which is
rich in phenylalanine residues.
UNUSUAL FEATURES OF THE LHRH RECEPTOR
Absence of a Carboxyl-terminal tail and desensitisation
The LHRH receptor is exceptional amongst G-protein coupled receptors by the
absence of a carboxy-terminal tail, a region which has a functional significance in
most other receptors in this super-family, being frequently implicated as a major
phosphorylation site in rapid desensitisation and internalisation in response to
continued exposure to the appropriate ligand and G-protein coupling [Dohlman et al,
1991; Inglese et al, 1993; Ostrowski, 1992] although other regions of the receptor
may also be important. There is considerable evidence to support a role for
phosphorylation in these events [Hausdorff, 1990). The intracellular portions of all G-
protein coupled receptors are rich in consensus sequences for phosphorylation by
kinases including protein kinase A (PKA), protein kinase C (PKC) and receptor-
specific kinases such as the p-adrenergic receptor kinase (PARK) [Hausdorff, 1990;
Ostrowski, 1992).
The LHRH receptor is exceptional in that it is necessarily dependent on regions of
the receptor other than the C-terminal tail for G-protein interactions, desensitisation
or internalisation. In aT3-1 cells the formation of inositol phosphates (IP) responses
is rapidly desensitised in response to TRH, but not after a 40-90 min exposure to
LHRH [Davidson et al, 1994b; Sealfon et al, 1993; Mitchell et al, manuscript in
preparation). These results are consistent with a lack of direct receptor-targeted
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desensitisation being due to an absence of an a C-terminal tail and would also
suggest that the putative phosphorylation sites which are present on the LHRH
receptor do not mediate rapid desensitisation (at least of the inositol phosphate
response). Therefore it seems likely that other mechanisms must be employed by
the LHRH receptor to achieve long term desensitised receptor numbers observed in
vivo following continuous administration of LHRH [Clayton et al, 1989; Gorospe et al,
1987; Smith et al, 1981].
Atypical amino acid substitutions in TM2 and TM7 and the spatial relationship
of these two domains
Another unusual characteristic of the LHRH receptor is the exchange of aspartate
(Asp) and asparagine (Asn) residues that are present in TM2 and TM7 respectively
in most other G protein-coupled receptors [Cook et al, 1993; Zhou et al, 1994]. The
Asp at position 87 of TM2 (murine receptor) which is usually highly conserved (98%)
and apparently essential for agonist binding in other G protein-coupled receptors, is
replaced with an Asn in the LHRH receptor [Probst et al, 1992]. Whereas an Asp
replaces the highly conserved Asn (95%) at position 318 in TM7 and may represent
a natural reciprocal mutation [Zhou et al, 1994], The NK 1 receptor has a Asn
substitution at position in 87 in TMD II and the thrombin receptor has a Asp at
position 318 in TMD VII, thus although other receptors may have one or other
substitution, the LHRH receptor is unique amongst this family of receptors in that it
contains both substitutions.
The implications of these substitutions is currently being investigated. Mutation of
Asn87 to Asp has been found to impair ligand binding and subsequent signal
transduction in the LHRH receptor [Cook et al, 1993; Sealfon et al, 1993; Zhou et al,
1994] consistent with findings in other receptors and further implying that this residue
is crucial to ligand binding. One group also observed a loss of binding and signalling
in the double mutant Asp87, Asn318 (a mutation which has effectively restored the
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Asp and Asn residues to their typical motifs in other receptors of this family) [Cook et
al, 1993]. However other workers who also observed a loss in binding due to the
Asp87 mutation, have reported a moderate degree of high affinity ligand binding and
a partial restoration of IP response in the double mutant [Probst et al, 1992; Sealfon
et al, 1993; Zhou et al, 1994; Mitchell et al manuscript submitted; see Chapter 5].
This restoration of ligand binding indicates that these two specific residues in TM2
and TM7 may be adjacent in space and could act in a complementary manner to
maintain the conformation of the receptor required for ligand binding [Zhou et al,
1994]. This has important implications on the three-dimensional structure of the
receptor as it places a constraint on possible alignments between TM2 and TM7
which has been incorporated into a model [Zhou et al, 1994], It is likely that TM2 and
TM7 share a common microenvironment, a condition that could be fulfilled by direct
hydrogen-bonding but which may also involve a more complex network of interacting
side chains in the two helices. In the current model of the mutated LHRH receptor,
Asp87 is assumed to be ionised and in a hydrogen bond interaction and could only
be an electron acceptor, whilst asparagine can act as both an electron acceptor
(C=0) and an electron donor (NH2). Thus the Asp87 mutant side chains would
electrostatically repel and impair binding through disruption of receptor structure,
whilst the double mutant or a Asn318 mutant would allow favourable interaction such
as hydrogen-bonding to occur. The observation that binding in the LHRH receptor is
disrupted by a single Asp87 mutation but not a single Asn318 or the double mutant is
consistent with this model [Zhou et al, 1994], Recently it has been proposed that
Asn87 and/or Asp318 are involved in the regulation of the LHRH receptor lifetime at
the cell surface. Mutant receptors were prepared containing an Asn at 318 or the
double mutation Asp87;Asn318, when these mutant receptors were stably expressed
in GH3 cells, the Asn318 and double mutation did not impair ligand binding as
observed previously [Zhou et al, 1994], but this mutation abolished the initial down-
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regulation that is observed by the wild type mouse and rat LHRH receptors [Awara et
al, 1996].
Atypical substitutions in TM3
Many G protein-coupled receptors contain a conserved sequence of several amino
acids at the end of TM3 and the beginning of the second cytoplasmic domain
[Bairoch, 1991]. This sequence contains a Asp-Arg-Tyr triplet which has been
implicated in G-protein coupling. In the LHRH receptor this sequence contains two
substitutions most notably a serine at position 140 within this triplet in (Asp-Arg-Tyr >
Asp-Arg-Ser) to form an additional potential phosphorylation site. However the
functional significance of this substitution remains unclear as mutations within the
triplet of the LHRH receptor had no effect on agonist binding or IP responses
[Davidson et al, 1994b].
Tissue distribution and regulation of expression of luteinising hormone-
releasing hormone (LHRH) receptors
LHRH receptors are found primarily in the anterior pituitary of several species and as
shown in rat at least, LHRH receptors are almost exclusive to gonadotrophs [Childs,
1984; Naor & Childs, 1986]. High affinity LHRH receptors have also been identified
in a number of other tissues, which include the hippocampus, lateral septal nucleus,
anterior cingulate, cortex, subiculum and entorhinal cortex in the central nervous
system (CNS) [Millan et al, 1985]. Consistent with their role in steroidogenesis and
other cellular events in the gonads, high affinity LHRH receptors have also been
identified in Leydig cells (but not Sertoli cells) of the testis, in granulosa and luteal
cells of the ovary, in the placenta (although these are low-affinity LHRH binding sites
which are probably a variant of those in the pituitary). Many tumorigenic tissues
including pituitary adenomas, human breast cancer tissue and cell lines, human
epithelial ovarian carcinomas and prostate tumours express LHRH receptors, where
they exert potential antiproliferative effects. Indeed LHRH analogues have been
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successfully employed as chemotherapeutic agent in some instances [Emons et al,
1993; Stojilkovic et al, 1994]. The availability of LHRH receptor cDNA has aided
investigation of the tissue distribution of LHRH receptors and any potential variations
in the levels of mRNAs. Both the mouse and rat receptor cDNAs have been used to
probe a variety of tissues which has corroborated much of the ligand binding data
[Stojilkovic et al, 1994].
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Figure 1.1

















1.5 SIGNAL TRANSDUCTION MECHANISMS ASSOCIATED WITH THE
LUTEINISING HORMONE-RELEASING HORMONE RECEPTOR
When LHRH binds to its receptor at the ceil membrane it triggers an array of
intracellular signal transduction pathways. The sequence and regulation of these
mediators is not fully clarified. However the development of the aT3-1 clonal
gonadotroph cell line and cloning of the LHRH receptor has led to an increase in our
understanding of these mechanisms and is likely to facilitate future studies. The
following mechanisms and components are postulated to be involved in LHRH
actions downstream of the LHRH receptor.
G-proteins
Binding of agonists to the ligand binding pocket of seven transmembrane domain G-
protein-coupled receptors such as the LHRH receptor, is thought to cause a
conformational change in the receptor that leads to dissociation of heterotrimeric G-
proteins into a- and Py-subunits and the subsequent interactions of these subunits
with the various effector systems. Several observations first indicated that LHRH
receptor actions are mediated by G-proteins. These include the ability of GTP
analogues to reduce the binding of LHRH agonists to bovine and rat pituitary LHRH
receptors [Limor et al, 1989; Perrin et al, 1989], and to enhance inositol phosphate
formation and gonadotrophin release in permeabilised pituitary cells [Andrews et al,
1986; Limor et al, 1989]. More recent studies have indicated that members of the
pertussis toxin-insensitive, Gq subfamily of G-proteins, mediate control of
phospholipase C (PLC) activity by LHRH [Hsieh & Martin, 1992]. In general, it
appears that the two most studied members of the Gq family Gq and Gn, are equally
effective in regulating PLC activity [Blank et al, 1991], and this is also likely to be the
case in gonadotrophs where cellular levels of Gq and Gi 1 are down regulated equally
by sustained stimulation with LHRH [Shah & Milligan, 1994]. G-protein involvement
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in the LHRH-induced PLC response was further investigated in the aT3-1 cell line.
LHRH or a G-protein activator fluoroaluminate (AIF4"), caused a dose- and time-
dependent IP accumulation [Anderson et al, 1993]. LHRH- or NaF-induced IP
accumulation in aT3-1 cells was insensitive to pretreatment with pertussis toxin (an
agent which inactivates G-proteins of the Gj/0 subclass of the G-protein family by
ADP-ribosylating the a-subunit), suggesting that Gj/0-proteins are not involved in the
PLC response, consistent with a role for Gq/n proteins in this response. Moreover,
immunoblot analysis of aT3-1 cell membranes revealed the presence of Gq
[Anderson et al, 1993]. More recently the distribution and relative levels of
expression of Gq/na subunits was investigated in aT3-1 cells as part of a wider
study of G-protein expression [Milligan, 1993]. Whilst Gq and Gn are both
expressed, the relative level of these two G-proteins varies, with higher steady-state
levels of immunoreactive Gna than Gqa.
Phospholipase C
Agonist binding to G-protein coupled, Ca2+-mobilising receptors (for example the
LHRH receptor) is associated with a rapid increase in phosphoinositide-specific
phospholipase C (PLC) activity, leading to hydrolysis of phosphatidylinositol 4, 5-
bisphosphate (PIP2) and formation of inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). There is now known to be a large family of at least 16 PLC
isoforms that fall into three main types: PLC-p, PLC-y and PLC-5. All three types of
PLC catalyse the hydrolysis of PIP2. The a subunits of the Gq family specifically
activate PLC-p 1 in vitro, with a weak activation of this enzyme reported by Py
subunits, whilst PLC-P2 is only weakly activated by Gaq subunits and powerfully
activated by Py subunits, indicating a role for Py subunits in mediating pertussis toxin-
sensitive phosphoinositide (PI) hydrolysis by G-proteins of the Gj/0 class. PLC-P3
could underlie both pertussis toxin-insensitive (Gq a subunits) and -sensitive (py
subunits) receptor linked PI hydrolysis, as it is activated by both a and Py subunits.
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PLC-y1 and 2 are activated following activation of some receptor tyrosine kinases, or
T-cell antigen receptors and some immunoglobulin receptors through activation of
the Src family of intracellular tyrosine kinases. The cellular mechanism for control of
PLC-81 and 2 is still unknown. All the PLCs require Ca2+ for catalytic activity and
may additionally be regulated by PKC and PKA [Koch et al, 1991; Musacchio et al,
1992; Rhee & Choi, 1992; Schlesinger& Ullrich, 1992].
Activation of PLC is a general characteristic of LHRH receptor signalling, consistent
with the role of the products of PLC activity in the cellular actions of LHRH in the
gonadotroph. LHRH-induced PI turnover in pituitary cells was demonstrated some
years ago [Naor & Catt, 1981] and PIP2 has since been identified as the major
substrate for PLC following LHRH receptor activation in gonadotrophs [Morgan et al,
1987; Naor & Childs, 1986]. LHRH causes a rapid and progressive increase in the
formation of IP3 and the higher phosphoinositols, inositol tetrakisphosphate and
inositol pentakisphosphate [Mitchell et al, 1988; Morgan et al, 1987; Schrey, 1985].
Furthermore LHRH-induced IP3 generation is biphasic, with an early peak within 10
sec and a subsequent slower rise and thus represents a primary and sustained
response to agonist stimulation. These responses can be abolished by the addition
of a specific LHRH receptor antagonist [Morgan et al, 1987]. Following PLC
activation, IP3 is catabolised by at least two pathways, dephosphorylation to 1(1,4)P2,
l(4)P and inositol and phosphorylation to 1(1, 3, 4, 5)P4 and subsequent
dephosphorylation to the inactive 1(1, 3, 4)P3 [Horn et al, 1991; Zheng & Guan,
1993].
Kinetic studies in aT3-1 cells have revealed that the time course of LHRH-induced PI
hydrolysis is similar to that observed in native gonadotrophs, with an initial rapid
peak followed by a sustained later phase [Anderson et al, 1993]. IP3 catabolism has
also been described in aT3-1 cells [Horn et al, 1991; Zheng & Guan, 1993]. The
potency with which LHRH stimulates IP accumulation in ccT3-1 cells is affected by
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estradiol pretreatment, suggesting that ovarian steroids modulate the coupling of
LHRH receptors to second messenger systems [McArdle et al, 1992; Mitchell et al,
1995a]. The cloned LHRH receptor can also induce PI hydrolysis when expressed in
host cells. In COS-1 cells transfected with receptor cDNAs, LHRH increased total
inositol phosphates [Chi et al, 1993; Eidne et al, 1992], whilst IP3 formation, in
particular, was also observed in COSM6 cells expressing mouse and rat cDNAs
[Perrin et al, 1993].
LHRH action in pituitary gonadotrophs also evokes a prominent increase in DAG
accumulation [Chang et al, 1987a], which associated with inositol phosphate (IP)
formation, indicating that DAG formation is associated with PLC hydrolysis of
phosphoinositides. DAG formation is biphasic with an initial spike within 45 s
followed by a larger peak between 15-30 min of stimulation. The amplitude of the
second sustained DAG peak in response to agonist is larger than the corresponding
IP peak [Chang et al, 1987a], indicating that as in other cell types, a significant
proportion of the DAG generated may also be derived from other pathways, such as
the hydrolysis of phosphatidylcholine by phospholipases A2 or D.
Ca2+ responses
Ca2+-mobilising receptors release Ca2+ into the cytoplasm from vesicular stores as a
consequence of IP3 binding to intracellular receptors on the mitochondrial
membranes and endoplasmic reticulum [Berridge & Irvine, 1989]. The cloned
mouse, rat and human receptors mediated LHRH-induced increases in Ca2+ as
measured by current responses in oocytes [Chi et al, 1993; Kaiser et al, 1992;
Tsutsumi et al, 1992], Ca2+ responses were additionally demonstrated for the mouse
and human receptors by Fura-2 fluorescence in transfected COS 7 cells and by
monitoring light emitted from aequorin-injected oocytes [Reinhart et al, 1992],
Intracellular Ca2+ ([Ca2+]j) measurements in pituitary and aT3-1 cells have confirmed
that LHRH stimulates a rapid peak increase followed by a lower but sustained
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elevation of [Ca2+]j. This matches the time scale of LHRH-induced IP3 release in a
time- and dose-dependent manner with an apparent EC50 similar to that observed for
LH release. The initial phase of the [Ca2+]i response is independent of extracellular
Ca2+, whilst the sustained phase is dependent on Ca2+ entry through voltage-
sensitive and -insensitive Ca2+ channels [Johnson et at, 1993b; Merelli et al, 1992;
Mitchell et al, 1988; Virmanni et al, 1990]. The temporal correlation between the
second phase of IP3 production and the extracellular Ca2+-dependant elevation of
[Ca2+]j suggests that IPs may regulate the dihydropyridine-insensitive component of
Ca2+ entry in gonadotrophs.
Protein kinase C
A key family of enzymes in LHRH-induced signal transduction is the protein kinase C
(PKC) family of protein serine/threonine kinases. DAG formed from PI hydrolysis by
PLC can elicit functional signals by activating this enzyme family. Briefly, all
members of this family are a single polypeptide chains with an N-terminal regulatory
domain and a C-terminal catalytic domain with several conserved and variable
sequences. The catalytic domain contains the ATP- and substrate-binding sites and
is subject to regulation by a pseudosubstrate sequence that is believed to bind to the
catalytic domain and maintain the enzyme in an inactive form. The regulatory
domain also contains the Ca2+, Zn2+, DAG/phorbol ester and phospholipid binding
sites. Several of these cofactors or compounds are able to unmask the catalytic
domain and cause activation of the enzymes [Nishizuka, 1992], The PKC isozymes
can be categorised into three groups: the 'classical' A group (a, pi, pil and y) isoforms
are responsive to Ca2+, phospholipid (particularly phosphatidyl serine; PS), DAG and
phorbol esters; the 'novel' group B (8, e, q and 0) isoforms lack the Ca2+-binding
domain and hence do not require Ca2+ for activation; the 'atypical' group C (£ and X)
isoforms are sensitive to PS but are not affected by Ca2+, DAG or phorbol esters.
The a, pi, pil, 5, e, £, X and 0 but not y orq isoforms have been identified by
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immunoblotting analysis in the anterior pituitary and GH3 cells and the a, e, C and 0
are found in the aT3-1 cell line [Johnson et al, 1993a; Johnson et al, 1996; Naor,
1990a].
PKC regulates numerous intracellular events including: Ca2+ release by modulation
of IP3 receptor channel functions; Ca2+ entry through voltage-sensitive Ca2+
channels, down-regulation of receptors, modulation of Na+, K+ and glutamate
channels, control of phospholipase activity and participation in exocytosis [Nishizuka,
1986]. PKC activity is modulated by an array of feedback regulation by a number of
the products from these intracellular events which it regulates. PKC activation is also
an essential element in the control of cell growth and differentiation, although it is not
necessarily an absolute requirement for all of these actions [Nishizuka, 1986]. PKC
also appears to be an important mediator of the LHRH priming effect. The priming-
induced increment in LHRH-induced LH release in vitro is selectively blocked by a
range of PKC inhibitors, without affecting unprimed or previously-primed responses
and K+- or ionomycin-induced LH release [Johnson et al, 1992; Thomson et al,
1993b]. However, the potency of the PKC inhibitor, H7, was very clearly less than
other inhibitors on this and other PKC mediated responses [Johnson et al, 1992;
Thomson et al, 1993b]. This initiated the hypothesis that the anterior pituitary may
additionally express a distinct form or potentially novel species of PKC. This species
of PKC is also involved in other LHRH receptor mediated responses including the
facilitation of pituitary L-type Ca2+ channels [Johnson et al, 1993b; Mitchell et al,
1988; Mitchell & Johnson, 1987], PLA2 (on pro-oestrous) [Thomson et al, 1994] and
PLD activation [Fennell et al, 1993]. A phorbol-activated, Ca2+-independent H7-
resistant PKC has since been characterised following partial separation from other




In addition to PLC, membrane phospholipids are the substrate for phospholipase A2
(PLA2). The action of PLA2 liberates a number of metabolites including
lysophospholipids and c/'s-unsaturated free fatty acids. Cytosolic PLA2 selectively
cleaves arachidonic acid (AA) from the sn-2 position which may act both as a
biological second messengers in its own right [Nishizuka, 1986] and also serves as
the precursor for lipoxygenases and epoxygenases (via the cyclooxygenase
pathway) which are important inflammatory mediators [Irvine, 1982; Samuelsson et
al, 1987]. PLA2 activity is also regulated by PKC, based on the observation that
phorbol esters and membrane permeant DAGs induce AA release [Gronich et al,
1988; Wijkander & Sundler, 1991]. PLA2 activation has a role in the cellular actions
of LHRH. Arachidonic acid and several of its metabolites stimulate gonadotrophin
release in anterior pituitary pieces in vitro, in perifused cells, or static primary cultures
of rat anterior pituitary cells and goldfish pituitary cells [Chang et al, 1986; Chang et
al, 1987b; Kiesel & Catt, 1987; Naor et al, 1985; Thomson et al, 1994]. The effects
on LHRH release can be mimicked by exogenous application of PLA2 and is
inhibited by several lipoxygenase inhibitors [Naor et al, 1985] or leukotriene
antagonists [Kiesel & Catt, 1987]. In our laboratory it has been shown that PLA2
inhibitors prevent LHRH priming but not unprimed or previously-primed LHRH-
induced LH release [Thomson et al, 1994] and that the magnitude of phorbol ester-
induced, PLA2-mediated, LH release matches those days of the oestrous cycle
where LHRH priming can occur [Thomson et al, 1994; Thomson et al, 1991]. On
pro-oestrous, LHRH-induced [3H]AA production is resistant to H7 but not to other
PKC inhibitors, whilst the response to phorbol ester displays H7-sensitive and
-resistant components [Thomson et al, 1994], The magnitude of [3H]AA responses
also matches the ability of tissues to display LHRH priming [Thomson et al, 1994],
23
Phospholipase D
The initial rise in DAG production following LHRH receptor stimulation is usually
followed by a sustained increase in DAG production [Liscovitch, 1992], Activation of
phospholipase D (PLD) promotes the hydrolysis of membrane phospholipids,
primarily phosphatidylcholine (PC), into choline and phosphatidic acid (PA) which
can be further metabolised to form DAG; thus activation of this pathway may
represent an important contribution to maintaining a sustained DAG accumulation.
In aT3-1 cells LHRH receptor activation results in a pronounced activation of PLD, as
assessed by measurement of accumulation of phosphatidylethanol or
phosphatidylbutanol (PEt or PBut), a specific product of PLD phosphatidyl
transferase activity when ethanol/n-butanol is added as an artificial phosphatidyl
group acceptor [Fennell et al, 1993; Netiv et al, 1991] This response occurs after a
brief delay (~2 min), is blocked by an LHRH receptor antagonist and is not
desensitised over a 120 min time course of exposure to LHRH [Fennell et al, 1993;
Netiv et al, 1991]. PKC a and (3i isoforms have been implicated in activation of PLD
[Eldar et al, 1993; Pai et al, 1991] and phorbol esters have been shown to partially
mimic the LHRH-induced response in aT3-1 cells [Fennell et al, 1993; Zheng et al,
1994], Responses to LHRH and phorbol esters are additive [Fennell et al, 1993].
Whilst LHRH-induced PLD activity is sensitive to standard PKC inhibitors, it appears
resistant to the inhibitory actions of H7 and the response to phorbol esters is
inhibited with greater potency than that to LHRH. Phorbol ester down-regulation of
phorbol-sensitive PKC isoforms diminished the response by 70% suggesting a
possible involvement of a phorbol ester-insensitive PKC isoform such as PKC £.
Interestingly a component of the PKC involvement in LHRH-induced PLD responses
appears to show properties consistent with the novel species of PKC described in
anterior pituitary PKC assays [Ison et al, 1993]. In addition LHRH-, but not phorbol
ester-induced PLD activation appears to involve a tyrosine kinase, as LHRH-induced
responses are sensitive to tyrosine kinase inhibitors [Fennell et al, 1993]. Also, two
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PLC inhibitors U73122 and neomycin, reduced the amplitude of the PLD response to
LHRH but did not effect phorbol ester-induced PEt accumulation [Zheng et al, 1994].
Thus it appears that PLD can be activated by two mechanisms in aT3-1 cells: one
involving tyrosine kinases and another a species of PKC (which is relatively resistant
to the PKC inhibitor H7); or by standard PKC species.
Tyrosine phosphorylation
LHRH elicits tyrosine phosphorylation of a number of proteins in aT3-1 cells and in
pro-oestrous pituitary cells (as assessed by antiphosphotyrosine immunoblots)
[Fennell et al, 1993]. Some of these tyrosine phosphorylations can be mimicked by
phorbol esters but not by ionomycin. The species of tyrosine kinases are not
established but immunoreactivity for src and fyn but not lyn, hck, yes or fgr has been
identified in these cells [Fennell et al, 1993]. PLC-dependent activation of tyrosine
kinases by LHRH has been described in aT3-1 cells, furthermore it appears likely
that this is an important event in the priming of inositol phosphate production which
underlies LHRH self priming [Mitchell et al, 1995a; Mitchell et al, 1995b].
Nevertheless the regulation of tyrosine phosphorylation in cellular responses to
LHRH is likely to be complex since PKC can activate tyrosine dephosphorylation
[Brautigan & Pinault, 1991] and LHRH-induced tyrosine phosphorylations have been
described [Liebow et al, 1991]. In pro-oestrous pituitary tissue LHRH-, but not
phorbol ester- or ionomycin-induced LH release is inhibited by tyrosine kinase
inhibitors but without a specific blockade of priming [Johnson et al, 1995]. One
possible functional role of tyrosine phosphorylation, might be the selective release of
LH over FSH (especially important for regulating the different time courses of the LH
and FSH surge in vivo), as LHRH-induced FSH release from pro-oestrous tissue
appeared to be relatively less sensitive to tyrosine kinase inhibitors [Johnson et al,
1995].
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cAMP and cGMP signalling
During prolonged stimulation of cultured pituitary cells, LHRH can induce a moderate
increase in both cAMP and cGMP [Liu & Jackson, 1981; Naor et al, 1975; Naor et al,
1978]. It is possible this is of importance in LHRH-induced gonadotrophin synthesis
but these second messengers do not appear to be involved in LHRH-induced
exocytosis of gonadotrophins [Conn et al, 1979; Naor & Catt, 1980]. It is notable that
LHRH-induced cAMP accumulation has not been observed in aT3-1 cells [Horn et al,
1991], and it is possible therefore that increases in cyclic nucleotides may result from
paracrine effects within the subpopulations of pituitary cells in primary culture.
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Figure 1.3
Schematic representation of the signal transduction mechanisms associated
with the LHRH receptor
1. Luteinising hormone releasing-hormone peptide
2. The luteinising hormone releasing-hormone receptor
3. Voltage-gated and receptor operated Ca2+ channe
4. Heterotrimeric G-protein (Gq/11)
5. Plasma membrane containing phospholipids
6. Adenylyl cyclase
7. Phospholipase C p
8. Phospholipase A2
9. Phospholipase D
10. protein kinase C
11. non-receptor tyrosine kinases
12. Endoplasmic reticuium(with IP3 receptors)
+ Choline + lysoPtdCho
targets associated with
LHRH priming
1.6 MITOGEN-ACTIVATED PROTEIN (MAP) KINASES
Background
In the late 1980s Sturgill and Ray first described a 42 kDa serine/threonine specific
protein kinase which was rapidly phosphorylated on both tyrosine and threonine in
response to stimulatory agents [Ray & Sturgill, 1987; Ray & Sturgill, 1988] This
enzyme was named microtubule-associated protein kinase 2 or MAP2 kinase,
because it utilised MAP 2 as a substrate in vitro [Ray & Sturgill, 1988] Over the next
few years this protein kinase acquired a number of names and acronyms from
independent research groups, but is now commonly referred to as mitogen-activated
protein (MAP) kinase, reflecting its well-documented role in cell cycle control and
activation in response to a wide array of diverse mitogens such as insulin, growth
factors (e.g. epidermal growth factor, platelet-derived growth factor; fibroblast growth
factor, insulin-like growth factor 1), phorbol esters and AIF4- [for early review see:
[Sturgill & Wu, 1991; Cobb et al, 1991; Thomas, 1992]. MAP kinase requires
phosphorylation at both tyrosine and threonine residues for full activity; removal of
phosphate either from threonine by phosphatase 2A or from tyrosine by CD45 results
in inactivation of these enzymes [Anderson et al, 1990; Boulton et al, 1991]. Both
these phosphorylations have been localised within a short tryptic peptide in
subdomain VIII [Payne et al, 1991] just upstream of the conserved Ala-Pro-Glu motif
found in all serine/threonine kinases [Hanks et al, 1988] and were assigned to
Thr183 and Tyr185 by alignment of the tryptic peptide with the cDNA sequence of
p42 MAP kinase [Boulton et al, 1991; Her et al, 1991]. The requirement for dual
phosphorylation to gain full activation of this enzyme led to the hypothesis that MAP
kinases represented a convergence point for signalling input from multiple pathways
[Anderson et al, 1990]. Furthermore serine/threonine-specific protein kinases have
been identified as regulatory effectors in numerous cellular activities, but often the
cell surface receptors that initiate these changes are protein tyrosine kinases [Cobb
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et al, 1991], therefore the discovery of a tyrosine-regulated serine/threonine kinase
which could effectively "switch" these signals prompted immense interest. However
MAP kinases are no longer regarded as "switch kinases", as it has since been shown
that these proteins are not directly activated by tyrosine kinase receptors. In a
remarkably short period since the discovery of MAP kinases, our understanding of
these enzymes, their regulation, cellular targets and expression has increased
dramatically.
The MAP kinase family
Much of our current knowledge of MAP kinase family and its regulators was
uncovered by homology screening for components of MAP kinase pathways in the
budding yeast Saccharomyces cerevisiae [recently reviewed in [Levin & Errede,
1995; Waskiewicz & Cooper, 1995]. MAP kinases are broad specificity, proline-
directed serine/threonine kinases which function in at least five, physiologically
distinct, signalling pathways in this yeast including the mating pheromone pathway
(Fus3/Kss1), pseudohyphal development and haploid invasive cell growth
(unnamed), cell integrity (Mpk1), sporulation (Smk1) and response to high osmolarity
(Hog1). Of these, the mating response pathway has most in common with
mammalian growth factor and G-protein receptor signalling. Following the discovery
of multiple, related but distinct, MAP kinase pathways in yeast, recent work has
highlighted the emergence of related MAP kinase pathways in mammalian cells.
Whereas mitogens, growth factors and a growing array of other agents, many of
which act through G-protein coupled receptors with no intrinsic tyrosine kinase
activity, lead to the activation of the ERK (extracellular signal-regulated kinase)
family [Cobb et al, 1991], many forms of cellular stress including cycloheximide
treatment, ultraviolet radiation (UV), tumour necrosis factor (TNFa) interleukin-1 and
heat shock lead to the activation of two related signalling pathways: the stress-
activated protein kinase (SAPK), also known as Jun N-terminal kinase (JNK),
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because they phosphorylate c-Jun at Ser63 and Ser73 to functionally activate it as a
transcription factor and p38 or CSBP/RK which is the mammalian counterpart of the
HOG1 high osmoregularity pathway in yeast [Davis, 1994; Kyriakis et al, 1994;
Pombo et al, 1994; Sanchez et al, 1994], Although the activators of these two
kinases overlap, there are distinct differences in the upstream activators and
downstream targets of SAPK and p38 [Zanke et al, 1996].
At present there are 5 members of the ERK family. ERKs 1 and 2 are by far the
most abundant and studied isoforms. ERK1 (44 kDa) and ERK2 (42 kDa) are the
products of two distinct genes but are highly related with 83% homology between the
two enzymes [Boulton et al, 1991]. They are most closely related to the cdc2 family
of kinases which are also regulated by dual phosphorylation and are between 37%
and 56% homologous to Fus3/Kss1. ERK3 (62.6 kDa) encodes a more distantly
related kinase with an additional 180 amino acid C-terminal extension, which is most
closely related to ERK1 (-50% within the catalytic domain) [Boulton et al, 1991;
Robbins et al, 1993], however within certain subdomains of the ERKs, these
enzymes are more highly conserved (e.g. Subdomain V, VI, VII, IX and XI) [Hanks et
al, 1988]. ERK 4 (45 kDa) was also identified by cross reactivity with ERK1 and
ERK2 antiserum [Boulton et al, 1991], and has since been characterised in PC12
cells, demonstrating similar characteristics of response to growth factors, as those
shown by ERKs 1 and 2 [Peng et al, 1996]. ERK5 is the largest of the ERK family at
815 amino acids; the C-terminus of ERK5 has sequences which suggest it may be
targeted to the cytoskeleton [Zhou et al, 1995]. ERKs 1 and 2 are uniformly
distributed but are especially prolific in the brain and peripheral nervous system.
ERK3 is found especially in hindbrain, the nervous system and skeletal muscle
[Boulton et al, 1991]. ERK5 is expressed in many adult tissues and is abundant in
the heart and skeletal muscle [Zhou et al, 1995]. The distribution pattern of ERK
expression suggests that each of these isoforms may have distinct functions in the
tissues and cell lines examined [Boulton et al, 1991; Cobb et al, 1991].
29
Molecular cloning revealed at least eight known members of the JNK/SAPK family
[Davis, 1994; Derijard et al, 1994; Kyriakis et al, 1994]. These are derived by
differential splicing from three or more genes (a, p and y) which range in size from
45-54 kDa and are 43-44% identical to the catalytic domains of ERK1 and ERK2.
JNK1 and JNK2 correspond to p46SAPKy and p54SAPKocll whilst a brain specific
isoform p493F12 has been isolated which corresponds to p54SAPKp [Mohitt et al,
1995]. Like the ERK family, the SAPK/JNKs require phosphorylation on a closely
spaced tyrosine and threonine within subdomain VIII. However members of this
family of proteins contain a proline between the phosphorylation sites (TPY),
whereas the ERKs contain glutamine (TEY) and p38s contain glutamic acid in this
position (TGY) [Davis, 1994; Kyriakis et al, 1994; Pombo et al, 1994; Sanchez et al,
1994]. Transcripts for this kinase are widely expressed, especially in skeletal
muscle. Also activated by stress, but differing in substrate specificity is p38, the
mammalian counterpart of the yeast HOG1 [Han et al, 1994].
Activation and upstream regulation of MAP kinases
Between the cell surface receptors and MAP kinase lies a complex, hierarchical
signalling system including adaptor proteins, GTPases and many protein kinases.
Up to six tiers in this cascade contribute to the amplification and specificity of signal
transduction which eventually leads to the activation of several signalling molecules
in the cytoplasm and nucleus. Of particular note, the tyrosine and threonine
phosphorylations required for full MAP kinase activity are achieved by one enzyme
from a family of dual-specificity tyrosine/threonine kinases [Crews, 1991; Gomez &
Cohen, 1991; Matsuda et al, 1992; Seger et al, 1992; Zheng & Guan, 1993]. Thus a
diverse range of external stimuli which lead to MAP kinase activation converge
upstream of MAP kinase by activating sequential cascades of highly related protein
kinases which form a core module consisting of a MAP kinase kinase kinase
(MAPKKK or MEKK), a MAP kinase kinase (MAPKK or MEK) and finally MAP kinase
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(MAPK). The known components of the MAP kinase pathways in yeast and
mammals is shown in Figure 1.3. This organisation provides multiple sites for signal
modulation as well as the potential for multiple sites for integration of input signals
and divergent output signals [Seger & Krebs, 1995; Waskiewicz & Cooper, 1995].
Pheromone response pathway in S. Cerevisiae- Fus3/Kss1
The mating response intracellular signalling pathway comprises a heterotrimeric G-
protein, small Ras-like GTPases and several sequentially acting protein kinases
[Errede & Levin, 1993]. Binding of the mating factor to the pheromone receptor
triggers a dissociation of the G-protein. The free py subunit stimulates a MAP kinase
module in a mechanism which additionally involves the serine/threonine kinase
Ste20. The Ste11 protein (the MEKK of this module) phosphorylates and activates
Ste7 (the MEK) which in turn phosphorylates and activates Fus3 and Kss1 (the
MAPKs). More recently it was revealed that Ste11, Ste7, Fus3 and Kss1 associate
independently with the protein Ste5 and similarly with each other [Choi et al, 1994;
Marcus et al, 1994; Printen & Sprague, 1994]. These observations are consistent
with Ste5 acting as a scaffold for the components of the MAP kinase module, which
has been suggested as a potential mechanism for minimising cross-interaction
between kinases involved in other similar paths in order to maintain the fidelity of
signal transmission in cells expressing components of multiple signalling pathways.
Mammalian mitogen/hormone responses - ERKs 1 and 2
At present the best understood of the mammalian MAP kinase pathways is that
leading to the activation of ERKs 1 and 2. Most stimuli which activate ERKs involve
activation of the Ras family of plasma membrane-anchored, small molecular weight
G-proteins. Growth factor- and cytokine-induced stimulation of tyrosine kinase-
receptors and associated tyrosine kinases, recruits many proteins to the plasma
membrane including Ras-specific guanine nucleotide releasing proteins (GNRPs;
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predominantly Sos) [Marshall, 1995]. Under the influence of a GNRP, Ras proteins
bind GTP resulting in the activation of the Ras signal. Increased Ras-GTP loading
by GNRPs is achieved through interaction of an adaptor protein Grb2 which contains
a "Src homology" (SH) 2 domain flanked by two SH3 domains. The SH2 and SH3
regions are binding sites for tyrosine phosphoproteins (SH2) and specific proline rich
motifs (SH3) respectively [Koch et al, 1991; Mussachio et al, 1992]. On one hand
Grb2 can bind Sos through its two SH3 groups on the other it can bind to tyrosine
kinase substrates (either the autophosphorylated tyrosine kinase receptor or She, a
substrate of Src kinases) [Egan et al, 1993; McCormick, 1993; Rozakis-Adcock et al,
1993]. MAP kinases can also be activated by seven transmembrane-domain
spanning G-protein -coupled receptors. As G-protein receptor-mediated activation of
MAP kinase is of most relevance to this particular study, this area will be covered in
more details in the discussions of the relevant chapters. However it appears that G-
protein coupled receptors can intercept the growth factor signalling cascade at an
early stage of the signalling cascade, often at the level of stimulating increased Ras-
GTP loading [Van Biesen et al, 1995; Van Corven et al, 1993, Davis, 1994], The
precise mechanisms of this action are as yet still unresolved but a general trend is
becoming apparent. Receptors which couple primarily to the Gj/0 family of G-
proteins such as the LPA and ci2 adrenergic receptor, appear to activate ERKs 1 and
2 through a Py-subunit-dependent activation of Ras and is independent of the aj/0
subunit or protein kinase C [Hawes et al, 1995, Faure et al 1995, Van Biesen et al,
1995, Luttrell et al, 1995]. Furthermore recently it has been proposed that this
activation involves interaction of pleckstrin homology domains within there signalling
cascade components [Luttrell et al 1995]. In contrast, it appears that receptors which
couple primarily to Gq/i 1 proteins such as the M2 muscarinic receptor activate Ras or
a downstream kinase Raf-1 in a mechanism which involes aq/n activation of PLCp
and consequently protein kinase C but does not involve the Py subunits [Hawes et al
1995; Buhl et al 1995]. Ras-GTP binds directly to the serine/threonine kinase Raf-1
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forming a transient membrane-anchoring signal [Avruch et al, 1994; Leevers et al,
1994]. Thus growth factor and G-protein coupled receptor signalling appear to
converge at Raf-1. In addition a number of Ras effectors including Ras-GTPase-
activating protein (GAP), phosphatidyl inositol 3-kinase, PKC£ and MEKK1 have
recently been identified [Marshall, 1996; Marshall, 1995],
Raf-1 is the MAPKKK or MEK kinase in this module, also analogous to Ste11 in the
yeast cascade. The native structure of Raf-1 is a large multisubunit protein complex
[Wartmann & Davis, 1994], Analysis of the structure of the Raf complex
demonstrates that it contains a single Raf protein kinase with the molecular
chaperones hsp90 and p50 and changes of the complex are not required or
observed in activated cells for activation of Raf-1 [Wartmann & Davis, 1994].
Localisation of Raf-1 to the plasma membrane is insufficient for full activation, as
membrane associated Raf-1 (by the addition of a constitutive membrane localisation
tag or by binding to Ras, in vitro) did not result in full activity [Leevers et al, 1994;
Stokoe et al, 1994], Furthermore membrane associated Raf-1 is activated 8-10 fold
by the EGF receptor in a Ras-dependent manner, suggesting the presence of
additional factors [Leevers et al, 1994; Stokoe et al, 1994], It is now known that the
Ras-induced translocation of inactive Raf, permits the multi-site phosphorylation and
phosphotransferase activity of Raf-1 by a variety of membrane associated kinases
[Morrison, 1995; Waskiewicz & Cooper, 1995]. The Src family of non-receptor
tyrosine kinases activate Raf-1 by phosphorylating Tyr340 and Tyr341 [Marais et ai,
1995]. Phorbol esters can also activate Raf-1 by activating PKC, which
phosphorylates and activates (in vitro) Raf-1 at residues Ser497, Ser499 and Ser619
[Van Marquadt et al, 1994; Van Renterghem et al, 1994]. Interestingly (as
mentioned previously), the zeta isoform of PKC (PKCQ is a downstream target of
Ras, perhaps by a direct interaction of Ras and PKC£, or by activation of the PI-3
kinase [Berra et al, 1995]. Another family of kinases which cause a striking
activation of Raf-1 are the ceramide-activated kinases (CAKs); CAKs stimulate Raf-1
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phosphotransferase activity by phosphorylation of Thr268 and Thr269 residues [Yao
et al, 1995].
The downstream target of Raf-1 is MEK 1 or 2 (MAPK or ERK kinase; also known as
MKK), the kinase equivalent to Ste7 in the yeast cascade. MEK was first identified
as a 45 kDa protein threonine/tyrosine kinase and was the first such enzyme
identified which showed dual specificity towards both tyrosine and threonine residues
[Crews, 1991; Gomez & Cohen, 1991; Matsuda et al, 1992; Seger et al, 1992; Zheng
& Guan, 1993]. MEKs 1 and 2 are activated following phosphorylation on Ser
residues 218 and 222 [Alessi et al, 1994; Pham et al, 1994; Yan & Templeton, 1994;
Zheng & Guan, 1994], The importance of phosphorylation of these residues was
further demonstrated. Substitution of Ser residues with Asn residues at 218 and 222
mimics the effect of Ser phosphorylation in MEK; expression of these mutant MEK
proteins has been shown them to be constitutively active in vitro and oncogenic in
vivo [Cowley et al, 1994; Mansour et al, 1994], MEK 1 is phosphorylated and
activated in vitro, by all three members of the Raf-1 family (A-Raf-1, B-Raf-1 and c-
Raf-1) [Jelinek et al, 1994; Wu et al, 1996]. Furthermore MEK1 is found to be bound
to the Raf-1 enzymes in inactive complexes in the cytoplasm [Jelinek et al, 1994; Wu
et al, 1996]. MEK 1 and 2 are the product of a distinct genes [Zheng & Guan, 1993].
MEK 1 is the isoform reported to be favoured by Ras activation [Jelinek et al, 1994],
however MEK2 (which is 7 amino acid longer and 81% homologous to MEK1), has
been suggested to be the most potent ERK activator in vitro. Mammalian MEKs 1
and 2 contain a proline-rich sequence which appears unique to Raf-1-activated
MEKs, as it is absent in the equivalent enzymes of the stress-activated MAP kinase
pathways and the yeast homologues [Catling et al, 1995]. MEK1 additionally
contains an important site of phosphorylation within this proline-rich sequence which
is required for the sustained activation of MEK1 in response to serum stimulation and
is absent in MEK2 (perhaps explaining the transient serum-induced activation of
MEK2 in Rat-1 fibroblasts) [Catling et al, 1995]. In contrast to ERK, where tested
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MEK appears to localise exclusively in the cytoplasm [Zheng & Guan, 1994], MEK 1
is additionally phosphorylated on Ser residues 218 and 222 by a number of other
kinases including: Mos a proto-oncogene-encoded 37 kDa serine/threonine kinase
isolated in Xenopus laevis oocytes [Papin, 1996; Pham et al, 1995]; a Ras-activated
kinase also from Xenopus oocyte cytosol, called REKS [Kuroda et al, 1995]; an
insulin-activated 56 kDa kinase in rat adipocytes, called MEKK-1; a murine Ste11-
related kinase known as MEKK1, which may also be directly activated by Ras
[Russell et al, 1995] and Ras-activated PKC£ [Berra et al, 1995]. The mechanism by
which PKC£ activates MEK requires further clarification, however may also involve
Raf-1 or other kinases. Recently 12 kDa protein has been reported, which is
proposed to enhance the rate at which ERK 2 is phosphorylated by MEK 1 and 2, but
this has yet to be characterised [Scott et al, 1995].
Recently a new Raf-like protein has been described; Ksr1 for kinase suppresser of
Ras, because its loss can compensate for the expression of activated Ras to restore
normal signalling in genetic studies of Drosophila melanogaster and Caenorhabditis
elegans [Kornfeld et al, 1995; Sundara & Han, 1995; Therrien et al, 1995]. Murine
and human forms have also been described [Therrien et al, 1995]. Ksr1 is about 35-
41% homologous to Raf-1 within the catalytic domain and contains some other
conserved sequences found in Raf-1. A notable difference to Raf-1 is the lack of the
Ras binding domain although Ksr1 contains a cysteine-rich zinc finger that is found in
other kinases such as PKC and Raf-1. Additionally Ksr1 contains a serine and
threonine-rich region and a motif found in Raf-1; FXFPXXS/T, as well as a putative
class II SH3 domain (PXXPXR/K). It is still to be clarified as to where Ksr1 fits into
our current understanding of the ERK 1 and 2 signalling pathway. Of interest is a
putative role as a MEK2 activator as MEK2 has never been found in complex with
any of the Raf family and is not activated in vitro by A-Raf, although it is by Raf-1 and
B-Raf [Wu et al, 1996]. At present, yeast two-hybrid systems have failed to detect
any interactions between Ksr1 and Ras, Raf or MEK 1 and 2 and it seems likely that
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this kinase functions upstream of Raf or on a parallel pathway which is partly
redundant with the Raf-MEK1 route.
Activated MEK 1 and 2 phosphorylate ERKs 1 and 2 at residues Thr183 and Tyr185
of the TEY motif in subdomain VIII. ERKs 1 and 2 are the only known substrates of
MEK1 (45 kDa) and MEK2 (46 kDa). MEK3 can form a complex with ERK1 in vitro,
however this is totally inactive as an ERK activator [Zheng & Guan, 1993].
Mammalian stress response pathways - SAPK/JNK and p38
The SAPK/JNK pathway has many parallels with the ERK pathway. This pathway is
activated by the Rho family of GTPases, Cdc42 and Rac1, analogous to activation of
ERKs by Ras [Coso et al, 1995; Minden et al, 1995; Olson et al, 1995], Expressing
activated versions of Rac1 or Cdc42 mutants, or their exchange factors, in COS-7
cells is sufficient to increase JNK1 activity 5-10 fold without increasing ERK activity
[Coso et al, 1995; Minden et al, 1995; Olson et al, 1995]. However, the membrane
localised Ras exchange factor Sos, which stimulates ERK1 and 2 does not affect
JNK activity [Waskiewicz & Cooper, 1995]. The downstream targets of Cdc42 or
Rac1 are not fully defined, although several candidate effectors have been
suggested including the p21 Cdc42- or Rac-activated serine/threonine kinases
(PAKs) [Bagrodia et al, 1995; Waskiewicz & Cooper, 1995]. The mammalian PAKs
are homologous to Ste20 [Marcus et al, 1995] and are activated upon the interaction
of their amino-terminal regulatory domains with the GTPases [Bagrodia et al, 1995;
Brown et al, 1996; Cahill et al, 1996]. Another more distantly related Ste20
homologue is the germinal centre kinase (GCK) which has also been shown to
activate the SAPK pathway in vitro [Pombo et al, 1995], further illustrating the
conservation of signalling pathways between yeasts and mammalian cells. The MAP
kinase module which leads to activation of JNKs consists of MEKK (homologous to
Ste11) which phosphorylates and activates SEK1 (SAPK or ERK kinase, also known
as MKK4 and JNKK). SEK doubly phosphorylates JNK in the TPY motif. SEK1
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shares 45% homology with MEK 1 and 2 but lacks the proline rich sequence found in
other members of this family [Lin et al, 1995; Sanchez et al, 1994],
There is at least 3 isoforms of MEKK cloned to date [Blank et al, 1996; Minden et al,
1995]. MEKK1 can cause phosphorylation of MEK 1 and 2 in vitro, and was first
thought to encode an activator of MEK in G-protein activated pathways [Minden et al,
1994]. However inducible expression of MEKK1 in NIH 3T3 cells activates JNK1
activity at least 4-fold, whereas ERK2 activity remains mostly unchanged [Minden et
al, 1995; Yan et al, 1994], Furthermore expression of activated MEKK resulted in
cell death in Swiss 3T3 and REF52 fibroblasts and enhanced UV-induced apoptosis
[Johnson et al, 1996]. In contrast Raf-1 kinase, which selectively activates ERKs,
did not induce any of the cellular changes associated with MEKK expression and cell
death. Thus the SAPK/JNK family appear likely to selectively regulate pathways in
apoptotic and cellular stress responses [Xu et al, 1995; Johnson et al, 1996].
Activation of MEKK1 may be possible by direct phosphorylation by Rac1, or may be
dependant on a second signal in addition to PAK phosphorylation [Waskiewicz &
Cooper, 1995]. Another MAPKKK-related protein termed MUK, has been identified
and characterised recently [Hirai et al, 1996]. MUK also appears to be a selective
activator of the SAPK/JNK pathway.
p38 (also named as CSBP or RK, reactivating kinase) is another MAP kinase
activated by a similar cascade of phosphorylation. p38 is dual phorphorylated on
tyrosine and threonine within a TGY motif by the upstream activators MKK3 and
MKK6 [Han et al, 1996; Raingeaud et al, 1996]. Little is known at present about the
upstream activators of MKK3 and MKK6, although more recently it has been
suggested that the PAK isoforms might also regulate p38 cascades [Cahill et al,
1996; Pelech, 1996]. Overexpression of MEKK1 failed to activate p38, whist raising
JNK activity within the same experiment [Derijard et al, 1995]. Similarly when
overexpressed SEK1 (MKK4) is also capable of causing activation of p38 but this is
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unlikely to be the physiological activator in vivo [Derijard et al, 1995; Lin et al, 1995].
In view of the similarity of the MAP kinases cascades, it is likely that a MEKK1 type
enzyme will be characterised which connects PAK (or other undiscovered protein)
signals with MKK3 and MKK6. The detection of p38 in the nucleus of activated cells,
suggests that p38 can mediate signalling to the nucleus [Raingeaud et al, 1996].
Similar to SAPK/JNKs, the p38 family may also have a role in apoptosis [Pelech,
1996].
MAP kinase inactivation by phosphatases
The down-regulation or inactivation of a response is of an equal importance as the
activation and amplification of the signal. ERKs 1 and 2 may be dephosphorylated
and hence inactivated by the actions of an array of MAP kinase-specific
serine/threonine and tyrosine phosphatases and broad range phosphatases [Alessi
et al, 1993; Anderson et al, 1990; Sun et al, 1993], These phosphatases also play
an important role in maintaining MAP kinases at a low basal catalytic activity prior to
activation. However, although a number of phosphatases have been demonstrated
to dephosphorylate MAP kinase in vitro, these may not necessarily be of as major
physiologically relevance in vivo.
MKP1 (also referred to as CL100 or 3CH134 ) was initially identified as a murine
serine/threonine/tyrosine phosphatase which specifically dephosphorylates both
regulatory threonine and tyrosine residues in ERKs 1 and 2 in vitro [Sun et al, 1993;
Duff et al, 1984; Alessi et al, 1993]. Interestingly, MKP1 does not dephosphorylate
JNK1, therefore distinct MAP kinase pathways might be differentially regulated.
Recently a related phosphatase, MKP2 has been characterised in PC12 cells
[Misrapress et al, 1995]. A number of related phosphatases have also been
identified including: PAC (phosphatase of activated cells)-1 [Ward et al, 1994] and
HVH2 a novel dual specificity phophatase [Guan & Butch, 1995]. MPK1 and its
relations are immediate early gene products which are strictly localised to the
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nucleus [Alessi et al, 1993; Guan, 1995; Ishibashi et al, 1994; Ward et al, 1994].
However whilst induction of MKP1/PAC1 might explain the slow dephosphorylation
which is observed in the nucleus other phosphatases must be present to account for
the rapid dephosphorylation of ERKs 1 and 2 observed in the cytoplasm [Wu et al,
1994],
The other predominant MAP kinase phosphatase is PP2A, one member of a family
of broad specificity protein serine/threonine phosphatases [Alessi et al, 1995b]. MEK
can also be inactivated by PP2A (but not by tyrosine phosphatase CD45 [Gomez &
Cohen, 1991] Following growth factor stimulation, PP2A becomes tyrosyl
phosphorylated (possibly by the src family); this temporarily inhibits it ability to
dephosphorylate substrates [Chen & Murakami, 1992]. Protein tyrosine specific
phosphatases have been identified in mammalian cells; in Xenopus oocytes a
phosphatase specific for tyrosine residues was found to be activated following
phosphorylation by MEK and has been suggested to dephosphorylate MAP kinase in
vivo [Sarcevic et al, 1993].
Phosphatases may regulate the MAP kinase cascade upstream of the MAP kinase
enzyme. In insulin signalling, Syp a tyrosine phosphatase is activated which is
reported to act immediately downstream of Ras [Sawada et al, 1995]. In yeast
several serine/threonine specific and tyrosyl phosphatases have been shown
genetically to participate in MAP kinase signalling. The overexpression of either
SLN1, PTP2 (a tyrosine phosphatase) or the PP2C genes PTC1 and PTC3 can
overcome a lethal mutation involving an inhibitor (SLN1) of the Hog1 MAP kinase
pathway [Maeda et al, 1994]. In fission yeast deletion of the three PP2C genes is
lethal [Shiozaki & Russell, 1995]. Also identified in S. cerevisiae is Msg5, a
phosphotyrosyl phosphatase which genetically opposes the actions of Fus3; Msg5 is
related to MKP1 and has been shown to inactivate Fus3 in vitro [Doi et al, 1994],
From these observations and others, it appears that MAP kinase is both co-
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ordinately regulated and spatially distributed with an increasing array of protein
phosphatases, as would be expected of such a key signalling protein.
Cellular targets of MAP kinases
Activated MAP kinases have been shown to phosphorylate numerous cellular
proteins. Downstream targets of ERKs 1 and 2 include another kinase called Rsk
(p90 ribosomal S6 kinase) [Sturgill & Wu, 1992] cytoplasmic phospholipase A2
(PLA2) [Lin et al, 1993], the tail of the EGF receptor [Takishimi, 1991] and the
microtubule associated protein MAP2 [Ray & Sturgill, 1988]. A downstream target of
p38 is the protein kinase, MAPK-activated kinase 2 (MAPKAPK2). MAPKAPK2 was
originally described as a kinase that was phosphorylated and activated by ERK2
[Stokoe et al, 1992]. This kinase may be responsible for the phosphorylation of heat
shock proteins including Hsp25 and Hsp27 in response to various stress [Rouse et
al, 1994; Stokoe et al, 1992]. Very recently a novel enzyme termed MAPKAPK3 has
been identified in a yeast two hybrid system [McLaughlin et al, 1996]. MAPKAPK3
shares 70% amino acid identity with MAPKAPK2 and has been shown in vitro and in
vivo to be another physiological target of p38 [McLaughlin et al, 1996]. A number of
upstream kinases such as Raf-1 and MEK are also targets for MAP kinase, thus
providing the opportunity for feedback regulation of the MAP kinase cascades
[Blenis, 1993; Davis, 1993].
In addition, activated MAP kinases can translocate to the nucleus, the location of
many transcription factors (TFs) and ternary complex factors (TCFs), these are
proteins which once phosphorylated bind in dimers to sequences in DNA to regulate
transcription [reviewed in Davis, 1995; Treisman, 1996]. The functional
consequences of transcription factor phosphorylation include, stabilising the
transcription factor protein, regulation of DNA binding, potentiation of transcriptional
activation, regulation of transcriptional repression or a combination of these effects
which effectively links transcriptional responses to mitogenic and stress stimuli
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[Treisman, 1996]. Downstream targets of ERK 1 and 2 include multiple
serine/threonine residues in the carboxy terminus of the TCFs Elk-1, SAP-1 and
possibly SAP-2 as well as Ets-1 and Ets-2 (all of the ETs domain-containing family),
these can form ternary complexes with a serum response factor (SRF) at the c-Fos
serum response element [Treisman, 1996]. Activation of the transcription factor c-
Jun is potentiated following phosphorylation by JNK/SAPK, this discovery led to the
isolation and characterisation of this group of MAP kinases [Minden et al, 1994]. The
mammalian bZIP transcription factor ATF-2 forms a transcriptional complex with c-
Jun and is also a target for JNK/SAPK, p38 [Treisman, 1996], It is likely that many
more MAP kinase phosphorylation sites exist, both in the nucleus and cytoplasm,
which will become increasingly obvious as our understanding of the genetic and
biochemical pathways increases.
In summary, MAP kinases including ERKs 1 and 2 are activated in a sequential
cascade by a range of extracellular stimuli including growth factors acting through
tyrosine kinase receptors. Activated MAP kinases phosphorylate a number of
downstream signalling components and transcription factors and are thus imortant to
many cellular processes like growth, differentiation and environmental stress and cell
division. It is now apparent that G-protein-coupled receptors can switch into this
cascade by activating Ras and Raf by means of the Py subunits or activating
upstream kinases such as Src or PKC, which gives the potential for G-protein
coupled receptor ligands to usurp these cascades for their actions and potentially for
mitogenic roles or altering cellular responsiveness in differentiated cell types. Here
we explored the potential ability of the LHRH receptor to activate ERKs in partially
(aT3-1) and wholly (pituitary cells) differentiated gonadotroph cells in the context of
the known ability to alter cellular respnsiveness.
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MAP kinase pathways in S.cerevisiae and in mammalian cells.
Structurally related components of the various pathways are shown with information
flow from top to bottom. Each MAP kinase module is shown in one long rounded
rectangle (shaded grey) containing the MAPKKK, MAPKK and MAPK. Pathways
may contain more than one MAPKKK, MAPKK or MAPK, which may exhibit variable
functional redundancy. Links to receptors and sensor molecules have been omitted
for simplicity. The activity of several of the pathways is controlled by GTPases of the
Ras superfamily, shown as open rectangles. The majority of MAP kinase modules is
controlled by additional upstream kinases shown in squares. These kinases are
members of different subfamilies of kinase (and they are not necessarily homologous
to the Ste20 protein in yeasts).
At least five MAPK modules have been characterised in yeast and other less well





Inhibitors: working stocks of inhibitors were made up at 10"2 M in dH20 or
dimethylformamide (DMF) and stored at -20°C or 4°C where appropriate before
dilution in the relevant medium.
PKC inhibitors: staurosporine (Streptomyces sp.), K252a {Norcardiopsis sp.)
Bisindolylmaleimide 1 (GF109203X; 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl] 3-
(1H-indol-3-yl)-maleimide) quercetin and chelerythrine chloride, all from Calbiochem-
Novabiochem, Nottingham, UK. Ro-31 8220 {[1-[3-(Amidoinothio)propyl-1 H-indoyl-
3-(1-methyl-1H-indoyl-3-yl)maleimide-methane sulphate} - gift from Roche Products
Ltd., Welwyn, Garden City, Herts, UK.
1-(5-lsoquinolinesulphonyl}-R series: -piperazine (C1/HA100), -homopiperazine (HA
1077), -2,5-dimethylpiperazine,-N-1 -(methylamino)ethyl) (H8),-N-(2-aminoethyl)
(H9) -N-(2-aminoethyl)-N-n-hexyl) from Cookson Chemical Co., -N-(2-
guanidinoethyl) (HA 1004), -2 methylpiperazine (H7) and -3-methylpiperazine
(isoH7) from Sigma,
tyrosine kinase inhibitors: tyrphostin A-47 (AG 213; a-cyano-(3,4-
dihydroxy)thiocinnamide), lavendustin A, {5-amino-[(N-2,5-dihydroxybenzyl)-N'-2-
hydroxybenzyl]-salicylic acid, lavendustin B, [5-amino-(N,N'-bis-2-hydroxybenzyl)-
salicylic acid], ST 271 (3-(3', 5'-di-isoprpyl-4'hydroxycinnamide), genistein (4',5,7-
trihydroxyisoflavone), geldanamycin, RG-13022 [a-(3'-pyridyl)-(3,4-dimethoxy)
cinnamonitrile] all from Calbiochem
tyrosine phosphatase inhibitor: Pervanadate was prepared by the addition of sodium
orthovanadate (Sigma) to a divalent cation-free Earles balanced salt solution
containing Hepes (30 mM) to a final concentration of 5 mM. The pH was adjusted to
pH 7.4 with NaOH, then H2O2 (1 M) was added to a final concentration of 1 mM, for
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15 min at room temperature before the addition of catalase (4 mg; Sigma) to remove
excess (Streptomyces hygroscopicus) H2O2 [Grinstein et al, 1990].
Phospholipase inhibitors: (PLA2 inhibitors) aristolochic acid sodium salt, from Biomol
Research Laboratories, c/o Semat, St. Albans, Herts, UK. Manoalide (Luffariella
variabillis) and Isotetrandine from Calbiochem. 4-(4-octadecyl)-4-oxobenzene-
butenoic acid from Cookson Chemicals; benzenesulphonamide 4 was a gift from Dr
Mike Clark, USA. (PLC inhibitors) U-73122, {1-6-(17p-3-methoxyestra-1,3,5(10)-
trien-17-yl)amino)hexyl]-1 H-pyrrole-2,5-dione} and U-73343, {1-6-(17p-3-
methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-2,5-pyrolidine-dione} both gifts from
Upjohn Pharmaceuticals, Kalamazoo, USA.
Activators/agonists LHRH and the antagonist peptide ([Ac-D-p-CI-Phe1-2, D-Trp3,
D-Arg6, D-Ala10]-LHRH, epidermal growth factor (EGF), mastoparan (Vespula
lewisii), forskolin (coleus fors/fo/j//-7p-acetoxy-8,p-epoxy-1a,6p,9a-trihydroxy-labd-
14-en-11-one) phorbol 12,13-dibutyrate (4a-and 4p-isomers), ionomycin (free acid,
Streptomyces conglobatus), 5-hydroxytryptophan (5-HT) and Cholera toxin (Vibrio
cholerae) were obtained from Sigma Chemical Co., Poole, Dorset, UK. Pertussis
toxin (Bordetella pertussis) and pertussis toxin B-oligomer were both obtained from
Calbiochem. (1S,3R)-aminocyclopentane dicarboxyclic acid (ACPD) was obtained
from Tocris Cookson, Bristol, UK. Buserelin (D-t-butyl-Ser6, des-Gly10, LHRH
ethylamide) was a gift from Hoeschst, AG.
Radiochemicals: Adenosine 5'-[y-35S-thio]trisphosphate (ATP-y-35S) specific
activity approximately 250 Ci/mmol, and [5, 6, 8, 9, 11, 12, 14, 25-3H(N)]-arachidonic
acid specific activity approximately 250 Ci/mMol) were obtained from NEN DuPont,
Germany, Na 125l from ICN Radiochemicals, Irvine, CA, USA and [3H]-inositol from
Amersham International pic., Aylesbury, Bucks, UK,.
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Anti-sera: Primary antisera: mouse monoclonal antibodies against ERK 1+2 (Zymed
Z033, Zymed Laboratories Inc., San Francisco, USA, affinity-purified rabbit
polyclonal antibodies to Gaq/i 1 (C1-19) raised against a peptide corresponding to
amino acids 341-359 mapping within a domain common to Gaq and Gan of mouse
cell origin and Ga-|2 (S-20) were purchased from Santa Cruz Biotechnology, Inc.,
anti-p tubulin antibody (Amersham N357), was from Amersham International pic, UK.
Rabbit anti-cAMP antiserum (RIB7) was a generous gift from Dr. I. Gow, Dept. of
Physiology, University of Edinburgh.
All secondary antisera and non-immune rabbit serum were gifted from the Scottish
Antibody Production Unit (SAPU), Carluke Lanarkshire, UK.
Oligonucleotides: mRNA antisense oligonucleotides corresponding to regions
around the initiation codon for ERK 2 (5'-CGC CAT GTT GGC TGC ACA GCC Gee¬
s'), and Gaq/11 (5'-CGC CAT (GC)AT GGA CTC CAG AGT-3') and Gcc12 (5'-GGG
TCC GCA CCC CGG ACA TGG-3') (murine sequences) were custom synthesised
and HPLC purified by Oswel DNA, University of Southampton, Southampton, UK.
Tissue Culture reagents: All tissue culture media, sterile glucose supplements,
Lipofectamine™ and "UltroSer G" was obtained from Gibco-BRL. Foetal calf serum
was obtained from Sera-Lab, Crawley Down, Sussex UK. and after batch testing for
sustained growth and standard assay results a batch was reserved for subsequent
use. Penicillin, streptomycin, L-glutamine and trypsin were obtained from Sigma. N-
[1-(2,3-dioleoyloxy) propyl]-N, N, N-trimethyl ammoniummethylsulphate (DOTAP)
was from Boehringer Mannheim and DEAE-Dextran was from Promega,
Southampton UK. Tissue culture plastics were obtained either from Costar, UK Ltd,
Bucks UK, or Greiner Laboritechnik Ltd, UK.
Miscellaneous: General biochemicals were from BDH and were all Analar grade.
MAP kinase selective peptide substrate Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg
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(APRTPGGRR) was synthesised by Dr J Keyte, Department of Biochemistry,
University of Nottingham, Nottingham, UK. Bovine serum albumin (fraction V and
essentially fatty acid free), isobutylmethylxanthine (IBMX), dithiothreitol (DTT), N-
tris(hydroxymethyl)methylglycine (Tricine), [4-(aminoethyl)benzenesulphonyl fluoride
(AEBSF), pepstatin, aprotinin, sodium orthovanadate (NaaVOzp, p-glycerophosphate,
leupeptin, trans-epoxysuccinyl-L-leucylamido-(4-guanido)-butane (E64), 2-
mercaptoethanol (EtSH) and sodium fluoride (NaF) were all obtained from Sigma.
Okadaic acid, ammonium salt was obtained from Calbiochem. Sagatal™, sodium
pentabarbitone; May and Baker, Dagenham, Essex, P81 phosphocellulose paper
from Whatman International limited Kent, UK, Coomassie® Plus protein assay
reagent and BSA standard solution from Pierce, Chester, UK; Immobilon-P™,
Millipore, Watford, Herts; Enhanced Chemi Luminescence (ECL) detection system,
Amersham International pic, Bucks, UK, Sep-Pak Cis cartridges, Waters
Chromatography, Watford, Hertfordshire, UK
2.2 ANIMALS
COB-Wistar rats were obtained from Charles River UK Ltd, Margate Kent UK or were
derived from a colony bred in this department from a stock originally obtained from
Charles River. Adult female (~200g) or male (~250g) rats were maintained under
controlled lighting (lights on from 05.00 to 19.00h) and temperature (22°C) with free
access to food pellets and tap water.
Female rats were assessed for a minimum of two 4 day oestrous cycles (as
determined by vaginal lavage). The cytological characteristics of the vaginal smears
in a 4-day cyclic rats were as follows;
Metoestrus: large numbers of leucocytes, epithelial cells and cornified
epithelial cells.
Dioestrus: leucocytes, epithelial cells and cornified epithelial cells, but in
smaller numbers than metoestrus animals.
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Pro-oestrus: mainly nucleated epithelial cells.
Oestrus: predominantly cornified epithelial cells.
To prepare OVX rats, female rats at various stages in of the oestrous cycle, were
bilaterally ovariectomised under halothane anaesthesia and left over a period of
4 weeks before use as with normal cycling animals.
Prior to experimentation rats were anaesthetised with "Sagatal" (30 mg/kg body
weight) by 11.00-12.00 am on the appropriate day of the cycle and killed by cervical
dislocation
2.3 CELL CULTURE
All cells were grown and maintained under a humidified atmosphere of 95% air/5%
CO2 at 37°C and received fresh medium every 3-4 days. Cells were harvested
either by trypsin digestion or using Hanks buffered saline (HBSS, without calcium,
magnesium or phenol red) containing 0.1% w/v EDTA. Medium was removed and
replaced with 1.5 ml of a 0.25% (v/v) trypsin solution or HBSS/EDTA and left for 5-10
min. After pelleting at 200 xgfor 10 min, cells were resuspended in an appropriate
volume and split into fresh flasks at a ratio of 1:3 for 75 cm2 flasks, 1:8 for 25 cm2 or
were seeded into 12, 24 or 48 well plates where appropriate for assay purposes.
aT3-1 mouse gonadotroph cells
aT3-1 cells (gift from Dr Pamela Mellon, the Salk Institute, USA.) were grown and
sub-cultured in Dulbecco's modified Eagle's medium (DMEM) with sodium pyruvate
(110 mg/l) containing 10% foetal calf serum (FCS) 2 mM glutamine, 100 U/ml
penicillin and 100 pg/ml streptomycin. Cells were passaged after reaching -100%
confluency in 75 cm2 flasks every 5-7 days.
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COS 7 fibroblast cell line
COS 7 cells (gift from Dr. Janet Allen, Glasgow University, UK), used for transient
transfection procedures, were grown in DMEM supplemented with 10% new-born
calf serum and 100 U/ml each of penicillin and streptomycin and were passaged
every 3-4 days.
Chinese Hamster ovary (CHO) cells
CHO cells, used to produce stably transfected cell lines, were grown and maintained
in Ham's F12 medium with 100 U/ml each of penicillin and streptomycin and were
passaged every 5-7 days when -60-80% confluent in 75 cm2 flasks.
2.4 METHODS
Cytosolic MAP kinase assay
Cells were grown to confluency in 25 cm2 (aT3-1) or 75 cm2 (transfected COS 7
(tCOS 7) or transfected CHO (tCHO)) flasks and then the medium replaced with
serum free medium for ~24h. Rat anterior pituitary glands were removed
immediately following decapitation. Hemisected pituitaries were randomly distributed
into 25 ml conical flasks containing 2 ml of pre-gassed and pre-warmed (37°C)
Hepes-buffered minimal essential medium with Earles salts (MEM). The
hemipituitary pieces were pre-incubated for 30 min in a shaking water bath at 37°C
under an atmosphere of 95% O2 : 5% CO2 after which the medium was discarded
and replaced with fresh medium. Where required inhibitory drugs were added
directly to the flasks from 100X concentration for 5 min before addition of the agonist
for 10 min (unless otherwise stated). When appropriate dimethylformamide (DMF)
vehicle was present in controls at 0.03% (v/v). This concentration of vehicle was
shown to have no effect on MAP kinase activity.
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After incubation with the pharmacological agent, aT3-1 cells, tCOS 7 and tCHO cells
or hemipituitaries were thoroughly aspirated and rapidly scraped from the flask and
homogenised into 200 pi of ice-cold homogenisation medium: 20 mmol Tris/I; 12 mM
EDTA/I, 50 mM 2-mercaptoethanol (EtSH)/l, 1 mM [4-(aminoethyl) benzenesulphonyl
fluoride (AEBSF)/I, pH 7.4 with HCI, containing 0.01% (w/v) leupeptin, 20 pM trans-
epoxysuccinyl-L-leucylamido-(4-guanidino)butane/l, 2 mg aprotinin/l, 1 pM
pepstatin/l, 2.5 mM NaaVCVI, 62.5 mM p-glycerophosphate/l and 200 nM okadaic
acid. The supernatant fraction was collected after centrifugation, 6000 x g, 45 min.
The 25 pi assay finally contained 20 mM Tris/I, 0.5 mM EGTA/I, 2.4 mM EDTA/I, 20
mM MgCl2/l, pH 7.5 with HCI, with 50 pM NaF/l, 50 mM EtSH/l and 200 nM okadaic
acid/I as well as the other peptidase and phosphatase inhibitors diluted 1 in 5 from
their concentrations in the 5 pi aliquot of cytosolic extract added to the assay.
Substrate peptide (APRTPGGRR; Clark-Lewis et al 1991) was used at 2 mmol/l.
Substrate-free blanks were determined in all cases. Assays were started with 100
pM of ATP-y[35S]/l (containing 0.58 pCi ATP-y[35S]/tube) and brief centrifugation.
Tubes were incubated for 40 min at 30°C (within the linear range of the assay).
Incubations were stopped by addition of 25 pi ice-cold trichloroacetic acid (120 g/l)
and 10 pi bovine serum albumin (20 g/l). After 15 min on ice, samples were
centrifuged (12000 x g for 5 min at 4°C), then 30 pi aliquots were spotted onto 4 cm2
pieces of P81 phosphocellulose paper. Papers were washed for 3 x 2 min in -10 ml
of H3PO4 (75 mM) and dried before scintillation counting. Specific MAP kinase
activity was defined by subtracting the substrate-free blanks which were generally
less than 25% of values with substrate and were unaltered by any of the present
treatments.
Immunoprecipitation of ERK 1 and 2
The specificity of this assay was monitored by immunoprecipitation using a
monoclonal anti-p42 /p44 antibody (Zymed Z033) conjugated to protein G-sepharose
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4B beads. The protein G-sepharose-4B (100 pi packed gel) was washed and
resuspended in 140 pi 25 mmol Tris/I, 150 mmol NaCI/l, 0.04% (v/v) Nonidet-P40,
0.25% (w/v) gelatin, pH 7.4 with HCI. MAP kinase antibody (Zymed Z033, specific
for p44 and p42 species; 50 pg), or a control anti-p tubulin antibody (Amersham
N357) was added to the gel and incubated for 2 h at room temperature with rolling.
The derivatised gel was washed twice and resuspended in homogenization buffer to
a final volume of 140 pi. Fifty pi aliquots, together with 50 pi cytosolic extract were
incubated for 18 h at 4°C with rolling. After brief centrifugation, the supernatant was
removed, the gel washed once and resuspended to 100 pi. Aliquots (10 pi) of
supernatant, of resuspended gel and of cytosolic extract (diluted 1:1) were assayed.
As seen in Figure 2.2, in cytosolic extracts for cxT3-1 cells treated with either nothing,
LHRH (100 nM, 10 min) or phorbol 12,13-dibutyrate (PDBu, 1 pM , 8 min), 71 ± 12%,
74 ± 10% and 67 ± 9% of the recovered activity was associated with the beads rather
than the supernatant. Corresponding values using the control anti-p tubulin antibody
of the same IgG subclass were 12 ± 8%, 4 ± 8% and 23 ± 13% respectively (means
± SEM, n=3).
Map kinase immunoblots
Phosphorylation of p42 and p44 MAP kinase was determined by the electrophoretic
mobility shift assay. aT3-1 cells were grown as before in 12 well plates and serum
starved for 24 h prior to experimentation. Incubation with pharmacological agents as
appropriate was as described for the MAP kinase assay. After the incubation period
the medium was aspirated and the cells washed once in 1 ml ice cold Hanks
balanced salt solution (HBSS), and the cells scraped immediately into 500 pi SDS
buffer; 50 mM Tris base, 5% p- mercaptoethanol, 2% sodium dodecyl sulphate, pH
7.2, heated to 100°C for 5 min and stored at -20°C.
Four pi of each sample was subjected to electrophoresis on a 7.5% homogenous
phast-gel, 30 min (10 mA, not exceeding 250 V). After separation by
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electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane
(Immobilon-P). Electroblotting was performed at 20°C for 15 min in 25 mM Tris
base, 192 mM glycine, 20% methanol, pH 8.3. A non-specific binding of antibody
was prevented by incubating the blots in 5% BSA/PBS overnight. Both SDS-
electrophoresis and electroblotting were performed on a Phast-system apparatus
(Pharmacia Biotech, Milton Keynes, Bucks).
The blots were washed 5X5 min at 20°C in PBS/0.1% Tween 20. Phosphorylated
MAP kinases were then identified by incubating with mouse monoclonal anti-MAP
kinase antibody (Zymed Z033), which recognises both p42 and p44 species of MAP
kinase, for 1-3 h in 0.25% BSA/PBS (diluted 1:1200) followed by extensive washing
in PBS/0.1% Tween 20. The blots were subsequently incubated with horseradish
peroxidase (HRP)-anti mouse IgG in 0.25% BSA/PBS/Tween 80 (diluted 1:5000).
After washing, immunostained proteins were visualised using the Enhanced Chemi
Luminescence (ECL) detection system.
Radioimmunoassay for cAMP
Prior to agonist stimulation, quiescent aT3-1 cells were washed extensively in MEM-
BSA (0.25%) and pre-incubated in medium containing 0.5 mM
isobutylmethylxanthine (IBMX) for 15 min. Stimulations were terminated by
aspirating the medium and addition of 0.1 N HCI to the cells (intracellular cAMP) or
addition of an equal volume of 0.2 N HCI (total cAMP). After freeze thawing the
plates to aid membrane breakdown the cells were homogenised by trituration in the
0.1 N HCI and stored at -40°C.
Duplicate 50 pi samples of homogenate in 0.1 N HCI were assayed for
immunoreactive cAMP using a double antibody precipitation radioimmunoassay
(Dufau et al 1973) after appropriate dilution in 50 mM sodium acetate buffer, pH 6.0,
0.1% BSA (fraction V), 0.1% sodium azide, using antiserum RIB7 at a final dilution of
1:200,000. All assays were performed in a final volume of 275 jxl in polypropylene
tubes (Alpha-Labs). After overnight incubation with -10K cpm of 125l-cAMP, donkey
anti-rabbit IgG and non-immune rabbit serum were added to a final titre of 1:40 and
1:400 respectively and incubated at 4°C. After 3 h, 700 pi of ice-cold PEG-6000
(6%) was applied and the bound label separated from free by centrifugation at 1,500
x g for 25 min at 4°C. Non specific binding was typically <10% and <5%
respectively. Standard curves were generated in the range of 25 to 512 pmole/tube
using cAMP as standard. Assayed cAMP content was determined by interpolation
from the % Bound counts versus log cAMP concentration curve or its logit
transformation, generated using the respective algorithm of the Packard Cobra
autogamma analysis package. Specific bound counts were typically 35% of total
counts applied. Percent bound counts (%B) is defined as:
X-NSB
B0-NSBX 100/o
Where X = cpm for standard/unknown sample, B0 = cpm in absence of cAMP, and
NSB is the non-specific cpm.
Logit % B is defined as:
%B
log100-%B
[3H]-Arachidonic acid release measurements
The release of [3H]-AA from pre-labelled cells in culture was measured by reverse
phase liquid chromatography on octadecyl silica cartridges (ODS) (Sep-Pak C-is
cartridges) using the solvent system described by Powell (1982). aT3-1 cells were
grown and sub-cultured as previously described The culture medium was removed
and replaced with fresh pre-warmed MEM containing 0.5 pCi of [5, 6, 8, 9, 11, 12,
14, 25-3H(N)]-arachidonic acid (specific activity approximately 250 Ci/mmol). The
cells were incubated for 18 hours at 37°C under a humidified atmosphere of 95%
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air/5% CO2. The cells were then washed three times in MEM containing 1% bovine
serum albumin (BSA; essentially fatty acid free).
After washing, the cells were incubated in MEM + 0.5% BSA (as a trap for released
[3H]-AA). Where required inhibitory drugs were added directly to the plate from 100X
concentration stocks for 10 min before the medium was aspirated and replaced with
fresh medium containing either no drug (basal) or LHRH (100 nM unless otherwise
stated) and the relevant inhibitors. When appropriate dimethylformamide was
present at 0.03% (v/v). This concentration of vehicle was shown to have no effect on
arachidonic acid release. After incubation for 15 min with the pharmacological
agents, the incubation medium was removed and placed in 2 ml ice-cold ethanol and
3.7 ml of distilled H2O was added (to give a final ethanol concentration of 30%) and
this was retained for [3H]-AA determination. The cells were washed twice in pre-
warmed and pre-gassed MEM + 1% BSA, then a final aliquot of pre-warmed and pre-
gassed MEM + 0.5% BSA was added to each. The cells were scraped into the
medium and added to 2 ml of ice-cold ethanol and was then diluted with distilled
water to give a final ethanol concentration of 30%.
Both the cell homogenates and the medium were centrifuged (10', 4°C, 3000 x g)
and the supernatant from each was retained and acidified to pH 3 with 1 M HCI. To
measure medium and tissue [3H]-AA levels, a 4 ml aliquot of the acidified
supernatant from each was loaded onto an ODS column (pre-washed with 5 ml
ethanol followed by 5 ml of dH20). Solvents were then passed through the columns
in the following order:
(a) 30% ethanol (20 ml) to elute polar substances such as polar lipids
(b) distilled H20 (20 ml) to remove the ethanol
(c) petroleum ether [BP 60-80°C](10 ml) to remove the water
(d) petroleum ether: CHCI3 (1:1, 20 ml) to elute fatty acids
(e) methyl formate (10 ml) to elute prostaglandins and leukotrienes.
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A 4 ml aliquot of the petroleum ether: CHCI3 fraction was allowed to evaporate off
overnight, then the radioactivity in the radioactivity in each sample was determined
by liquid scintillation counting. The radioactivity in 200 pi samples of the acidified cell
homogenate and of the incubation medium supernatants was also determined to
give a total amount of label incorporated into the cells. The amount of [3H]-AA
released could then be expressed as a percentage of the total amount incorporated
into the cells thus: dpm in 200 (il supernatant + 200 |il cell homogenate (X 20) = dpm
in 4 ml (total radioactivity applied to the column); dpm in 4 ml of the petroleum ether:
CHCI3 fraction (X5) = dpm in 20 ml eluted from column (total radioactivity eluted from
column).
total radioactivity applied to column
total radioactivity eluted from column
Experiments with addition of authentic [3H]AA after cell homogenisation showed that
>80% of [3H]-AA detected was found to be in fraction (d) (the petroleum ether: CHCI3
fraction) as shown in Figure 2.7a This correlates with observations made by Powell
(1982) who showed that, whereas the more polar phospholipids were probably
passed through the column without being retained, fatty acids, such as [3H]-AA, and
monohydroxy fatty acids were eluted by mixtures of petroleum ether and CHCI3.
Methyl formate (fraction e) can elute prostaglandins and thromboxanes from the
column. There was some evidence (Figure 2.7) that LHRH treatment of aT3-1 cells
additionally increases formation of these AA metabolites. LHRH treatment did not
appear to significantly increase the levels of radioactivity in the solvent fractions of
the cell homogenates (Figure 2.7 b). However the results must be used with
restricted interpretation as it is unclear as to how measurements of total cellular [3H]-
AA levels reflect changes in pools relevant to receptor-operated PLA2. Internal
positive controls were incorporated in each experimental design.
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[3H]inositol phosphate measurement
aT3-1 cells were grown and sub-cultured as before in 12-well plates, then normal
growth medium was removed and replaced with 0.5 ml/well Earles Balanced Salt
solution (EBSS) containing 10 mM glucose and 0.2% w/v BSA with myo-[3H]inositol
2 pCi/well and incubated for 16 h under 95/5% O2/CO2. After washing, 10 mM LiCI
was added for 15 min before stimulation with agonist for 30 min. Incubations were
stopped by aspiration and the addition of 700 pi cold 1.34 M trichloracetic acid before
assaying. Following centrifugation of cell homogenates at 12,000 x g for 5 min at
4°C, aliquots of supernatant were transferred to tubes containing 50 pi EDTA (pH
7.0) and 500 pi 1:1 1,1, 2-trichloro-trifluoro-ethane: tri-N-octylamine for solvent
extraction of labelled phospholipids. After extensive vortexing and centrifugation at
12,000 x g for 5 min (4°C), 300 pi aliquots of the upper aqueous phase were added
to 200 pi 1M NaHC03 with Universal indicator and adjusted to pH 8. Labelled
hydrophilic inositol-containing compounds were separated on 1 ml columns of
Dowex 1 x 8 (formate, mesh size 200-400).The columns were washed extensively
with water before sample application and then 20 column volumes of water, 5
column volumes of 1 M ammonium formate, 0.1 M formic acid were applied to elute
unmodified inositol phosphates respectively.
Translocation of PKC (monitored as pHJPDBu binding sites)
Cytosolic [3H]PDBu binding was performed in a method similar to that described by
Leach et al 1983. After stimulation for 15 min in culture flasks, the medium was
aspirated and cells were scraped into 0.5 ml of ice-cold 'Kuo' buffer (20 mM Tris-HCI
(pH 7.5) 50 mM 2-mercaptoethanol, 2 mM EDTA and 1 mM [4-(aminoethyl)
benzenesulphonyl fluoride] (AEBSF) containing 0.01% leupeptin and 20 pM
transepoxysuccinyl-L-leucylamido-(4-guanido) butane (E 64) and homogenised.
Samples were centrifuged (38,000 x g , 20 min, 4°C). The supernatant and pellet
were carefully separated and the pellet rehomogenised in 0.5 ml 'Tris-BSA' (50 mM
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Tris-HCI, pH 7.4), 4 mg/ml essentially fatty acid-free bovine serum albumin. While
membrane binding was carried out in Tris-BSA, cytosolic binding assays additionally
contained 1 mM CaCl2 and 75 mM magnesium acetate and 1.25 mg/ml sonicated
phosphatidyl serine, sodium salt (Lipid products Ltd, Nuffield, UK) [Leach et al,
1983]. Assays were conducted in a total volume of 250 jxl (30 min, 37-C), with 5 nM
[3H]PDBu (approximately 0.03 pCi per assay tube) and DMF (0.5% final
concentration) or 10 pM PDBu in DMF for total and non-specific binding
measurements, respectively. Tissue samples gave a total binding of less than 10%
of total radioactivity present. Protein was precipitated at 4°C by the addition of 100 pi
of 12 mg/ml bovine y-globulin and 300 pi of 24% polyethyleneglycol 8000 in 50 mM
Tris-HCI (pH 7.4). After 20 min, assay tubes were centrifuged (12,000 x g, 5 min,
4°C), the supernatant aspirated and the 3H radioactivity in each pellet determined
after solubilisation.
[125l]buserelin binding measurement
The equilibrium binding assay uses the LHRH agonist [125l]buserelin and is carried
out essentially as described in Mitchell et al 1988. Cells from each 75cm2 culture
flask were scraped into 20 ml ice-cold 25 mM Tris HCI pH 7.4, homogenised and
centrifuged (38,000 x g for 20 min at 4°C). The membrane pellet was resuspended
in ice-cold 25 mM Tris HCI pH 7.4 containing a final concentration of 0.1% BSA.
Aliquots of 100 pi were assayed using approximately 130,000 dpm of [125l]buserelin
per assay tube. The ligand specific activity was approximately 200-300 Ci/mmol.
After 90 min on ice, membranes were pelleted by centrifugation (14,000 x g for 10
min at 4°C) and the supernatant carefully aspirated. Non-specific binding (in
presence of 3 pM LHRH) was in the range of 7,000-11,000 dpm per assay tube. The
affinity of the binding sites for [125l]buserelin (expressed as IC50 values) was
estimated in a self-displacement assay using unlabelled buserelin in the range of
0.03-30 nM. Data were fitted by a non-linear error-weighted procedure (P-fit,
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Elsevier Biosoft) to give best-fit IC50 values and then the Bmax values were
calculated by the method of Swillens [Swillens, 1992].
Transfections
Preparation of cDNA
The mouse LHRH receptor cDNA [Tsutsumi et al, 1992] was inserted into the
expression vector pcDNA neomycin (clone SCS-56). The mutant LHRH receptors
(generated in pSelect by oligonucleotide-directed mutagenesis; [Zhou et al, 1994])
were prepared in pcDNA/AMP (Invitrogen, San Diego, USA). The 5-HT2C receptor
cDNA (PMVR7SRIc, a gift from Dr D Julius [Julius et al, 1988] was prepared as in
Lutz et al 1993. The metabotropic glutamate receptor (mGlu 1a) cDNA, pmGRI, a
gift from Professor S Nakianishi [Masu et al, 1991] was digested with BamH1 and
Not1 and the 4.65 Kb insert excised from agarose gel using the Pharmacia
Sephaglas kit. This was subsequently subcloned into pcDNAI (InVitrogen). All
cDNA used for expression in host cells was purified first through CsCI density
gradients.
DEAE dextran (method for transient transfection of cells)
COS 7 cells were grown and maintained in DMEM supplemented with 10% newborn
calf serum and penicillin/streptomycin. Cells were trypsinised and replated at -50%
confluency into 75 cm2 flasks on the afternoon prior to transfection.
During the morning of transfection, the cells were washed 2x5 min with pre-warmed
OptiMEM supplemented with 100 U/ml each of streptomycin and penicillin at 37°C
before exposure to transfecting medium for 4 h. The transfecting medium consisted
of OptiMEM/streptomycin/penicillin, 400 |ig/ml DEAE dextran (Promega), 100 pM
chloroquine phosphate (Sigma) and 10-20 ^g of plasmid containing pcDNA, with a
1.2 Kb EcoR1/Xho1 fragment of the mouse GnRH Receptor cDNA, full coding
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sequence, per flask. This was replaced with 10% DMSO in PBS for 2 min, then
DMEM/2% UltroSer G/penicillin/streptomycin. Cells were grown for 24 h, then
trypsinised and re-plated. Cells were harvested 48 h later.
DOTAP method for transfection
In order to produce a stable cell line expressing functional LHRH receptors, CHO
cells were grown and maintained as described previously until reaching 60-80%
confluency prior to transfection. The cells were incubated overnight in the
transfection medium containing; OptiMEM streptomycin/penicillin, DOTAP, 20
pig/dish pcDNA, incorporating a 1.2 Kb EcoR1/Xho1 fragment of the mouse GnRH
Receptor cDNA, and a neomycin resistance gene. The following day the medium
was replaced with Hams F12 supplemented with 2% UltroSer G and
streptomycin/penicillin (100 U each) for -24 h, when the medium was again replaced
with fresh medium also containing the neomycin analogue, geneticin (500 pg/ml).
Cells were selected one month later by placing cloning rings over individual colonies
in order to remove and replate them. Finally the cells were assessed for expression
of functional LHRH receptors by equilibrium binding of [125l]buserelin (an LHRH
receptor agonist), according to previously described procedures [Mitchell et al, 1988].
Transfection of antisense oligonucleotides using Lipofectamine™
Antisense oligonucleotides were usually supplied as a lyophilised powder and were
resuspended in sterile dH20 according to the manufacturer's instructions then
aliquoted and stored at -20°C. Any further dilutions before use were in sterile
OptiMEM. Approximately 24 h prior to transfection aT3-1 cells were split and re-
seeded into 12 well plates (-15,000 cells/ml) in normal growth medium and allowed
to reach 60-70% confluency. Solutions were prepared for transfection in 200 jxl/ml
OptiMEM (Gibco) with 20 pi lipofectamine™ reagent (Gibco) ± 100 pi of the
oligonucleotide solution (10 pM). Liposomes were allowed to form for 45 min at
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room temperature with gentle agitation then made up to 1 ml with warm OptiMEM.
During the morning of transfection the ocT3-1 cells were washed 2x5 min with pre-
warmed OptiMEM at 37°C before exposure to transfecting medium for 14-24 h. The
transfection medium was aspirated and the cells washed 2x5 min with OptiMEM
then incubated in normal growth medium for a further 24-48 h at 37°C before being
assayed or harvested for immunoblotting.
Protein assays
Where protein content was required to be determined in the following studies a
Pierce protein assay kit (Pierce, Chester, UK) was used. This method uses an assay
reagent based on the Bradford method (1976) consisting of Coomassie Blue G-250,
phosphoric acid, methanol, water and solubilising agents. When Coomassie Blue
binds to proteins in an acidic solution, an absorbance shift from 465 to 595 nM
occurs [Davis, 1988]. A standard curve for protein concentration determinations was
constructed in microtiter plates in a total volume of 300 pi within the range of 75-1500
pg/ml with a standard solution of BSA (essentially fatty acid free, 2 mg/ml, Pierce) in




Effects of various agents (added during the assay) on constitutive MAP kinase
activity from rat hippocampus cytosol extract
Table 1
Effects of various protein kinase inhibitor directly on MAP kinase activity from
rat hippocampus
The hippocampus was immediately removed from decapitated rats and
homogenised in 2-3 vol of MAP kinase homogenisation buffer: 20 mmol Tris/I; 12
mM EDTA/I, 50 mM 2-mercaptoethanol (EtSH)/l, 1 mM [4-
(aminoethyl)benzenesulphonyl fluoride (AEBSF)/I, pH 7.4 with HCI, containing 0.01%
(w/v) leupeptin, 20 pM trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane/l, 2
mg aprotinin/l, 1 pM pepstatin/l, 2.5 mM NaaVCVI, 62.5 mM p-glycerophosphate/l
and 200 nM okadaic acid. The supernatant fraction was collected after
centrifugation, 6000 x g, 45 min. The 25 pi assay finally contained 20 mM Tris/I, 0.5
mM EGTA/I, 2.4 mM EDTA/I, 20 mM MgCI2/l, pH 7.5 with HCI, with 50 pM NaF/l, 50
mM EtSH/l and 200 nM okadaic acid/I as well as the other peptidase and
phosphatase inhibitors diluted 1 in 5 from their concentrations in the 5 pi aliquot of
cytosolic extract added to the assay. Substrate peptide (APRTPGGRR; Clark-Lewis
et al. 1991) was used at 2 mmol/l. Substrate-free blanks were determined in all
cases. Assays were started with 100 pM of ATP-y[35S]/l (containing 0.58 pCi ATP-
y[35S]/tube) and brief centrifugation.
Tubes were incubated for 40 min at 30°C (within the linear range of the assay).
Incubations were stopped by addition of 25 pi ice-cold trichloroacetic acid (120 g/l)
and 10 pi bovine serum albumin (20 g/l). After 15 min on ice, samples were
centrifuged (12000 x grfor 5 min at 4°C), then 30 pi aliquots were spotted onto 4 cm2
pieces of P81 phosphocellulose paper. Papers were washed for 3 x 2 min in -10 ml
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of H3PO4 (75 mM) and dried before scintillation counting. Specific MAP kinase
activity was defined by subtracting the substrate-free blanks which were generally
less than 25% of values with substrate and were unaltered by any of the present
treatments. All determinations are means ± SEM where n=>6.
Table 2
Effects of phorbol esters and a related activator of PKC (added during the
assay) on constitutive MAP kinase activity from rat hippocampal cytosol
To determine whether phorbol esters or a related compound could directly activate
MAP kinase in vitro, the hippocampus was immediately removed from decapitated
rats and a crude cytosolic preparation was prepared as described above. Aliquots of
the cytosolic fraction were included in the MAP kinase activity assay described
above with the inclusion where appropriate of 4a-phorbol 12,13-dibutyrate (4a-
PDBu), 4p-phorbol 12,13-dibutyrate (4p-PDBu), mezerein and phorbol 12-myristate
13-acetate (PMA) at 1 or 10 pM for 40 min, substrate-free blanks were determined in
all cases. Thereafter the reaction was terminated as above. All determinations are
means ± SEM where n=>6.
Table 3
Effects of phosphatase treatment on the constitutively-active MAP kinase
activity from rat hippocampal cytosol
To determine that MAP kinase activity was dependent on phosphorylation of the
enzyme, aliquots of the crude cytosolic fraction of rat hippocampus were prepared as
above, and then assayed after a 20 min incubation, at 37°C with either no addition,
0.3 U sweet potato acid phosphatase per 200 pi aliquot, or phosphatase in the
presence of 10 mM sodium pyrophosphate (more than 10 X the Kj for sweet potato
acid phosphatase). Pyrophosphate was added to the same concentration in the
other samples prior to assay. Reactions were terminated and MAP kinase activity
determined as before. All determinations are means ± SEM where n=>6.
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table 2
Treatment Concentration specific [35S]thiophosphorylationof APRTPGGRR (as % control)
4 a-PDBu
1 pM 109 ± 14
10 pM 118± 12
1 pM 83+15
4 p-PDBu
10 pM 99 ±11
1 pM 88 ± 11
mezerein
10 pM 74 ± 5
1 pM 104 ±5
PMA
10 pM 91 ±6
table 3
Preincubation specific [35S]thiophosphorylation of
APRTPGGRR (dpm per assay)
control 1440 + 152
0.3U sweet potato acid phosphatase 388 ±226
phosphatase + 10 mM pPi 1517 + 215 j
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APPENDIX 2
Preparation of stripped foetal calf serum
Removal of thyroid hormones
Dowex 1 x8-400 resin (chloride form) was washed extensively in distilled water, then
passed through a 0.22 pm filter. The resin was then incubated with heat-inactivated
foetal calf serum (100 mg wet wt/ml serum) for 5 h on a rotor. The resin was
removed by centrifugation (1000 x g, 10 min). Fresh resin was added to the
supernatant (100 mg wet wt/ml serum) then incubated for 15-18 h at room
temperature. The resin was removed by centrifugation (1000 x g, 10 min) followed
by passing the supernatant through a 0.8 pm filter.
Removal of steroids
Activated charcoal was mixed with distilled H20 and centrifuged (3000 x g) for 20
min. The water was discarded and the charcoal was incubated with the thyroid
hormone-stripped foetal calf serum (0.02 g wet wt/ml serum), initially at 37°C for 40
min followed by 30 min at 55°C. The charcoal was removed by centrifugation (10
min, 300 x g) followed by passage through filters of 0.8 pm, 0.45 pm and 0.22 pm in
succession.
Steroid-free DMEM
Phenol red free DMEM was obtained from Gibco BRL. This was additionally
supplemented with sucrose (also from Gibco BRL) to give a final concentration of
4500 g/l which is equivalent to the sucrose concentration in the standard DMEM
preparation . Penicillin and streptomycin were added to give a final concentration of
100 U/l and 0.1 mg/ml respectively. Stripped foetal calf serum was added to give a
10 % final concentration. All additions were under aseptic conditions.
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APPENDIX 3
lodination of cAMP using the lodogen™ method
Labelling of cAMP with 125lodine for use in radioimmunoassay was performed using
the lodogen™ method essentially as described by Salacinski, McLean, Sykes et al
(1981). lodogen™ coated polypropylene 1.5 ml conical eppendorf centrifuge tubes
(Sarstedt) were prepared by adding 50 pi of 0.04 mg/ml lodogen (Sigma) in
dichloromethane which was evaporated to dryness in a 37°C water bath in a fan
extraction fume hood. 2'-0-monosuccinyl cAMP tyrosyl methyl ester (Sigma, cAMP)
was stored in aliquots at 25 pM in dh^O at -70°C before use.
Five microlitres of Na 125l (ICN Radiochemicals, Irvine, CA, USA) containing 0.5 mCi
(-0.25 nmol Na 125l) were incubated with 0.25 nmol of cAMP-TME in a total volume
of 50 pi in 0.5 M sodium phosphate buffer pH 7 in an lodogen™ coated tube. After
12 min at room temperature the reaction was terminated by the addition of 1 ml 0.1%
trifluoroacetic acid (TFA) and applied to a Sep-Pak C-is octadensilyl (ODS) cartridge.
The cartridge was washed with three 2 ml aliquots of 0.1% TFA followed by 2 ml
each of a stepwise gradient of methanol (10-80%) containing 0.1 % TFA. Free iodine
elutes in the initial wash, the 20% fraction was used in the cAMP radioimmunoassay.
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Figure 2.1
Flow diagram of the method used to determine cytosolic MAP kinase activity in




challenge with agonist ± Inhibitor, 10 min
37°, 02/ C02-; 95:5%
\
homogenise in 2 vols, of buffer
(20 mM Tris HCI (pH 7.5),12 mM EDTA, 50 mM 2-EtSH, 0.1 mM AEBSF)
+ 0.01% leupeptin, 20 mM E64, 2 mg/ml aprotinin, 1 mM pepstatin, 2.5 mM vanadate
62.5 mM (3-glycerophosphate + 200 nM okadaic acid
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20 mM Tris. HCI (pH 7.5)
0.5 mM EGTA
20 mM MgCI2
± 2 mM MAPK substrate peptide
(in 5 pi Tris-EGTA buffer + 250 pM NaF,
200 mM 2-EtSH +800 nM okadaic acid)
50 (J.M ATPyS/ATPy^S
I
reaction started with bench-top centrifuge, then 40 min, 30°C
\
stop with addition of ice-cold 12% TCA + 20 mg/ml BSA
\
spin (5 min, 16000 x g 4°C)
\
spot 35 (il snt. onto 4 cm2 P81 cellulose phosphate paper
wash for 3 x 2 min in 75 mM H3PO4,
dried and counted by liquid scintillation counting
Figure 2.2
Cytosolic MAP kinase activity in pellet and supernatant fractions of aT3-1 cells
treated with nil, LHRH or PDBu after immunoprecipitation with anti ERK (1 and
2) or anti p-tubulin antisera
aT3-1 cells were treated as in protocol for anti MAP kinase immunoprecipitation then
pellet (P) and supernatant (S) fractions were included in a cytosolic MAP kinase
assay
[3 5S]thiophosphorylation
of the substrate peptide (dpm x 103)

















Flow diagram of methodology for the cAMP radioimmunoassay
cxT3-1 cells
I
incubate in MEM + 0.1% BSA + 0.5 mM IBMX
15 min, (37°, 02/ C02-; 95:5%)
\
challenge with ± forskolin ± agonist ± inhibitors
10 min, (37°, O2/ C02-; 95:5%)
\
aspirate, then addition of 0.5 ml ice-cold 0.1 N HCI
I
freeze-thaw membranes -70°C X 2
scrape and agitate in 0.1 N HCI
*
cAMP radioimmumoassay
samples of homogenate or




in 50 mM sodium acetate buffer, pH 6.0,
0.1% BSA (fraction V), 0.1% sodium azide)
+
-10K cpm of [125l]-cAMP-TME
\
overnight incubation at 4°C
I
Addition of donkey anti-rabbit IgG (final titre 1:40
in 50 mM sodium acetate buffer, pH 6.0,
0.1% BSA (fraction V), 0.1% sodium azide))
+
non-immune rabbit serum (final titre 1:400)
\
incubation at 4°C for 3 h
\
700 pi of ice-cold PEG-6000
bound label separated from free by centrifugation
(1,500 x g, 25 min, 4°C)
\
aspirate supernatant and y-radiation counting
Figure 2.4
Characterisation of primary antisera (RIB 7) used in cAMP radioimmunoassay
(a) cAMP primary antibody (RIB 7) dilution curve
Linear relationship of total bound counts with increasing RIB 7 dilution. Total applied
cpm = 13500 cpm and non specific binding was 350 cpm
(b) cAMP standard curve
cAMP concentration standard curve using RIB 7 at a final dilution of 1:200,00.
















3 x 1 ml MEM + 1% BSA washes
\
resuspend 1 ml MEM + 1% BSA
\
add drugs
(15 min, 37°C, 95% 02/5% C02)
\
remove medium
medium in 30% ethanol
adjust to ~pH 3
\
aT3-1 cells
wash 3 x 1 ml
MEM + 1% BSA
octadeclysilyl cartridges \
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(10 min, 4°C, 3000 x g)
\
remove supernatant




Typical example of the levels of radioactivity in solvent fractions from (a) the
medium and (b) the cell homogenate from control and LHRH treated aT3-1
cells
aT3-1 cells were incubated in medium containing either no drug (basal) or LHRH
(100 nM) for 15 min. The radioactivity in the solvent fractions of the medium (a) and
cell homogenate (b) from each treatment was determined. The fractions are as
follows; a: distilled H20; b: 30% ethanol; c: petroleum ether; d: petroleum
ether:CHCl3 (1:1); e: methyl formate; f: 100 % ethanol. Values are means ± SEM for
4 determinations.



































PROTEIN (MAP) KINASE BY THE LHRH
RECEPTOR IN aT3-1 CELLS
3.1 INTRODUCTION
Mitogen-activated protein kinase appears to be expressed ubiquitously and
represents a common point of convergence for a wide range of signals originating
from numerous cell surface receptors [Sturgill & Wu, 1991]. The transduction of a
mitogenic signal from the membrane to the nucleus by growth factor receptors (eg
the epidermal growth factor (EGF) receptor) which have intrinsic tyrosine kinase
activity is now well defined (as examined at greater length in the main introduction)
and involves the formation of a membrane-associated multi-protein complex which
catalyses the GTP-exchange and resulting activation of a low molecular weight G-
protein Ras [Aronheim et al, 1994], Functional activation of GTP-liganded Ras
seems to be required for activation of Raf-1 kinase activity [Dent et al, 1992; Howe et
al, 1992; Kyriakas et al, 1992] which in turn phosphorylates and activates the direct
upstream activator of MAP kinase MEK-1, [Zheng & Guan, 1993]. Activation of Ras
has been postulated to bring Raf-1 into the proximity of the membrane for a second
regulatory event [Leevers et al, 1994]. Alternatively activators of PKC (such as
phorbol esters) [Kazlauskas & Cooper, 1988; Nori et al, 1992] or a direct G-protein
activator, fluoroaluminate [Anderson et al, 1991], have been reported to activate
MAP kinase. More recently it has been reported that a number of receptors coupled
to heterotrimeric G-proteins can stimulate MAP kinase activity. The signalling steps
involved at present are less clearly defined than that of growth factor receptors and
were unpublished at the onset of this study, hence this area will be considered in
more depth in the discussion of this chapter.
Although the LHRH receptor is not commonly associated with mitogenesis [Batticane
et al, 1991], in light of the diversity of events which MAP kinase regulates and the
ability of agents which activate PKC or G-proteins to stimulate MAP kinase, it is
possible that MAP kinase may participate in this receptors downstream signalling (as
activation of the LHRH receptor results in phosphoinositide hydrolysis, Ca2+
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mobilisation and activation of PKC [Stojilkovic et al, 1994]). Furthermore there is
also a few reports that MAP kinase is involved in secretion [Kanda et al, 1994;
Offermans et al, 1994a; Ohmichi et al, 1994; Williams, 1995], which is the main
endpoint of LHRH action on pituitary cells. In order to monitor stimulus-induced MAP
kinase activity we have developed an in vitro assay measuring [35S]
thiophosphorylation of a selective peptide substrate containing the target motif
characteristic of MAP kinases [Mitchell et al, 1994; Mitchell et al, 1993; Sim et al,
1994] and used an electrophoretic mobility shift assay to determine phosphorylation
of p42 and p44 MAP kinase. Using a number of pharmacological agents we have
determined that the LHRH receptor is capable of both phosphorylating and activating
MAP kinase and have attempted to further resolve this novel signalling cascade.
3.2 RESULTS
Employing the [35S]thiophosphorylation assays described in Chapter 2, the
potential activation of MAP kinase in the aT3-1 gonadotroph cell line was
investigated over a time course of 0-120 min with 100 nM LHRH (Figure 3.1).
After a short lag of approximately 2 min, MAP kinase activity increased rapidly,
reaching a peak by 10 min that represented an increase to 245 ± 9% of basal
activity ( mean ± SEM, n=6). This increased activity remained elevated for
approximately 40 min, gradually declining thereafter leaving a significant residual
activation at 120 min. LHRH-induced MAP kinase activity was concentration-
dependent (Figure 3.2a), being nearly maximal by 100 nM LHRH and showing an
apparent EC50 value (the concentration required for 50% of maximal activation) of
3.4 ± 0.4 nM. This value was comparable to that for LHRH-induced inositol
phosphate formation in this cell line which was 2.8 ± 0.3 nM [Sim et al, 1995].
LHRH-induced activity was competitively inhibited by a highly selective LHRH
antagonist [Ac-D-p-CI-Phe1 •2, D-Trp3, D-Arg6, D-Ala10]LHRH [Humphries, 1978],
over a concentration range of 0.3 - 3000 nM with an IC50 of 38.2 ± 13 nM
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antagonist (Figure 3.2b), confirming that the evoked activity was a specific result
of LHRH receptor activation. The antagonist alone had no effect on MAP kinase
activity.
A protein kinase C (PKC) activator 4p-phorbol-12,13-dibutyrate (PDBu, 1pM)
could partially mimic the LHRH-induced increase in activity (Figure 3.1). The
effect of PDBu peaked slightly earlier than that of LHRH to 197 ± 13% of basal
activity between 5-8 min (mean ± SEM, n=6) but had returned to basal levels by
60 min in contrast to the LHRH-stimulated activity. This effect was also
concentration-dependent (50 ± 8 nM, 8 min; mean ± SEM, n=6) being nearly
maximal at 1 pM PDBu and was again shown to be specific as it was not
mimicked by the inactive isomer 4a-PDBu; 0-10 pM; 8 min; maximum activity 110
± 9% of basal, n=6 (Figure 3.3a). With the exception of epidermal growth factor
(EGF), no other potential activator tested including sphingosine and ceramide was
seen to significantly increase MAP kinase activity in these cells (results not
shown). Basal (unstimulated) levels of MAP kinase activity in these cells
remained constant throughout an equivalent time course measured for all
agonists and were on average a mean value of 4000 dpm per assay tube
compared to stimulated counts in the region of 4500-13000 dpm per assay tube.
Non-specific counts were never more than 1500 dpm per assay tube. For all
subsequent experiments using aT3-1 cells, MAP kinase activity was elicited by
100 nM LHRH and 1pM PDBu at 10 and 8 min respectively. The specificity of this
assay for MAP kinase activity was monitored by immunoprecipitation with a
monoclonal anti-p42/p44 antibody and is described in full in Chapter 2.
Having firmly established an LHRH-induced activation of MAP kinase a number of
other approaches were used to further determine elements of this signalling
cascade. The effect of number of selective PKC inhibitors was studied. LHRH-
elevated activation appears to be dependent on PKC since the response was
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effectively inhibited by all the PKC inhibitors examined (Figure 3.4a). IC50 values
(the concentration required to inhibit 50% of the maximal response) for inhibition
by GF109203X [Toullec et al, 1991], Ro 31-8220 [Davis et al, 1989] and H7
[Nakadate et al, 1989], of LHRH-induced MAP kinase activity were 1.8 ± 0.12,
0.64 ± 0.08 and 168 ± 12 |iM (mean ± SEM, n=6) respectively. These values are
consistent with other known PKC mediated responses, especially in anterior
pituitary tissue [Johnson et al, 1992]. In addition, when compared to a control set
of cells, 92 ± 10% (mean ± SEM, n=4) of the LHRH-induced activity was inhibited
when phorbol ester-sensitive isoforms of PKC were down-regulated by an 18h
exposure to 300 nM PDBu. Control cells were exposed to vehicle (0.3% DMF)
over the same time period (Figure 3.3b).
As anticipated, GF109203X, Ro 31-8220 and H7, also strongly inhibited PDBu-
induced MAP kinase activity and this data is shown in Figure 3.4b. The IC50
values are 0.26 ± 0.02, 0.57 ± 0.03 and 43.5 ±5.1 (iM respectively (mean ± SEM,
n=6). All inhibitors were incubated with the cells for 2 min before addition of
LHRH and where appropriate vehicle alone was added to a control flask. At
nearly maximal concentrations (5 and 1 and 300|iM for GF109203X, Ro-31 8220
and H7 respectively) none of the inhibitors had any effect on basal MAP kinase
activity in aT3-1 cells and had previously been shown to have no direct effect on
MAP kinase when included together with a crude cytosolic preparation of
hippocampus tissue in an in vitro activity assay of MAP kinase (see Appendix 1).
A potential involvement of tyrosine kinases was also investigated. The tyrosine
kinase inhibitors genistein [Akiyama & Ogawara, 1991] and N-methyl 2, 5-
dihydroxycinnamate (MDC) [Isshiki et al, 1987] inhibited the LHRH-induced MAP
kinase response with apparent IC50 values of 15 ± 0.6 pM and 33 ± 7 pM
respectively.
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Pre-treatment with pertussis toxin has been shown to inactivate G-proteins of the
Gj/o class by catalysing the ADP-ribosylation of a specific cysteine residue in the
a-subunit of the heterotrimer thus preventing receptor interaction and the
consequent GDP/GTP exchange [Milligan, 1988]. Preincubation for 15-18 h has
been shown to be fully adequate for down-regulation of any pertussis toxin-
sensitive G-proteins in this way [Milligan, 1988]. In Figure 3.6a, treatment of aT3-
1 cells for 18 h with pertussis toxin in the range of 3-300 ng/ml clearly inhibited
LHRH-induced MAP kinase activity. A maximum inhibition of approximately 75%
was seen at the highest concentration used and the IC50 was 32 ± 4 ng/ml (mean
± SEM, n=8). This effect was shown to be specific to the active holotoxin and not
some non-specific consequence such as membrane perturbation (Figure 3.6b) as
under similar conditions, treatment of the cells with either the inactive B-subunit of
pertussis toxin [O'Neill et al, 1992] or N-ethyl maleimide-inactivated holotoxin
[Banga et al, 1987] at a concentration of 100 ng/ml, had no significant effect on
LHRH-induced MAP kinase activity (104 ± 10%, 95 ± 8% of control LHRH
responses respectively. Also shown in Figure 3.4b none of the pertussis toxin
treatments had any effect on basal (unstimulated) activity.
Mastoparan is a peptide activator of G-proteins with reported selectivity for Gj/0
over other G-proteins and hence can be used to monitor Gj/0 action without the
requirement for receptor activation [Gil et al, 1991; Higashijima et al, 1988]
Mastoparan however is known to be toxic at high concentrations and has reported
membrane perturbing effects [Higashijima et al, 1988]. In aT3-1 cells
mastoparan, like LHRH, caused a marked increase in MAP kinase activity at 10
min. This was maximal at 10 pM and represented an increase of 190 ± 9% of
basal activity (mean ± SEM, n=6). Mastoparan had no effect on inositol
phosphate formation in these cells as seen in Figure 3.7a at concentrations up to
12.5 pM. The concentrations used here are similar to those used by other
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laboratories in apparently Gi/0-specific responses [Gil et al, 1991; Higashijima et
al, 1988].
Mastoparan-induced MAP kinase activity was substantially inhibited by pre-
treatment with pertussis toxin (60 ± 4%; 100 ng/ml) but not by the PKC inhibitor
GF109203X (12 ± 0.9%, 3pM, mean ± SEM, n=4) as shown in Figure 5.3b Figure
3.5b. In contrast, PDBu-induced activity was essentially prevented by
GF109203X as expected and was unaffected by pertussis toxin (85 ± 7% and 10
± 2% respectively; mean ± SEM, n=6). These data would suggest that the PKC
activation necessary for LHRH action was not downstream of Gj/0 derived Py
subunits activating PLC p2 or 3, but more likely a result of Gq/i 1 -mediated
stimulation of PLC pi. It would also precludes the possibility that the pertussis
toxin sensitive component was executed downstream of PKC rather than by direct
receptor interaction. The combination of PDBu and mastoparan caused greater
MAP kinase activation than either alone (Figure 3.7b). From the data obtained
under these conditions it is not possible to determine whether the interaction
between the two effects is cumulative or additive although no evidence for
synergy was observed.
In order to confirm the results with the MAP kinase activity assay an independent
technique was applied, MAP kinases are activated by phosphorylation on both a
tyrosine and threonine residue by dual specificity kinases, therefore the
phosphorylation-induced gel mobility shift in immunoreactive p42 and p44 MAP
kinases can be monitored as an index of their activation [deVries et al, 1992]. Figure
3.8 shows both p42 and (to a lesser extent) p44 species displayed a component of
reduced electrophoretic mobility after LHRH stimulation for 10 min. This effect was
concentration-dependant with a shift already detectable at 1 nM, being maximal at
10-100 nM LHRH Figure 3.8a). The increase in LHRH-induced MAP kinase
phosphorylation is detectable after 2 min, reached a maximum at 5-10 min and
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remains elevated for at least 60 minutes (Figure 3.8b). Treatment of the cells with
PDBu (1 |llM) also resulted in phosphorylation of p42 and p44 MAP kinase Figure
3.8c). It is apparent that the entire pool of MAP kinase present in aT3-1 cells was
not completely phosphorylated to the active form in these conditions. Confirming the
thiophosphorylation data, both the PKC inhibitor GF109203X (3pM; Figure 3.9) and
since we shown with the in vitro kinase assay a potential role for a tyrosine kinase
involvement during LHRH action in aT3-1 cells, this was further investigated. The
tyrosine kinase inhibitors genistein and to a lesser extent piceatannol [Gaehlen and
McLaughlin, 1989] inhibited the LHRH-induced shift in mobility of immunoreactive
MAP kinase (Fig. 3.9). Piceatannol and genistein also inhibited PDBu-induced
tyrosine phosphorylations and MAP kinase activation, suggesting a putative role for
tyrosine kinases downstream of PKC (data not shown). The tyrosine phosphatase
inhibitor pervanadate [Grinstein et al 1990] also stimulated MAP kinase
phosphorylation and hence reduction in mobility (although not to the extent of LHRH
or PDBu), further implying a requirement for tyrosine phosphorylation in MAP kinase
activation. This effect was also more prominent in the presence of LHRH (100 nM)
which may also imply that LHRH-induced phosphorylation and activation is
dependent on dual signalling input.
Pertussis toxin inhibited LHRH-induced phosphorylation and prevented the band shift
(Figure 3.10). U73122 inhibits activation by interfering with G-protein coupling,
because it prevents agonist- but not ionomycin-induced inositol phosphate
responses in neuroblastoma cells [Thompson et al, 1991]. On the other hand,
neomycin binds to phosphatidylinositol 4,5-bisphosphate and interferes with its
hydrolysis by agonist-activated PLC [Slivka & Insel, 1988]. These two agents
prevented the band shift implying a requirement for the products of PI hydrolysis




The evidence presented in Chapter 3 clearly demonstrates a marked and sustained
phosphorylation and activation of p42 and p44 MAP kinase by the LHRH receptor.
This response was highly dependent on PKC action and could be partially mimicked
by phorbol ester. Tyrosine phosphorylation was also required. Inhibition of this
response by pertussis toxin and partial mimicry by mastoparan (in a pertussis
sensitive manner) provided evidence for Gj/0-mediated signal transduction by the
LHRH receptor in addition to the well characterised hydrolysis of phosphoinositide by
PLCp-1 and activation of PKC, mediated by Gq/n [Anderson et al, 1993; Hsieh &
Martin, 1992; Shah & Milligan, 1994; Mitchell et al submitted 1995]. The LHRH
receptor is an unusual member of the rhodopsin family of seven transmembrane-
domain G-protein linked receptors. Recent sequence data have revealed a number
of atypical sequence motifs and the complete lack of a C-terminal tail and hence the
loss of some key potential phosphorylation sites implicated in desensitisation
[Tsutsumi et al, 1992]. This may account for its characteristic resistance to rapid
homologous desensitisation [Davidson et al, 1994b; Fennell et al, 1993] and as
shown here, its ability to interact not only with Gq/n but also Gi/0 and sustain a
relatively long-lasting activation of MAP kinase.
The present results strongly support a hypothesis that the LHRH receptor in aT3-1
cells can interact with multiple G-protein families. MAP kinase phosphorylation was
prevented by two PLCp inhibitors neomycin and U73122 [Bleasdale et al, 1990;
Smith et al, 1990] and pertussis toxin. Mastoparan or pertussis toxin had no effect
on LHRH-induced inositol phosphate production in aT3-1 cells [Sim et al, 1995]
dismissing the possibility that PKC activation arises from Py subunits released from
Gj/o leading to the activation of PLCp 2 or 3. Notably, until this study, there has been
no clear evidence that the LHRH receptor can interact with any other G-protein other
than Gq/n (Figure 3.5) [Stojilkovic et al, 1994], Only one isolated report has
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described partial sensitivity to pertussis toxin of LHRH-induced [3H] inositol
phosphate formation, but that was in the absence of any corresponding changes in
gonadotrophin secretion [Hawes et al, 1993]. However pertussis toxin can
demonstrate some anomalous effects, independent of the attenuation of Gj/0
activation [Banga et al, 1987; Burch et al, 1988; O'Neill et al, 1992], Like the
blockade of LHRH-induced MAP kinase activation here, authentic ADP-ribosylation
of G|/o is seen only with pertussis holotoxin and not with N-ethylmaleimide-treated
toxin or the toxin B-oligomer [Banga et al, 1987; O'Neill et al, 1992],
The present results provide strong evidence for an obligatory role of PKC in MAP
kinase activation, since the response was greatly attenuated by PKC depletion and
was fully blocked by several PKC inhibitors. The use of phorbol ester down-
regulation as a means of assessing PKC involvement nevertheless should be treated
with a degree of caution. Long term treatment with phorbol esters will not only cause
intense activation of phorbol ester-sensitive PKC isoforms which may lead to
numerous secondary effects within the cells, but many other signalling proteins such
as Raf-1, myosin heavy chain kinase, DAG-kinase and a low molecular weight G-
protein Vav amongst others [reviewed in Liscovitch & Cantley, 1994] contain
cysteine-rich motifs which are target sequences for phorbol ester interaction hence
may therefore be affected by this treatment. aT3-1 cells are known to express the a,
e and £ isoforms of PKC at high levels [Johnson et al, 1993a]. Each of these
isoforms displays somewhat varying pharmacological, and probably also targeting
specificities [Martiny-Baron et al, 1993]. However in this present study no attempt
was made to assess the relative contributions of individual isoforms to MAP kinase
activation. On examination of the IC50 values for inhibition by two members of the
bisindolylameide series of PKC inhibitors, GF 109203X and Ro-31 8220, on the
PKC-mediated, LHRH stimulation of MAP kinase activity, in comparison with their
inhibition of the various known isoforms in a cell free assay system, the profile would
suggest involvement of a Ca2+-independent isoform or isoforms, for example PKC-e
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[Martiny-Baron et al, 1993; Toullec et al, 1991]. Compared to various PKC isoforms
in cell free assays [Schaap & Parker, 1990], LHRH stimulated MAP kinase activity
displayed a relative resistance to the inhibitor H7. The IC50 value, 168 ±12 pM, for
this response is nonetheless consistent with a recently characterised Ca2+-
independent PKC isoform found in the anterior pituitary gland of rats [Ison et al,
1993]. It is likely that at the relatively high concentration of PDBu used in these
experiments, uniform activation of all PDBu-sensitive PKCs will occur. Thus a
different PKC isoform or sub-set of isoforms to that of LHRH may well be activated in
these cells which would account for the appreciable differences observed between
the IC50 values for these agents between LHRH- and PDBu-stimulated MAP kinase
activity. Such differences were also observed between PDBu and LHRH in
phospholipase D (PLD) activity also in aT3-1 cells [Fennell et al, 1993] and in the
LHRH or PDBu-induced LH release from anterior pituitaries in vitro [Johnson et al,
1992; Thomson et al, 1993b; Thomson & Mitchell, 1993]. It is also possible that if
PKC is only one of several possible components leading to LHRH-induced MAP
kinase response that the LHRH response may be somewhat less sensitive to PKC
inhibitors than the MAP kinase activation elicited by a PKC-specific stimulus. Long
term exposure to phorbol esters will downregulate the phorbol ester-sensitive PKC
isoforms present in the cells [Hug & Sarre, 1993; Huwiler et al, 1991]. Using this
regime, PKC a, and e have been shown to be fully downregulated in ocT3-1 by 18
hours [Johnson et al, 1993a]. The atypical Ca2+-independent isoform, PKC-£ only
has one cysteine-rich zinc finger domain and is therefore not downregulated by
phorbol esters which require two zinc finger domains for their molecular recognition
[Chen & Murakami, 1992; Ways et al, 1992]. This would make PKC-£ a poor
candidate for the PKC action. However a phorbol sensitive PKC-£ isomer may be
involved since it has been reported that PKC-^ translocates to the membrane as a
result of PMA treatment in human platelets [Crabos et al, 1992] and has been shown
to be downregulated as a result of PDBu-treatment in aT3-1 cells [Johnson et al,
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1993a] Although PKC-C, has been proposed as an essential effector for Ras function
[Dominguez et al, 1992], conflicting reports of PKC £'s role in MAP kinase activation
exist. In Xenopus oocytes, PKC £ is associated with activation of the MEK-MAPK
cascade [Carnero et al, 1995; Diaz-Meco et al, 1994], and this may be required for
proliferation [Diaz-Meco et al, 1994]. However it has been proposed that PKC £ does
not likely mediate Ras-induced signal transduction as PKC ^-mediated activation of
downstream pathways was sensitive to cyclohexamide (CHX), whilst Ras-induced
pathways such as activation of GVDB, MAP kinase or S6 kinase II were insensitive to
CHX [Carnero et al, 1995]. Furthermore in NIH 3T3 cells overexpression of PKC £
did not alter the growth characteristics or transform cells or potentiate Ras-mediated
effects [Crespo et al, 1995b]. The concentrations of agents that were effective in the
present experiments are in line with concentrations used in other laboratories [Buhl
et al, 1995; Cook et al, 1992; Purkiss & Boarder, 1992; Toullec et al, 1991] and taken
together the data indicate an assured role for PKC, but of course do not conclusively
preclude the possibility that some other kinase may be involved in MAP kinase
activation.
The present results suggest a role of tyrosine phosphorylation but at what stage this
is required is unresolved. Immunoblotting experiments showed that aT3-1 cells
contain src and fyn (but not fgr, hck, lyn or yes) [Fennell et al, 1993]. The inhibitor
genistein is known to inhibit several classes of protein-tyrosine kinases including src
and fyn [Akiyama & Ogawara, 1991]. Genistein has now also been shown to inhibit
at higher concentrations, some serine/threonine kinases (ie PKC) [Hollenberg, 1994]
but MDC and piceatannol, which are structurally unrelated to genistein, also
prevented MAP kinase activation. Stimulation of aT3-1 cells with LHRH results in
tyrosine phosphorylation of a number of proteins with molecular weights of 65-75,
125 and 130 kDa in addition to p42 and p44 MAP kinase [Wolbers et al, 1995].
Interestingly this corresponds closely to the weights of a number of proteins which
are tyrosine phosphorylated downstream of the lysophosphatidic acid (LPA) [Hordijk
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et al, 1994]. These tyrosine phosphorylations are probably not all involved in MAP
kinase activation and their function remains unclear at present. An involvement of
both PKC and as yet unidentified tyrosine kinases is similar to the LHRH-induced
PLD activation in cxT3-1 cells [Fennell et al, 1993] and to platelet-activating factor
(PAF)-induced PLD activation in CHO cells [Liu et al, 1994]. In the latter case the
possibility that MAP kinase may be involved in PLD activation was assessed. It was
concluded that these enzymes are activated through a common pathway which acts
in a parallel but not linear sequence.
It is becoming increasingly obvious that MAP kinase can be activated by a wide array
of G-protein linked receptors. These include amongst others, receptors which are
predominantly linked to Gq/n such as Mi and M3 muscarinic, cc-ib adrenergic,
endothelin, angiotensin II, bombesin, TRH, histamine, P2U nucleotide receptors, and
cholecystokinin (CCK)/gastrin receptors [Bogoyevitch et al, 1993; Cazaubon et al,
1993; Crespo et al, 1995a; Duan & Williams, 1994; Ely et al, 1990; Faure et al, 1994;
Hawes et al, 1995; Ohmichi et al, 1994; Pang et al, 1993; Seufferlein et al, 1995;
Wang et al, 1992; Wheeler-Jones & Pearson, 1995]; those that are predominantly
linked to Gj/0 such as the acio adrenergic, M2 muscarinic, D2 dopaminergic and ai
adenosine receptors, chemoattractant C5 and C3 receptors [Albas et al, 1993; Buhl
et al, 1995; Crespo et al, 1994; Faure et al, 1994; Grinstein et al, 1994] and those
that readily interact with both families of G-proteins such as LPA, thrombin and PAF
[Honda et al, 1994; Hordijk et al, 1994; Kahan et al, 1992b].
Receptors that couple to the heterotrimeric G-proteins Gq or Gj can stimulate
phosphoinositide (PI) hydrolysis through the interaction of the cxq or Gj-py subunits
with the p-isoforms of the effector enzyme PI-PLC. PI hydrolysis produces both
inositol 1,4,5-trisphosphate and diacylglycerol, leading to activation of protein kinase
C (PKC), which can also stimulate MAP kinase activity in some cases. However it
now also seems apparent that distinct pathways exist for activation of MAP kinase by
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these different classes of G-protein and these pathways can be distinguished by a
number of characteristics. It now appears that Gq/n signalling to MAP kinase
require a subunit activation of PI-PLCp, are PKC-dependent and are in some
instances Ras independent. In contrast Gj/0 receptor signalling is conveyed by (3y
subunits to Ras with a likely involvement of tyrosine phosphorylation [Hawes et al,
1995].
The responses leading to phosphorylation and activation of MAP kinase following
Gq/11 and especially Gj/0-linked receptors activation often are accompanied by an
increased GTP loading of Ras [Albas et al, 1993; Duan et al, 1995; Hawes et al,
1995; Hordijk et al, 1994; Ohmichi et al, 1994] and are severely attenuated by
overexpression of dominant negative mutant Ras [Crespo et al, 1994; Hawes et al,
1995]. However Ras-independent paths also exist [LaMorte et al, 1994; Van
Renterghem et al, 1994]. This suggests that these Gq/i 1 and Gj/0-mediated
responses are predominantly utilising a conventional Ras-Raf cascade of activation
[Avruch et al, 1994], Proposed alternatives to Raf include: MEK kinase [Lange-
Carter et al, 1993], now known to be involved in the signalling cascades which lead
to activation of the Jun N-terminal kinase/stress-activated protein kinases
(JNK/SAPK) a family of serine-threonine kinases which are closely related to ERKs
[Coso et al, 1995; Minden et al, 1994; Xu et al, 1995] although MEKK can activate
ERKs by overexpression [Minden et al, 1994]; or Mos a Ras-independent pathway
observed in Xenopus oocytes [Posada et al, 1993]. The role of Ras in PKC-
dependent MAP kinase activity is complicated. There have been reports of PKC
acting both upstream and downstream of Ras [De Vries-Smits et al, 1992; Downward
et al, 1990; Harwood & Cambier, 1993; Nori et al, 1992]. Correspondingly, PKC may
inactivate the Ras GTPase-activating protein GAP [Downward et al, 1990],
potentially cause activation of GTP exchange factors [Feig & Schaffhausen, 1994],
and in the case of PKC a and p, may directly phosphorylate the Ras target Raf-1
[Kolch et al, 1993; Sozeri et al, 1992], It is not clear, however, that PKC action on
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Raf-1 actually increases its functional activation of MAP kinase kinase (MEK)
[Macdonald et al, 1993]. It has been proposed that the activation of Ca2+-
independent PKC isoforms (such as e) by the products of phosphatidyl choline-
specific phospholipase C may be capable of Ras-independent stimulation of Raf-1
[Daum et al, 1994], Although TRH promotes both GTP loading of Ras and
phosphorylation of Raf-1, these effects are reported to be PKC-independent but
accompanied by tyrosine phosphorylation of a potential director of Ras activation,
SAjc[Ohmichi et al, 1994], The precise mechanism by which PKC activates Raf-1 is
as yet unresolved and under investigation.
Gj-linked receptor activation seems to be mediated not by the a subunit but by Py
subunits [Faure et al, 1994; Hawes et al, 1995; Luttrell et al, 1995; Van Biesen et al,
1995]. When GTPase deficient as, oq, an subunits (which are rendered
constitutively activate by this mutation) and Py subunits were expressed in HEK 293
cells, only the Py subunits induced phosphorylation of MAP kinase [Ito et al, 1995].
Furthermore, in COS and CHO cells transfected with a2A adrenergic receptor (AR),
stimulation of MAP kinase activity was blocked by expression of the carboxy
terminus-peptide from the p-adrenergic receptor (PARK ct), which sequesters Py
subunits, or dominant negative mutants of Ras (Ras N17) and/or Raf-1 (N*Raf) but
was unaffected by PKC depletion by downregulation. In contrast under similar
conditions the Gq-linked receptors, a1 b AR or Mi were inhibited by downregulation
and expression of N*Raf but unaffected by expression of pARKct or RasN17 [Hawes
et al, 1995]. Also in COS 7 cells, overexpression of Py subunits or PLCP2 (which is
predominantly activated by Py), as well as constitutively active aq subunits could
increase MAP kinase activity whereas mutationally activated aj was without effect
[Faure et al 1994]. Stimulation of MAP kinase by p-adrenergic receptors which are
typical of those that act through Gs may also involve Py subunits. Exposure of COS
7 cells to a p-adrenergic agonist increases MAP kinase activity, which was not
mimicked by expression of an GTPase-deficient, constitutively activated mutant as or
79
by PKA stimulating agents [Crespo et al, 1995a]. Furthermore activation was not
inhibited by depletion of PKC but was completely abolished by expression of PARK ct
peptide (including the Py binding domain) or Ras-inhibiting molecules [Crespo et al,
1995a]. Although now widely accepted that Gq-linked receptors signal via a
subunits, some studies of the G-protein subunit responsible for mediating Gq-
coupled receptor-stimulated MAP kinase activation have shown conflicting results
[Crespo et al, 1994; Faure et al, 1994; Koch et al, 1994]. aT, the Ga subunit of
transducin, which sequesters free GPy subunits, inhibited Mi receptor-stimulated
MAP kinase activation [Crespo et al, 1994], suggesting that Gq-coupied receptor
activation was mediated by py subunits, although another study reported that neither
Mr or bombesin receptor-stimulated MAP kinase activation was attenuated by aT
[Faure et al, 1994].
A partial PKC-dependence of M-| muscarinic receptor-mediated MAP kinase
activation has been observed in both CCL 39 and COS 1 host cells [Kahan et al
1992b; Qian et al 1993], whereas the M3 receptor (but not the epidermal growth
factor (EGF) receptor response in SH-SY5Y cells was completely prevented by PKC
downregulation or by the PKC inhibitor, calphostin C [Offermans et al, 1993].
Activation of MAP kinase by endothelin-1 (ET-1) in renal mesangial cells,
cardiomyocytes and astrocytes is substantially inhibited by PKC downregulation and
is unaffected by pertussis toxin [Bogoyevitch et al, 1993; Cazaubon et al, 1993;
Wang et al, 1992]. Similarly, in CHO host cells both the Mi receptor- and a-ie
adrenergic receptor-mediated MAP kinase activation are completely abolished by
PKC depletion [Hawes et al, 1995]. Activation of MAP kinase by bombesin, but not
EGF, in Swiss 3T3 cells was inhibited over 60% after PKC downregulation or by the
inhibitor, H7 [Pang et al, 1993]. In GH3 cells, TRH-induced
phosphorylation/activation of MAP kinase was decreased by approximately 60%
after PKC down regulation [Ohmichi et al, 1994], It is not yet clear whether the
different degrees of PKC dependence displayed by these Gq-linked receptors reflect
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different signal transduction abilities by the receptors themselves or differences in
the pathway components in the cells where they are expressed (for example the
complement of PKC isoforms present in the cell or the target proteins).
Gj/o receptor-mediated MAP kinase activation appears not to be dependent on PKC,
since the pertussis toxin-sensitive MAP kinase response to 012CIO receptors in Rat-1
fibroblasts is unaccompanied by any phosphoinositide hydrolysis and cannot be
reliably mimicked by phorbol esters [Albas et al, 1993; Hordijk et al, 1994]. In
accordance with this, (3y-mediated MAP kinase responses which were induced by
either activation of the transfected 012CIO receptor or overexpression of Py subunits
in COS 7 cells, were unaffected by PKC depletion [Hawes et al, 1995]. Furthermore,
a direct comparison of Mi and M2 muscarinic receptors expressed in COS cells
confirmed a partial inhibition of Mi but not M2 receptor responses by PKC-down-
regulation, while responses to EGF were little affected [Crespo et al, 1994]. M2
receptor responses were prevented by pertussis toxin while Mt receptor responses
were virtually unaffected. Correspondingly, the activation of MAP kinase by
overexpression of a GTPase-deficient mutant <Xj2 subunit (in Rat-1 but not COS 7
cells) is unaltered by PKC down-regulation [Gupta et al, 1992].
In the case of thrombin and LPA receptors, MAP kinase activation is pertussis toxin-
sensitive whilst other response such as phosphoinositide hydrolysis and tyrosine
phosphorylation, as well as control response to basic fibroblast growth factor (FGF)
and EGF are unaffected [Hordijk et al, 1994; Hung et al, 1992; Kahan et al, 1992b].
Interestingly, thrombin-induced tyrosine phosphorylation but not MAP kinase
activation is required for DNA synthesis [Rao et al, 1994]. The MAP kinase
activation caused by LPA in Rat-1 cells cannot be mimicked by endothelin, despite
the ability of endothelin to elicit phosphoinositide hydrolysis and tyrosine
phosphorylation in these cells [Hordijk et al, 1994]. As found with the receptors
signalling singly through Gj/0, MAP kinase responses to LPA and thrombin probably
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depend little on PKC. In Rat-1 cells, the MAP kinase response to LPA was not
mimicked by phorbol esters (although it was inhibited by a general kinase inhibitor
staurosporine) [Hordijk et al, 1994] and the response to thrombin was unaffected by
PKC-down regulation [Gupta et al, 1992]. In umbilical vein endothelial cells or CCL
39 cells however, thrombin-evoked MAP kinase activation was attenuated by a
selective PKC-inhibitor, Ro 31-8220, or by PKC downregulation, although
surprisingly in the latter case the response to FGF was similarly inhibited [Kahan et
al, 1992b; Wheeler-Jones & Pearson, 1995]. Another receptor which uses multiple
G-proteins to transmit signals is the platelet-activating factor (PAF) receptor. As with
thrombin and LPA, PAF stimulates MAP kinase activation and phosphoinositide
hydrolysis. This cascade leading to MAP kinase activation is partially sensitive to
pertussis toxin (approximately 60%) whereas PI hydrolysis is completely PTx-
insensitive. These observations are very similar to our findings with the LHRH
receptor in aT3-1 cells. Of some note is that in contrast to work from other groups
suggesting a requirement of Ras in Gj protein activation of MAP kinase, this group
found no evidence for increased Ras-GTP loading [Honda et al, 1994].
The role of tyrosine phosphorylation in MAP kinase activation has also been
investigated. LPA stimulated MAP kinase activation in Rat-1 cells involves a tyrosine
kinase-dependent step which appears to lie downstream of Gj/0 but upstream of Ras,
based on the sensitivity of LPA-induced MAP kinase activation to the tyrosine kinase
inhibitor, genistein [Hordijk et al, 1994]. However tyrosine phosphorylation of a
number of proteins, induced by LPA and stimulation of the human
cholecystokinin/gastrin receptor, including the focal adhesion kinase p125 (FAK)
were independent of MAP kinase activation [Hordijk et al, 1994; Seufferlein et al,
1995]. In COS 7 host cells the Src type non-receptor tyrosine kinases have been
implicated in MAP kinase activation [Hawes et al, 1995]. Further investigation of (3y-
mediated signals by overexpression of Py subunits or the expression of the Gj-linked
a2C10 receptor revealed the phosphorylation of two proteins (~50KDa) which co-
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immunoprecipitated with the adaptor protein She [Touhara et al, 1995]. Beta-gamma
subunit-stimulated phosphorylation of She has been suggested as a mechanism by
which Py transduces signals to Ras. She phosphorylation was inhibited by two
tyrosine kinase inhibitors genistein and herbimycin A and an inhibitor of
phosphatidylinositol 3-kinase (PI3K), wortmannin, (suggesting that She can be
phosphoryiated by multiple kinases) as well as expression of the (3ARKct peptide
which acts as an antagonist to Py subunit-mediated signals but not by expression of a
dominant negative Ras [Touhara et al, 1995]. Additionally tyrosine phosphorylation
of She in COS 7 cells has also been shown to lead to an increased association of
She with the adaptor protein Grb-2 and the Ras-GTP exchange factor Sos, providing
evidence that py subunits do not interact directly with Sos. Moreover disruption of
the Shc-Grb-2-Sos complex prevents py-mediated MAP kinase activation indicating a
requirement for She interaction in this activation mechanism. These observations
(and others) suggest that Gi-coupled receptors and receptor tyrosine kinases share a
common pathway from a very early stage [Touhara et al, 1995; Van Biesen et al,
1995]. The manner in which She is recruited to the membrane in py-mediated signal
transduction is still unresolved, however it is possible that interactions between Py
subunits and pleckstrin homology (PH) domains may have a significant role [Luttrell
et al, 1995]. The PH domain is a sequence of approximately 120 amino acids which
is homologous to a region in pleckstrin (the major substrate of PKC in platelets), they
are found in a variety of signalling molecules. By analogy with SH2 and SH3 (Src
homology) domains, it is suggested that these domains mediate protein-protein
interactions in signalling processes [Koch et al, 1991; Lemmon et al, 1996]. PH
domains bind Py subunits with varying affinities. Expression of plasmid minigene
constructs containing PARK, PLCy, IRS-1, Ras-GRF and Ras-GAP PH domains in
COS 7 host cells significantly inhibited both inositol phosphate formation and MAP
kinase activation by the Gj-linked OC2CIO receptor. In contrast only the PLCy-PH
domain peptide had any effect on a Gq-linked Mi receptor responses suggesting that
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the inhibitory effect of most of the PH domains was py subunit-specific [Luttrell et al,
1995]. Thus these peptides behave as antagonists for Py subunit-mediated signals
and taken together with the data presented earlier from Hawes, Van Biesen and co¬
workers provide strong evidence for Py subunit-mediated signalling downstream of
Gj- but not Gq-coupled receptors. Furthermore these data imply that PH domains
may have a valid role in protein-protein interactions required for intracellular
signalling cascades (particularly leading to MAP kinase activation). An involvement
of tyrosine kinases in Gq-mediated signalling is also observed. In cardiac myocytes
and neonatal fibroblasts angiotensin II stimulated tyrosine phosphorylation of a
number of proteins with molecular weights of 42-,44-,75-to 80- and 120- to 130 kDa
[Sadoshima et al, 1995], This appeared to be downstream of PKC activation but in
this instance Ca2+ release seemed more important than tyrosine phosphorylation to
MAP kinase activation [Sadoshima et al, 1995]. The LHRH receptor is therefore
unusual in that it displays aspects of both Gj/0 and Gq/n signalling cascades. The
participation of Ras or Raf-1 has not been investigated as yet. Certainly this would
help to clarify any ambiguity in this signalling cascade, as would providing evidence
that Py subunits released from Gj/0 were necessary. This could presumably be
achieved using antisense cDNA to Py subunits DNA sequences or by expression of
the pARKct peptide to sequester the py subunits, although the latter could only be
performed in a host cell system such as COS7 cells with co-expression of the mouse
LHRH receptor. It appears from the data with mastoparan, pervanadate and phorbol
that either Gj or PKC can elicit a modest MAP kinase activation. However to observe
the maximal effect, "dual input" from both these cascades is essential. From these
results alone it is still unclear precisely how these signals integrate. One explanation
is that concurrent paths are triggered from both G-proteins and that these converge
additively either at Ras by increasing GTP loading or at the level of Raf-1. Another
possibility is that PKC or a tyrosine kinase, perhaps acting downstream of PKC, may
exert some facilitatory action on the Gj/0-mediated signal. Alternatively PKC may
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represent the predominant signalling cascade mediated by the LHRH receptor but its
ability to interact with multiple G-proteins, possibly only under certain circumstances,
may allow the eel Is/receptor to control the level of MAP kinase response and so only
triggers a downstream event once a threshold level of MAP kinase activation has
been achieved. This is an enticing hypothesis if MAP kinase activity was only
increased in response to LHRH in gonadotrophs at certain stages in the oestrous
cycle for example LHRH 'self priming1 effect [Mitchell et al, 1994] or possibly in some
circumstances, mitogenesis [Batticane et al, 1991; Lewis et al, 1986; Linkie et al,
1981; Van Bael et al, 1994], Another receptor which has displayed some sensitivity
to both pertussis toxin and PKC is another rhodopsin family member, the thrombin
receptor [Kahan et al, 1992b]. Its sustained activation by this dual mechanism has
likewise been associated with mitogenicity [Kahan et al, 1992b], although other
signals from the thrombin receptor desensitise rapidly [Vouret-Craviari & Van
Obberghen-Schilling, 1992]. Furthermore, the thrombin receptor in common with the
LHRH receptor has a D for N substitution in the conserved NPXXY motif in
transmembrane domain seven. It is possible that this or another of the non-
canonical sequence motifs may account for a sustained activation of MAP kinase by
this unusual dual mechanism of MAP kinase activation.
It seems likely that dual input mechanisms are more common than first thought.
Aspects of both thrombin, ATP and PAF receptor activation of phospholipase A2
(PLA2) in CHO cells, although incompletely defined, are reported to require the
interaction of pathways of two G-proteins Gi2 and Gq [Honda et al, 1994; Murray-
Whelan et al, 1995]. Activation of MAP kinase following stimulation of the endothelin
B receptor with ET-1 in cultured astrocytes was mediated by two independent
signalling pathways, a PKC-dependent and a pertussis toxin-sensitive G-protein
mediated pathway, whereas ET-1 stimulation of phosphoinositides is insensitive to
PTx treatment [Kasuya et al, 1994]. Recently it has been reported that maximum
MAP kinase activation from G-protein coupled anaphylatoxin C5a receptors
85
expressed in transfected HEK 293 cells requires two independent regulatory signals
[Buhl et al, 1995]. Stimulation of the C5a receptor resulted in a minimal activation of
MAP kinase which was pertussis toxin sensitive and unaffected by PKC inhibitors. In
contrast co-expression of the C5a receptor with the a subunit of Gie (a homologue of
Gq, [Amatruda et al 1991]), resulted in both a robust stimulation of PLCp and MAP
kinase activity which was inhibited by approximately 60% by either GF109203X or
pertussis toxin. It was further shown that ai6 was a necessity for the maximal MAP
kinase response as it could not be reconstituted by overexpression of a combination
of py subunits and PLCp. Moreover there is considered to be insufficient PLCp 2 or 3
in these cells for a wholly py mediated PLC response of a large size [Buhl et al,
1995]. The requirement for additional signal input has also been suggested in other
cases. Down regulation of PKC in 3T3-L1 cells attenuated but not fully blocked the
MAP kinase activation by leukaemia inhibitory factor (LIF). On the contrary EGF
activation of MAP kinase in these cells was unaffected by down-regulation implying
again that full activation of MAP kinase by LIF required multiple signalling pathways
[Schiemann & Nathanson, 1994]. Phorbol ester or stimulation of the Mi receptor
expressed in COS cells could activate MAP kinase however expression of a
GTPase-deficient aq mutant (otq Q209L) could persistently stimulate PI hydrolysis but
not MAP kinase activity, implying an additional effector must be involved in Mi
mediated MAP kinase signalling pathway [Qian et al, 1993]. Furthermore a two
signal model is proposed for activation of Raf-1. Although both Src and Ras can
independently activate the autokinase activity of Raf-1 to a limited extent, both are
required to fully activate Raf-1. Of the two signals it is suggested that the Ras signal
is indirect and an intermediate such as a kinase or a lipase is involved [Williams et al.
1992; Marshall, 1996]. This type of regulation is observed in many examples in
neurobiology where an enzyme for example adenylyl cyclase or a receptor such as
the NMDA receptor serve as a "coincidence detector" to recognise and integrate two
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or more distinct signals and modify the amplitude of the output response [Bourne &
Nicoll, 1993],
The ability of MAP kinase or its immediate upstream activators Raf-1 and MEK to be
regulated by multiple signal inputs therefore provides the potential for a graded
response and tremendous diversity for regulation. Furthermore it is evident from a
number of recent reports, that there is a much greater degree of crosstalk between
differing classes of receptors such as receptor-tyrosine kinases, seven
transmembrane domain G-protein-coupled receptors and ion channel receptors,
rather than these receptor activating exclusive pathways with unique signalling
components as was originally anticipated. For example, it is proposed that G-protein
coupled receptors such as endothelin, LPA and thrombin utilise the EGF receptor as
a downstream mediator in a transactivation mechanism to bring about activation of
MAP kinase and hence gene expression and DNA synthesis in Rat-1 cells [Daub et
al, 1996]. The EGF receptor (EGFR) and the neu oncoprotein became rapidly
tyrosine-phosphorylated in response to thrombin, LPA and endothelin-1. Inhibition of
EGFR function by tyrphostin AG 1478 or expression of a dominant negative mutant of
the EGFR prevented MAP kinase activation in response to the GPCRs or EGF but
had no effect on a control PDGF-stimulated activation. This would indicate that
these mitogens (and possibly others) mediate cell proliferation through a ligand-
independent induction of tyrosine phosphorylation of the receptor-tyrosine kinases
EGFR and p185neu [Daub et al, 1996], however this report failed to address whether
this was a specific property of the EGF receptor or whether all receptor tyrosine
kinases could be substituted in this role. Furthermore if the PDGF receptor was
present in these cells as shown by the use of PDGF to monitor MAP kinase
activation as a control response it presumably could not substitute as the link for
GPCR action. In another report it is proposed that a pertussis toxin-sensitive G-
protein (probably Gj) is required (as an additional signal to tyrosine phosphorylation)
for activation of PLCy and the consequent EGF-induced phosphoinositide turnover in
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rat hepatocytes [Yang et al, 1991; Yang et al, 1993]. In yet another article, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor signalling was
found to involve a pertussis toxin sensitive G-protein, coupled to a protein kinase
cascade [Wang & Durkin, 1995]. This is particularly surprising as AMPA is an
ionotrope (channel) receptor and would not usually be expected to interact with G-
proteins. AMPA, but not N-methyl-D-aspartate (NMDA) which can also stimulate
MAP kinase in rat cortical neurones by Ca2+ influx, was shown to cause an
association of the Pysubunit to a Ras protein complex and hence activation of MAP
kinase in a Ca2+-influx-dependent manner [Wang & Durkin, 1995]. The proposed
mechanism is similar to that proposed forTMD VII domain Gj-coupled receptors such
as the oi2 adrenergic receptor [Hawes et al, 1995], where the Pysubunits interact and
activate Ras following ligand-induced dissociation from the a; subunit. This opens up
the possibility of even greater diversity as synergistic parallel pathways may be put to
use in a cell or receptor specific manner. It is not surprising that a key signalling
molecule such as MAP kinase would command such varied and complex control.
Ultimately the magnitude of the response will depend on multiple factors such as the
ability of a receptor to interact with one or more G-proteins, or the complement of
signalling machinery present in that cell.
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Figure 3.1
Time course of LHRH and PDBu-induced MAP kinase activation in aT3-1 cells.
Figure 3.1 shows the specific [35S]thiophosphorylation of MAP kinase substrate
peptide after different times of incubation of aT3-1 cells with luteinising hormone
releasing-hormone (LHRH, (#), 100 nM) or phorbol 12,13-dibutyrate; (PDBu, (A)
), 1pM; vehicle, (■)). Each value is the mean ± SEM from 4-6 separate
determinations. Basal levels of MAP kinase activity remained constant
throughout the time course measured.
 
Figure 3.2
Concentration response curves for MAP kinase activity in aT3-1 cells
The specific [35S]thiophosphorylation of MAP kinase substrate peptide was
measured at various concentrations of agonist or antagonist. Each value is the
mean ± SEM from 6-8 determinations. Baseline activity in unstimulated cells was
subtracted and the agonist-evoked responses were normalised to the activity
obtained with the maximally effective dose. Curve fitting and derivation of the EC50
or IC50 values was then conducted as described in Chapter 2.
The Concentration-response curves for LHRH (#) is shown in (a) with EC50 values of
3.4 ± 0.4 nM. The pharmacological specificity of LHRH was tested by the addition of
increasing concentrations of an LHRH antagonist [Ac-D-p-CI-Phe1^, D-Trp3, D-Arg6,





























































Concentration response curves for MAP kinase activity in aT3-1 cells
The Concentration-response curves for 4[3-phorbol 12,13-dibutyrate; 4p-PDBu (■) is
shown in (a) with EC50 values of 50 ± 8 nM. The pharmacological specificity of this
reagents was tested by replacing 4p-PDBu with the essentially inactive stereoisomer
4a-PDBu (□) which had a maximum effect of 110 ± 9% at concentrations up to 10
pM.
(b) Down-regulation of phorbol-sensitive PKC isoforms and the effect on
LHRH-induced MAP kinase activity.
LHRH (100 nM)-induced MAP kinase activity after 10 min was monitored in aT3-1
cells which had previously been exposed to 300 nM PDBu or vehicle (<0.3% DMF)
for 18 h. Results are shown as fold of basal activity and are the means (± SEM) of at




Inhibition of MAP kinase activity by various PKC inhibitors.
The concentration-dependence of effects on (a)LHRH (100 nM, 10 min) and (b)
PDBu (1 pM, 8 min)-induced MAP kinase substrate peptide [35S]thiophosphorylation
is shown in Figure 3.3. All inhibitors were added for 2 min prior to agonist and where
required vehicle alone was added to control flasks. All data are expressed as a
percentage of the LHRH- or PDBu-induced activity and are means ± SEM (n = 6-8).
After curve fitting as described previously the IC50 values obtained for GF109203X
(▲), Ro 31-8220 (■) and H7(#) were 1.8 ± 0.12 pM, 0.64 ± 0.08 pM and 168 ± 12
pM respectively for LHRH (a) and 0.26 ± 0.02 pM, 0.57 ± 0.03 pM and 43.5 ± 5.1 pM
respectively for PDBu (b).
 
Figure 3.5
Inhibition of LHRH-induced MAP kinase activity by tyrosine kinase inhibitors.
The concentration-dependence of effects of tyrosine kinase inhibitors on LHRH (100
nM, 10 min)-induced MAP kinase substrate peptide [35S]thiophosphorylation is
shown in Figure 3.5. All inhibitors were added for 2 min prior to agonist and where
required vehicle alone was added to control flasks. All data are expressed as a
percentage of the LHRH-induced activity and are means ± SEM (n = 4).
After curve fitting as described previously, IC50 values obtained for genistein (•) and




Inhibition of LHRH-induced MAP kinase activity in ocT3-1 cells by pertussis
toxin.
Figure 3.6 (a) shows the concentration-dependence of inhibition of MAP kinase
substrate peptide [35S]thiophosphorylation in aT3-1 cells when preincubated for 18 h
with pertussis toxin (PTx). The IC50 value for this effect was 32 ± 4 ng/ml with a
maximum inhibition of -75% at 300 ng/ml. Inhibition of MAP kinase responses by >
10 ng/ml pertussis toxin was statistically significant (p < 0.05, Mann-Whitney U-test).
This effect was shown to be a specific effect of an active holotoxin as under the
same conditions neither the B-subunit or N-ethyl maleimide (NEM)-inactivated
holotoxin had any significant effect on MAP kinase substrate peptide
[35S]thiophosphorylation. None of these treatments had any significant effect on




Characteristics of mastoparan- and phorbol-ester-induced MAP kinase
activation
(a) Shows the concentration-dependence of the effects of mastoparan (10 min
incubation) on MAP kinase substrate peptide [35S]thiophosphorylation (O) and
[3H]inositol phosphate formation (A). Values are the means ± SEM from 6 and 4
separate determinations respectively, (b) Shows the activation of MAP kinase
induced by 10 min incubations with mastoparan (10 pM), phorbol 12,14-dibutyrate
(PDBu; 1pM) and the combination, as well as the effects thereon of GF109203X (GF;
3 pM) and pertussis toxin (PTx; 100 ng/ml for 18 h). Values are the means ± SEM
from 6-9 separate determinations. (*) Indicates statistically significant inhibition of





























Anti-MAP kinase immunoblots showing dose- and time-dependent relationship
of LHRH-induced phosphorylation of MAP kinase.
Phosphorylation of p42 and p44 MAP Kinase was determined by the electrophoretic
mobility shift assay. In response to agonist, MAP kinases are activated by
phosphorylation on both a tyrosine and threonine residue, therefore the
phosphorylation-induced gel mobility shift in immunoreactive p42 and p44 MAP
kinases can be monitored (deVries et al., 1992). In all cases, no other distinct
staining was detected in the lanes. Each observation was replicated in the
experiment and was typical of three separate experiments.
Anti-p42/p44 MAP kinase immunoblots were carried out after protein separation by
electrophoresis as described in Chapter 2. (a) Shows the concentration-dependence
of LHRH-induced reduction in mobility of p42 (and to a lesser extent p44). Lanes 1,
2, 3, 4, 5 and 6 show results from 10 min incubations with 0, 1 nM, 3 nM, 10 nM, 30
nM and 100 nM LHRH respectively.
(b) shows the time course of LHRH-induced phosphorylation of p42 and p44 MAP
kinase. Lanes 1, 2, 3, 4, 5 show results from 0, 5, 10, 20, 40 and 60 min incubations
with LHRH (100 nM). A reduction in mobility was apparent within 5 min as seen in
lane 2 and subsequent lanes. Unstimulated aT3-1 cells showed no change in
phosphorylation over the 60 min time course (not shown).
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Figure 3.9
Effects of various inhibitors on LHRH-induced phosphorylation of p42 and p44
MAP kinase.
Anti-MAP kinase immunoblots showing LHRH-induced mobility shifts and the
observed effects of several different inhibitors of a number of signalling cascade
components. In all cases, no other distinct staining was detected in the lanes. Each
observation was replicated in the experiment and was typical of three separate
experiments.
In (a), the effects of piceatannol, genistein (inhibitors of tyrosine kinases) and
GF109203X (a PKC inhibitor) on the LHRH-induced mobility shift are shown. Lanes
1, 2, 3, 4 and 5 show control, 100 nM LHRH, 100 nM LHRH with 30 pM piceatannol,
100 nM LHRH with 100 pM genistein and 100 nM LHRH with 3 pM GF109203X
respectively.
In (b) the effects of a tyrosine phosphatase inhibitor, pervanadate ( see Chapter 2 for
preparation details) are shown. aT3-1 cells were preincubated with pervanadate for
15 min before the addition of 100 nM LHRH for 15 min. Lanes 1, 2, 3 and 4 show


































The effects of PLC inhibitors and pertussis toxin on LHRH-induced
phosphorylation of p42 and p44 MAP kinase
Anti-MAP kinase immunoblots showing LHRH-induced mobility shifts and the
observed effects of several different inhibitors which act at the level of G-proteins. In
all cases, no other distinct staining was detected in the lanes. Each observation was
replicated in the experiment and was typical of three separate experiments.
(a) displays the effects of U73122 a PLC inhibitor. Lanes 1, 2 and 3 show
respectively, control, 100 nM LHRH and 100 nM LHRH with 2pM U73122.
(b) shows the effects of another PLC inhibitor neomycin. Lanes 1, 2, 3 and 4 show
respectively control, 100 nM LHRH, 5 mM neomycin and 100 nM LHRH with 5 mM
neomycin.
(c) illustrates the effect on LHRH-induced phosphorylation of p42 and p44 MAP
kinase of pertussis toxin (a Gj/o inhibitor). Lane 1, 2 and 3 show respectively control,































FURTHER EVIDENCE FOR AN
INTERACTION OF THE LHRH
RECEPTOR WITH THE G|/0 FAMILY OF
G-PROTEINS
4.1 INTRODUCTION
During the course of investigations into the upstream regulation of LHRH-induced
MAP kinase activation described in Chapter 3, it became apparent that there was a
pertussis toxin-sensitive component to this LHRH-induced activity. Furthermore the
LHRH-induced activity was partially mimicked by a G-protein activating peptide
mastoparan, which has been reported to selectively activate Gj proteins in vitro [Gil et
al, 1991; Higashijima et al, 1988]. Together these observations formed the first
suggestion that the LHRH receptor did not exclusively interact with Gq/n but may
functionally interact with multiple G-proteins. This phenomenon is not uncommon,
many receptors can interact with multiple effector systems through the activation of
multiple G-proteins [Milligan, 1993; Offermans & Schultz, 1994], For example,
heterologous expression of the (X2CIO adrenergic receptor in Rat-1 fibroblast cells
has been noted to result in the activation of phospholipase D as well as inhibition of
adenylyl cyclase [MacNulty et al, 1992]. Furthermore in these cells the single
defined receptor was shown to activate two separate G proteins, Gj2 and Gj3, and
adenylyl cyclase regulation at least, was attributable to Gj2 [Milligan et al, 1991].
Additionally following high level expression of (X2C10 adrenergic receptors in CHO
cells both inhibition and stimulation of adenylyl cyclase has been observed and
immunoprecipitates of this receptor with an (X2CIO adrenoreceptor antibody
contained both Gj and Gs [Eason et al, 1992]. Similarly, thrombin receptor activation
can stimulate PLC activity as well as inhibiting adenylyl cyclase, and PLC activity is
not prevented by pertussis toxin treatment, suggesting PLC activation is mediated by
Gq/11 as opposed to Gj Py subunits [Hung et al, 1992]. Another example of receptor-
multiple G-protein interaction is the thyrotrophin-releasing hormone (TRH) receptor.
In GH3 cells ligand-induced activation of PLCpi was attenuated by
immunoprecipitation of Gq/n antibodies [Hsieh & Martin, 1992], whilst TRH-evoked
adenylyl cyclase activation in GH3 cells was prevented by treatment with anti-Gas
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antiserum [Paulssen et al, 1992], Activation of the thyrotrophin (TSH) receptor also
results in stimulation of adenylyi cyclase and PLC when expressed in COS 7 or CHO
cells [Van Sande et al, 1990] suggesting interaction with both Gq/n and Gs. In
addition it is widely appreciated that cells might receive signalling input through
numerous receptors at any one time which may consequently activate multiple
intracellular signalling systems further propagating the diversity of the outcome to the
initial stimulus. The integration of these signals and the sum of potential cross-talk
between these effector systems will ultimately regulate the magnitude and length of
any one receptor-mediated response.
In this light, it follows that if the LHRH receptor is capable of stimulating G-proteins
other than Gq/n then LHRH may act not only to stimulate the release of LH but may
modulate other responses in its target tissue or indeed these auxiliary pathways may
modulate responses to itself. It was therefore important to further examine the basis
for pertussis toxin-sensitivity of LHRH-induced MAP kinase activation. The G-
proteins designated as Gj (Gja-|, Gja2, Gja3) are substrates for pertussis toxin. The
discovery and nomenclature of the Gj family of G-proteins resulted from the inhibitory
effect these oligomers exerted on intracellular adenosine 3', 5'-cyclic monophosphate
(cAMP) formation (from adenosine triphosphate, ATP) catalysed by adenylyl cyclase
[Taussig et al, 1993; Wong et al, 1991]. It therefore seemed logical to determine the
potential effects of LHRH on cAMP formation in aT3-1 cells as a simple assay for
LHRH mediated Gj activation with a presumed LHRH-induced inhibition of cAMP
formation resulting if this hypothesis was correct.
To date nine full length cDNA clones for adenylyl cyclases have been identified
[Bakalyar & Reed, 1990; Cali et al, 1994; Feinstein et al, 1991; Gao & Gilman, 1991;
Ishikawa et al, 1992; Katsushika et al, 1992; Krupinski et al, 1989; Paterson et al,
1995; Premont et al, 1992] all of which have between 1064-1248 amino acid
residues. Adenylyl cyclases have a predicted topology within the membrane
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consisting of a short cytoplasmic amino terminus followed by a cassette of six
putative transmembrane spans (Mi) and a large cytoplasmic domain (C-|). This motif
is repeated forming the M2 and C2 domains. This structure is similar to certain ion
channels and to ATP-dependent transporters, particularly the P-glycoprotein and the
cystic fibrosis transmembrane conductance regulator [Cooper et al, 1995; Taussig &
Gilman, 1995]. Two regions in particular designated C-|a and C2a are highly
conserved (-93%) amongst the isoforms and it is these regions that are considered
to be the catalytic domains. Notably these regions are highly homologous to each
other and to the catalytic domains of both cytosolic and membrane bound guanyl
cyclases. Although it is still unresolved whether both domains are of equal
importance in catalysis. Other regions of interest include the conserved peptide
sequences spanning amino acids 425-444 and 495-522 in C-|, representing a
putative internal inhibitory domain [Kawabe et al, 1994] and the site of
Ca2+/calmodulin interaction [Vorherr et al, 1993; Wu et al, 1993] respectively. As a
result of the recent cloning and expression of adenylyl cyclases a wealth of
information now exists on their regulation. All nine isoforms are commonly activated
by either Gas or by forskolin, a diterpene which acts directly on adenylyl cyclase
catalytic subunits and conversely all AC are inhibited by P-site inhibitors such as 3'-
AMP, adenosine and related analogues [Tang & Gilman, 1992], However it is now
apparent that each isoform is uniquely regulated by a variety of influences and
consequently the traditional view that Gai inhibits all adenylyl cyclase has been
reassessed. In addition to G-protein a subunits, Py dimers [Katada et al, 1987;
Smigel, 1986; Tang & Gilman, 1991], phosphorylation [Dohlman et al, 1991;
Jacobowitz et al, 1993; Kawabe et al, 1994] and Ca2+[Boyajian et al, 1991;
Debernardi et al, 1993; Ishikawa et al, 1992; Katsushika et al, 1992; Tang et al,
1991; Yoshimura & Cooper, 1992] all exert either facilitatory or inhibitory influences
on adenylyl cyclases. Furthermore cell-specific differences in the regulation of
specific adenylyl cyclase isoforms have also been described [Taussig & Gilman,
92
1995], for example Type II adenylyl cyclase was reported to be inhibited by Gaj
subunits when expressed in COS 7 cells [Chen & Ivengar, 1993], however no such
regulation was observed when this isoform was expressed in Sf9 membranes
[Taussig & Gilman, 1995], or HEK 293 cells [Federman et al, 1992]. Most
importantly, differences in adenylyl cyclase isotype profiles in a cell type may
produce opposite outcomes, with respect to cAMP regulation, to the effects of Gj or
Gq coupled receptors stimulation. Therefore caution should be applied to the
interpretation of results measuring adenylyl cyclase activity or cAMP formation in
whole cell situations and generalisations regarding receptor regulation of a particular
species of adenylyl cyclase cannot be made unless a fully defined system is
available.
In this Chapter we have examined the potential effects of LHRH on cAMP formation
induced by forskolin and pituitary adenylyl cyclase-activating peptide (PACAP). Type
I PACAP receptors belong to the seven transmembrane spanning G-protein-coupled
superfamily of receptors [Hashimoto et al, 1993; Pisegna & Wank, 1993; Spengler et
al, 1993]. Occupancy of these receptors has been shown to activate adenylyl
cyclase presumably via Gas, as well as PLC in aT3-1 cells and PC12 cells [Deutsch
& Sun, 1992; Schomerus et al, 1993]. The experiments in this chapter were
performed with the aim of highlighting any further pertussis toxin-sensitive responses
to LHRH which would corroborate our earlier data rather than attempting to be a
definitive study of the enzymes involved.
4.2 RESULTS
Cyclic AMP formation stimulated in response to forskolin and PACAP-38 was
assessed in aT3-1 cells in the presence of the broad spectrum phosphodiesterase
inhibitor [Beavo, 1970] isobutyl-1-methylxanthine (IBMX; 0.5 mM). Extracellular,
intracellular and total cAMP measurements were performed over a time course of 90
min. However only minimal cAMP was detected in the extracellular medium during
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the first 45 min and responses were near maximal within 30 min (data not shown),
therefore all subsequent measurements were performed after a 30 min incubation
and represent the intracellular cAMP concentrations.
Forskolin stimulated a massive concentration-dependent increase in cAMP formation
with responses to 1 pM forskolin typically being in the order of 70-120 fold of the
basal cAMP concentrations measured. PACAP-38 stimulated a concentration-
dependent increase in cAMP (not shown) which was maximal at 100 nM and
represented an approximately 40 fold increase over the basal concentrations
measured. Near maximal doses were used in all subsequent experiments. LHRH
clearly reduced the stimulatory effects of both forskolin and PACAP-38 in a
concentration-dependent manner (Figure 4.1) although approximately 45% of either
the forskolin- or PACAP-38-stimulated activity remained uninhibited by LHRH at the
highest concentration tested (1 pM). LHRH had no effect on basal levels of cAMP
(Table 4.2).
Subsequent studies concerned the likely mechanism underlying the effect of LHRH.
Since we have shown that the LHRH-mediated MAP kinase response is attenuated
by pertussis toxin [Sim et al, 1995; Chapter 3+5], we investigated if the LHRH
receptor was resulting in the inhibition of cAMP formation through the interaction of
Gccj/o with adenylyl cyclase. Pertussis toxin reversed the majority of the LHRH-
mediated inhibition of forskolin- and PACAP 38- stimulated cAMP formation in a
dose-dependent manner (Figure 4.2). This effect was specific to active holotoxin as
it was not observed with NEM-inactivated holotoxin or B-subunit alone. However
PTx (200 ng/ml) was unable to fully restore the forskolin (1 pM)- stimulated cAMP
concentration with a portion of this response in the region of 17 ± 5% (mean ± SEM,
n=8) still inhibited in the presence of LHRH (300 nM). This effect was not as
apparent with PACAP-38 where 92 ± 4% (mean ± SEM, n=6) of the PACAP-38 (100
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nM)- stimulated cAMP concentration restored. PTx alone did not significantly alter
basal cAMP concentrations (Table 4.2).
Since the LHRH receptor stimulates PKC activity in the anterior pituitary gland [Ison
et al, 1993; Johnson et al, 1992] and in the aT3-1 gonadotroph cell line [Horn et al,
1991; Johnson et al, 1995], we investigated whether activation of PKC by LHRH
could possibly explain this inhibitory action. The effect of the PKC activator PDBu
(1 pM) was compared to that of LHRH on forskolin (100 nM)-stimulated cAMP
formation (Figure 4.3a). PDBu displayed a tendency to be very slightly elevated
above basal cAMP formation however this did just achieve a statistical significance
(Wilcoxon signed rank test). Cyclic AMP production in response to PDBu in
combination with forskolin was also slightly elevated in contrast to the effect of LHRH
on forskolin-evoked cAMP formation (still 55 + 7% inhibition within the same
experiment). In response to the combination of forskolin + LHRH + PDBu cAMP
formation was again slightly elevated compared to forskolin + LHRH, suggesting that
PDBu was acting to slightly elevate cAMP formation in all conditions but had no
specific effect on cAMP formation. The effects of the general kinase inhibitor
staurosporine and the PKC inhibitor GF109203X and the tyrosine kinase inhibitors
genistein and RG-13022 on these responses were also assessed (Table 4.1). None
of the kinase inhibitors had any effect on basal cAMP formation or that in the
presence of LHRH or PTx (Table 4.2). However GF109203X and staurosporine
displayed a consistent trend to a small increase in cAMP formation in the presence
of forskolin, forskolin + LHRH and forskolin + LHRH + PTx (Table 4.1). This did not
reach statistical significance under the present conditions. Genistein and RG-13022
had no apparent effects except for a slight inhibition of the forskolin-stimulated
response. This was a consistently observed effect but again failed to reach a
statistical significance. The role of PKC was further investigated by long term
exposure to PDBu (300 nM) to downregulate phorbol ester-sensitive PKC isoforms.
Under these conditions the responses to all treatments (forskolin (F), forskolin +
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LHRH (F+L), and forskolin + LHRH + pertussis toxin (F+L+PTx)) were all reduced in
comparison to control cells which had not been exposed to the phorbol ester (Figure
4.3b). Downregulation caused a marked effect on the F and F+L+PTx treatments,
where the cAMP responses to these agents were reduced by 45 ± 6% and 55 ± 7%
(mean ± SEM, n=6) compared to the responses in cells treated with vehicle. The
response in the presence of F+L was only slightly reduced 20 ± 4% (mean ± SEM,
n=6), in the down-regulated cells. LHRH inhibited the forskolin-stimulated cAMP
formation by 25 ± 7% (compared to the usual 55 ± 6%; mean ± SEM, n=8), this 25%
inhibition was also largely reversed by PTx. These results were shown to be
statistically significant using the Wilcoxon signed rank test. Again it appears that this
phorbol ester, PKC downregulation protocol is acting non-specifically to dampen
down the whole cAMP formation system.
Since LHRH also elevates intracellular Ca2+ levels in its target cells (including aT3-1
cells) [Anderson et al, 1993; Merelli et al, 1992; Mitchell et al, 1988], we investigated
the possibility that Ca2+ may participate in mediating inhibition of cAMP
accumulation. Experiments were carried out to determine the Ca2+-dependence of
forskolin-evoked cAMP production and its inhibition by LHRH effect (Figure 4.4).
Elevation of intracellular Ca2+ by ionomycin had no effect on cAMP formation either
alone or in combination with forskolin (Figure 4.4a). Reduction of cytosolic Ca2+ by
incubation of aT3-1 cells in MEM supplemented with 5 mM EGTA did however cause
a large reduction in stimulated cAMP formation (Figure 4.4b). This effect was most
prominent on the response to forskolin alone which had decreased by 55 ± 10%
(mean ± SEM, n=6), with F+L+PTx decreased by 44 ± 8% (mean ± SEM, n=6) with
respect to responses in the absence of EGTA. In the presence of EGTA, LHRH had
no inhibitory effect on forskolin-evoked cAMP production, in contrast to the situation
in normal medium LHRH appeared to facilitate the lower response to forskolin that
occurred in the presence of EGTA and displayed a small increase in basal or
forskolin-evoked cAMP formation. Whilst the combination of PDBu and forskolin
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displayed a trend towards an additive response using the Wilcoxon signed rank test
this was not found to reach statistical significance
4.3 DISCUSSION
We investigated the influence of LHRH on forskolin- and PACAP-induced cAMP
formation. LHRH clearly had an inhibitory effect on both forskolin- and PACAP-
stimulated responses and this was susceptible to the Gj/0 antagonist pertussis toxin
(Figure 4.1). Taking into account earlier studies too, it is now possible to infer that
activation of the LHRH receptor consequently results in activation of Gaq/n, Gocj/0,
the release of Py subunits, raised intracellular Ca2+ and activation of intracellular
protein kinases, primarily PKC, all of which have the potential to regulate adenylyl
cyclases and cAMP formation. Intracellular cAMP levels may also be regulated by
phosphodiesterases [Beavo, 1995] which are often activated in response to
Ca2+/calmodulin [Sharma et al, 1988]. Furthermore, each of the nine cDNA clones
for mammalian AC which have been identified to date, have been shown to be
regulated in a distinctive manner by these mediators probably reflecting the diverse
structural differences in the clones [Cooper et al, 1995; Tang & Gilman, 1992;
Taussig & Gilman, 1995]. Clearly LHRH may regulate cAMP formation in numerous
ways with the capacity for multiple sites of cross-talk between these regulatory
mechanisms.
The activation of Gj/0 appears to be a significant event in LHRH-mediated inhibition
of cAMP formation as PTx reversed the majority of LHRH-mediated inhibition of this
response (Figure 4.2). This observation further adds to the data concerning a role
for Gi/o proteins in LHRH receptor signalling [Sim et al, 1995; Chapter 3+5]. PTx
treatment will inactivate oci/0 subunits through ADP-ribosylation, thus preventing an
inhibitory interaction of this subunit with AC. An alternative possibility is that the
parallel release of Py subunits from the heterotrimer is also prevented, which in some
circumstances also act in an inhibitory manner on Gs-evoked AC activation [Tang et
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al, 1991]. PTx was however unable to fully restore the agonist stimulated levels of
cAMP formation suggesting additional regulatory events. This action may be
indicative of a more widespread role for LHRH as a modulator of other concurrent
stimuli for example PACAP, although the extent to which such interactions occur in
gonadotrophs is as yet undetermined.
LHRH-induced activation of PKC in target cells is well documented including aT3-1
cells [Horn et al, 1991; Johnson et al, 1994; Stojilkovic et al, 1994], PKC in particular
is known to play a pivotal role in the crosstalk between activators of AC which
stimulate Gas and phosphoinositide hydrolysis [Cooper et al, 1995; Tang & Gilman,
1992]. PKC (or indeed other kinases potentially activated in response to LHRH)
therefore were strong candidates for mediators of the LHRH inhibitory effect. Brief
phorbol ester stimulation of PKC in aT3-1 cells (20 min) was unable to mimic the
LHRH-induced inhibition of forskolin-stimulated cAMP accumulation [Figure 4.3].
Furthermore although not achieving statistical significance, PDBu displayed a trend
to increase basal or forskolin- and forskolin + LHRH-evoked cAMP formation. The
protein kinase inhibitors GF109203X, staurosporine, genistein and RG-13022 were
ineffective against the LHRH inhibition of forskolin-stimulated responses [Table 4.1],
for example LHRH inhibition in the absence of inhibitors is usually found to be 53 ± 3
%, and in the presence of GF109203X, staurosporine, genistein and RG-13022 were
47 ± 4%, 42 ± 4%, 55 ± 7% and 56 ± 5% respectively, further evidence that a kinase
does not seem to be mediating the LHRH effect. GF109203X and staurosporine,
when included with forskolin and LHRH and PTx, appeared to increase the capacity
for PTx reversal of the LHRH inhibition of this response. However in the presence of
these inhibitors, there is a small increase in all the cAMP formation responses.
Chronic treatment of aT3-1 cells with PDBu also had a considerable effect on cellular
cAMP formation. Under these conditions all forskolin-stimulated responses were
significantly reduced and the proportional inhibitory effect of LHRH was reduced (ie.
32 ± 8% inhibition, compared to approximately 55 ± 6% in untreated cell). In PKC-
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down regulated cells LHRH inhibition of forskolin-stimulated cAMP accumulation was
still partially PTx sensitive (ie LHRH + PTx now gave 82 ± 6% inhibition). However
with reduced LHRH effects and the present number of replications the effect of PTx
in these conditions did not reach statistical significance. Therefore PKC does not
seem to be required for the acute effect of LHRH on forskolin-evoked cAMP
accumulation, although it is still possible that activation of PKC leads to some
increase and some decrease in AC responses which is impossible to discern in the
whole cell assay used here. The forskolin-evoked activation of ACs however does
seem to be dependent on a longer term PKC presence for expression of a full
magnitude response. Taken together these results imply that there is no critical role
of PKC (or other kinase sensitive to these inhibitors) in the LHRH-mediated inhibition
of forskolin-evoked cAMP formation. One previous study of LHRH inhibition of
PACAP-stimulated cAMP formation suggested that PKC was responsible for
mediating the LHRH inhibition [McArdle et al, 1994], In this report they concluded
that this PKC action was exerted at an early stage of PACAP receptor signalling and
was not intrinsically at the level of G-proteins, however their only evidence of a PKC
involvement was by an acute treatment with phorbol ester and despite the additional
attempts to clarify the role of PKC with kinase inhibitors or PKC downregulation no
evidence in agreement with their observations was found. This study also failed to
observe a LHRH inhibition of either forskolin- or Gas-induced cAMP accumulation or
a PTx-sensitive component to the LHRH inhibition of PACAP-stimulated cAMP
formation, however was in agreement with the Ca2+data (concerning both the
ionophore and EGTA). At present it remains unclear as to why our data is different,
it is possible that alternative cell culturing regimes and a different passage number
may effect the results as slight changes in aT3-1 cells become apparent as the
passage number increases. Alternatively it is known that different serum sources
can affect the growth and responses of aT3-1 cells [P. Mellon; L. Anderson, personal
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communication] and ail our experiments were carried out after at least 18 h in serum
free medium.
LHRH increases cytosolic Ca2+ levels in gonadotrophs [Johnson et al, 1993b;
Mitchell et al, 1988] and aT3-1 cells [Anderson et al, 1993; Johnson et al, 1993b;
Merelli et al, 1992]. From these results it seems unlikely that cAMP inhibition is a
reflection of raised Ca2+ perhaps inhibiting AC as the Ca2+ ionophore, ionomycin,
was unable to mimic this inhibitory effect and had a very slight stimulatory effect on
cAMP formation alone (Figure 4.4). LHRH inhibition of forskolin- and PACAP-
stimulated cAMP accumulation occurred in the presence of a phosphodiesterase
inhibitor IBMX therefore is unlikely to be acting by activating a Ca2+/calmodulin-
dependent phosphodiesterase. Reduction of cytosolic Ca2+ with EGTA had a
profound effect on cellular cAMP formation. This treatment prevented LHRH
inhibition of forskolin-evoked cAMP accumulation. However in these conditions the
forskolin-stimulated response was greatly reduced (Figure 4.4). This profile could be
consistent with a high proportion of Ca2+/calmodulin-dependent AC isoforms in these
cells which are rendered ineffective by the absence of Ca2+. The increased cAMP
formation in the presence of LHRH could possibly be explained if subset of AC
present in ocT3-1 cells were unaffected by Ca2+/calmoduIin but were stimulated by
subunits. This would require the Py subunits to be derived from G-proteins other
than Gj/o as PTx treatment did not decrease the cAMP accumulation any further. An
alternative possibility exists if certain Ca2+-independent AC isoforms were more
responsive following phosphorylation induced by LHRH receptor activation, but this
seems unlikely as the PKC inhibitor GF109203X would prevent such an action on
cAMP accumulation. Alternatively if LHRH is activating cytosolic phosphatases, a
tonic inhibitory influence such as phosphorylation of AC or a G-protein may be
removed as a consequence of LHRH action which could in turn increase cAMP
formation. Alternatively it could be not only those AC isotypes that are indifferent to
Ca2+, but also Ca2+-inhibited isotypes whose response is now exposed and
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consequently as they would be more active would account for a bigger percentage of
the EGTA-reduced response.
The cloning of AC has facilitated the investigations of isoform specific regulation
[Cooper et al, 1995; Tang & Gilman, 1992; Taussig & Gilman, 1995]. G-protein
regulation of adenylyl cyclases can be mediated both by a and Py subunits. As
previously stated, all the isoforms are stimulated by Gas. Transfection of cells with
cDNAs encoding constitutively activate Got; subunits lowered intracellular
concentrations of cAMP suggesting that these proteins could inhibit AC [Wong et al,
1991]. When tested on expressed Type I, V and Type VI AC isoforms, Goq displayed
prominent inhibition of Gas- and forskolin-stimulated activity, although this effect was
less prominent on Type I AC and the inhibition was largely confined to the forskolin-
stimulated response [Taussig & Gilman, 1995; Taussig et al, 1993]. Type II AC has
also been reported to be inhibited by Gocj/0 [Chen & Ivengar, 1993]. However this
has been contested and there appears to be more evidence favouring activation of
this isoform by Py subunits liberated from the Gj/0 heterotrimer [Federman et al, 1992;
Tang & Gilman, 1991; Taussig & Gilman, 1995]. To date only Type I AC has been
shown to be inhibited by Py subunits [Tang & Gilman, 1991], In contrast Py subunits
are stimulatory for Type II [Tang & Gilman, 1991] and Type IV [Gao & Gilman, 1991]
AC (in the presence of activated Gas). Changes in Ca2+ can have pronounced
effects on cellular cAMP concentrations depending on the AC isoforms present.
Types I, VIII and to a lesser extent Type III are all markedly stimulated by
Ca2+/calmodulin. The other isoforms are insensitive to Ca2+/calmodulin. In
comparison, Types V and VI AC are inhibited by low micromoiar concentrations of
Ca2+, but are insensitive to calmodulin therefore this seem to be a direct interaction
of the Ca2+ ion with the cyclase [Ishikawa et al, 1992; Katsushika et al, 1992;
Yoshimura & Cooper, 1992].
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Cellular cAMP concentrations are likely to be highly dependent on the state of
phosphorylation in a cell as many receptors which stimulate or inhibit AC are the
substrate for kinases including PKA, PKC and (3-adrenergic receptor kinase,
consequently phosphorylation often results in desensitisation or down regulation of
these receptors [Dohlman et al, 1991]. Alternatively kinases may phosphorylate
components of the AC signalling system. In one case a mutational swap approach
has been used which has implicated the C2b domain as the region required for PKC
regulation of AC II [Taussig & Gilman, 1995; Cooper et al, 1995]. Phosphorylation of
AC isoforms as a consequence of ligand-induced kinase activation, has been
suggested to potentially regulate AC activity. Whilst this is acknowledged as a valid
regulatory mechanism, isotype specific effects appear to be a contentious area of
research with many conflicting reports in press [reviewed in [Taussig & Gilman,
1995]. Activity of Type II AC is reported to be substantially augmented by
phosphorylation by activated PKC [Jacobowitz et al, 1993; Lustig et al, 1993;
Yoshimura & Cooper, 1993]. This effect may be indirect or involve a specific isoform
of PKC, however not all laboratories have been able to mimic this effect [Taussig &
Gilman, 1995]. These differences might be explained as Taussig et al have
expressed Type II AC in Sf9 membranes and added activated protein kinase C,
whereas the other groups have transfected the Type II AC cDNA into a host cell
expression system and it is likely that cell specific differences may be acting to
promote this phosphorylation response. Type V AC activity is enhanced in vitro
specifically by PKC a and 8 [Kawabe et al, 1994]. As PKC a is often activated in
response to Gq/n -mediated pathways and PKC 8 has been reported to be activated
following growth factor receptor activation, a potential for cross-talk between Gq/n
and tyrosine kinase regulated signalling pathways and this AC has been suggested
[Kawabe et al, 1994], although the physiological relevance of this observation is
disputed as only a weak effects have been noted in vivo [Jacobowitz et al, 1993].
Reports of Type I AC phosphorylation are again disputed, nonetheless there are
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reports that phosphorylation enhances forskolin- [Choi et al, 1993] and
Ca2+/calmodulin- [Jacobowitz et al, 1993] stimulated activity. At present there are
few reports of regulation of adenylyl cyclase activity by phosphorylation at the level of
G-proteins [Carlson et al, 1989; Daniel-lssakani et al, 1989]. Nevertheless Gas has
been reported to be phosphorylated by both protein kinase C and protein kinase A in
vitro [Pyne et al, 1992] and G-proteins, including Goes, are reported to be a substrate
for the protein tyrosine kinase Src [Hausdorff et al, 1992]. Furthermore
phosphorylation of Goc; by PKC has been suggested as a mechanism for
phosphorylation-mediated inhibition of Ca2+ mobilisation in human platelets [Yatomi
et al, 1992]. It is therefore possible that G-protein phosphorylation, as well as AC
phosphorylation, may become more apparent as a form of regulation in the future.
In summary through the interaction of the a; (inhibitory) or (3y subunits (which can
stimulate or inhibit AC activity) with AC isoforms and or aq interaction with other
effector systems which might consequently raise Ca2+ or activate PKC (which can
stimulate or inhibit AC activity) we find that three distinct patterns of G-proteins
regulation of AC exist: Gq and Gj both stimulate AC activity; Gq and Gi both inhibit; Gj
inhibits/Gq stimulates. All the isoforms are positively regulated by Gtxs subunits. It is
therefore apparent that AC isoforms have evolved such that there is little apparent
redundancy amongst the isoforms with respect to the precise profile of regulation.
Amongst the isoforms isolated to date there exists a large potential for cross-talk and
integration of signals mediating from at least Gs, Gq/n and Gj/0 linked receptors and
possibly growth factor tyrosine kinase receptors.
Information concerning isoform-specific regulation of AC'S is obviously important
especially to the understanding of cAMP formation in the brain where individual
isoforms are specifically expressed in discrete regions [reviewed in Cooper et al,
1995]. Expression of AC isoforms in tissues such as the anterior pituitary gland
however remains largely undescribed. At present there is no published information
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on the AC isoforms present in aT3-1 cells. From data presented in this chapter, it
appears that multiple isoforms are being expressed as the profile of regulation
demonstrated does not obviously correspond to any one isoform based on our
current understanding of this field. The present evidence therefore suggests that
LHRH is indeed functionally capable of activating the Gj/0 family of G-proteins.
Recent experiments in our laboratory have demonstrated agonist-regulated co-
immunoprecipitation of Gjai/2 together with the LHRH receptor [Mitchell et al
manuscript in preparation], which clearly authenticates our inferences from the MAP
kinase and cAMP assay data. The LHRH receptor now joins an increasing number
of receptors which are promiscuous in their interactions with G-proteins.
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Table 4.1
Effects of protein kinase inhibitors on forskolin-stimulated cAMP responses
with LHRH and pertussis toxin in aT3-1 cells
Where appropriate pertussis toxin (PTx; 100 ng/ml) was added to the normal growth
medium to a finai concentration of 100 ng/ml for -18 h. Thereafter aT3-1 cells were
preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at 37°C before the
addition of forskolin (1 pM) and LHRH (300 nM) as indicated for 30 min. All inhibitors
were added 5 min prior to stimuli. The table shows the mean values ± SEM of data
from at least 6-8 determinations. Data were first expressed as a % of the forskolin-
stimulated response in each individual experiment so that the normalised forskolin-
stimulated value applies to all incubations. Typical values for basal, LHRH, PTx and
forskolin were in the region of 0.8-1.2, 0.6-1.0, 0.6-1.1 and 70-120 nmoles/50 pi
respectively. None of the inhibitors had any significant effect on basal cAMP
accumulation or that in the presence of LHRH or PTx (data shown in Table 4.2).
Table 4.1
Effect of inhibitors on condition




+ LHRH + PTx
nil 100 47 + 3 88 ±10
GF109203X
(5 (iM)
110 ± 9 53 ±4 95 ±8
staurosporine
(100 nM)
115 ± 15 58 ±4 96 ±8
genistein
(30 nM)
94 ± 13 45 ±7 80 ± 12
RG-13022
(10 (iM)
97 ±3 46 ±5 90 ± 11
Table 4.2
Effects of protein kinase inhibitors on basal cAMP responses with LHRH and
pertussis toxin in aT3-1 cells
Where appropriate pertussis toxin (PTx; 100 ng/ml) was added to the normal growth
medium to a final concentration of 100 ng/ml for -18 h. Thereafter aT3-1 cells were
preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at 37°C before the
addition of forskolin (1 pM) and LHRH (300 nM) as indicated for 30 min. All inhibitors
were added 5 min prior to stimuli. The table shows the mean values ± SEM of data
from at least 6-8 determinations. Data were first expressed as a % of the basal
response in each individual experiment so that the normalised basal value applies to
all incubations. Typical values for basal, LHRH, PTx were in the region of 0.8-1.2,
0.6-1.0, 0.6-1.1 nmoles/50 pi respectively. None of the inhibitors had any significant
effect on basal cAMP accumulation or that in the presence of LHRH or PTx.
Table 4.2
Effect of inhibitors on condition
inhibitor (% of basal cAMP formation)
basal LHRH PTx
nil 100 95 + 7 106 ±5
GF109203X
(5 fiM)
106 ±9 97 ±3 108 ±5
staurosporine
(100 nM)
105 ±5 98 ±6 104 + 6
genistein
(30 |iM)
94 ±3 96 ±7 105 ± 4
RG-13022
(10 |iM)
97 ±3 98 ± 5 103 ±5
Figure 4.1
Effect of LHRH on forskolin- and PACAP-stimulated cAMP formation in aT3-1
cells.
aT3-1 cells were preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at
37°C before the addition of forskolin (1 pM), PACAP (10 pM) and LHRH (0.3-1000
nM) as indicated for 30 min. Values are means ± SEM of data from at least 6-8
determinations. Data is expressed as the concentration of cAMP (nmoles) in a 50 pi
sample from each individual well.
Concentration of LHRH (nM)
Concentration of LHRH (nM)
Figure 4.2
Effect of pertussis toxin on LHRH inhibition of forskolin- and PACAP-
stimulated cAMP formation in aT3-1 cells.
Where appropriate pertussis toxin (PTx) was added to the normal growth medium to
a final concentration of 3-300 ng/ml for -18 h. Thereafter aT3-1 cells were
preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at 37°C before the
addition of forskolin (1 pM), PACAP (10 nM) and LHRH (300 nM) as indicated for 30
min. Values are means ± SEM of data from at least 6-8 determinations. Data is









































Effects of acute and chronic PDBu treatment on forskolin-stimulated cAMP
formation with LHRH and pertussis toxin in aT3-1 cells.
Figure 4.3a shows the acute effects of PDBu on cAMP formation. aT3-1 cells were
preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at 37°C before the
addition of forskolin (1 pM), PDBu (1 pM) and LHRH (300 nM) as indicated for 30
min.
Figure 4.3b shows the effects of PDBu down regulation of phorbol ester-sensitive
PKC isoforms on cAMP formation in aT3-1 cells. PDBu or pertussis toxin (PTx) was
added to the normal growth medium to a final concentration of 300 nM or 100 ng/ml
respectively for -18 h where indicated. cxT3-1 cells were preincubated in MEM/BSA
(0.1%) with IBMX (0.5 M) for 15 min at 37°C before the addition of forskolin (1 pM)
and LHRH (300 nM) as indicated for 30 min.
Values are means ± SEM of data from at least 3-6 determinations. Data is
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Effects of ionomycin and EGTA (agents which affect Ca2+ mobilisation) on
forskolin-stimulated cAMP formation with LHRH and pertussis toxin in aT3-1
cells.
Figure 4.4a shows the effects of the Ca2+ ionophore, ionomycin, on cAMP formation.
cxT3-1 cells were preincubated in MEM/BSA (0.1%) with IBMX (0.5 mM) for 15 min at
37°C before the addition of forskolin (1 pM), ionomycin (30 pM) and LHRH (300 nM)
as indicated for 30 min.
Figure 4.4b shows the effects of the Ca2+ chelator EGTA on cAMP formation in aT3-
1 cells. Pertussis toxin was added to the normal growth medium to a final
concentration of 100 ng/ml for -18 h and aT3-1 cells were preincubated in MEM/BSA
(0.1%) with IBMX (0.5 M) ± EGTA (5 mM) for 45 min at 37°C before the addition of
forskolin (1 pM) and LHRH (300 nM) as indicated for 30 min.
Values are means ± SEM of data from at least 3-6 determinations. Data is

























DIFFERENTIAL ACTIVATION OF MAP
KINASE BY PHOSPHOLIPASE C-
COUPLED RECEPTORS
5.1 INTRODUCTION
We have previously demonstrated that stimulation of the native LHRH receptor in
aT3-1 cells results in the phosphorylation and activation of MAP kinase [Sim &
Mitchell, 1995a; Sim et al, 1994; Sim et al, 1995; Wolbers et al, 1995]. This novel
signalling cascade appears to be dependent on two signalling inputs, both PKC
activation via Gq stimulation of PLC and a pertussis toxin-sensitive G-protein [Sim et
al, 1995 and Chapter 3]. Since this work was first undertaken it has become
apparent that many G-protein coupled receptors can activate this important family of
enzymes, especially those receptors that are coupled to Gj/0-proteins [Crespo et al,
1994; Faure et al, 1994; Johnson et al, 1994; Koch et al, 1994]. The mechanisms
involved are not fully clarified but it seems that for Gi/0-receptors, the signal is
transduced to MAP kinase by the Py subunits, tyrosine phosphorylation and Ras
[Hawes et al, 1995]. Gq/n coupled receptor signalling is less clearly defined but
would appear to involve phosphoinositide (PI) hydrolysis and PKC activation [Hawes
et al, 1995; Koch et al, 1994], although whilst in some cases PKC activation is
sufficient to activate Raf-1 and hence MAP kinase, other Gq-mediated signalling
systems require additional signal input such as Ras activation and/or tyrosine
phosphorylation [Buhl et al, 1995; Qian et al, 1994; Seufferlein & Rozengurt, 1995].
In this Chapter we have transiently expressed (in COS 7 cells) several PLC-coupled
receptors of structurally-dissimilar subfamilies, in order to assess whether or not their
ability to activate PLC and cause phosphoinositide hydrolysis correlates with an
ability to activate MAP kinase. The receptors investigated are the LHRH receptor
(an atypical rhodopsin family member), the 5-hydroxytryptamine (5-HT)2c receptor (a
more conventional rhodopsin family member) and the mGlu 1a metabotropic
glutamate receptor (from a distinct family with large extracellular domains and
lacking many of the structural motifs conserved in the rhodopsin family).
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In a few cases, for example the thrombin receptor in CCL 39 cells, the
spingosylphosphorylcholine receptor (SPC) in Swiss 3T3 cells and the platelet
activating factor (PAF) receptor when transfected in CHO cells evidence for "dual
activation" of MAP kinase by both PKC-dependent and pertussis toxin-sensitive
paths has been reported [Honda et al, 1994; Kahan et al, 1992b; Seufferlein &
Rozengurt, 1995]. Interestingly these receptors have all been reported to interact
with more than one G-protein [Offermans & Schultz, 1994; Sim et al, 1995], notably
the thrombin receptor, another member of the rhodopsin family of G-protein coupled
receptors, which displays an unusual Asp for Asn substitution in the seventh
transmembrane domain (TMD VII) [Vu et al, 1991]. This is similar to the LHRH
receptor which displays a double reciprocal mutation of Asn for Asp87 in TMD II and
Asp for Asn318 in TMD VII [Tsutsumi et al, 1992]. Thus it is possible that the TMD
VII Asp-containing motif of the LHRH receptor is critical to its ability to activate MAP
kinase. Using site-directed mutagenesis, two mutants of the murine LHRH receptor
have been produced, Asp318Asn and Asn87Asp; Asp318Asn. Both these mutants
retained the ability to bind ligand with high affinity and activate PLC in response to
specific agonists [Mitchell et al, 1996; Zhou et al, 1994]. The ligand binding
characteristics and PLC responses as well as MAP kinase activation were monitored
for both mutants and the wild type receptor after transient expression in COS 7 host
cells, in order to assess whether these atypical sequence motifs are important to
MAP kinase activation by the LHRH receptor.
5.2 RESULTS
When transiently expressed in COS cells, the LHRH, 5-HT2C and the mGlu 1a
receptor showed a marked and concentration dependent increase in [3H]inositol
phosphate formation in response to LHRH, 5-hydroxytryptophan (5-HT) and (1S,
3R)-aminocyclopentane dicarboxyclic acid (ACPD) respectively (Figure 5.1a). Under
these conditions, the maximum responses observed for the LHRH and 5-HT2C
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receptors were similar and that for the mGlu 1a receptor was slightly less
representing a 4.5 ± 0.4, 3.7 ± 0.3 and 2.9 ± 0.4 fold increases over basal activity
respectively (means ± SEM, n=4). The EC50 values for inositol phosphate formation
by the respective agonists were 11+6 nM, 118 ± 81 nM and 7.0 ± 5.4 ju.M for LHRH,
5-HT and ACPD. None of these agonists stimulated [3H]inositol phosphate formation
in any of the cells expressing the other receptors or in untransfected COS 7 cells and
basal levels of [3H] inositol phosphates were not significantly different between cells
transfected with the different cDNAs.
The ability of these receptors (expressed in COS 7 host cells) to activate MAP kinase
in response to LHRH, 5-HT and ACPD was also examined. The transfected LHRH
receptor mediated a prominent concentration-dependent MAP kinase response to
LHRH (Figure 5.1b), which reached a maximum of 119 ± 9% increase over basal
activity at 10 min exposure to LHRH. The EC50 value for this response was 34 + 2
nM (means ± SEM, n=7). Also seen in Figure 5.1b the 5-HT2C and mGlu 1a
receptors were only able to elicit a minimal activation of MAP kinase with maximum
responses of 14 ± 7% and 21 ± 9% over basal following stimulation for 10 min with
20 pM 5-HT and 100 pM ACPD respectively (means ± SEM, n=5). These
experiments with 5-HT and ACPD were repeated over a time course of 0-30 min to
address the possibility that these receptors were activated only transiently or after a
significant delay. No greater response was observed over this period. In contrast
[3H]inositol phosphates continued to accumulate throughout a 30 min time course in
response to LHRH, 5-HT and ACPD with only a slight reduction after 3-4 min (data
not shown), demonstrating that functional coupling of the receptor was still apparent
during this period.
In Figure 5.2, LHRH-induced inositol phosphate formation (a), and MAP kinase
activation (b), are compared in three cell lines to demonstrate that this phenomenon
is not restricted to COS 7 cells. These include COS 7 cells where the receptor is
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transiently expressed, a Chinese Hamster ovary (CHO) cell line, CHO 7.5, which
stably expresses the LHRH receptor, and the aT3-1 cell line where the LHRH
receptor is endogenously expressed. In aT3-1 cells and CHO 7.5 cells, 100 nM
LHRH caused a 5.8 ± 0.6 and a 6.2 ± 0.7 fold increase over basal in [3H]inositol
phosphate formation with EC50 values for this response of 2.8 ± 0.3 nM and 3.1 ± 0.2
nM respectively. This compares with mean values of 4.5 fold and 11 nM in COS 7
host cells (above). MAP kinase activation in these cell lines was concentration
dependent and reached a maximum of 245 ± 9% and 198 ± 11% of basal activity
with corresponding EC50 values of 3.4 ± 0.6 nM and 97 ±11 nM respectively.
Corresponding values in COS 7 host cells were 219 ± 8% and 34 nM (above).
Experiments were carried out to investigate the possible involvement of PKC in MAP
kinase activation by the LHRH receptor expressed in COS 7 and CHO 7.5 cells
(Table 5.1) and are compared to data obtained by this receptor in aT3-1 cells. The
MAP kinase response to LHRH (100 nM for 10 min) was mimicked by the PKC
activator, PDBu (1 pM for 10 min) in both cases. The responses to LHRH and PDBu
were inhibited by the highly selective PKC inhibitor GF109203X [Toullec et al, 1991],
with very similar IC50 values, 1.4 ± 0.4 pM and 1.3 ± 0.3 pM respectively for COS 7
cells (Figure 5.3) and 1.8 ± 0.6 pM and 0.8 ± 0.2 pM respectively for CHO 7.5 cells
(means ± SEM, n=4-6). This pattern was also observed for two other PKC inhibitors:
Ro-31 8220 [Davis et al, 1989] (0.36 ± 0.12 nM and 0.27 + 0.11 nM; for LHRH and
PDBu responses in CHO cells) and H7 [Hidaka et al, 1984] (69.8 ± 24 nM and 30.6 +
13 nM for corresponding responses in COS 7 cells; 36.7 ± 13 nM and 32.9 ± 10 nM
in CHO 7.5 cells).
The ability of the LHRH receptor to activate MAP kinase evidently appears to rely on
PKC. However the other PLC-stimulating receptors tested here do not seem to have
the ability to evoke such a response, within the limits of detection of the present
assay. Therefore the ability of these receptors to activate PKC was examined to see
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assay. Therefore the ability of these receptors to activate PKC was examined to see
if any differences were apparent [Lutz et al, 1993]. The translocation of [3H]PDBu
binding sites from the cytosol to membrane fractions is a critical step in activation of
conventional PKC isoforms (ie phorbol ester-sensitive PKC isoforms) [Bazzi &
Nelsestuen, 1987]. It can be seen in Table 5.2 that in agreement with the data
showing a similar ability of the LHRH, 5-HT2c and mGIu 1a receptors to elicit
[3H]inositol phosphate formation all these receptors achieved a comparable
translocation/activation of PKC (with on average 33, 39 and 31% of the [3H]PDBu
binding sites being recovered in the membrane compared to 12, 14 and 11% in
unstimulated cells). Control responses of these cells to PDBu (300 nM) resulted in a
stronger translocation/activation with on average translocation of 60-80% of the
[3H]PDBu binding sites to the membrane [Lutz et al, 1993]. This treatment also
caused translocation/activation of PKC in CHO 7.5 cells with 49 + 6% of the
[3H]PDBu binding sites being recovered in the membrane compared to 12 ± 0.8% in
untreated cells. PKC a is the only conventional PKC isoform present in COS 7 cells
[Kosaka et al, 1988]. It has previously been shown that translocation to the
membrane of PKC a in response to 100 nM LHRH was largely prevented as a result
of removing free Ca2+ from the medium by the addition of 3 mM EGTA (14 ± 6%
incremental translocation to the membrane compared to 33 ± 8% in normal medium;
means ± SEM, n=5) [Lutz et al, 1993].
It is possible that MAP kinase activation by the LHRH receptor in transfected cells
may be an inappropriate consequence of overexpression of the receptor protein. To
address this possibility, the affinity and number of LHRH receptors was determined
by equilibrium binding with the LHRH agonist [125]buserelin. In samples of the
transfections used for the previous experiments, the Kp and Bmax of specific
[125]buserelin binding sites were 1.0 ± 0.4 nM and 0.93 ± 0.3 pmol/mg protein for the
LHRH receptor expressed in COS 7 cells and 0.4 ± 0.3 and 0.59 ± 0.26 pmol/mg
protein for the receptor expressed in CHO 7.5 cells. aT3-1 cells expressed 1.27 ±
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0.29 pmol/mg protein of [125]buserelin binding sites which had a Kd of 0.6 ± 0.3 nM.
These corresponding values would indicate that both the number and affinity of
LHRH receptors expressed in these host cells equates with LHRH receptor numbers
in a cell line which naturally express the receptor and the ability of this receptor to
activate MAP kinase is unlikely to be an artefact of overexpression of the receptor
protein.
The uncommon pattern of PKC dependence and pertussis toxin sensitivity for LHRH-
induced MAP kinase activation in aT3-1 cell [Sim et al, 1995; Chapter 3] has also
been reported for the thrombin receptor [Kahan et al, 1992b]. The thrombin receptor
also displays an atypical Asp substitution for the generally conserved Asn in TMD
VII, therefore it is possible that (in addition to PKC activation) the ability of the LHRH
receptor to activate MAP kinase relies in some way upon this unusual characteristic
of the receptor. MAP kinase activation by the wild type receptor was therefore
compared to two mutant receptors developed by site-directed mutagenesis and
containing a Asp318Asn substitution and a double reciprocal Asn87Asp;Asp318Asn
substitution. The Asn87Asp single mutant receptor displayed no ligand binding and
was therefore discarded from subsequent studies. Table 5.3 shows the ligand
binding characteristics and, [3H]inositol phosphate responses and MAP kinase
activation for these experiments. Both the Asp318Asn mutant and the
Asn87Asp;Asp318Asn double mutant displayed less than 50% (47% and 29%
respectively) of the wild type [125]buserelin binding sites/mg of protein after
transfection with equal amounts (25 pg) of cDNA in COS 7 cells, indicating
expression of a substantially reduced number of functional receptors. However the
Kd value of 1.1 ± 0.3 and 0.8 ± 0.3 nM for the mutant and double mutant were
comparable to a Kq value of 1.0 ± 0.6 nM for the wild type receptor suggesting that
the functional receptors present have a similar affinity for ligand. This pattern is
mimicked by the [3H]inositol phosphate formation and MAP kinase responses where
the EC50 values for each activity are similar with respect to the wild type receptor but
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both mutants displayed greatly reduced maximum responses. Therefore it is
apparent that where functional mutant receptors are present they are equally
capable of activating PLC and MAP kinase. Furthermore it is improbable that the
atypical amino acid substitutions in TMD VII (and TMD II) confer the especially
powerful ability of the LHRH receptor to activate MAP kinase.
The effects of pertussis toxin on MAP kinase activation by the wild type and mutant
LHRH receptors was also assessed in COS 7 cells to determine if it reflected the
inhibition detected in aT3-1 cells [Sim et al, 1995; Chapter 3]. Control LHRH-
induced MAP kinase activity (100 nM, 10 min) represented an increase of 95 ± 7%,
42 ± 6% and 19 ± 9% of basal MAP kinase activity for the wild type, Asp318Asn
mutant and the Asn87Asp;Asp318Asn double mutant respectively. After a 18 h
pretreatment with pertussis toxin, LHRH-induced activity was reduced to 38 ± 6%
and 19 ± 5% for the wild type and Asp318Asn mutant. The reductions caused by
pertussis toxin were statistically significant in both cases (p< 0.05, Mann-Whitney Li¬
test). Under the present experimental conditions, the MAP kinase response to LHRH
in the Asn87Asp;Asp318Asn double mutant was considered too small to accurately
determine any inhibition by pertussis toxin. Pertussis toxin treatment had no effect
on [3H]inositol phosphate formation by any of these receptors (Figure 5.4b) and was
shown to be specific to the pertussis toxin holotoxin, as neither the B-subunit [O'Neill
et al, 1992] or N-ethyl maleimide (NEM)-inactivated holotoxin had any significant
effect on LHRH-mediated MAP kinase activity.
5.3 DISCUSSION
When the LHRH, 5-HT2C and mGlu 1a receptors were transiently expressed in COS
7 host cells after transfection of their cDNAs, all three receptors mediated both a
strong [3H]inositol phosphate formation (Figure 5.1) and the translocation of PKC
from the cytosol to the membrane (Table 5.2). Amongst Gq/i 1-protein coupled
receptors that are reported to cause activation of MAP kinase it is proposed that a
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functional coupling to PLC by the Ga subunits and a PKC-dependent step is involved
[Faure et al, 1994; Hawes et al, 1995]. The Gq-linked receptors, ale AR or IV^
(when expressed in COS 7 cells) were inhibited by downregulation or PKC inhibition
with GF109203X and expression of mutationally inactive Raf, but were unaffected by
expression of p-adrenergic receptor kinase carboxy terminus peptide (which
sequesters Py subunits) or mutationally inactive Ras [Hawes et al, 1995]. Also in
COS 7 cells, overexpression of Py subunits or PLCP2 (which is predominantly
activated by Py), as well as constitutively active aq subunits could increase MAP
kinase activity whereas mutationally activated a; was without effect [Faure et al,
1994]. However in COS 7 cells, demonstration of a functional coupling to PLC by
measurement of [3H]inositol phosphate formation and activation of PKC by showing
a shift in the [3H]PDBu binding sites from the cytosol to the membrane fraction was
insufficient to cause a significant MAP kinase activation by the 5-HT and mGlu 1a
receptors. In contrast the LHRH receptor elicited a substantial and sustained
activation of MAP kinase in addition to [3H]IP formation and PKC translocation. This
closely paralleled the activation of MAP kinase previously demonstrated in the aT3-1
gonadotroph cell line [Sim et al, 1995; Chapter 3] and was further shown to have this
property in a stably transfected CHO cell line containing the LHRH receptor. In all
cell lines MAP kinase activation was achieved by the phorbol ester, 12,13 phorbol
dibutyrate (PDBu) showing a greater response than the LHRH-mediated response in
COS 7 and CHO cells and a weaker response in <xT3-1 cells. In all cases both
LHRH- and PDBu-induced MAP kinase activation was substantially attenuated by
inclusion of a number of specific PKC inhibitors. It is interesting to note from the data
concerning the IC50 values in Table 5.1 that in the host cell lines containing the
transfected receptors the ICsofor inhibition of LHRH- and PDBu-induced activity
were of a similar potency for GF109203X and Ro-31 8220 and H7 suggesting that it
is largely a similar species of PKC isoform that is involved in the transduction of both
these signals to MAP kinase. In contrast, in aT3-1 cells there is a marked difference
113
between the potency of inhibition of LHRH- and PDBu-stimulated responses
especially with respect to inhibition with H7. COS 7 and CHO cells are reported to
only contain a and £ isoforms [Kosaka et al, 1988; Ways et al, 1992]. These
observations are in agreement with earlier investigations form our laboratory; only
PKC a and PKC £ were present in COS 7 cells [Johnson et al, 1995] whilst in CHO
cells the only one strongly staining band was present corresponding to PKC £,
although no clear staining was observed there was some evidence for very low
levels of PKC a and PKC 0 in these cells which was below the reasonable levels of
detection of the current experimental conditions (not shown) [Simpson, personal
communication]. The aT3-1 cell line is known to contain at least the a, e and £
isoforms at high levels and additionally an apparently novel isoform or modified
variant of a PKC isoform which has recently been characterised in the anterior
pituitary [Ison et al, 1993]. The pharmacological characteristics of this PKC appear
to be similar to the PKC involved in the LHRH-induced activation of MAP kinase
activation in the aT3-1 cell line [Sim et al, 1995; Chapter 3] and anterior pituitary
tissue [Mitchell et al 1994; Chapter 6]. The differences in PKC isoforms available in
the cells are likely to be reflected in the variances observed in the IC50 values
obtained for these reagents. The isozyme-specific potency of two compounds which
are like the PKC inhibitors GF109203X and Ro-31 8220 (Go 6850 and Go 6976) has
been investigated using recombinant PKC isoforms in an in vitro kinase assay
[Martiny-Baron et al, 1993]. This study found that the IC50S varied considerably,
especially between the Ca2+ dependent and independent isoforms. Furthermore that
the compound identical to GF109203X, inhibited the PKC isozymes with a rank order
of oc>Pi>e>5>C. Our data would strongly suggest a requisite role for PKC and PLC in
this signalling cascade, however it would appear that these alone are insufficient to
cause activation of MAP kinase by all receptors. The 5-HT and mGlu 1a receptors
both caused translocation of PKC and [3H]IP formation to the same extent as the
LHRH receptor after transfection with identical amounts of cDNA (25 pg). It therefore
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seems unlikely (unless these receptors require a lower functional occupancy to elicit
PLC activation than the LHRH receptor) that the inability of these two receptors to
activate MAP kinase is due to lower expression of receptors. It was confirmed that
the LHRH receptor was not being expressed in excess of physiological levels by
measurement of the [125l]buserelin binding to the LHRH receptor expressed in COS
7 cells. At the time of these experiments were undertaken, no good agonist was
available for binding studies on the mGlu 1a receptor or the 5-HT2C receptor so the
question that lower receptor numbers were expressed cannot be entirely ruled out.
However this would only be crucial if the receptor number as well as level of IP
formation and activation of PKC is important.
From these results, it would therefore seem likely that some secondary signal input
must be additionally required. Alternatively the structure of the receptor may
somehow allow the receptor to interact with the appropriate intracellular machinery to
activate MAP kinase. The LHRH receptor is an unusual member of the rhodopsin
superfamily of seven transmembrane-domain (TMD VII) G-protein-coupled receptors.
Sequence analysis has revealed a number of atypical amino acid substitutions in
TMD II and VII including an Asn for Asp at residue 87 and an Asp for Asn at residue
318 [Tsutsumi et al, 1992]. These residues lie in close proximity to each other in the
three dimensional structure and are probably joined by a hydrogen bond between the
two residues [Zhou et al, 1994], The substitution in TMD VII occurs within a
generally conserved Asn-Pro-X-X-Tyr motif in rhodopsin family members [Tsutsumi
et al, 1992; Zhou et al, 1994], An identical substitution in this conserved motif is also
found in another member of this family, the thrombin receptor [Vu et al, 1991].
Correspondingly the thrombin receptor is also capable of activating MAP kinase
[Kahan et al, 1992b]. Remarkably the thrombin receptor, but not the Mi muscarinic
or 5-HT2c (all PLC-coupled receptors), in CCL 39 hamster fibroblasts was able to
cause mitogenesis which may be attributed to its ability to activate MAP kinase
[Kahan et al, 1992a; Seuwen et al, 1990]. Using site-directed mutagenesis of the
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murine LHRH receptor, three mutant receptors were generated (Asp318Asn,
Asn87Asp and Asn87Asp;Asp318Asn) to assess the effects on intracellular
signalling of these substitutions by re-instating the typical conserved sequence [Zhou
et al, 1994]. The mutation of Asp(318) to Asn is able to maintain the hydrogen bond
between TMD II and TMD VII and it appears that Asn is able to act as both donor or
acceptor in this site [Zhou et al, 1994]. The double reciprocal mutation, or a single
Asn for Asp(318) should therefore be able to maintain the structural integrity of the
receptor and ligand binding characteristics. Interestingly the single mutation of
Asn87 to Asp resulted in a complete loss of agonist binding [Zhou et al, 1994] and
was therefore not used in further studies. The two mutants were both shown to elicit
significant [3H]inositol phosphate formation and MAP kinase activation albeit with
greatly reduced responses compared to the maximal measured response of the wild
type LHRH receptor. Similar observations have previously been made [Zhou et al,
1994]. Measurement of LHRH binding characteristics of these receptors with the
superagonist [125l]buserelin, revealed a vastly reduced number of high affinity ligand
binding sites in cells transfected with identical amounts of cDNA for the mutant and
wild type receptors. However, all three variants bound the ligand with similar affinity
which may suggest that these mutations in some way interfere with protein folding,
insertion or targeting to the plasma membrane, rather than an impairment of
functional coupling to PLC and MAP kinase. The reduction of maximal [3H]inositol
phosphate formation and MAP kinase responses in each case reflect a reduced
population of functional LHRH receptors as the EC50 values for the responses are all
similar to those obtained for the wild type receptor. Furthermore the maximal
responses for PLC and MAP kinase achieved by the mutants reflected quite closely
the Bmax value from the ligand binding. The findings from a parallel study of the
corresponding mutants of the rat LHRH receptor were contradictory [Cook et al,
1993]. It was suggested that the mutants were unresponsive with respect to
[3H]inositol phosphate formation and furthermore that the double mutant did not bind
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ligand. However it is possible that the sensitivity of the assay used may be
insufficient at the low levels at which the mutant receptors are expressed.
These results indicate that the atypical substitution in TMD VII does not alone permit
the LHRH receptor to cause activation of MAP kinase. An alternative possibility may
be that the Asp Pro X X Tyr motif is important to the ability of the receptor to interact
with multiple G-proteins, particularly Gj/0. Many of the G-protein coupled receptors
that are capable of activating MAP kinase are either coupled to pertussis toxin-
sensitive Gj/o proteins such as the M2 muscarinic receptor [Crespo et al, 1994] and
the a2A-adrenergic receptor [Albas et al, 1993; Hawes et al, 1995] or to multiple G-
proteins such as the LPA receptor [Hordijk et al, 1994], PAF receptor [Honda et al,
1994], endothelin receptor [Bogoyevitch et al, 1995; Kasuya et al, 1994] thrombin
receptor [Winitz et al, 1994] (although the signals generated from multiple G-proteins
are not necessarily involved in activation of MAP kinase). It has previously been
demonstrated for the LHRH receptor that agonist-induced MAP kinase response are
sensitive to pertussis toxin [Sim et al, 1995; Wolbers et al, 1995]. The response of
the double mutant was considered too small for accurate investigation but
assessment of the effect of 100 ng/ml pertussis toxin on LHRH-induced MAP kinase
by the Asp318Asn receptor was shown to be similar to the wild type receptor
resulting in a significant attenuation of the response and indicating that the Asp 318
motif was not critical to interaction with Gj/0 proteins. Although the atypical motif in
TMD VII appears inconsequential to the interaction of the LHRH receptor with Gj/0
proteins [Sim & Mitchell, 1995a; Wolbers et al, 1995], the ability of the LHRH
receptor to interact with multiple G-proteins and generate multiple signal inputs is still
likely to be pivotal to the ability of this receptor (and perhaps many others) to activate
MAP kinase .
Another unusual aspect of the LHRH receptor is the absence of the carboxyl terminal
tail which is characteristic of all receptors of the TMD VII G-protein linked
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superfamily. The carboxy-terminal sequence of most receptors contain many
serine/threonine residues which are potential phosphorylation sites for kinases, such
as p-adrenergic receptor kinase (PARK) and PKC and PKA [Hausdorff, 1990;
Ostrowski, 1992], These sites (and potentially others in the third intracellular loop)
may be phosphorylated in response to chronic exposure to a receptor agonist and
are involved in rapid homologous desensitisation of these receptors [Probst et al,
1992; Wojcikiewicz et al, 1993]. Many of the responses induced by the wild type
LHRH receptor do not appear to desensitise, including [3H]inositol phosphate
formation in either COS 7, GH3 or aT3-1 cells [Davidson et al, 1994b; Mitchell et al
unpublished observation] and PLD [Fennell et al, 1993; Naor, 1990b; Stojilkovic et al,
1994]. Curiously the Asp318Asn and Asn87Asp;Asp318Asn mutants of the LHRH
receptor displayed a rapid and transient PLD (but not PLC) response to LHRH,
despite a reported involvement of PLC activity upstream of PLD in cxT3-1 cells
[Stojilkovic et al, 1994] and COS 7 and CHO cells transfected with wild type LHRH
receptors [Mitchell et al, unpublished observation]. Thus these residues (or at least
Asn 318) must somehow allow this response to become susceptible to
desensitisation. MAP kinase activity observed in response to LHRH is relatively long
lasting being sustained at high levels for 40 min and remaining significantly above
basal for over 2 h [Sim et al 1994; Chapter 3]. The capacity of the LHRH receptor to
sustain the upstream signalling responses may perhaps be mandatory to the ability
to activate MAP kinase. In support of this, a truncated mutant of the platelet
activating factor (PAF) receptor is reported to show a non-desensitising [3H]inositol
phosphate formation and increased MAP kinase activity in response to PAF when
expressed in host cells [Honda et al, 1994; Takano et al, 1994], A sustained
activation of MAP kinase is also seen for the thrombin receptor in quiescent hamster
CCL 39 cells, whilst the Mi muscarinic receptor elicited only a transient activation in
these cells [Kahan et al, 1992b]. However this could not be assigned to the capacity
of the thrombin receptor, but not the Mi receptor, to sustain non-desensitising
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signalling responses, as some components of the M-| and M3 muscarinic receptors
PLC activation are resistant to rapid desensitisation [Hu et al, 1991; Wojcikiewicz et
al, 1993]. Moreover in contrast to PLC responses by the LHRH receptor [Davidson
et al, 1994b], intracellular responses of the thrombin receptor such as PLD activation
[Nieto et al, 1994] and phosphoinositide hydrolysis [Paris et al, 1988], desensitise
rapidly. Interestingly the thrombin receptor, in contrast to the Mi muscarinic and 5-
HT2C receptors (which also cause marked PLC activation), was able to cause
mitogenesis which may in part be a reflection of its ability to cause a sustained
activation of MAP kinase. Furthermore of the receptors we investigated, the ability to
activate MAP kinase cannot all be attributable to sustained PLC activation, as whilst
the mGlu 1a receptors PLC responses appear to desensitise rapidly [Aramori &
Nakanishi, 1992], the 5-HT2C receptor in some cases, for example agonist-induced
phosphoinositide turnover in the choroid plexus, is resistant to inactivation [Conn &
Sanders-Bush, 1986]. Taken together, it therefore seems that no obvious correlation
between desensitisation of PLC coupling and the ability to activate MAP kinase
exists.
One further possibility which was not investigated here as to why the LHRH receptor
but not the mGlu or 5-HT2C receptors can activate MAP kinase is the ability of
receptors to cause tyrosine phosphorylation. This unexpected property of G-protein
linked receptors is reported for the LPA [Hordijk et al, 1994], thrombin [Rao et al,
1994], PAF [Honda et al 1995; Lui et al 1995], endothelin [Cazaubon et al 1993], and
LHRH [Johnson et al, 1995; Wolbers et al, 1995] receptors. Additionally the LHRH
receptor has a tyrosine residue at position 323 in close proximity to the carboxyl
terminus. Phosphorylation of this tyrosine residue may somehow allow an
interaction with intracellular binding proteins which could in principle enable the
LHRH receptor to activate additional cascades traditionally utilised by the growth
factor receptors. Alternatively, increasing evidence is being reported on the
importance of Src homology (SH) 2 and SH3 binding domains or pleckstrin homology
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(PH) domains in interactions between adaptor proteins and downstream signalling
components such as the activation of Ras by Py subunits [Luttrell et al, 1995] or the
phosphorylation-dependent attraction/activation of guanosine nucleotide exchange
factors via adaptor proteins [Honda et al, 1994; Liu et al, 1994]. Therefore it is
possible that the LHRH receptor, but not all PLC-coupled receptors has the ability to
utilise such mechanisms. Furthermore there is now accumulating evidence of cross¬
talk between receptor tyrosine kinases cascades and G-protein-coupled receptor
signalling cascades [Daub et al, 1996; Yang et al, 1991], Evidence for this
hypothesis has centred on the EGF receptor. It was first suggested that stimulation
of the EGF receptor resulted in increased tyrosine kinase-dependent activation of
PLCy via a pertussis toxin-sensitive G-protein (Gj), furthermore Gj was
coimmunoprecipitated with the EGF receptor following exposure to EGF [Yang et al,
1991]. Further research by this group has confirmed these observations and
additionally shown a requirement for activation of the tyrosine kinase domain of the
EGF receptor [Yang et al, 1991]. More recently, it has been suggested that G-
protein linked receptors activate MAP kinase by a transactivation mechanism
whereby G-proteins can intercept signalling pathways usually utilised by tyrosine
kinase growth factor receptors [Daub et al, 1996]. At present there still appears to be
more evidence supporting the more conventional idea that G-protein coupled
receptors can activate MAP kinase on there own merits, however it is possible that
these isolated examples may hint at underlying mechanisms still to be unravelled.
In conclusion, it is still unclear why activation of some, but not all PLC-coupled
receptors can result in an increased MAP kinase activity. The factors which
determine this ability are as yet undetermined but are likely to be dependent on
many circumstances such as the ability to activate specific kinases or intracellular
signalling cascade components although from the evidence presented in this
Chapter it appears that rather than the ability to cause sustained activation of PLC
and PKC translocation, the ability to interact with multiple G-proteins may be
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Table 5.1
Effects of GF109203X, Ro-31 8220 and H7 on LHRH- and PDBu-stimulated MAP
kinase activity in host COS 7 and CHO cells and aT3-1 cells
COS 7 and CHO cells previously transfected with plasmids containing cDNA for the
wild type LHRH receptor or aT3-1 cells were treated as indicated for 10 min.
Inhibitors were present for 2-5 min prior to agonist stimulation and where required
vehicle alone was added to a control flask. All data are expressed as a percentage
of the LHRH- or PDBu-induced activity and are means ± SEM (n=4-6). Curve fitting
was carried out as described previously.
Table 5.1
Effects of GF109203X, Ro-31 8220 and H7 on LHRH- and PDBu-
induced MAP kinase activity in host and native cells
IC50 (|iM) for inhibitors in host cells
or aT3-1 cells
Inhibitor Treatment
aT3-1 COS 7 CHO
GF109203X
LHRH (100 nM) 1.8 ± 0.12 1.4 ±0.4 1.8 ±0.6
PDBu (1 (xM) 0.28 ± 0.02 1.3 ±0.4 0.8 ±0.2
Ro-31 8220
LHRH (100 nM) 0.64 ± 0.08 NA 0.36 ± 0.12
PDBu (1 (xM) 0.57 ±0.03 NA 0.27 ±0.11
H 7
LHRH (100 nM) 168 ±12 69.8 ± 24 36.7 ± 13
PDBu (1 (xM) 43.5 ±5.1 30.6 ± 13 32.9 ± 10
Table 5.2
Agonist-induced translocation of PKC in cells expressing wild type LHRH, 5-
HT2C or mGlu 1a receptors
COS 7 cells previously transfected with plasmids containing cDNA for the mouse
wild type LHRH, 5-HT2C and mGlu 1a receptors were treated as indicated for 15
min, then immediately homogenised. The values represent specific equilibrium
binding of [3H]PDBu as dpm per tube in cytosol and membrane fractions prepared
from the COS 7 cells. Non-specific binding was in the range of 500-950 dpm per
tube for cytosol and 260-400 dpm for membranes. Results are the means ± SEM
•k
from 4-6 experiments. Values marked , showed a statistically significant change
from control values by the Student's t-test (p< 0.05)
Table 5.2
Agonist-evoked translocation of PKC in cells expressing LHRH,












Control 2927± 457 417± 85 12
LHRH LHRH (100 nM) 1734 ± 250 846±102 33
PDBu (300 nM) 539±181 897 ±110 62
Control 2573 ± 309 429 ±175 14
5-HT2C 5-HT (20 pM) 1544 ± 277 996 ±166 39
PDBU (300 nM) 608±102 951 ±123 61
Control 3886 ± 495 523 ± 202 11
mGlu 1a ACPD (100 pM) 2419 ± 366 1102 ± 223 31
PDBu (300 nM) 377±172 1198 ± 210 76
Table 5.3
Ligand binding, inositol phosphate and MAP kinase responses of wild type and
mutant LHRH receptors
COS 7 cells were previously transfected with plasmids containing cDNA for the wild
type and mutant mouse(Asp318Asn and Asn87Asp;Asp318Asn) LHRH receptors.
Concentration-response data for [3H]inositol phosphate formation and MAP kinase
activity were determined over a range of 0-1000 nM LHRH as described previously.
Each value is the mean ± SEM from 4-6 determinations. Basal inositol phosphate
formation was in the range of 400-800 dpm and basal [35S]thiophosphorylation of the
MAP kinase substrate peptide was usually 1200-1800 dpm. Baseline activity in
unstimulated cells was subtracted and the agonist-induced curves were normalised
to the activity obtained with the maximally effective dose. Curve fitting was then
conducted as described in Chapter 2 and the EC50 values determined.
Non-specific [125l]buserelin binding (in the presence of 3 pM LHRH) was in the range
of 7000-11000 dpm per tube while specific binding ranged from 5000-114000 dpm
per tube. The affinity of the binding sites for [125l]buserelin was expressed as IC50
values, which were estimated by a self-displacement assay using unlabelled
buserelin (0.03-30 nM). A non-linear error-weighted program (P. fit, Elsevier Biosoft)
was used to calculate IC50 values and Bmax values were determined by the method
of Swillens [Swillens, 1992].
Table 5.3
Ligand binding, inositol phosphate and MAP kinase responses
of wild type and mutant LHRH receptors.
Response measured
LHRH receptor structure




































Agonist-induced [3H]inositol phosphate formation and MAP kinase activation
in COS 7 cells
Figure 5.1 shows concentration-response curves for agonist-induced [3H]inositoi
phosphate formation (a) and MAP kinase activation (b), in COS 7 cells expressing
the LHRH, 5-HT2C or mGlu 1a receptors. The agonists used were LHRH (1-1000
nM; •) for the LHRH receptor, 5-HT (1-300 piM; ■) for the 5-HT2C receptor and
ACPD (1 -300 pM; ▲) for the mGlu 1 a receptor. Each value is the mean ± SEM from
4-6 separate determinations.
In (a), all the transfected cells were preincubated for 10 min with 10 mM LiCI and
represents the total [3H]inositol phosphate accumulation in 30 min incubations with
the appropriate agonists in the presence of 10 mM LiCI. Basal levels of inositol
phosphate accumulations were similar in all transfections and were in the range of
400-700 dpm per assay.
In (b), the specific [35S]thiophosphorylation of MAP kinase substrate peptide was
measured at various concentrations of agonist. Each value is the mean ± SEM from
4-6 determinations. Baseline activity in unstimulated cells was subtracted and the
agonist-induced curves were normalised to the activity obtained with the maximally
effective dose. Curve fitting was then conducted as described in Chapter 2. Basal
unstimulated levels of MAP kinase activity remained very similar between
transfections and untransfected cells and were in the range of 1200-1800 dpm per
assay. In each transfection a sample was stimulated with PDBu (1pM) as a positive
control for the assay and additionally samples were shown to evoke [3H]inositol
phosphate responses to the appropriate ligand.
Stimulus-ind cedMAPkinasactivity(%increaseoverbasalctivity) ocn o
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LHRH-induced [3H]inositol phosphate formation and MAP kinase activation in
COS 7, CHO and aT3-1 cells
Figure 5.2 shows concentration-response curves for [3H]inositol phosphate
accumulation (a) and MAP kinase activity (b) in response to LHRH (0-1000 nM) in
COS 7 (A) , CHO (■) transfected with the wild type LHRH receptor and aT3-1 (•)
cells. Each value is the mean ± SEM from 4-6 separate determinations.
In (a), all transfections were preincubated with 10 mM LiCI and represents the total
[3H]inositol phosphate accumulation in 30 min incubations with the appropriate
agonists in the presence of 10 mM LiCI. Basal levels of inositol phosphate
accumulations were similar in all transfections and were in the range of 400-700 dpm
per assay. In (b), the specific [35S]thiophosphorylation of MAP kinase substrate
peptide was measured at various concentrations of agonist. Baseline activity in
unstimulated cells was subtracted and the LHRH-induced curves were normalised to
the activity obtained with the maximally effective dose. Curve fitting was then
conducted as described in Chapter 2. Basal unstimulated levels of MAP kinase
activity remained constant between transfections and untransfected cells and were in
the range of 1200-1800 dpm per assay. In each transfection a sample was
stimulated with PDBu (1pM) as a positive control for the assay and additionally
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Figure 5.3
Effects of GF109203X on LHRH- and PDBu-induced MAP kinase activity in COS
7 and CHO cells expressing the mouse LHRH receptor
Figure 5.3 shows the concentration dependence of the effects of a highly selective
PKC inhibitor GF109203X on LHRH- (•) and PDBu- (■) induced MAP kinase activity
in COS 7 (a) expressing the wild type mouse LHRH receptor.
GF109203X was added 5 min prior to addition of LHRH 100 nM or PDBu 1 pM for a
further 10 min (a time previously reported to see maximal stimulation of MAP kinase
activity). Each value is the mean ± SEM of between 4-6 experiments and was
calculated as before. Basal activity remained constant between transfections.




















Effects of pertussis toxin on LHRH-induced MAP kinase activity in wild type
and mutant receptors expressed in COS 7 cells
Figure 5.4 shows the LHRH-induced [35S]thiophosphorylation of MAP kinase
substrate peptide by the wild type and Asp318Asn mutant LHRH receptors, and the
resulting inhibition when treated with pertussis toxin.
Following an 18h pretreatment ± 100 ng/ml of pertussis toxin, COS 7 cells
expressing the wild type and Asp318Asn mutant LHRH receptors were incubated
with 100 nM LHRH for 10 min. Inhibition of MAP kinase responses for the wild type
and Asp318Asn mutant respectively by 100 ng/ml pertussis toxin were statistically
significant (p < 0.05, Mann-Whitney U-test). This effect were shown to be a specific
effect of an active holotoxin as under the same conditions neither the B-subunit or N-
ethyl maleimide (NEM)-inactivated holotoxin had no significant effect on MAP kinase
substrate peptide [35S]thiophosphorylation. None of these treatments had any




ACTIVATION OF MAP KINASE IN
ANTERIOR PITUITARY TISSUE AND THE
RELATIONSHIP TO LHRH PRIMING1 IN
FEMALE RAT PITUITARIES
6.1 INTRODUCTION
An apparently unique property of the LHRH receptor is the phenomenon of LHRH
self priming (previously described in Chapter 1). This mechanism by which this
increase in pituitary responsiveness to LHRH occurs is still fully unresolved however
a facilitation of second messenger production and subsequent intracellular events
has been observed during LHRH priming [Mitchell et al, 1988] which may point to a
plausible mechanism hence clarifying the second messenger pathways involved in
priming has been a focus of our laboratory's research interests. The induction of
priming is dependent on transcription, translation and the integrity of microfilaments
[Pickering & Fink, 1979] and also involves ultrastructural changes in cytoskeletal and
secretory elements [Lewis et al, 1985]. Furthermore activation of phospholipase A2
(PLA2) is also crucial to the induction of the phenomenon [Thomson et al, 1994].
MAP kinase is involved in many cellular events particularly mitogen-induced
transcription , cell cycle control and cellular responses to environmental stress
[Davis, 1995; Pelech, 1996; Waskiewicz & Cooper, 1995]. Investigations into
downstream targets of MAP kinase have revealed many cytosolic and nuclear
proteins which may be phosphorylated by MAP kinase in response to many stimuli,
including components of signal transduction cascades, and hence a consensus
target phosphorylation sequence for MAP kinase was identified [Clark-Lewis et al,
1991]. Amongst these are transcription factors such as c-Jun and c-Fos, the p90
ribosomal S6 kinase (p90rsk), the high molecular weight PLA2, cytoskeletal proteins
including the microtubule associated protein 2 (MAP-2) [Alvarez et al, 1991; Hoshi et
al, 1992; Lin et al, 1993; Nguyen et al, 1993; Seth et al, 1992; Sturgill et al, 1988] as
well as an increasing list of proteins which contain a potential target MAP kinase
phosphorylation motif but which as yet there is no direct evidence for direct MAP
kinase regulation [Treisman, 1996]. These observations made MAP kinase of
particular interest to our investigations as it appears that there is a remarkable
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correlation between MAP kinase targets and proteins involved in the priming effect
and therefore the discovery that activation of the LHRH receptor can phosphoryiate
and activate MAP kinase in the aT3-1 gonadotroph cell line [Sim et al, 1995, Chapter
3+5] (an effect which was maximal within 10 min and remained elevated for 40 min
corresponding to the onset of LHRH priming) was of great interest. Additionally,
LHRH priming but not initial unprimed LHRH-induced gonadotrophin secretion, is
mediated by form of PKC with distinctive properties [Johnson et al, 1992] that
appears to be very similar to that of a novel or modified species of PKC which has
been characterised in the anterior pituitary [Ison et al, 1993]. Moreover LHRH-
induced activation of MAP kinase in aT3-1 cells also is prevented by PKC inhibitors
with a low potency by H7 (compared to other PKC inhibitors), similar to the
aforementioned PKC.
We investigated whether LHRH can induce MAP kinase activation in anterior
pituitaries in vitro and whether this may be pertinent to LHRH-priming by examining
the potential LHRH-induced MAP kinase activation in anterior pituitary tissue from
rats on different days of the oestrous cycle, as the magnitude of LHRH-priming
observed changes characteristically throughout the oestrous cycle [Aiyer et al, 1974;
Aiyer & Fink, 1974; Fink, 1979; Waring & Turgeon, 1980]. LHRH-priming is also
dependent on prior exposure to gonadal steroid hormones (and perhaps other
factors) [Fink, 1988c], therefore pituitary tissue from rats which had been
ovariectomised was also assessed and the effects of these hormones on LHRH-
induced MAP kinase activity in aT3-1 cells was investigated. Finally pilot
experiments were carried out to explore the pharmacological characteristics of
LHRH-induced MAP kinase activity, but owing to the heterogeneous nature of the




otT3-1 cells were grown to -50% confluency in normal growth medium. The medium
was then replaced with DMEM without Phenol red supplemented with 100 mg/ml
glucose, 2 mM l-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin and 10%
steroid-stripped foetal calf serum (see Appendix 2) for 72 h and in serum-free
medium for a further 24 h. Oestrogen (1 nM), progesterone (200 nM) or both
hormones were added 48 h and 3 h respectively prior to the addition of 100 nM
LHRH or 1 pM PDBu. Thereafter the aT3-1 cells were treated as usual as described
in the methods section.
6.3 RESULTS
Employing the [35S]thiophosphorylation assay described in Chapter 2, the potential
activation of MAP kinase in female rat anterior pituitary tissue was investigated over
a time course of 0-60 min with 1 nM LHRH (Figure 6.1). In pro-oestrous anterior
pituitary tissue but not tissue from oestrous or ovariectomised rats, MAP kinase
activity increased rapidly, after a short lag of approximately 5 min, reaching a peak
by 15 min that represented an increase of 75 ± 9% over basal activity (mean ± SEM,
n=6). This increased activity then gradually declined thereafter leaving a significant
residual activation at 60 min. Unstimulated tissue showed no significant change in
MAP kinase activity throughout the 60 min incubation (data not shown). LHRH-
induced MAP kinase activity was concentration-dependent (Figure 6.2a), being
statistically significant at 1-100 nM LHRH (Wilcoxon signed rank test). MAP kinase
activity induced by LHRH was nearly maximal by 100 nM and showed an apparent
EC50 value (the concentration required for 50% of maximal activation) of 0.53 ± 0.19
nM (Figure 6.2). Tissue from ovariectomised rats showed no response to LHRH at
concentrations up to 100 nM. The MAP kinase response to LHRH was examined in
anterior pituitary tissue taken from each day of the oestrous cycle and from
ovariectomised rats. LHRH (100 nM) caused significant activation of MAP kinase
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only in tissue from dioestrous and pro-oestrous rats in agreement with the data
concerning pro-oestrous and oestrous rats shown in Figure 6.2 and confirming that
LHRH could only evoke a MAP kinase response in tissue that was capable of
displaying LHRH priming [Mitchell et al, 1994],
It is clear that the majority of the enzymatic activity assayed represented authentic
p42/p44 MAP kinase since Table 6.1 shows that 70-80% of either control or LHRH-
stimulated activity was immunoprecipitated by the anti-MAP kinase gel conjugate,
whereas less than 20% was bound by the control reagent.
Experiments with ionomycin and the phorbol ester, PDBu were performed to assess
whether the products of phosphoinositide hydrolysis evoked by the LHRH receptor
such as Ca2+ mobilisation or PKC activation could mimic the LHRH-induced activity.
Table 6.2 shows the effects of ionomycin. At 30 p.M, a maximal concentration for this
drug, ionomycin failed to increase MAP kinase activity alone or have any significant
effect in combination with LHRH. PDBu (1 pM), activated MAP kinase in pro-
oestrous tissue with a maximal effect also at around 15 min (Figure 6.4a) indicating
an involvement of PKC in this response, lonomycin also failed to potentiate the
PDBu (1 pM)-evoked response (Table 6.2). PDBu-evoked MAP kinase activation
was also seen in tissue from ovariectomised rats (Figure 6.4a) acting as a positive
control in those tissues where LHRH fails to elicit priming of LHRH release [Mitchell
et al, 1994], or activation of MAP kinase. Interestingly both LHRH- and PDBu-
induced MAP kinase was apparent in pituitary tissue from male rats (Figure 6.4b).
LHRH-induced MAP kinase activation appears to be mimicked by phorbol ester in
anterior pituitary tissue and is sensitive to both PKC and tyrosine kinase inhibitors in
aT3-1 cells [Sim et al, 1995; Chapter 3+5]. The effects of these agents were
therefore investigated on agonist-mediated MAP kinase activation in pro-oestrous
anterior pituitary tissue. The selective PKC inhibitor GF109203X [Toullec et al, 1991]
inhibited the MAP kinase response induced by LHRH (100 nM) with an IC50 of 2.1 ±
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0.9 pM and that evoked by PDBu (1 pM) with an IC50 of 1.2 ± 0.4 pM (means ± SEM,
n=6). Neither the PKC inhibitor H7 (at concentrations up to 300 pM) [Hidaka et al,
1984] nor the tyrosine kinase inhibitor lavendustin A (at concentrations up to 10 pM)
[Hsu et al, 1991] reduced LHRH-induced MAP kinase activation (Figure 6.5). At 10-
30 pM, H7 slightly increased the response to LHRH. None of the inhibitors had any
effect on basal MAP kinase activity (data not shown).
The effects of pertussis toxin on LHRH-induced MAP kinase activation were
examined. Pituitaries from pro-oestrous rats were cut in quarters to aid tissue
penetration and incubated in MEM with pertussis toxin (300 ng/ml) for 3-4 h. After
this time pertussis toxin had no significant effect on LHRH-induced MAP kinase
activation or on basal activity. The LHRH response was slightly reduced compared
to normal incubation periods, perhaps indicating that after this time the viability of the
tissue was diminished. Longer incubations with pertussis toxin as examined in
aT3-1 cells [Sim et al, 1995; Chapter 3+5] were therefore impossible.
Since LHRH priming is prevented by the protein synthesis inhibitor cycloheximide
(CHX) [Pickering & Fink, 1979], we investigated whether it affected the LHRH-
induced MAP kinase activation. In the presence of 50 pM CHX the LHRH (100 nM)-
induced MAP kinase was elevated with respect to the response to LHRH (100 nM)
alone and CHX (50 pM) alone also caused a small increase in the basal MAP kinase
activity measured (Table 6.4).
As it seems apparent that LHRH is only capable of eliciting a MAP kinase response
in anterior pituitary tissue from rats on days of the oestrous cycle during which LHRH
priming is evident and furthermore that LHRH priming is additionally dependent on
oestrogen [Fink, 1988c], we investigated the effects of the steroid hormones
oestrogen and progesterone on LHRH- and PDBu-induced MAP kinase activation in
ocT3-1 cells (Figure 6.6). In aT3-1 cells grown in steroid-stripped medium without
further supplements a minimal (but significant) LHRH- and PDBu-evoked MAP
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kinase response was observed (1.6 ± 0.02 and 1.3 ± 0.09 fold over basal control),
although the PDBu-evoked response was on the border of statistical significance;
Wilcoxon signed rank test. In the presence of oestrogen (1 nM) significant agonist-
evoked MAP kinase activation was clearly evident in aT3-1 cells. In these cells the
MAP kinase activation evoked by LHRH (100 nM) was an increment of 2.77 ± 0.03
fold over the basal control MAP kinase activity and the corresponding response to
PDBu (1 |iM) was 1.95 ± 0.06 fold over control. In aT3-1 cells supplemented with
progesterone, the MAP kinase responses to LHRH and PDBu were significantly
above basal MAP kinase activity (1.8 ± 0.04 and 1.56 ± 0.03) however they were
significantly reduced (approximately 42% and 20% respectively) with respect to the
responses observed in oestrogen-supplemented cells and were not significantly
greater than responses observed in steroid-stripped medium. Finally in steroid-free
medium supplemented with both oestrogen and progesterone the LHRH- and PDBu-
evoked MAP kinase activity was also significantly greater than basal activity (1.8 ±
0.02 and 1.5 ± 0.06 fold over basal control) but was again significantly reduced
compared to those responses in oestrogen-supplemented medium. LHRH- but not
PDBu-induced MAP kinase activity was greater in the presence of oestrogen and
progesterone than in the presence of progesterone alone.
6.4 DISCUSSION
LHRH has a number of distinct actions on the anterior pituitary gland. In addition to
stimulating the release and synthesis of gonadotrophins [Schally et al, 1973], LHRH
also has a self-potentiating effect so that intermittent stimulation with repeated
identical doses of LHRH causes a progressively increasing secretion of LH in
response [Aiyer et al, 1974]. This self potentiation effect, observed in humans,
monkeys, sheep and rats is probably involved in the generation of the massive LH
surge which precedes ovulation [Fink, 1995]. The precise mechanisms underlying
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the priming effect are still unclear, however they are clearly distinct from the usual
(unprimed) LH secretion [Fink, 1988a] (see also Table 1.1).
The magnitude of the priming phenomenon varies characteristically on different days
of the oestrous cycle being maximal on pro-oestrous. Compared to pro-oestrous, the
priming effect of LHRH was less evident at dioestrous, was much less at
metoestrous and could not be demonstrated at oestrous [Aiyer et al, 1974]. In
contrast initial (unprimed) LH release responses to LHRH varied with a rank order
showing the greatest LH release in pro-oestrous and then from
oestrous/ovariectomised and male rats with little change in metoestrous and
dioestrous rats [Johnson et al 1992; Mitchell et al 1994], The first hour of incubation
with LHRH, is important to the development of LHRH priming. During this period
inclusion of various agents such as protein synthesis inhibitors, PLA2 inhibitors and
various protein kinase inhibitors can prevent the subsequent facilitated LH release
brought about by priming (but not the standard unprimed LH release) [Curtis et al,
1985; Fink, 1988a; Johnson et al, 1992; Thomson et al, 1993b].
From our data presented here it is clear that activation of the LHRH receptor can
lead to MAP kinase activation in the anterior pituitary gland in vitro in a
concentration- and time-dependent manner. LHRH-induced MAP kinase activity is
achieved with an EC50 value of 0.53 nM LHRH therefore occurs at physiological
relevant concentrations (LHRH priming is typically induced by a physiologically
relevant dose of 0.85 nM). Activation of MAP kinase is detectable within 10-60 min
of incubation with LHRH and therefore is active during the period which is critical to
the induction of the priming phenomenon. Furthermore it seems that the LHRH-
induced MAP kinase activation may be selectively involved in the development of the
LHRH self priming phenomenon, as significant MAP kinase activation was observed
only in rat pituitary tissue from pro-oestrous and dioestrous when the LHRH self
priming effect is at its greatest. Furthermore a degree of LHRH priming has been
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noted in male rat pituitaries [Nazian, 1986] which is likely to explain the apparent
anomaly in our hypothesis that LHRH-induced MAP kinase activation is only
important to LHRH priming.
At the time these experiments were performed the recently described MEK inhibitor
[Alessi et al, 1995a] was unavailable. Furthermore to date no specific inhibitors of
MAP kinases have been described. Therefore we assessed whether any of the
common kinase inhibitors had any direct effect on constitutive MAP kinase activity
detected in vitro from rat hippocampus tissue [see Appendix 1]. However although
some compounds displayed weak effects none of the agents tested appeared to
potently inhibit MAP kinases. Furthermore approaches such as the use of antisense
oligonucleotides to downregulate the ERK proteins or expression of dominant
positive or negative mutants of ERKs would be inappropriate as they cannot be
employed in intact anterior pituitary tissue and cultured dispersed anterior pituitary
cells are known to lose the ability to display LHRH priming [Fink, 1988b]. In view of
this it is difficult as yet to directly probe the functional contribution of MAP kinase to
LHRH priming. Nevertheless, there is a remarkable correlation between the targets
of MAP kinases and the array of cellular events known to be involved in priming.
Relevant targets may include c-Jun and c-Fos, RNA polymerase II, p90rsk, high
molecular weight PLA2 and MAP-2 and it has been reported that a cdc2-like kinase
with a similar substrate motif phosphorylates neurofilaments [Shetty et al, 1993].
The priming phenomenon is dependent upon protein synthesis, activation of PLA2,
the integrity of microfilaments and involves ultrastructural changes in the marginal
presentation of secretory granules in gonadotrophs [Fink, 1988a]. Phosphorylation
of MAP-2 protein by MAP kinase is reported to disrupt microtubule-microfilament
interaction [Hoshi et al, 1992] which may lead to facilitated stimulus-secretion
coupling [Malaisse et al, 1975].
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MAP kinase activation has also been reported in other secretory responses including
thyrotrophin-releasing hormone-induced prolactin secretion in GH3 and GH4 pituitary
cells [Kanda et al, 1994; Ohmichi et al, 1994] which interestingly involves divergent
pathways including a PKC- and tyrosine kinase-dependent mechanism similar to our
observations in LHRH-induced MAP kinase activation in aT3-1 cells. Similarly MAP
kinase activation has been implicated in secretion of digestive enzymes in response
to cholecystokinin and acetylcholine receptor stimulation in pancreatic acinar cells
[Williams, 1995], insulin secretion in response to secretagogues [Frodin et al 1995;
Persaud et al 1996], catecholamine secretion from bovine adrenal chromaffin cells
[Cox et al 1996], responses to secretory stimuli in rat basophillic leukaemia (RBL)-
cells and serotonin release in RBL cells [Offermans et al, 1994b]. Additionally MAP
kinase is also selectively activated during thrombin-induced platelet activation and
aggregation and since platelets are nonproliferative cells MAP kinase activation
cannot lead to a mitogenic signal therefore may regulate cytoskeletal or secretory
changes during platelet activation [Papkoff et al, 1994]. In Saccharomyces
cerevisiae bud emergence requires polarisation of the cytoskeleton and secretory
vesicles to a specific site on the cell surface. A SLT2 (MPK1) MAP kinase
homologue has been identified which functions downstream or in parallel with a
cdc28 protein kinase in promoting bud formation and apical growth [Levin & Errede,
1995]. Accordingly activation of MAP kinases may be a common element in a wide
spectrum of cellular responses involving cytoskeletal changes and vesicle
movement.
During priming LHRH induces the release of LH by two routes. LHRH causes an up-
regulation of LHRH-induced second messenger formation as prior exposure to LHRH
specifically enhanced LHRH-induced inositol phosphate production and mobilisation
of Ca2+from intracellular stores [Mitchell et al, 1988], whilst the ligand binding and
Ca2+ influx through dihydropyridine-sensitive Ca2+ channels remains unaltered. In
addition, the priming effect involves a general facilitation of stimulus-secretion
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coupling such that other secretagogues including K+ and ionomycin can elicit
enhanced secretory responses [Johnson & Mitchell, 1991; Pickering & Fink, 1979]
However K+ and ionomycin can only increase the amount of hormone available for
release [Johnson & Mitchell, 1991] and only LHRH has the capacity to increase
cellular responsiveness to itself [Pickering & Fink, 1979]. Although LHRH-induced
mobilisation of intracellular and extracellular Ca2+ appears to be of importance to
LHRH-induced gonadotrophin secretion [Bates & Conn, 1984; Bourne & Baldwin,
1980; Limor et al, 1987; Pickering & Fink, 1979] and there is evidence that the
release of intracellular Ca2+ may participate in LHRH priming [Curtis et al, 1985], it
appears that increased Ca2+ is not critical to the induction of priming [Johnson et al,
1991; Johnson et al, 1993b]. Mobilisation of Ca2+ appears incidental to LHRH-
induced MAP kinase activation in priming as ionomycin was ineffective either alone
or in combination with LHRH (Table 6.2). It is unlikely that Ca2+ failed to elicit any
response due to inability of ionomycin to penetrate the tissue as the studies on the
role of Ca2+ in LH release have shown a response in hemipituitaries under similar
incubation conditions with similar concentrations of this agent [Johnson et al, 1991;
Johnson et al, 1993b; Mitchell et al, 1988]. Indeed this result is consistent with
evidence that elevation of Ca2+ does not elicit the induction of LHRH priming, but
rather that it is critically dependent upon a form of PKC [Johnson et al, 1993b].
LHRH-mediated MAP kinase activation also seems to be dependent on PKC as the
response is strongly inhibited by the potent PKC inhibitor GF109203X and can be
mimicked by phorbol ester in both tissue which can display priming and tissue from
males and ovariectomised rats. This data is consistent with LHRH-mediated MAP
kinase activation in the aT3-1 gonadotroph cell line and would suggest that activation
of MAP kinase in these tissues is under similar regulation. Rat pituitary tissue has
been shown to contain the a, p, 8, e and C isoforms of PKC [Maeda & Lloyd, 1993].
The cxT3-1 cell line has been shown to express at high levels the a, e and £ isoforms
[Johnson et al, 1993a; Johnson et al, 1996]. Interestingly LHRH-induced MAP
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kinase is not inhibited by the PKC inhibitor H7 at the concentrations used here. This
is not uncommon to PKC dependent responses observed in pro-oestrous anterior
pituitary tissue [Johnson et al, 1991; Johnson & Mitchell, 1991; Johnson et al, 1992;
Johnson et al, 1994; Johnson et al, 1995; MacEwan & Mitchell, 1991; MacEwan et
al, 1991; Thomson, 1992b; Thomson et al, 1994; Thomson et al, 1993b; Thomson &
Mitchell, 1993]. The induction of the priming phenomenon is dependent upon a
species of PKC (which is H7-resistant but sensitive to GF109203X, staurosporine
and Ro31-8220) acting subsequently through a protein synthesis-dependent step to
activate PLA2 (Johnson et al 1992; Thomson & Mitchell, 1993; Thomson et al 1993).
A PKC-like enzyme considered to correspond to this species has recently been
characterised in anterior pituitary and lung but not in the other tissues tested
(including mid brain, cerebellum, liver, spleen and COS 7 cells) [Ison et al, 1993]. Its
Ca2+-independent activity was notably resistant to H7 but sensitive to staurosporine
and Ro 31-8220. The distribution of this activity and its pharmacological
characteristics do not obviously correlate with any of the 10 currently described PKC
isoforms and thus probably reflects a novel, or modified PKC species. It is possible
that MAP kinase is regulated by this PKC species. Such a signalling sequence
would be further consistent with the proposed involvement of PKC species as an
intermediary in LHRH priming as its activation by LHRH (like priming) is dependent
on a PKC which is sensitive to PKC inhibitors including GF109203X but not to H7.
PKCs other than those transducing signals from the LHRH receptor can clearly
activate MAP kinase in heterogeneous pituitary tissue because PDBu can still
activate the enzyme in tissue where LHRH is ineffective (Figure 6.4). Both a, p and e
isoforms of PKC can activate Raf and hence MAP kinase [Dent et al, 1992; Sozeri et
al, 1992], although both PKC a and p are H7-sensitive [Ison et al 1993; Thomson et
al 1993a]. The evidence here for a modest facilitation of the LHRH response by H7
is consistent with the possibility of reciprocal regulation by H7-resistant and H7-
sensitive forms of PKC (or other kinases) (Figure 6.5). There is evidence for such
133
dual regulation of voltage-sensitive Ca2+ channels by different forms of PKC
[Johnson et al 1991; Johnson et al 1993b; MacEwan et al 1991]. The regulated step
underlying the varying ability of LHRH to activate MAP kinase may well be upstream
of MAP kinase itself but downstream of the LHRH receptor since PDBu was still
effective in tissue which does not respond to LHRH but has adequate LHRH receptor
numbers (Figure 6.4; [Mitchell et al, 1988]). Interestingly it is clear that expression of
a variety of PKC isoforms is induced by E2 treatment of anterior pituitary cells
[Thomson et al, 1994a].
In response to LHRH receptor-activation a number of proteins are tyrosine
phosphorylated [Wolbers et al 1995; Johnson et al 1995] including the non-receptor
tyrosine kinases (nrTK) Src and Fyn [Fennell et al, 1994]. LHRH-, but not PDBu-
induced phospholipase D (PLD) activity is inhibited by the tyrosine kinase inhibitor
lavendustin A in aT3-1 cells [Fennell et al, 1993], implying a possible role for a nrTK
in LHRH signal transduction. From our initial experiments in aT3-1 cells and pro-
oestrous pituitary tissue lavendustin A was unable to prevent LHRH-induced MAP
kinase activation therefore we surmised that there was no role for tyrosine kinases in
this response in anterior pituitary tissue [Mitchell et al, 1994] Since then we have
investigated the role of tyrosine kinases more thoroughly in aT3-1 cells and it is now
apparent that LHRH-induced MAP kinase activity is sensitive to certain tyrosine
kinase inhibitors (although not lavendustin A). It is possible that the LHRH receptor
may be activating a different subset of nrTKs in parallel cascades which lead to PLD
and MAP kinase in aT3-1 cells. Recently in our laboratory we have demonstrated a
role for tyrosine phosphorylation in LHRH-induced gonadotrophin secretion probably
in the later stages of the stimulus-secretion pathway although this is not specific to
the priming phenomenon as both initial and augmented release were affected to
some degree [Johnson et al, 1995]. Furthermore in the aT3-1 cell line, the LHRH
receptor can lead to activation of tyrosine kinases downstream of PLC, which
appears to play a critical role in the augmentation of LHRH-induced inositol
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phosphate production which underlies the LHRH self-priming phenomenon [Mitchell
et al, 1994]. In view of these more recent observations it is clear that a more
thorough investigation is required in pituitary tissue regarding the role of tyrosine
kinases in the MAP kinase response.
The lack of effect of cycloheximide on LHRH-induced MAP kinase activation here is
consistent with the possibility that the protein synthesis-dependent step in priming
may be downstream of MAP kinase activation or that these steps may occur in
parallel rather than in series. The slight increase observed in response to
cycloheximide may be due to the loss of synthesis of a negative regulatory protein or
some other component of a cascade which crosses with the MAP kinase activation
cascade. It would be difficult to determine the protein responsible as the regulation
of MAP kinase represents the convergence of many as yet unresolved inputs, but it
is unlikely to be specifically relevant to LHRH-induced activation as there is no
further potentiation in the presence of LHRH.
In aT3-1 cells LHRH-induced MAP kinase activation is dependent on both PKC and
a pertussis toxin-sensitive step [Sim & Mitchell, 1995a; Sim & Mitchell, 1995b]
Chapter 3+5]. We were unable to make any reasonable analysis of the involvement
of Gj/o proteins in LHRH signal transduction in the anterior pituitary gland.
Techniques currently used for this analysis involve long periods of incubation either
with pertussis toxin, to inactivate the aj/0 subunit by an ADP ribosylation catalysed by
the toxin, or with antisense oligonucleotides to effectively deplete the protein from
cells by blocking de novo synthesis of the protein. Pituitary prisms are unsuitable for
these treatments as tissue samples may be impenetrable to these agents and do not
survive well for long periods in vitro. Furthermore as discussed earlier, dispersed
anterior pituitary cells could not be used in these experiments as these cells do not
display LHRH-priming [Fink, 1988b]. The effect of pertussis toxin on LHRH-induced
LH secretion in pituitary pieces was investigated as a pilot experiment to determine
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whether long term incubations in vitro would be viable for future experiments of this
nature. Anterior pituitaries were cut into four and maintained for 24 h in culture
dishes under O2/CO2 at 37°C in the presence or absence of oestrogen (E2; 1 nM)
and or pertussis toxin (PTx; up to 1 pg/ml). Basal or LHRH-induced LH secretion
was measured over 3 h. In the first hour of exposure to LHRH, LH was secreted
from the pituitary pieces with a rank order of potency of PTx with E2 (60 ± 8 ng/ml of
LH) > PTx (47 ± 9 ng/ml) > E2 (38 ± 5 ng/ml) > control (ie LHRH alone; 24 ± 4 ng/ml)
with the responses to E2, PTx, E2 with PTx being significant greater than control,
(LHRH alone)-mediated LH release and E2 with PTx being significantly greater than
E2 (Students t-test) however the secretion observed in the 2nd hour (when primed
release is typically observed) were not significantly different from 1st hour secretion
therefore LHRH priming was not maintained under these conditions [Johnson et al
unpublished observation]. At present we are therefore unable to investigate aspects
of PTx and the LHRH priming phenomenon as this requires long term incubations,
however from these observations it appears that PTx may have some anomalous
effects on LHRH-mediated LH secretion.
We have shown that LHRH-induced MAP kinase activation in the aT3-1 cell line is
dependent on exposure to oestrogen (Figure 6.6). Indeed in a pilot experiment,
supplementing the normal growth medium with 0.3 nM oestrogen for 48 h slightly
increased the LHRH-induced MAP kinase response in aT3-1 cells (data not shown)
to approximately 1.2 fold of the usual agonist-induced response. This appears to
mimic the conditions required in the anterior pituitary. LHRH priming is dependent
on prior exposure to oestrogen [Fink, 1988b], furthermore oestrogen levels peak on
the morning of pro-oestrous therefore coinciding with the onset of LHRH priming
[Aiyer & Fink, 1974], Synthesis of the p-subunit of LH or FSH does not occur in the
aT3-1 cell line and as a consequence the gonadotrophins are not secreted [Windle
et al, 1990]. This limits the usefulness of this cell line as a model system for studying
the physiological aspects of LHRH responses (especially the primed release of LH)
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but this is the only gonadotroph cell line available. Despite this, aT3-1 cells appear
to be a good model for studying receptor mediated responses [Windle et ai, 1990;
Eidne et al, 1992; Anderson et al, 1993; Davidson et al, 1994; Shah & Milligan, 1994;
Mitchell et al, 1995a, b; Sim et al, 1995]. The result demonstrating a dependence on
oestrogen exposure for strong LHRH-induced MAP kinase activation in aT3-1 cells
(Figure 6.6) also mirrors the dependence on oestrogen of both the priming effect
[Fink, 1988c] and LHRH-induced MAP kinase activation in the anterior pituitary gland
(Figure 6.3). A similar result was obtained for LHRH-induced PLD activity in aT3-1
cells grown in steroid-free medium augmented by oestrogen [Fennell, 1995].
Oestrogen is also capable of bringing about an ability of LHRH to prime other LHRH-
mediated responses in aT3-1 cells including inositol phosphate formation [Mitchell et
al, 1995a] and can restore levels of LHRH-stimulated arachidonic acid release in
ovariectomised rats to levels observed in pro-oestrous rat pituitaries [Thomson et al,
1994]. Oestrogen is likely to have many effects on pituitary cells particularly the
increased expression of critical proteins which may include many signal transduction
components or regulatory proteins. LHRH-induced MAP kinase, PLA2 (in the
pituitary) and PLD activation are all dependent on PKC [Fennell, 1995; Sim &
Mitchell, 1995a; Thomson et al, 1994]. Additionally there is an increase in PKC
expression and activity following exposure to oestrogen [Thomson et al, 1993a].
Therefore one of the effects of oestrogen which is relevant to our investigations is an
increased expression of one or more PKC isoform. Oestrogen treatment has been
shown to increase mRNA levels of the a, p, 8, e and C, isoforms of PKC in normal and
tumorigenic rat pituitaries [Maeda & Lloyd, 1993].
aT3-1 are usually grown in medium containing Phenol red which has a modest
oestrogenic activity [Berthois et al, 1986; Welshons et al, 1988]. Moreover Phenol
red concentrations typically used in culture media are capable of modulating LHRH
responsiveness in superfusion of dispersed anterior pituitary cell cultures (an effect
which is more prominent at certain stages of the oestrous cycle) [O'Conner & Kellom,
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1990]. Therefore the inclusion of Phenol red in a tissue culture medium should be
considered where a putative oestrogen-exposure could modulate the response as it
is likely to be critical to the outcome of any measured response. The status of aT3-1
cells with respect to modelling a gonadotroph exposed in situ to cyclic hormonal
changes is unknown. This is clearly important to aT3-1 cells also, as (shown in
Figure 6.6), strong MAP kinase responses were only observed in oestrogen-
supplemented hormone-free growth medium. However these were of a similar
magnitude to cellular responses typically observed in normal growth medium
containing Phenol red.
In summary, from the results presented in this chapter it appears that LHRH-induced
MAP kinase activation may have a critical role in the unique LHRH-self priming effect
in anterior pituitary tissue, as this was only apparent on appropriate days of the
hormonal cycle and furthermore like primed LH secretion this is likely to be
dependent on exposure to oestrogen as it was not observed in ovariectomised rats.
Additionally we have shown that aT3-1 cells appear to have a requirement for
oestrogen and whilst normal growth medium is not supplemented by oestrogen, the
oestrogenic effects of Phenol red appear sufficient to account for this requirement.
Taken together, aT3-1 cells grown in a Phenol red containing medium may well
represent a reasonably faithful model of oestrogen-exposed gonadotrophs in situ.
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Table 6.1
Immunoprecipitation of MAP kinase activity in pro-oestrous rat
anterior pituitary tissue with protein G-Sepharose-4B derivatised
reagent
Anterior hemipituitary pieces were incubated in MEM for 25 min. The medium was
discarded and replaced with fresh medium only or containing 100 nM LHRH for 15 min.
Thereafter the tissue was treated as in protocol (Chapter 2) for anti MAP kinase
immunoprecipitation then pellet (P) and supernatant (S) fractions were included in a
cytosolic MAP kinase assay. Values are means ± SEM from 3 determinations.
Condition Antibody reagent Supernatant
Pellet
MAP kinase activity recovered
(x103 dpm per assay)
Nil 1.84 ±0.26 NA
Control Anti-MAP kinase 0.56 ±0.18 1.39 ±0.10
Anti-p-tubulin 1.62 ±0.15 0.40 ± 0.06
Nil 2.93 ±0.16 NA
LHRH Anti-MAP kinase 0.55 ±0.13 2.09 ± 0.09
Anti-p-tubulin 2.58 ±0.19 0.64 ±0.15
Table 6.2
Effects of ionomycin on MAP kinase activation in pro-oestrous
rat anterior pituitary tissue
Anterior pituitary tissue from pro-oestrous rats was pre-incubated in MEM for 25 min.
The medium was discarded and replaced with fresh medium containing either nil,
ionomycin (30 pM), 100 nM LHRH, LHRH (100 nM) + ionomycin (30 pM), 12, 13
phorbol dibutyrate (PDBu; 1 pM) or PDBu (1 pM) + ionomycin (30 pM). After 15 min
the tissue was removed and immediately homogenised in 2 vol homogenisation buffer.
Thereafter MAP kinase activity was determined as in methods section. Values are
means ± SEM from 6 determinations. All values marked (+) are significantly greater
than MAP kinase activity in control unstimulated pro-oestrous pituitary tissue matched
pair t-test on raw data (p>0.05).
Condition MAP kinase activity
(x103 dpm per assay)
control 2.28 ±0.14
ionomycin 2.45 ±0.14
LHRH 3.85 ± 0.29 (+)
ionomycin + LHRH 3.93 ±0.21 (+)
PDBu 3.99 ± 0.31 (+)
PDBu + ionomycin 4.05 ± 0.29 (+)
Table 6.3
Effects of pertussis toxin on MAP kinase activation in pro-
oestrous rat anterior pituitary tissue
Pairs of anterior pituitary quarters from pro-oestrous rats were pre-incubated in MEM
or MEM containing of pertussis toxin (300 ng/ml) for 3 h. The medium was discarded
and replaced with fresh medium containing either nil, pertussis toxin (300 ng/ml), 100
nM LHRH or LHRH (100 nM) + pertussis toxin (300 ng/ml). After 15 min the tissue
was removed and immediately homogenised in 2 vol homogenisation buffer.
Thereafter MAP kinase activity was determined as in methods section. Values are
means ± SEM from 4 determinations. MAP kinase activity values marked (+) are
significantly greater than those in control unstimulated pro-oestrous anterior pituitary
tissue by matched pair t-test on raw data (p>0.05). PTx + LHRH was not
significantly different than LHRH-induced MAP kinase activity (p<0.05).
Condition MAP kinase activity
(x103 dpm per assay)
Control 2.08 ±0.09
pertussis toxin 2.35 ±0.15
LHRH 2.95 ± 0.25 (+)
pertussis toxin + LHRH 2.93 ±0.21 (+)
Table 6.4
Effects of cycloheximide on MAP kinase activation in pro-
oestrous rat anterior pituitary tissue
Anterior hemipituitaries from pro-oestrous rats were pre-incubated in MEM for 25 min.
The medium was discarded and replaced with fresh medium alone or additionally
containing cycloheximide (CHX; 50 pM). After 10 min the medium was again replaced
with fresh medium containing either nil, CHX (50 pM), 100 nM LHRH or LHRH (100
nM) + CHX (50 pM). After 15 min the tissue was removed and immediately
homogenised in 2 vol homogenisation buffer. Thereafter MAP kinase activity was
determined as in methods section. Values are means ± SEM from 6 determinations.
MAP kinase activity that was significantly greater than control unstimulated activity is
indicated (+) (p<0.05). CHX + LHRH was not significantly greater than LHRH-induced
MAP kinase activity by matched pair t-test on raw data (p> 0.05).
Condition MAP kinase activity
(x103 dpm per assay)
control 3.08 ± 0.43
CHX 4.05 ± 0.86 (+)
LHRH 7.05 ± 0.38 (+)
CHX + LHRH 7.93 ±0.91 (+)
Figure 6.1
Time course of LHRH-induced MAP kinase activation in female rat anterior
pituitary tissue
Anterior hemipituitaries from pro-oestrous, oestrous and ovariectomised rats was
pre-incubated in MEM for 25 min. The medium was discarded and replaced with
fresh medium alone or containing 1 nM LHRH (•). After the appropriate time the
tissue was removed and immediately homogenised in 2 vol of homogenisation
buffer. Thereafter MAP kinase activity was determined as in methods section. Basal
MAP kinase activity showed no apparent difference between tissue from all origins









































Concentration-dependence of LHRH activation of MAP kinase in female rat
anterior pituitary tissue
Anterior hemipituitaries from pro-oestrous and ovariectomised rats were pre-
incubated in MEM for 25 min. The medium was discarded and replaced with fresh
medium alone or containing LHRH (•). After 15 min the tissue was removed and
immediately homogenised in 2 vol of homogenisation buffer. Thereafter MAP kinase
activity was determined as in methods section. Basal MAP kinase activity showed
no apparent difference between tissue from different origins falling consistently
between 800-1200 dpm per assay. Values are means ± SEM from 8 determinations.
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Figure 6.3
LHRH-induced MAP kinase activation in anterior pituitary tissue taken from
different stages of the oestrous cycle in female rats
Anterior hemipituitaries from metoestrous, dioestrous, pro-oestrous, oestrous and
ovariectomised rats were pre-incubated in MEM for 25 min. The medium was
discarded and replaced with fresh medium alone or containing 100 nM LHRH. After
15 min the tissue was removed and immediately homogenised in 2 voi of
homogenisation buffer. Thereafter MAP kinase activity was determined as in
methods section. Basai MAP kinase activity showed no apparent difference between
tissue from all origins falling consistently between 800-1200 dpm per assay. Values
are means ± SEM from 6 determinations.
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Figure 6.4
(a) Time course of phorbol ester-induced activation of MAP kinase in female rat
anterior pituitary tissue
Anterior hemipituitaries from pro-oestrous (•) and ovariectomised (■) rats were pre-
incubated in MEM for 25 min. The medium was discarded and replaced with fresh
medium containing 1 pM phorbol 12, 13-dibutyrate (PDBu) for the appropriate time.
(b) MAP kinase activation in male anterior hemipituitaries
Anterior pituitary tissue was removed from male rats and following a 25 min
preincubation with warm MEM the medium was replaced with fresh medium
containing or that additionally containing LHRH (100 nM) or PDBu (1 pM) for 15 min.
After the appropriate time the tissue was removed and immediately homogenised in
2 vol of homogenisation buffer. Thereafter MAP kinase activity was determined as in
methods section. Basal MAP kinase activity showed no apparent difference between
tissue from all origins falling consistently between 800-1200 dpm per assay and did
not alter significantly over 40 min control incubations (data not shown). Values are





Effects of kinase inhibitors on LHRH- and PDBu-induced activation of MAP
kinase activity in rat anterior pituitary tissue
Anterior hemipituitaries from pro-oestrous and male rats were pre-incubated in MEM
for 25 min. The medium was discarded and replaced with fresh medium alone or
additionally containing GF109203X (•), H7 (A).or lavendustin A (■). After 10 min
the medium was again replaced with fresh medium alone or containing 100 nM
LHRH in addition to the appropriate concentration of inhibitor. After 15 min the tissue
was removed and immediately homogenised in 2 vol of homogenisation buffer.
Thereafter MAP kinase activity was determined as in methods section. Basal MAP
kinase activity was unaffected by inclusion of the inhibitors alone (not shown) and as
before values were in the region of 800-1200 dpm per assay. Values are means ±











Effects of oestrogen and progesterone on LHRH- and PDBu-induced MAP
kinase activity in aT3-1 cells
aT3-1 cells were grown in steroid-free medium for 96 h. Oestrogen (1 nM),
progesterone (200 nM) or oestrogen (1 nM) and progesterone (200 nM) were added
48 h or 3 h respectively prior to the addition of 100 nM LHRH or 1 pM phorbol 12,13-
dibutyrate (PDBu) for 10 min. Thereafter MAP kinase activity was determined as in
methods section. Basal MAP kinase activity was not significantly different between



















ACTIVATION OF PLA2 BY THE LHRH
RECEPTOR DOES NOT APPEAR TO
REQUIRE UPSTREAM ACTIVATION OF
MAP KINASE
7.1 INTRODUCTION
Phospholipases A2 (PLA2) selectively release fatty acids from the sn-2 position of
phospholipids and are widely distributed in mammalian tissues. This reaction is
particularly important when arachidonic acid (AA) is released as a consequence, as it
serves as the rate-limiting step in the formation of the biologically active eicosonoids,
prostaglandins and leukotrienes, important mediators in inflammatory responses
[Irvine, 1982; Samuelsson et al, 1987]. The other product of PLA2 is a
lysophospholipid which can be further metabolised into platelet activating factor
(PAF) which is also important in inflammation [Hanahan, 1986; Irvine, 1982],
PLA2 can be classified into two distinct forms based on their apparent cellular roles
and location. The secreted form of PLA2 (sPLA2) which function in phospholipid
digestion and inflammatory responses and a more recently described cytosolic PLA2
(cPLA2) which are probably involved in receptor-linked signal transduction
mechanisms [Mayer & Marshall, 1993]. Owing to their relative abundance earlier
studies had focused on the secreted forms which are classified into two groups
[Scott et al, 1990; Thunissen et al, 1990]. Group 1 (pancreatic type) enzymes have
been characterised in lung, spleen, pancreas and snake venom whereas Group 2
PLA2s are found in platelets, spleen and liver and additionally in inflammatory
exudes. Although the primary structure of these enzymes differ, they exhibit close
similarities in their Ca2+ binding regions [Wery et al, 1991] and high Ca2+-
dependence for activation [Vadas et al, 1985]. cPLA2 was purified and cloned
around 1990 by several groups from a variety of tissues including a macrophage cell
line, RAW 264 [Leslie et al, 1988], U937 cells [Clark et al, 1990; Kramer et al, 1991;
Sharp et al, 1991] and rat kidney [Gronich et al, 1990]. cPLA2 is expressed in a
variety of cells including platelets, macrophages, fibroblasts, kidney mesangial cells
and epithelial cells [Gronich et al, 1990; Leslie et al, 1988; Rehfeldt et al, 1993;
Takayama et ai, 1991].
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There are considerable differences between the two forms of PLA2S. The SPLA2S
have an apparent molecular mass of approximately 14 kDa, contain seven disulphide
bonds (which render them sensitive to reducing agents such as dithiothreitol) and are
present in secretory granules to protect the enzymes from the reducing environment
found in the cytosol. They require millimolar concentrations of Ca2+ for their action
[Dennis, 1983] which is more consistent with the calcium concentrations present in
the extracellular environment and display no fatty acid preference at the sn-2 position
[Schalkwijk et al, 1990]. These characteristic are more suited to SPLA2S role as a
digestive enzyme or in the maintenance of membrane homeostasis or in the
extracellular production of inflammatory mediators. SPLA2 is also found to a high
degree in arthritic joints [Vadas et al, 1985] therefore it is also a key enzyme in the
pathology of certain disease conditions such as arthritis [Murakami et al, 1990].
In contrast the cPLA2 appear to be heterogeneous with an apparent molecular mass
ranging in size between 30-110 kDa [Mayer & Marshall, 1993] and are insensitive to
reducing agents. They are active at submicromolar Ca2+ concentrations which are
equivalent to those within the cytosol and are translocated to the plasma membrane
following activation in response to hormonal stimulation. This was apparent from the
observation that in the presence of a Ca2+ chelator the PLA2 enzymatic activity was
present in the cytosol, but on addition of submicromolar Ca2+ the activity was found
mainly in the membrane fraction [Channon & Leslie, 1990; Clark et al, 1991]. Unlike
sPLA2, cPLA2 display a high selectivity towards AA at the sn-2 position of
phospholipids especially phosphatidylcholine and phosphatidylethanolamine
[Channon & Leslie, 1990; Clark et al, 1990; Rehfeldt et al, 1993], generating AA.
This is more consistent with their role in initiation of inflammatory responses by
providing the precursor for inflammatory mediators. Additionally it has been
demonstrated that when both forms of PLA2 were overexpressed in CHO cells it
was CPLA2 (but not SPLA2) that was responsible for the rapid thrombin- or ATP-
stimulated formation of AA, as demonstrated by the increased release of arachidonic
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acid in response to the stimulus [Lin et al, 1992], Molecular cloning and expression
of an 85 kDa CPLA2 have revealed no sequence homology between this and the
SPLA2S. However the amino-terminal 140 amino acids of CPLA2 includes a 45 amino
acid phospholipid binding motif (CaLB) with distinct homology to the C-2 region
which is conserved in Ca2+-dependent PKC isoforms, in the synaptic vesicle protein
p65, (which has been implicated in vesicle fusion with the plasmalemma), in
GTPase-activating protein (GAP) and in phospholipase Cy (PLCy) [Clark et al, 1991].
This motif is probably responsible for targeting the enzyme to the plasma membrane
(or natural membrane vesicles), in a Ca2+-dependent manner upon activation by
agonists, in order to facilitate access to the phospholipid substrate [Channon &
Leslie, 1990; Lin et al, 1992],
Arachidonic acid and its metabolites formed in response to ligands that occupy G-
protein coupled receptors, have also been implicated as both first and second
messengers in a number of cellular processes [Axelrod, 1990; Burch et al, 1986;
Gupta et al, 1990; Tsujishita et al, 1994]. Therefore the regulation of production of
AA may be an important control point in many biological responses as well as
inflammation. cPLA2 is often activated in response to Ca2+-mobilising receptors
such as bradykinin, ATP and thrombin which also activate phospholipase C and
hence activate PKC. Additionally growth factors such as epidermal growth factor
(EGF) or platelet-derived growth factor (PDGF) have also been shown to increase
AA release. Serine phosphorylation of CPLA2 by PKC in response to agonist, or
direct activation of PKC by phorbol esters has been shown to increase activity
several fold in addition to the presence of Ca2+ [Hasegawa-Saskai, 1985; Lin et al,
1992; Margolis et al, 1988]. Furthermore staurosporine prevented phosphorylation
and activation of CPLA2 and agonist-induced activity was sensitive to phosphatase
treatment, all of which imply that phosphorylation may have some regulatory role in
CPLA2 activity. More recently a role has also been suggested for tyrosine
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phosphorylation [Glaseret al, 1993; Goldman et al, 1992; Kast et al, 1993; Schramek
et al, 1994; Tsujishita et al, 1994; Zor et al, 1993].
The activity of CPLA2 can also be increased by phosphorylation by MAP kinase [Lin
et al, 1993; Nemenoff et al, 1993]. Lin and co-workers suggested the site of cPLA2
phosphorylation by MAP kinase (Ser-505) is identical to the major site
phosphorylated in response to phorbol ester treatment and further that site-directed
mutagenesis of this Ser to Ala prevented MAP kinase activation of cPLA2. In a
slightly contradictory report on a study investigating phosphorylation of expressed
domains of cPLA2 by PKC and MAP kinase, it was suggested that MAP kinase
selectively phosphorylates the domain of cPLA2 which contains the MAP kinase
consensus sequence, whereas PKC phosphorylates all three expressed domains
and the results of peptide mapping indicated these sites were different to those
phosphorylated by MAP kinase [Nemenoff et al, 1993]. However both reports
indicate at least some regulatory role by this family of enzymes. Recently it has
been reported that cPLA2 is a target of the proline-directed kinase p38 (a MAP
kinase family enzyme) in response to either thrombin or the thrombin receptor
agonist peptide in platelets [Kramer et al, 1995].
The role of PLA2 in LHRH-mediated responses has also been investigated. AA and
its lipoxygenase and epoxygenase metabolites may have a second messenger
function in LHRH receptor signalling. In cultured anterior pituitary cells, LHRH can
induce an increase in [3H]-AA release from prelabelled cells and AA can induce LH
release [Chang et al, 1986; Naor & Catt, 1981]. Addition of a PLA2 activator, mellitin
or PLA2 exogenously to cultured cells also induced LH release from cultured anterior
pituitary cells [Kiesel et al, 1985]. The PLA2 inhibitor, quinacrine, prevented 40% of
the LH/FSH secretory response to LHRH and the remainder was blocked by a DAG
lipase inhibitor [Chang et al, 1987a]. These results would suggest that LHRH may
induce AA release by a route involving both DAG lipase and PLA2 action. In our
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laboratory the role of PLA2 in the LHRH self-priming effect was investigated
[Thomson et al, 1994], The induction of LHRH priming but not LHRH-induced LH
release was inhibited by a number of inhibitors of PLA2. Furthermore, LHRH-
induced [3H]-AA release was relatively resistant to the PKC inhibitor H7, consistent
with earlier findings for H7-inhibition with respect to the PKC responsible for the
induction of priming. This would indicate that the form of PKC responsible for
induction of LHRH priming can activate PLA2.
There is clear evidence that both PLA2 and MAP kinase are involved in the
physiological event of LHRH priming [Thomson et al, 1994; Mitchell et al, 1994 and
Chapter 6]. It would evidently be of great interest to ascertain if these two LHRH-
mediated responses were linked in that PLA2 represented a downstream target for
MAP kinase in the anterior pituitary cells. Given that cPLA2 contains the MAP kinase
consensus phosphorylation sequence and further that phosphorylation of PLA2 may
increase the activity of this enzyme this appears to be a plausible hypothesis. The
anterior pituitary is of a heterogeneous nature and possible difficulties may have
arisen with respect to tissue permeability to various agents and long term viability in
vitro required for some of the experiments it was desirable to perform. Consequently
this study was undertaken in the aT3-1 cell line as a model system.
7.2 RESULTS
In pilot experiments, it has previously been demonstrated that a 15 min incubation
with LHRH 100 nM resulted in a significant release of [3H]-AA (3-7 fold of basal) in
aT3-1 cells [Thomson, 1992a]. This effect was further investigated using the [3H]-AA
release assay described in Chapter 2. In aT3-1 cells LHRH-induced [3H]-AA release
was concentration-dependent over a range of 0.3-300 nM after a 15 min incubation
with LHRH and displayed an apparent EC50 value of 3.56 ± 0.8 nM (Figure 7.1a).
Basal and 100 nM LHRH [3H]-AA release was in the region of 0.4 and 1.2-2.8% of
the total [3H]-AA incorporated into the aT3-1 cells. In COS 7 cells transiently
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transfected with the "wild type" LHRH receptor, LHRH also resulted in the release of
[3H]-AA which was 2.97 ± 0.25 fold over basal release with 100 nM LHRH after 15
min. The ATP-induced [3H]-AA release at 15 min was also investigated to compare
the magnitude of the release induced by occupation of a transfected receptor (the
LHRH receptor) with that of an endogenously expressed receptor (P2 purinergic).
ATP (100 (xM), similar to LHRH, resulted in a 3.15 ± 0.4 fold of basal [3H]-AA
release. Basal and 100 nM LHRH-mediated [3H]-AA release was in the region of
0.25% and 0.6-0.8% of the total radioactivity incorporated into COS 7 cells. Both
basal and stimulated [3H]-AA release were lower in the COS 7 cells compared to
aT3-1 cells. However the signal to noise ratio of the LHRH-induced response was
approximately equal in both cell lines and it would appear that any differences in
[3H]-AA release can be attributed to cellular differences rather than a receptor-
mediated defect.
AA can be liberated from arachidonyl phospholipids in a number of ways but is often
released primarily as a result of the actions of phospholipase A2 (PLA2). The high
molecular weight species of PLA2 (otherwise known as CPLA2) has been implicated
in AA release in response to hormone stimulation [Lin et al, 1992]. To investigate
whether the [3H]-AA produced in response to LHRH in aT3-1 cells can be attributed
to CPLA2 action, a number of PLA2 inhibitors were tested on LHRH-induced [3H]-AA
release. However to date, no effective inhibitors of the high molecular weight
species have been identified, although some non selective 14 kDa PLA2 inhibitors
are reported to have a weak activity towards the high molecular weight species
[Mayer & Marshall, 1993]. We have tested the following PLA2 inhibitors on LHRH-
induced PLA2 activity in ocT3-1 cells: 4-(4-octadecyl)-4-oxobenzenebutenoic acid
[Kohler et al, 1992]; manoalide [Potts et al, 1992] and a benzenesulphonamide
compound, N-[1 -(2-pheny lethy l)-4-piperid inyl]-4-[N-methyl-N-[(E)-3-[4-
(methylsulphonyl) phenyl]-2-propenoyl] amino]-benzenesulphonamide hereafter
referred to as benzenesulphonamide 4 [Oinuma et al, 1990]. These agents
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appeared to have a weak potency, but significantly inhibited the LHRH-induced [3H]-
AA release, with 4-(4-octadecyl)-4-oxobenzenebutenoic acid (500 pM) and
manoalide (5 pM) inhibiting >80% of the LHRH response and benzenesulphonamide
4 (10 pM) inhibiting -60% of the LHRH-mediated response at the maximum
concentrations tested here (Table 7.1). In contrast aristolochic acid (0-300 pM) and
Br-Phe-Ac-Br (0- 300 pM), which are reported to be highly selective towards the low
molecular weight species of PLA2 [Mayer & Marshall, 1993], had no effect.
Additionally the DAG lipase inhibitor RHC 80267 (200 pM) did not inhibit LHRH-
mediated [3H]-AA release (results not shown). These results indicate that the
majority of the [3H]-AA release observed appears to be from the action of a CPLA2,
although a residual component of between 20-40% of the [3H]-AA release was not
prevented by these agents at the maximum concentration tested. None of these
inhibitors had any significant effect on basal [3H]-AA release (results not shown).
Stimulation of the LHRH receptor is known to result in the activation of PKC as a
consequence of the formation of DAG through PLC activation [Stojilkovic et al, 1994].
Phosphorylation of CPLA2 by kinases including PKC may have a role in activation of
this enzyme in response to hormonal stimulation. The effects of phorbol esters, PKC
activators, on [3H]-AA release were assessed. Table 7.2 shows that none of the
phorbol esters tested including 4-(3 phorbol 12,13 dibutyrate (300 nM), mezerein (300
nM) and 1,2-dioctanoyl-sn-glycerol (200 pM) was able to elicit any significant change
in [3H]-AA release from aT3-1 cells. A role for PKC upstream of PLA2 was also
investigated by determining the effects of a number of PKC inhibitors on LHRH-
induced [3H]-AA release. As can be seen in Table 7.3, neither H7 (30 pM),
GF109203X (5 pM) nor staurosporine (300 nM) was able to inhibit the LHRH-induced
[3H]-AA release in aT3-1 cells. None of these inhibitors had any significant effect on
basal [3H]-AA release (results not shown).
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cPLA2 has also been proposed to be regulated by tyrosine phosphorylation. The
role of tyrosine phosphorylation in LHRH-induced [3H]-AA release in aT3-1 cells was
therefore assessed. However as shown in Table 7.4 none of the tyrosine kinase
inhibitors or pervanadate, a tyrosine phosphatase inhibitor [Grinstein et al, 1990],
displayed any inhibition of the LHRH-mediated response measured. None of these
inhibitors had any significant effect on basal [3H]-AA release (results not shown).
The pharmacology of the LHRH-induced [3H]-AA release was further analysed by
assessing the effects of agents which act at the level of G-proteins. One of these
agents, isotetrandrine, is reported to be a specific inhibitor of PLA2 activation of
receptors, which acts by uncoupling PLA2 from G-proteins [Hashizume et al, 1991].
Isotetrandrine was able to inhibit >75% of the LHRH-induced [3H]-AA release which
suggested the involvement of a G-protein-mediated coupling (Figure 7.2 a). In aT3-1
cells a high concentration of pertussis toxin (300 ng/ml; for 18 h) had no effect on
basal or LHRH-induced [3H]-AA release (Figure 7.2 b). To further investigate the
role of G-proteins in PLA2 activity in aT3-1 cells, single stranded phosphorothioate
oligonucleotides antisense to non-conserved sequences around the translocation
initiation site of Gaq/n (5'-CGC CAT (GC)AT GGA CTC CAG AGT-31) and Goc-|2 (5-
GGG TCC GCA CCC CGG ACA TGG-3') were prepared. Cells were treated with
antisense reagents for 18 h as described in Chapter 2. In Figure 7.3a it can be seen
that the relevant antisense reagents successfully down regulated expression of Goc-|2
or Goiq/11 without effecting expression of the other G-protein. The transfection
procedure had no significant effect on protein synthesis or cell mortality as
determined by Bradford protein concentration assay and Coomassie blue protein
staining [Davis, 1988] of the Immobilon-P membranes following electroblotting of the
proteins from the SDS gels (on which the proteins in the cell samples were
separated by electrophoresis). Transfection of antisense oligonucleotides to Ga-|2
but not Gaq/ii almost entirely inhibited the LHRH-induced pH]-AA release (Figure
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7.3 b) providing evidence to suggest that the LHRH receptor interacts with another
G-protein class, G12 to activate an isoform of cPLA2.
To determine if PLA2 was a target of MAP kinase in aT3-1 cells the antisense
approach was again used as at present there is no commercially available MAP
kinase inhibitor. aT3-1 cells were transfected with single stranded phosphorothioate
oligonucleotides antisense to non-conserved sequences around the translocation
initiation site of ERKs 2 (5'-CGC CAT GTT GGC TGC ACA GCC GCC-3') for 24 h
then returned to normal growth medium for 48 h. This treatment almost entirely
removed the p42 and p44 ERK proteins, therefore this oligonucleotide could not be
used as a specific reagent towards ERK 2 activation, although this treatment had no
significant effect on the LHRH-induced [3H]-AA release (Fig 7.4).
7.3 DISCUSSION
Addition of LHRH to aT3-1 cells clearly results in a concentration-dependent
increase in [3H]-AA release, presumably through the action of a phospholipase A2.
The assay employed here has several drawbacks; it measures [3H]-AA release and
not directly PLA2 activity, it measures the total [3H]-AA released into the extracellular
medium over a 15 min stimulation and therefore does not give true indication of the
kinetics of the response or the [3H]-AA released within the cytosol, there is no
information on absolute [3H]-AA concentrations just relative levels of radioactivity and
no lysophospholipid measurements are made to confirm that it is a PLA2 activity that
is measured. Regardless of this, the assay has been shown to be an accurate
measure of cellular AA production [Powell, 1982], Given the evidence from this
Chapter regarding the attenuation by the PLA2 inhibitors in addition to evidence from
other labs concerning receptor mediated PLA2 activation and the Ca2+ requirements
for the PLA2s, it is most likely that the [3H]-AA release measured largely reflects the
activity of a high molecular weight species of PLA2.
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The high molecular weight forms of phospholipase A2 (CPLA2) have been implicated
in hormone-stimulated release [Lin et al, 1992]. This is the most likely candidate for
AA release as this isoform and not the low molecular weight forms has a preference
for AA at the sn-2 position and are more likely to be active at the physiological levels
of Ca2+ present in the activated cells. However AA can be mobilised in response to
hormone stimulation by other routes such as the actions of DAG lipase on DAG
produced from the action of PLC on membrane phospholipids [Bell et al, 1979] or
from PLD followed by phosphatidate phosphohydrolase [Billah & Anthes, 1990].
Although the type II SPLA2S display no preference for AA at the sn-2 position and are
generally secreted, the actions of this class of enzymes in response to hormonal
stimulus cannot be entirely ruled out. In one study addressing this possibility, the
functions of type II SPLA2S was investigated by stable transfection into a fibroblast
cell line [Pernas et al, 1991]. Although Type II SPLA2S were secreted from these
cells by phorbol esters or the G-protein activator, AIF4", and the rate of secretion was
unaffected by these agents, a considerable amount of SPLA2 remained associated
with the cell and the transfected cells displayed significantly elevated levels of
stimulated radiolabeled AA release in response to AIF4' or phorbol esters compared
to similarly treated untransfected cells. This suggests that type II SPLA2S may in
some circumstances be involved in stimulated AA release, however this study is not
conclusive and other explanations may exist. By contrast another study reported
that CHO cells overexpressing type II sPLA2 did not show an increased AA release in
response to thrombin or ATP, whereas stimulated CHO cells transfected with the 85
kDa PLA2 displayed increased AA release over control untransfected cells [Lin et al,
1992].
The effects of several pharmacological agents was tested on the LHRH-mediated
[3H]-AA release. There is a lack of good effective inhibitors for the high molecular
weight species of PLA2 [Marki et al, 1993; Mayer & Marshall, 1993]. In the study by
Marki and co-workers where the potencies of several PLA2 inhibitors was tested on
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both CPLA2 and SPLA2, some weak inhibition of CPLA2 was only seen with two of
seven reference compounds and some phosphate free analogues or 1,2-amino
alcohols [Marki et al, 1993]. As well as the classical inhibitors, aristolochic acid and
an active site-directed inhibitor, 4-bromophenol-acylbromide (Br-Phe-Ac-Br; BPB),
several very potent type II SPLA2 inhibitors have been identified including the natural
marine sponge products, manoalide and scalaradial (IC50 -10-15 nM). However
these agents are largely unselective as they act through reversible inhibition of lysine
residues [Mobilo & Marshall, 1989; Potts et al, 1992], We tested manoalide, a new
agent from the aroylacrylic acid series of inhibitors, OBAA (4-(4-octadecyl)-4-
oxobenzenebutenoic acid) and benzenesulphonamide 4. These agents, at high
concentrations were able to inhibit a significant portion of the LHRH-mediated [3H]-
AA release whilst other agents such as aristolochic acid, Br-Phe-ac-Br were
ineffective at the concentrations tested (Table 7.1). Where assessed previously in
the literature IC50 values for manoalide against SPLA2 and CPLA2 action have been
reported as 3.2 + 0.5 pM and ineffective at 30 pM (highest concentration tested)
[Marki et al, 1993] or 0.017 pM and >30 pM [Mayer & Marshall, 1993], 43 pM and
>100 pM for BPB against SPLA2 and CPLA2 action. No literature was found where
the potency of the agents aristolochic acid, OBAA or benzenesulphonamide 4 were
compared between the two forms of PLA2. however IC50 values of 40 pM [Mayer &
Marshall, 1993], 70 nM [Kohler et al, 1992] and 9 nM [Oinuma et al, 1990]
respectively have been quoted for these agents on SPLA2 activity. Additionally the
DAG lipase inhibitor RHC 80267 did not inhibit LHRH-mediated [3H]-AA release
(results not shown). Taken together these results would argue against the possibility
that SPLA2 is responsible for the AA release observed in response to LHRH in aT3-1
cells as the potencies of inhibition should be much greater than those observed and
further suggest that a CPLA2 species is activated here.
The LHRH-mediated [3H]-AA release was unaffected by incubation with phorbol
esters or with PKC or tyrosine kinase inhibitors and would therefore indicate that
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these kinases play no direct regulatory role in LHRH-induced activation of PLA2 in
aT3-1 cells. Nevertheless cPLA2 can be activated in response to a variety of agents
including thrombin, ATP, bradykinin, vasopressin, phorbol esters and growth factors
such as PDGF and EGF [Bonventre et al, 1990; Goldberg et al, 1990; Gronich et al,
1988; Margolis et al, 1988; Rehfeldt et al, 1991; Wijkander & Sundler, 1991] all of
which may stimulate kinases in the cytosol. Phosphorylation of cPLA2 has been
demonstrated to increase activity in conjunction with raised intracellular Ca2+ in a
variety of tissues including intact cells and lysates from kidney mesangial cells
treated with EGF, macrophage cell lines and a monocyte cell line, THP-1 [Bonventre
et al, 1990; Goldberg et al, 1990; Gronich et al, 1988; Rehfeldt et al, 1991]. Lin and
co-workers also reported serine phosphorylation of cPLA2 induced by either ATP,
thrombin, phorbol esters or the calcium ionophore A23187 and demonstrated that
this stable modification correlates with the agonist induced increase in cPLA2 activity
[Lin et al, 1992]. It has been suggested that Ca2+ is required to promote cPLA2
membrane binding as with the Type II sPLA2s and is not involved in catalysis
[Ghomashchi et al, 1992; Wijkander & Sundler, 1992]. One possible function of a
phosphorylation event is to decrease the Ca2+ concentrations required for membrane
association. The properties of a partially purified PLA2 from phorbol ester-stimulated
cells were compared to the cPLA2 from unstimulated cells [Rehfeldt et al, 1993].
Both enzymes displayed an identical Ca2+-dependence for enzyme activation but
significant differences were found in the Ca2+-dependent membrane association of
the enzymes obtained from the two sources. The PLA2 from the phorbol ester-
treated cells showed membrane association at much lower Ca2+ concentrations due
to a stable modification of the enzyme for example phosphorylation. Phosphorylation
of cPLA2 however does not necessarily lead to increased activity. In the study by
Wijkander and Sundler, PKC dependent phosphorylation of PLA2 was observed
without a corresponding increase in enzyme activity [Wijkander & Sundler, 1991] and
additionally two other studies reported that PLA2 was not activated in response to
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short term phorbol ester treatment despite the translocation of PLA2 to the
membrane within 5-10 min [Rehfeldt et al, 1991; Shibata et al, 1992], Thus factors
additional to PKC-dependent phosphorylation may be required in some instances.
Tyrosine phosphorylation may additionally have a role in cPLA2 responses. In
murine resident peritoneal macrophages eicosanoid formation in response to various
stimuli including zymosan, A23187 and PMA was prevented by the tyrosine kinase
inhibitors genistein and tyrphostin-25. These inhibitors had no effect on human
synovial fluid PLA2 activity in vitro or in intact cells. Additionally monoclonal anti-
phosphotyrosine blots of agonist treated peritoneal cells demonstrated an increase in
protein tyrosine phosphorylation [Glaser et al, 1993]. These results suggest a
protein tyrosine kinase-mediated phosphorylation event in PLA2 signal transduction.
Pervanadate enhanced by 4-10 fold the PLA2 activity induced by reactive oxygen
species, phorbol ester and a Ca2+-ionophore in macrophages [Goldman et al, 1992],
Further investigation of this pathway demonstrated that a combination of
pervanadate and TPA led to massive tyrosine phosphorylation, the sustained
activation of tyrosine kinase activity and inhibition of tyrosine phosphatase activity as
well as activation of PKC and a myelin basic protein kinase activity [Zor et al, 1993].
In a mouse keratinocyte cell line HEL-30 transforming growth factor-alpha (TGF-a)
stimulated the rapid release of AA in a time- and dose-dependent manner due to the
action of a cPLA2 activity which was found to be membrane associated [Kast et al,
1993]. This activity was shown to be attributable to a cPLA2 activity, as the activity
was found in the cytoplasmic fraction and was Ca2+ dependent, furthermore it co
immunoprecipitated with an anti-PLA2 antibody and had an apparent molecular
weight of 100-110 kDa following SDS-PAGE electrophoresis. This activation of
cPLA2 was found to be independent of the PLC products DAG and IP3 or PKC.
Moreover cPLA2 was found to be tyrosine phosphorylated by this treatment. In rat
mesangial cells, chronic exposure to endothelin-1 (ET-1) stimulates prostaglandin
release via the increased activity and gene expression of cPLA2 [Schramek et al,
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1994], acute exposure to ET-1 also stimulates CPLA2 activity in these cells.
Herbimycin A, a cellular-TK inhibitor, abrogated the ET-1-induced CPLA2 expression
and hence activity whilst PKC inhibitors or heparin (which can inhibit intracellular
Ca2+ increase as well as MAP kinase activation and cell proliferation) were
ineffective on this response [Schramek et al, 1994]. Suspension of permeabilised
HL-60 or U937 cells in acidic or alkaline conditions causes the release of various
fatty acids, particularly AA [Tsujishita et al, 1994], The effects of pervanadate and
genistein on this reaction were assessed. The concomitant production of
lysophospholipids, particularly lysophosphatidylcholine, suggested that PLA2 played
a major role in this action. In alkaline conditions the release of fatty acids, stimulated
by permeabilisation, and lysophospholipids was enhanced by pervanadate and this
enhancement was reversed by the inclusion of genistein, suggesting a role for
tyrosine phosphorylation in this release reaction. Additionally this effect was
increased further in the presence of a G-protein activator GTP[yS] or AIF4". However
this last result should be interpreted with caution as some of the activity measured
may reflect an arachidonic acid-non selective PLA2 isoform.
Since it was first reported that CPLA2 contains a MAP kinase consensus
phosphorylation sequence and that phosphorylation of CPLA2 by the family of MAP
kinases can increase activity [Lin et al, 1993; Nemenoff et al, 1993], considerable
evidence has accumulated regarding the inter-relationship of these enzymes.
Nevertheless whilst MAP kinase is capable of activating CPLA2 and these two
enzymes are often both stimulated in response to one agonist in many cells, PLA2 is
not always a downstream target for MAP kinase. In one study macrophage cells
were exposed to a range of stimuli including zymosan, phorbol ester, okadaic acid
and A23187, all of which had previously shown to induce AA release through CPLA2
activity [Qui & Leslie, 1994], The results demonstrated a complex pattern of cPLA2
regulation. PMA and zymosan trigger PKC activation that leads to activation of MAP
kinase and PLA2, whereas in okadaic acid treated cells, MAP kinase and PLA2
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activation are PKC independent. Alternatively in A23187-treated cells PLA2
activation is both PKC and MAP kinase independent [Qui & Leslie, 1994]. In
fibroblast cells both PLA2 and MAP kinase are stimulated in response to thrombin
and ATP. Both of these responses are inhibited by PTx pre treatment or down-
regulation of PKC. Expression of a mutant Gctj subunit having Gly 203 mutated to
Thr (aj2G203T) inhibited AA release independent of adenylyl cyclase inhibition,
Ca2+-mobilisation and MAP kinase activation [Winitz et al, 1994]. This result defines
a role of Gocj in the control of PLA2 activity in addition to regulation by PKC and MAP
kinase. Arachidonic acid may also serve to regulate the activity of MAP kinase. In
vascular smooth muscle cells (VSMC), AA activated MAP kinase in a time- and
dose-dependent manner. It appears likely that this is, at least in part, due to the
conversion of AA to 15-hydroxyeicosatetraenoic (15-HETE) and is additionally
dependent on PKC, as AA activation of MAP kinase was blocked by PKC
downregulation or nordihydroguaiaretic acid (NDGA), a potent inhibitor of the
lipoxygenase system [Rao et al, 1994], Furthermore in rat liver epithelial WB cells, it
is reported that p42 and p44 MAP kinase is activated in response to polyunsaturated
fatty acids, especially AA. This mechanism is highly dependent on PKC as it is
prevented by phorbol ester sensitive PKC downregulation and translocation of the a,
5 and e isoforms has been demonstrated in response to AA [Hii et al, 1995].
Although receptor mediated AA release was not investigated in this study, it is
evident that a downstream consequence of PLA2 action in this cell type may be MAP
kinase activation
Our original intention was to ascertain whether PLA2 represented a downstream
target for MAP kinase activated in response to LHRH in the aT3-1 cell line, as
activation of both these enzymes appear critical to the LHRH self-priming effect
observed in rat pro-oestrous tissue [Mitchell et al, 1994; Thomson et al, 1994]
Chapter 6]. Significant responses to LHRH were observed for both these enzymes,
however depletion of ERK by transfection of the antisense oligonucleotide
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corresponding to ERK2 had no effect on LHRH-induced [3H]-AA release. This
oligonucleotide appeared to be non specific to ERK 2, as the corresponding band to
ERK 1 was also diminished by this treatment. Thus it would appear that in this
instance phosphorylation of a PLA2 by ERK is unnecessary and that this activity is
otherwise regulated. It would obviously be of interest in the future to investigate a
putative role of p38 sub-family of MAP kinase members in LHRH-induced PLA2
activation in the light of the recent observations by Kramer and co workers who have
shown that p38 like cPLA2 is activated in response to thrombin in platelets and have
further suggested that CPLA2 may be a target for p38 kinase in platelet activation
[Kramer et al, 1995].
PLA2 regulation by G-proteins became evident with the observation that some PLA2
responses in intact cells were pertussis toxin-sensitive indicating that the receptor
was coupled to PLA2 by a Gj/0 protein [Burch et al, 1986]. Furthermore GTP
analogues and AIF4- are able to stimulate arachidonate release [reviewed in Axelrod,
1990; Cockcroft et al, 1991; Cockroft, 1992], Many receptors that couple to PLA2
also couple to PLC, which can in principle activate PLA2. However it has been
demonstrated that Gj proteins mediate this effect based on a number of
observations; pertussis toxin selectively inhibits PLA2 and not PLC; that neomycin
(which selectively inhibits PLC activation by substrate sequestration) selectively
inhibits PLC and not PLA2 and that PMA can inhibit PLC without affecting PLA2
[Burch & Axelrod, 1987; Burch et al, 1986; Conklin et al, 1988]. However (excluding
the neomycin data) this evidence does not rule out the possibility that PLC activation
is required in parallel. Indeed it has been suggested in some instances that a
requirement for PLC activation prior to PLA2 activation is necessary for Ca2+
mobilisation [Cockcroft et al, 1991]. Collagen- and thrombin-induced AA release and
platelet aggregation has been extensively investigated by a number of groups [Akiba
et al, 1989; Fuse & Tai, 1987; Nakashima et al, 1987; Silk et al, 1989]. Both AA
release and platelet aggregation has been suggested to be caused mainly by CPLA2,
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and furthermore that this PLA2 activation is also regulated by G-proteins. One group
has investigated the effects of bisclaurine alkaloids, including isotetrandine, on PLA2
and PLC activity in this system [Akiba et al, 1992; Hashizume et al, 1991]. Their
findings suggest that these agents but especially isotetrandine, has a specific
potency against PLA2 activity [Hashizume et al, 1991] and that bisclaurine alkaloids
appear to exert their effects by uncoupling of the G-protein from the enzyme
(probably through alkaloid-induced changes in the membrane properties) rather than
by affecting the enzyme directly or the ligand-receptor interaction [Akiba et al, 1992].
The pertussis toxin-sensitive G-proteins Goci/0 appear to be most commonly
associated with CPLA2 activation [Axelrod et al, 1988; Cockcroft et al, 1991].
Recently expression of a mutant Get; subunit (aiG203T) has been reported to inhibit
AA release by at least two groups [Murray-Whelan et al, 1995; Winitz et al, 1994].
This mutant oij-subunit was further shown to specifically inhibit Ca2+ activation (but
not phorbol ester activation) of AA release [Murray-Whelan et al, 1995]. The high
affinity cholecystokinin (CCK) receptor is coupled to PLA2 by a G-protein in
pancreatic acini [Tsunoda & Owyang, 1993; Tsunoda & Owyang, 1995]. A non-
hydrolysable guanosine nucleotide analogue, GTP[yS] stimulated amylase secretion
which was inhibited by anti PLA2 antibodies in permeabilised pancreatic acini.
Furthermore the actions of the high affinity CCK receptor agonist (CCK-OPE) were
inhibited by isotetrandrine and Gq antagonist-2A which inhibits Gq activation,
however the actions of CCK-OPE were not inhibited by Gqa antibodies but were
inhibited by a Gp subunit antibody [Tsunoda & Owyang, 1995]. From these
observations it appears that the Py subunit of Gq may be critical in mediating this
response.
Another G-protein proposed to be involved in AA release responses is the recently
cloned Ga-i2[Chan et al, 1993; Xu et al, 1993]. To date little is known about the
function of this family of a-subunits. It is known that the thrombin receptor and the
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thromboxin A2 receptor couple to G12 and G13 during platelet activation [Offermanns
et al 1994] and platelet activation has also been implicated with PLA2 activation in
platelets [Kramer et al 1995]. In one study the oncogenic effects of the G12 were
investigated [Xu et al, 1993]. Overexpression of the wild type 0112 subunit was
weakly transforming in contrast to the activated a-12 subunit which acted as a potent
oncogene. This observation is confirmed in another study, activated a-12 and (X13
induced neoplastic transformation in Rat-1 and NIH 3T3 fibroblasts
[Voynoyasenetskaya et al, 1994], Transformation by a-12 correlates with alterations
in the eicosanoid pathway but not with alterations in Pl-specific PLC or other G-
protein linked second messengers [Xu et al, 1993]. Interestingly G12 deficient mice
have been proposed as a model for inflammatory bowel disease perhaps also
suggesting a role for ai2 in AA mobilisation as part of an inflammatory response
[Rudolph et al, 1995].
In summary, LHRH-induced [3H]-AA release which may involve a CPLA2 seems to be
unaffected by protein kinase inhibition, ERK 2 depletion or phorbol esters, but is
potently inhibited by isotetrandine in aT3-1 cells. Despite the ability of this receptor
to activate the Gj/0 family of G-proteins [Sim et al, 1995; Chapter 3+4], LHRH-
mediated [3H]-AA release was unaffected by pertussis toxin pretreatment thereby
eliminating a role for Gai/0 in this response. Interestingly using the antisense
oligonucleotide approach, depletion of the ai2 subunit and not aq/n subunits
abolished the LHRH-mediated [3H]-AA release. Taken together these data would
indicate that this response may be substantially regulated by a signalling pathway
reliant on G-proteins probably of the G12 family.
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Table 7.1
Effects of various PLA2 inhibitors on LHRH-induced [3H]arachidonic acid
release from aT3-1 cells
aT3-1 cells pre-labelled with 0.5 pCi/ well of [3H]-AA were incubated in medium
containing no drug or a PLA2 inhibitor for 15 min. The medium was discarded and
replaced with fresh medium containing LHRH and inhibitor where appropriate for a
further 15 min. Thereafter the [3H]-AA release measurements were determined. All
values are the mean ± SEM of between 3-8 determinations (actual values are shown
in brackets). LHRH-induced [3H]-AA release was significantly greater than baseline





as % of total label
incorporated
mean % of LHRH-
stimulated [3H]AA
release
basal 0.4 ± 0.03 (10)
LHRH (100 nM) 1.8 ± 0.59 (10) 100% (+)
LHRH + aristolochic acid
300 (iM 1.76 ±0.42 (8) 98%
LHRH + br-phe-ac-br
300 (iM 1.75 ±0.32 (8) 97%
LHRH + 4-(4-octadecyl)-4-
oxobenzenebutenoic acid
1.5 |iM 1.65 ±0.89 (8) 92%
5.0 |iM 1.45 ±0.30 (8) 81%
50 |iM 1.08 ± 0.12 (8) 60% (*)
500 |iM 0.33 ± 0.05 (8) 18% (*)
LHRH + manoalide
0.5 [iM 1.73 ±0.10 (6) 96%
1.0 (iM 1.48 ±0.13 (6) 82%
2.5 (iM 1.01 ±0.02 (6) 56% (*)
5.0 (iM 0.26 ± 0.05 (6) 14% (*)
LHRH + benzenesulphonamide 4
0.3 (iM 1.67 ±0.12 (6) 93%
1.0 (iM 1.35 ± 0.09 (6) 75%
3.0 (iM 1.24 ± 0.04 (6) 69% (*)
10 (iM 0.68 ± 0.05 (6) 38% (*)
Table 7.2
The effects of phorbol esters on [3H]arachidonic acid release from aT3-1 cells
aT3-1 cells pre-labelled with 0.5 pCi/ well of [3H]-AA were incubated in medium
containing either vehicle or a phorbol ester for 15 min. Thereafter the [3H]-AA
release measurements were determined. All values are the mean ± SEM of between
4-8 determinations (actual values are shown in brackets). As a control response,
LHRH-induced [3H]-AA release was significantly greater than baseline. None of the
phorbol esters tested significantly increased the [3H]-AA release.
Table 7.2
The effects of a phorbol ester and related PKC-activating agents on
[3H]arachidonic acid release from aT3-1 cells
aT3-1 cells pre-labelled with 0.5 jxCi/ well of [3H]-AA were incubated in medium
containing either vehicle or drugs for 15 min. Thereafter the [3H]-AA release
measurements were determined. All values are the mean ± SEM of between 4-8
determinations (actual values are shown in parentheses). As a positive control
response in the same experiment, LHRH-induced [3H]-AA release was shown to be
significantly greater than baseline (+). None of the PKC-activators tested significantly
increased the [3H]-AA release matched pair t-test on raw data.
Treatment Concentration
[3H]-AA
(% of total label
incorporated)
basal 0.59 ± 0.03 (8)
LHRH 100 nM 1.61 ±0.18 (8) (+)
12, 13-phorbol
dibutyrate
300 nM 0.60 ± 0.04 (6)
mezerein 300 nM 0.62 ± 0.05 (6)
1, 2-sn-dioctanoyl
glycerol
200 pM 0.58 ± 0.04 (6)
Table 7.3
Effects of PKC inhibitors on LHRH-induced [3H]arachidonic acid release in
aT3-1 cells
aT3-1 cells pre-labelled with 0.5 juCi/ well of [3H]-AA were incubated in medium
containing no drug or a PKC inhibitor for 15 min. The medium was discarded and
replaced with fresh medium containing LHRH and inhibitor where appropriate for a
further 15 min. Thereafter the [3H]-AA release measurements were determined. All
values are the mean ± SEM of between 4-8 determinations (actual values are shown
in brackets). LHRH-induced [3H]-AA release was significantly greater than baseline.
None of the PKC inhibitors tested significantly inhibited the LHRH-induced [3H]-AA
release
Table 7.3
Effects of PKC inhibitors on LHRH-induced [3H]arachidonic acid release in
aT3-1 cells
aT3-1 cells pre-labelled with 0.5 juCi/ well of [3H]-AA were incubated in medium
containing no drug or a PKC inhibitor for 15 min. The medium was discarded and
replaced with fresh medium containing LHRH and inhibitor where appropriate for a
further 15 min. Thereafter the [3H]-AA release measurements were made. All values
are the mean ± SEM of between 4-8 determinations (actual values are shown in
parentheses). LHRH-induced [3H]-AA release was significantly greater than baseline
(+). None of the PKC inhibitors tested significantly inhibited the LHRH-induced [3Hj-






(% of total label
incorporated)
basal 0.59 ± 0.03 (8)
LHRH 100 nM 1.61 ±0.18(8) (+)
LHRH +H7 30 pM 1.54 ±0.10 (4) (+)
LHRH + GF109203X 5 pM 1.45 ±0.03 (4) (+)
LHRH + staurosporine 300 nM 1.58 ± 0.06 (4) (+)
Table 7.4
Effects of various tyrosine kinase inhibitors on LHRH-induced [3H]arachidonic
acid release in aT3-1 cells
aT3-1 cells pre-labelled with 0.5 pCi/ well of [3H]-AA were incubated in medium
containing no drug or a tyrosine kinase inhibitor for 15 min. The medium was
discarded and replaced with fresh medium containing LHRH and inhibitor where
appropriate for a further 15 min. Thereafter the [3H]-AA release measurements were
determined. All values are the mean ± SEM of between 4-8 determinations (actual
values are shown in brackets). LHRH-induced [3H]-AA release was significantly
greater than baseline. None of the tyrosine kinase inhibitors tested significantly







(% of total label
incorporated)
basal 0.32 ± 0.03 (8)
LHRH 100 nM 1.11 ±0.18 (8)
LHRH + geldanamycin 30 (iM 1.12 ± 0.18 (6)
LHRH + genistein 100 pM 1.01 ± 0.24 (6)
LHRH + lavendustin A 3 pM 1.08 ±0.06 (6)
LHRH + N-methyl 2,5-
dihydroxycinnamate
300 |iM 1.20 ± 0.02 (6)
LHRH + piceatannol 30 (iM 0.92 ± 0.04 (6)
LHRH + ST 271 100 pM 1.28 ±0.5 (6)
LHRH + pervanadate 1 mM 0.95 ± 0.06 (6)
Figure 7.1
LHRH-stimulated [3H]arachidonic acid release
(a) Dose-dependent ^Hjarachidonic acid release in aT3-1 cells
The specific [3H]-AA release from aT3-1 cells was measured at various
concentrations of LHRH for 15 min. Each value is the mean ± SEM of 6
determinations. Baseline [3H]-AA release in unstimulated cells was typically in the
region of 0.4% of the total radioactivity incorporated by the cells, this was subtracted
and the agonist induced curves were normalised to the activity obtained with the
maximally effective dose. Curve fitting was then conducted as described in Chapter
2. The EC50 value for the response was 3.4 ± 0.4 nM.
(b) Agonist-induced pHJarachidonic acid release in COS 7 cells transfected
with the wild type LHRH receptor.
COS 7 cells were transfected with cDNA for the wild type LHRH receptor and
subsequently challenged with LHRH (100 nM) or ATP (100 |iM) for 15 min. Each








Effects on LHRH-induced [3H]arachidonic acid release in aT3-1 cells of agents
which inhibit at the level of G-proteins.
Figure 7.2 (a) shows the effect of various concentrations of a G-protein/PLA2
inhibitor, isotetrandine on LHRH-induced [3H]-AA release. Basal [3H]-AA release in
unstimulated cells was subtracted and the values expressed as a % of the maximum
LHRH-induced response. Each value represents the mean ± SEM of at least 4
determinations.
The effects of pertussis toxin, the B-oligomer of pertussis toxin and a chemically-
inactivated holotoxin on LHRH-induced [3H]-AA release are shown in figure 7.2 (b).
None of the treatments had any significant effect on either basal or LHRH-induced
release. Means ± SEM, n=6.
Figure 7.2





nil pertussis toxin pertussis toxin NEM-inactivated
B-oligomer pertussis toxin
Figure 7.3
Effects of expression of antisense oligonucleotides to the G-proteins G^or
Gq/11.
cxT3-1 cells were transfected for 18 h with oligonucleotides of the antisense
sequence to the G-proteins G12 or Gq/n. A control set of cells underwent the
transfection procedure but with no antisense oligonucleotides. The cells were
allowed to grow for a further 36-48 h in normal growth medium before on [3H]-AA
release was assayed.
(a 1) shows anti-Gi2 immunoblots which were carried out after protein separation by
electrophoresis. Lanes 1 and 2 show ± Gq/n oligonucleotides in lipofectamine
vesicles and lanes 3 and 4 show ± G12 antisense oligonucleotide in lipofectamine
vesicles.
(a 2) shows anti Gq/n immunoblots which were carried out after protein separation
by electrophoresis. Lanes 1 and 2 show ± G12 antisense oligonucleotides in
lipofectamine vesicles and lanes 3 and 4 show ± G^n oligonucleotide in
lipofectamine vesicles.
(b) shows the corresponding [3H]-AA release data for aT3-1 cells from the same
transfection as panel (a) incubated with nil or 100 nM LHRH for 15 min. Each value
is the mean ± SEM where n=4. Basal levels of [3H]-AA release were not seen to be
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Effects of expression of antisense oligonucleotides to ERK 1+2
cxT3-1 cells were transfected for 18 h with oligonucleotides of the antisense
sequence to ERKs 1+2. A control set of cells underwent the transfection procedure
but with no antisense oligonucleotides. The cells were allowed to grow for a further
36-48 h in normal growth medium before the effect on [3H]-AA release was assayed.
Panel (a) shows anti-ERK 1+2 immunoblots which were carried out after protein
separation by electrophoresis. Lanes 1 shows untreated aT3-1 cells, lanes 2 and 3
show ± ERK 1+2 antisense oligonucleotide in lipofectamine vesicles.
Figure 7.2 b shows the corresponding [3H]-AA release data for aT3-1 cells from the
same transfection as panel (a) incubated with nil or 100 nM LHRH for 15 min. Each
value is the mean ± SEM where n=4. Basal levels of [3H]-AA release were not seen

































The luteinising hormone-releasing hormone (LHRH) receptor is a member of the
rhodopsin family of seven transmembrane-spanning domain, G-protein coupled
receptors. To date the predominant signalling pathways that have been described in
response to LHRH receptor activation, are phosphoinositide hydrolysis and Ca2+
mobilisation following activation of phospholipase (3 (PLCP) via a heterotrimeric
G-proteins of the Gq/n class [Anderson et al, 1993; Davidson et al, 1994a; Davidson
et al, 1994b; Stojilkovic et al, 1994], In this study we have investigated the potential
activation by the LHRH receptor of a key signalling enzyme, the mitogen-activated
protein (MAP) kinase. At the onset of this study, there was little evidence implicating
MAP kinase in G-protein-coupled receptor signalling cascades and most literature
centred on the role of MAP kinases in growth factor tyrosine kinase-mediated
signalling [Cobb et al, 1991; Sturgill & Wu, 1992], Consequently we devised an in
vitro kinase activity assay [Sim et al, 1994], to investigate whether a G protein-
coupled receptor, such as the LHRH receptor, could lead to MAP kinase activation in
the aT3-1 mouse clonal gonadotroph cell line (which endogenously expresses the
LHRH receptor), in anterior pituitary tissue or in COS 7 and CHO host cells,
transfected with wild type and mutated LHRH receptors (tCOS 7 and tCHO).
In the ccT3-1 cell line, the LHRH receptor was shown to bring about a marked and
sustained activation of MAP kinase (Chapter 3). These data from the in vitro kinase
assay were confirmed by anti-ERK 1 and 2 immunoblots which showed an LHRH-
induced, phosphorylation-dependent decrease in electrophoretic mobility on SDS-
PAGE gels of p42 and to a lesser extent of p44 MAP kinase. LHRH-induced MAP
kinase activation could be partially mimicked by the phorbol ester, 12,13-phorbol
dibutyrate (PDBu) and was abolished in cells where phorbol-ester sensitive PKC
isoforms had been downregulated by chronic exposure to PDBu. Further
investigations revealed LHRH- and PDBu-induced MAP kinase activation was
sensitive to a number of selective PKC inhibitors including GF109203X, Ro-31 8220
and H7. These data suggested an obligatory role for PKC in LHRH-induced MAP
kinase activation, although LHRH-evoked responses may rely on a different isoform
or subset of isoforms of PKC than those activated by phorbol ester, as evident from
the varying IC50S observed on inhibition of MAP kinase responses evoked by these
two agonists. This pharmacological profile is consistent with a novel or modified
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PKC isoform [Sim et al, 1994] which has been associated with LHRH-induced PLD
activation in aT3-1 cells and with PLA2 activity associated with LHRH priming in pro-
oestrous pituitary tissue [Fennell et al, 1994; Thomson et al, 1994]. Tyrosine
phosphorylation may also be an important mediator of this response as LHRH-
induced MAP kinase activity was additionally sensitive to the tyrosine kinase
inhibitors genistein, piceatannol and MDC and could be partially mimicked by the
tyrosine phosphatase inhibitor pervanadate. Furthermore LHRH-induced MAP
kinase phosphorylation (and in pilot experiments using the activity assay; not shown)
was prevented by PLC inhibitors. These findings concur with the pathways recently
proposed for MAP kinase activation downstream of a number of Gq-coupled
receptors (for example Mi muscarinic) where phosphoinositide turnover and PKC
activation also appear to be an upstream requirement in this response [Buhl et al,
1995; Gupta et al, 1992; Hawes et al, 1995]. Interestingly LHRH-evoked MAP
kinase activity is additionally sensitive to pertussis toxin and could be partially
mimicked (in a pertussis toxin-sensitive manner) by a reported Gj activating peptide,
mastoparan. We therefore propose a hypothesis where the LHRH receptor is
capable of activating MAP kinase by a Gaq/n - and PKC-dependent mechanism or a
Gccj/o-dependent pathway, but to see the full extent of this response a dual signalling
input through Gaq/n and Goci/0 is required. This dual mechanism is relatively
unusual in G-protein-mediated MAP kinase activation at present. However a small
number of examples such as the PAF receptor [Honda et al, 1994; Takano et al,
1994], the thrombin receptor [Kahan et al, 1992b; Kramer et al, 1995; Seuwen et al,
1990] and the C5a receptor [Buhl et al, 1995] would appear to require input from both
pertussis toxin-sensitive and insensitive G-proteins. This type of dual input
requirement to bring about a maximal response, may become more widely apparent
in the future.
The ability of the LHRH receptor to phosphorylate and activate MAP kinase has
further been demonstrated by expression of the wild type mouse LHRH receptor in
COS 7 and CHO host cells (Chapter 5). This response was also sensitive to PKC
inhibition, although the unusual sensitivity to the PKC inhibitor H7 was not observed
here suggesting that the LHRH receptor can utilise other PKC isoforms to mediate
MAP kinase activation. This response was also sensitive to pertussis toxin,
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highlighting the importance of the dual input mechanism in LHRH signalling and
confirming that this was not a cell-specific artefact. We have also shown that the
ability to bring about a strong PLC response and cause translocation of PKC is not
always sufficient to bring about MAP kinase activation (Chapter 5). Following
expression of the wild type mouse LHRH receptor or the 5-HT2C (another rhodopsin
family member) or the mGlu 1a receptor (a more distantly related receptor) in COS 7
cells, only the LHRH receptor was able to induce a strong MAP kinase response,
whilst sustained inositol phosphate formation and translocation of PDBu binding sites
to the membrane fraction was observed for all these receptors. The ability to cause
MAP kinase activation could not be directly attributed to one of the unusual structural
motifs within this receptor, the natural reciprocal mutation between Asn and Asp in
TMD II and TMD VII [Zhou et al, 1994], Mutation of the mouse LHRH receptor to
restore the more typically observed residues in these domains, and transient
transfection of these receptors in COS 7 host cells, resulted in attenuated MAP
kinase responses. However significant activation was observed and the magnitude
of the response was proportionate to the reduced IP responses observed in mutant
compared to wild type receptors (Chapter 5). From these studies alone it is
impossible to explain what property of the LHRH receptor (but not all PLC-coupled/
PKC activating receptors), confers the ability to particularly strongly activate MAP
kinase, although it is likely to be reliant upon the ability to interact with multiple G-
proteins or possibly other atypical regions within the receptor.
The LHRH receptor is unusual in that as well as the atypical structural motifs found in
the LHRH receptor [Zhou et al, 1994; Davidson et al, 1994], it displays a unique 'self
priming' phenomenon, whereby LHRH causes an augmentation of secretory
responsiveness following prior exposure to LHRH [Fink et al, 1988]. There is a
notable correlation between MAP kinase targets and the changes expressed in
LHRH priming [Mitchell et al, 1994], Accordingly, having clearly established an
LHRH-induced activation of MAP kinase in a clonal pituitary cell line, it was of great
interest to see that this response was apparent in intact anterior pituitary tissue. In
anterior pituitary tissue from pro-oestrous rats, LHRH caused concentration-
dependent activation of MAP kinase, furthermore the magnitude of this response
correlated with that of LHRH priming on various days of the oestrous cycle. This
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response could also be mimicked with phorbol esters and was inhibited (in a similar
manner to LHRH-induced activity in aT3-1 cells) by PKC inhibitors (Chapter 6).
Taken together this demonstrates an association of MAP kinase with the priming
effect of LHRH [Fink, 1988] and suggests that it may have a significant role in the
induction and development of this phenomenon. Definitive test awaits specific
inhibitors of MAP kinase or its activation pathways or its deletion or overexpression
by antisense or expression of mutant constructs. The regulated step determining the
onset of the priming phenomenon probably lies upstream of MAP kinase but
downstream of the LHRH receptor as phorbol ester was still effective in tissue where
priming was not observed (but which had adequate LHRH receptor numbers)
[Mitchell et al, 1994], At present we have found no evidence to support the
hypothesis that in response to LHRH, PLA2 represents an important cellular target of
MAP kinase (Chapter 7). PLA2 activation may also have been associated with the
priming phenomenon as both of these responses are implicated in this effect
[Mitchell et al, 1994; Thomson et al, 1994] and are observed in aT3-1 cells (Chapter
3 and 7). Both PLA2 and ERK responses have been associated with platelet
activation in response to thrombin; however these responses were also unconnected
in platelet activation [Kramer, personal communication]. Further investigation
revealed that p38 (not ERK) was both activated in response to thrombin and
responsible for PLA2 activation, therefore it would obviously be interesting to
investigate the effects on MAP kinase and PLA2 activation of expression of antisense
oligonucleotides against p38 in aT3-1 cells, especially since recent literature includes
several examples of G-protein activation (including notably activated G-|2 and G13
subunits [Vara Presad et al 1995]) of p38 and the JNK/SAPK family of MAP kinases
[Kramer et al, 1995]. Additionally the importance of ovarian steroids to the ability of
the LHRH receptor to cause activation of MAP kinase has been demonstrated. In
ccT3-1 cells grown in steroid-free medium, a predominant LHRH-induction of MAP
kinase activity was only observed in the additional presence of oestrogen (Chapter
6). Taken together with the observations that in female rat anterior pituitaries MAP
kinase activity was co-ordinately regulated with the oestrous cycle (and thus cyclic
changes in oestrogen exposure), it suggests that the ability of this receptor to interact
with MAP kinase may not necessarily be an intrinsic property of this receptor.
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Alternatively whilst the LHRH receptor can cause a strong activation of MAP kinase
at higher concentrations in cultured cells (i.e. aT3-1, tCOS 7 and tCHO) under
physiological conditions in vivo, this response is only significant when a number of
criteria are fulfilled (including prior exposure to steroid hormones), which further
suggest that the MAP kinase response may be critical to the 'self priming
phenomenon'. This observation could obviously have significance in a number of
clinical applications such as the development of novel contraceptives or treatments
for infertility. Furthermore any agent which could selectively modify LHRH receptor
activation of a particular signalling pathway such as the MAP kinase cascade, could
offer therapeutic advantages in tumours associated with the presence of low affinity
LHRH receptors [Emons et al, 1993].
It has become apparent in as a result of these studies that the LHRH receptor joins
an increasing number of receptors which are promiscuous in their interactions with
G-proteins [Milligan, 1993; Offermans & Schultz, 1994; Chapters 3, 4, 5 and 7]. In
addition to the well documented functional coupling to Gq/n proteins [Anderson et ai,
1993; Shah & Milligan, 1994; Stojilkovic et al, 1994], the data concerning the
inhibition of the MAP kinase response by pertussis toxin (Chapter 3 and 5) and
partial mimicry by mastoparan, in a pertussis toxin-sensitive manner (Chapter 3),
provided the first evidence for Gi/0-mediated signal transduction by the LHRH
receptor. Additionally we have clearly demonstrated a pertussis toxin-sensitive
inhibition of forskolin- and PACAP-induced cAMP formation in aT3-1 cells (Chapter
4). This inhibition may additionally be dependent on other factors such as
intracellular Ca2+ concentrations or the phosphorylation state of the cells, all of which
are potentially altered following LHRH activation of the receptor. However we found
no evidence to suggest that this effect was directly due to LHRH-induced Ca2+
mobilisation or PKC activation. Furthermore in experiments examining LHRH
activation of PLA2 we have provided the first evidence suggesting that the LHRH
receptor can also interact with the G12 class of G-proteins in aT3-1 cells (Chapter 7).
Thus it appears (as is the case for many receptors) that it is no longer correct to
regard the LHRH receptor, as a receptor coupled to one G-protein which activates
one signalling cascade. It is evident from the results presented here, that the LHRH
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receptor can activate a variety of different G-proteins to generate multiple
intracellular signals. Over the course of this study evidence has accumulated to
support this concept in many other receptors [Offermans & Shultz, 1994; Milligan,
1993; Gudermann et al 1996]. It is also an intriguing possibility that G-protein-
coupled receptors can intercept intracellular signalling cascades classically
associated with growth factor- and cytokine-stimulated responses, an avenue of
LHRH receptor signalling which may be of interest to investigate in the future.
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ABSTRACT
A MAP kinase activity assay was developed to determine whether
the LHRH receptor could activate this enzyme (particularly
during LHRH priming). In anterior pituitary tissue from pro-
oestrous rats LHRH caused concentration-dependent activation of
MAP kinase after 5-10 min and continued for up to 60 min of
incubation. The magnitude of this response correlated with that
of LHRH priming on various days of the oestrous cycle but not
with the magnitude of 1st hour (unprimed) LHRH-induced LH
release. The response to LHRH was mimicked by a phorbol ester
but not by ionomycin and was blocked with high potency by GF
109203X but not by H7 (in a similar manner to the PKC species
that mediates LHRH priming). Neither the tyrosine kinase
inhibitor lavendustin A nor the protein synthesis inhibitor
cycloheximide blocked LHRH-induced MAP kinase activation.
The possible functional significance of MAP kinase activation in
gonadotrophs is considered with respect to LHRH priming.
INTRODUCTION
The priming effect of LHRH is an augmentation of the secretory
responsiveness of gonadotrophs which develops fully within
about 30-45 min of exposure to LHRH and is dependent on prior
exposure to gonadal steroids (and perhaps other factors) (Fink,
1988). The induction of priming is mediated by a form of protein
kinase C (PKC) (Johnson et al. 1992) with distinctive properties
similar to those of an apparently novel species recently
characterized in anterior pituitary tissue (Ison et al. 1993).
Downstream of this PKC, activation of phospholipase A2 (PLA2)
is essential for induction of the phenomenon (Thomson et al.
1993a). Inhibitors of transcription, translation and microfilament
integrity disrupt LHRH priming (Pickering & Fink, 1976; 1979)
which also involves ultrastructural changes in cytoskeletal/
secretory elements (Lewis et al. 1979).
The mitogen-activated protein kinase (MAP kinase) family is a
group of serine/threonine protein kinases which are believed to
participate in mitogen-induced transcription and translation (Cobb
et al. 1991). The consensus target motif for MAP kinase (Clark-
Lewis et al. 1991) has been recognised in a number of cellular
proteins including jun and myc, p90 ribosomal S6 protein kinase
(p90rsk), high molecular weight PLA2 and microtubule-associated
protein 2 (MAP-2) all of which appear to be targets in vivo
(Sturgill et al. 1988; Alverez et al. 1991; Hoshi et al. 1992; Seth
et al. 1992; Lin et al. 1993; Nguyen et at. 1993). In view of the
concordance between the targets of MAP kinase and the changes
brought about in LHRH priming, we investigated the possibility
that this enzyme may be activated and play a functional role
during LHRH priming.
MATERIALS AND METHODS
Cob Wistar rats were maintained and vaginal smears examined as
described previously (Johnson et al. 1992; Thomson et at.
1993b). Bilateral ovariectomy was performed under halothane
anaesthesia and the rats were left for a period of 4 weeks before
experiments. All chemicals were obtained from LC
Laboratories/Calbiochem, Novabiochem, Nottingham, Notts,
U.K., or Sigma Chemical Co., Poole, Dorset, U.K. The MAP
kinase substrate peptide was prepared by solid phase synthesis.
ATP-y[35S] (specific activity 1198 Ci/mmol) was from NEN,
Dreieich, Germany. Statistical analyses were carried out using
the Mann-Whitney U-test and curve-fitting was performed by the
program P.fit (Biosoft, Cambridge, Cambs, U.K.), as described
previously (Thomson et al. 1993b).
Hormone release experiments: Anterior pituitary glands were
removed between 11.00 and 12.00 h on specified days of the
oestrous cycle and experiments carried out as described
previously (Johnson et al. 1992; Thomson et al. 1993b), with
consecutive hourly incubations in the presence of LHRH
(1 nmol/1). Medium was radioimmunoassayed for LH using
NIADDK rat LH-RP2 as standard.
MAP kinase assay; Hemipituitaries (3 per 2 ml) were pre-
incubated for a recovery period of 30 min in minimal essential
medium (37°C, under 95% 02/5% CO2) and then any inhibitory
drugs were added with new medium. Five min later LHRH (0.2 -
100 nmol/1) 4(3-phorbol 12,13-dibutyrate (PDBu, 1 pmol/1), or
ionomycin (30 pmol/1) were added for 15 min unless otherwise
stated. Where required, dimethylformamide was present at 0.03%
(v/v). This concentration of vehicle was shown to have no effect
on MAP kinase activity. Tissue was homogenized in 100 pi of
ice-cold homogenization medium: 20 mmol Tris/1; 12 mmol
EDTA/1, 50 mmol 2-mercaptoethanol (EtSH)/l, 1 mmol
phenylmethyl-sulphonylfluoride/I, pH 7.4 with HC1, containing
0.01% (w/v) leupeptin, 20 pmol trans-epoxysuccinyl-L-
leucylamido-(4-guanidino)butane/l, 2 mg aprotinin/1, 1 pmol
pepstatin/1, 2.5 mmol Na3V04/l, 62.5 mmol (3-glycerophosphate/l
and 200 nmol okadaic acid/1. The supernatant fraction was
collected after centrifugation. The 25 pi assay finally contained
20 mmol Tris/1, 0.5 mmol EGTA/1, 2.4 mmol EDTA/1, 20 mmol
MgCl2/l, pH 7.5 with HC1, with 50 pmol NaF/1, 50 mmol EtSH/1
and 200 nmol okadaic acid/1 as well as the other peptidase and
phosphatase inhibitors diluted 1 in 5 from their concentrations in
the 5 pi aliquot of cytosolic extract added to the assay. The
selective MAP kinase substrate peptide (APRTPGGRR; Clark-
Lewis et al. 1991) was used at 2 mmol/1. Substrate-free blanks
were determined in all cases. Assays were started with 100 pmol
ATP-yS/1 (containing 0.58 pCi ATP-y[35S]/tube) and brief
centrifugation. Tubes were incubated for 40 min at 30°C (within
the linear range of the assay). Incubations were stopped by
addition of 25 pi ice-cold trichloroacetic acid (120 g/1) and 10 pi
bovine serum albumin (20 g/1). After 15 min on ice, samples
were centrifuged (12000 g for 5 min at 4°C), then 30 pi aliquots
were spotted onto 4 cm2 pieces of Whatman P81 paper. Papers
were washed for 3x2 min in 10 ml of H3PO4 (75 mmol/1) and
dried before scintillation counting. Specific MAP kinase activity
was defined by subtracting the substrate-free blanks which were
generally less than 25% of values with substrate and were
unaltered by any of the present treatments.
Immunoprecipitation: Protein G-Sepharose-4B (100 pi packed
gel) was washed and resuspended in 140 pi 25 mmol Tris/1, 150
mmol NaCl/1, 0.04% (v/v) Nonidet-P40, 0.25% (w/v) gelatin, pH
7.4 with HC1. MAP kinase antibody (Zymed Z033, specific for
p44 and p42 species; 50 pg), or a control and-(3 tubulin antibody
(Amersham N357) was added to the gel and incubated for 2 h at
room temperature with rolling. The derivatized gel was washed
twice and resuspended in homogenization buffer to a final volume
of 140 pi. Fifty pi aliquots, together with 50 pi cytosolic extract
were incubated for 18 h at 4°C with rolling. After brief
centrifugation, the supernatant was removed, the gel washed once
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and resuspended to 100 |xl. Aliquots (10 pi) of supernatant, of
resuspended gel and of cytosolic extract (diluted 1:1) were
assayed.
RESULTS
It is clear that majority of the enzymic activity assayed
represented authentic p44/p42 MAP kinase since Table 1 shows
that 70-80% of either control or LHRH-stimulated activity was
immunoprecipitated by the anti-MAP kinase gel, whereas less
than 20% was bound by the control reagent.
TABLE I: Immunoprecipitation of MAP kinase activity with protein
G-Sepharose-4B dcrivatized reagents.
MAP kinase activity recovered
(xlO3 dpm per assay)
Condition Antibody reagent Supernatant Pellet
a. Control Nil 1.84 ±0.26 —
Anti-MAP kinase 0.56 ±0.08 1.39 ±0.18
Anti-p-tubulin 1.62 ±0.32 0.40 ± 0.08
b. LHRH Nil 2.93 ± 0.32
(100 nmol/1)
Anti-MAP kinase 0.55 ±0.18 2.09 ± 0.34
Anti-p-tubulin 2.58 ± 0.36 0.64 ± 0.20
Values are the means ± S.E.M. from 3 determinations.
In pro-oestrous anterior pituitary tissue but not that from oestrous
or ovariectomized rats, LHRH (1 nmol/1) induced a marked
increase in MAP kinase activity after a brief delay (in the order of
5 min), peaking at around 15 min and then declining gradually to
60 min (Fig. 1). Unstimulated tissue showed no significant
change in MAP kinase activity through 60 min incubation (data
not shown). The response of pro-oestrous tissue to LHRH (15
min incubation) was statistically significant at 1-100 nmol
LHRH/1 and showed an EC50 value of 0.53 ± 0.19 nmol/1 (Fig. 2).
Tissue from ovariectomized rats showed 110 response to LHRH
even up to a concentration of 100 nmol/1. The responses of
anterior pituitary tissue from rats on different days of the oestrous
cycle and from ovariectomized rats were compared in terms of
acute LHRH-induced LH release, LHRH priming and LHRH-
induced MAP kinase activation (Table 2). The 1st hour
(unprimed) release of LH induced by LHRH (1 nmol/1) was
greatest in tissue from pro-oestrous followed by ovariectomized
and oestrous rats. In contrast, LHRH priming (the increment in
LH release in a 2nd hour with LHRH) was greatest in tissue from
pro-oestrous and dioestrous rats. LHRH (100 nmol/1) caused
significant activation of MAP kinase only in tissue from pro-




FIGURE 1. Time course of LHRH (1 nmol/1) activation of MAP kinase
in anterior pituitary tissue from pro-oestrous (•), oestrous (A) and
ovariectomized (■) rats. All basal activity at zero time was within 850-1000
dpm per assay. Values are means + S.E.M. from 5-6 determinations. *p <
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FIGURE 2. Concentration-dependence of LHRH activation of MAP kinase in
anterior pituitary tissue from pro-oestrous (•) and ovariectomized (■) rats are
shown. Values are means ± S.E.M. from 5 determinations. *p < 0.05
compared with basal activity.
Experiments were carried out to assess whether either of the
obvious consequences of phosphoinositide hydrolysis evoked by
the LHRH receptor, ie Ca2+ mobilization and PKC activation,
could mimic the LHRH-induced activation of MAP kinase.
Stimuli were deliberately presented at concentrations giving near-
maximal responses. Despite causing marked release of LH from
pro-oestrous anterior pituitary tissue (Johnson et al. 1992),
ionomycin (30 pmol/1) failed to increase MAP kinase activity (84
± 12% of control at 15 min; mean ± S.E.M. of 4 determinations).
Although facilitation of LHRH-induced mobilisation of
intracellular Ca2+ is one of the downstream consequences of
LHRH priming (Mitchell et al. 1988), this result is consistent
with evidence (Johnson et al. 1992) that elevation of Ca2+ does
not elicit induction of the phenomenon, but rather that it is
critically dependent upon a form of PKC. Indeed, PDBu (1
(imol/l) activated MAP kinase in pro-oestrous tissue with a
maximal effect after approximately 15 min incubation (Table 3).
A similar effect of PDBu was seen in tissue from ovariectomized
rats (Table 3); acting as a positive control in this tissue where
LHRH failed to elicit either priming of LH release or activation of
MAP kinase (Table 2, Fig. 2) and indicating that PKCs other than
those transducing signals from the LHRH receptor can activate
Journal of Endocrinology (1994) 140, R15-R18
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TABLE 2: LHRH-induced LH release, priming and MAP kinase activation in
anterior pituitary tissue taken from different stages of the oestrous cycle.





1st hour 2nd hour
LHRH-induced MAP
kinase activation




(% increase over basal activity)
Pro-oestrous Ovariectomized
Oestrous 13.6 ± 1.4* 28.0 ± 2.5* 0.06 ± 0.09 0 0± 7 0±6
Metoestrous 4.3 ± 1.0* 25.5 ± 3.0* 0.11 ±0.14 5 44 ±4* 78 ± 11*
Dioestrous 6.1 ±0.9* 57.9 ±4.8* 0.71 ±0.12* 10 75 ± 11* 99 ± 16*
Pro-oestrous 29.2 ± 1.8* 142.3 ± 16.7* 0.94 ±0.10* 15 89 ± 14* 84 ± 12*
Ovariectomized 14.8 ± 1.6* 15.4 ± 2.0* 0.10 ±0.12 20 68 ± 12* 57 ± 14*
40 44 ±5* 36 ± 10*
LHRH was used at a concentration of 1 nmol/1 for the LH release experiments
and 100 nmol/1 for the MAP kinase activation experiments. Basal release of
LH from tissue from all origins fell within the range 3-6 pg/1 with the one
exception of tissue from ovariectomized rats (14-20 pg/1). Basal MAP kinase
activity showed no apparent differences in tissue from all origins, falling
consistently within the range 800-950 dpm per assay. Values are means ±
S.E.M. from 6-12 determinations. *p < 0.05 compared with corresponding
basal incubations.
MAP kinase in heterogeneous pituitary tissue. Preliminary
experiments carried out with the aT3-l gonadotroph cell line
have also demonstrated LHRH-induced activation of MAP kinase
through a PKC-dependent route which is dependent on previous
exposure to steroids (Sim etal. 1993).
The selective PKC inhibitor GF 109203X (Toullec et al. 1991)
inhibited the MAP kinase activation evoked by LHRH (100
nmol/1) with an IC50 of 2.1 ± 0.9 pmol/1 and that evoked by
PDBu (1 pmol/1 with an IC50 of 1.2 ± 0.4 pmol/1 (means ±
S.E.M., n = 4-6). LHRH priming elicited by 1 nmol LHRH/1 was
inhibited by GF 109203X with an IC50 of 3.9 ± 1.6 pmol/1 (mean
± S.E.M., n = 5), whereas 1st hour (unprimed) responses were
unaffected at 10 pmol GF 109203X/1. Neither the PKC inhibitor
H7 (Hidaka et al. 1984) nor the tyrosine kinase inhibitor
lavendustin A (Hsu etal. 1991) reduced LHRH-induced MAP
kinase activation (Fig. 3). At 10-30 pmol/1, H7 slightly increased
the response to LHRH. None of the inhibitors affected basal
MAP kinase activity. Since LHRH priming is prevented by the
protein synthesis inhibitor cycloheximide (Pickering & Fink,
1979), we investigated whether it affected LHRH-induced MAP
kinase activation. In the presence of 50 pmol cycloheximide/l,
the activation of MAP kinase induced by 100 nmol LHRH/1 in
pro-oestrous tissue was unaltered (92 ± 14% of that in
cycloheximide-free controls; mean ± S.E.M., n = 4), although
cycloheximide alone caused a small increase in the basal MAP
kinase activity measured.
DISCUSSION
Activation of MAP kinase in pro-oestrous rat anterior pituitary
tissue occurs at physiologically-relevant concentrations of LHRH
and is detectable from 10-60 min of incubation (Figs. 1, 2). The
magnitude of LHRH-induced MAP kinase activation correlates
closely with that of priming phenomenon on different days of the
oestrous cycle; showing significant activation only on pro-oestrus
and dioestrus when the priming phenomenon is at its greatest
(Table 2). The magnitude of 1st hour (unprimed) responses to
LHRH varied with a different rank order showing the greatest
responses in tissue from pro-oestrous and then from
oestrous/ovariectomized rats. This demonstrates an association of
MAP kinase activation with the priming effect of LHRH and may
suggest that this enzyme plays a significant role in development
of the phenomenon. Because specific inhibitors are unavailable,
Values are the means ± S.E.M. from 4-6 determinations,

















FIGURE 3: Effects of GF 109203X (•). H7 (■) and lavendustin A (A) are
shown on the MAP kinase activity induced by incubation of pro-oestrous
anterior pituitary tissue with 100 nmol LHRH/1. Values are the means ±
S.E.M. from 4-8 determinations. *p < 0.05 compared with drug-free controls.
it is difficult as yet to directly probe the functional contribution of
MAP kinase to LHRH priming. Nevertheless, there is a
remarkable correlation between the targets of MAP kinases and
the array of cellular events known to be involved in priming.
Relevant targets may include jun and myc, RNA polymerase II,
p90rsk, high molecular weight PLA2 and MAP-2 and it has been
reported that a cdc2-like kinase with a similar substrate motif
phosphorylates neurofilaments (Shetty et al. 1993). The priming
phenomenon is dependent upon protein synthesis, activation of
PLA2, the integrity of microfilaments and involves ultrastructural
changes in the marginal presentation of secretory granules in
gonadotrophs. Phosphorylation of MAP-2 protein by MAP
kinase is reported to disrupt microtubule-microfilament
interaction (Hoshi et al. 1992) which may lead to facilitated
stimulus-secretion coupling (Malaisse et al. 1975).
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The induction of the priming phenomenon is dependent upon an
apparently novel H7-resistant species of PKC which acts through
a protein synthesis-dependent step to activate PLA2 (Johnson el
at. 1992; Thomson & Mitchell, 1993; Thomson et al. 1993a). It
is possible that MAP kinase is an intermediary in this sequence
because its activation by LHRH (like priming) is dependent on a
PKC which is sensitive to PKC inhibitors including GF 109203X
but not to H7 (Fig. 3; Johnson et al. 1992; 1993; Thomson et al.
1993b; Ison et al. 1993). The evidence here for a modest
facilitation of the LHRH response by H7 is consistent with the
possibility of reciprocal regulation by H7-resistant and H7-
sensitive forms of PKC (or other kinases) (Fig. 3). There is
evidence for such dual regulation of voltage-sensitive Ca2+
channels by different forms of PKC (Johnson et al. 1989;
MacEwan era/. 1991; Johnson et al. 1993). Other forms of PKC
can clearly activate MAP kinase in anterior pituitary tissue
because PDBu can still activate the enzyme in tissue where
LHRH is ineffective (Table 2). Both a and (3 isoforms of PKC
can activate raf and thence MAP kinase (Sozeri et al. 1992; Dent
et al. 1992), although both PKC a and (3 are H7-sensitive (Ison et
al. 1993; Thomson et al. 1993b). The regulated step underlying
the varying ability of LHRH to activate MAP kinase may well be
upstream of MAP kinase itself but downstream of the LHRH
receptor since PDBu was still effective in tissue which does not
respond to LHRH but has adequate LHRH receptor numbers
(Table 3; Mitchell et al. 1988). The lack of effect of
cycloheximide on LHRH-induced MAP kinase activation here is
consistent with the possibility that the protein synthesis-
dependent step in priming may be downstream of MAP kinase
activation or that these steps may occur in parallel rather than in
series. The mechanism of MAP kinase activation by G protein-
coupled receptors (such as the LHRH receptor here, the M;
muscarinic receptor and the thrombin receptor; Ely et al. 1990;
L'Allemain et al. 1992; Qian et al. 1993) may involve a pathway
distinct from that for growth factor receptors (Lange-Carter et al.
1993). In the case of priming by the LHRH receptor at least, we
have shown the dependence of MAP kinase activation on a form
of PKC, but not on tyrosine kinase activity, as is required for
activation of the enzyme by growth factors.
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Abstract
The LHRH receptor in aT3-l gonadotrope cells was shown to bring about a marked and sustained activation of MAP
kinase. This response was prevented by protein kinase C inhibition or down-regulation and could be partially mimicked by
phorbol ester. Additional evidence for inhibition of this response by pertussis toxin and partial mimicry by mastoparan (in a
pertussis toxin-sensitive manner) provides the first evidence for G;/G0-mediated signal transduction by the LHRH receptor.
This dual mechanism of MAP kinase activation appears to be exceptional amongst the G protein-linked receptors that have
been investigated.
Keywords: MAP kinase; Protein kinase C; G protein; LHRH receptor
1. Introduction
Mitogen-activated protein kinases (MAP kinases)
are activated in response to various external stimuli,
and regulate a diverse array of cellular events which
are important not only in cell cycle regulation but also
in the transduction of non-mitogenic signals,
sometimes in highly-differentiated cell types (Davis,
1993). MAP kinases are activated by phosphorylation
on both tyrosine and threonine residues by a family of
dual specificity kinases which in turn are activated by
several distinct kinases including raf isoforms, MEK
kinase, and mos. Whilst tyrosine kinase growth factor
receptors have been shown to activate MAP kinase in
a multistep process that involves raf, ras, adaptor
proteins and GTP exchange factors, the pathways of
activation utilised by G protein-linked receptors are
less well understood.
Luteinising hormone-releasing hormone (LHRH)
*
Corresponding author, Tel.: 44 131 650 3550; Fax: 44 131 662
0240.
controls gonadotropin release from the anterior pitu¬
itary gland and regulates gonadal function. The LHRH
receptor is a seven transmembrane domain, G pro¬
tein-linked receptor (Tsutsumi et al., 1992), activation
of which (by means of Gq/11 (Hsieh and Martin, 1992;
Shah and Milligan, 1994)) results in phosphoinositide
hydrolysis, Ca2+ mobilisation and activation of PKC
(Stojilkovic et al., 1994). The present experiments
utilise the aT3-l gonadotrope cell line (Horn et al.,
1991) to investigate the potential activation of MAP
kinase by the LHRH receptor and the mechanisms
responsible.
2. Materials and methods
2.1. Chemicals and data analysis
All chemicals were obtained from Calbiochem,
Nottingham, Notts, UK, or Sigma Chemical Co.,
Poole, Dorset, UK. The MAP kinase substrate pep¬
tide was prepared by solid phase synthesis. [y-35S]ATP
and [3H]inositol (specific activity 1198 and 17
Ci/mmol respectively) were from NEN, Dreieich,
0303-7207/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved.
SSDI 0303-7207(95)03616-F
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Germany. Statistical analyses were carried out using
the Mann-Whitney U-test and curve-fitting was per¬
formed by the program P.fit (Biosoft, Cambridge,
Cambs, UK).
2.2. Cytosolic MAP kinase assay
aT3-l cells were grown (in DMEM with 0.11 g/1
Na pyruvate, 100 U/ml each of penicillin/strep-
tomycin and 10% foetal calf serum) to confluency in
sets of 25-cm2 flasks and quiesced with serum-free
medium for 24 h prior to assay. Agonists were present
for 10 min (unless otherwise stated), with antagonists
additionally for 1 min beforehand. Vehicle (dimethyl-
formamide 0.03% (v/v)) was present in controls and
had no effect on MAP kinase activity. After stimula¬
tion, the medium was aspirated, and cells were homo¬
genized in 200 p. 1 of ice-cold buffer containing EDTA,
2-mercaptoethanol (EtSH), and inhibitors of phos¬
phatases and peptidases before assaying as described
previously (Mitchell et al., 1994b). Briefly, the super¬
natant fraction was collected after centrifugation at
12000 X g for 30 min at 4°C, and 5-/al aliquots were
assayed in buffer containing EGTA, EDTA, MgCl2,
EtSH and inhibitors of phosphatases and peptidases,
in the presence of the selective MAP kinase substrate
peptide (APRTPGGRR) (Mitchell et al., 1994b) and
100 /jlM [y-35S]ATP (containing 0.58 /xCi [y-
35S]ATP/tube). After 40 min at 30°C (within the
linear range of the assay), incubations were stopped
by addition of ice-cold trichloroacetic acid and bovine
serum albumin. Following 15 min on ice, samples
were centrifuged (12000 X g for 5 min at 4°C), then
supernatant aliquots were spotted onto phosphocellu-
lose paper squares (Whatman P81) which were washed
extensively in 75 mM H3P04 before scintillation
counting. Specific MAP kinase activity was defined by
subtracting the substrate-free blanks which were gen¬
erally less than 25% of control values with substrate
and were unaltered by any stimuli. The specificity of
this assay for MAP kinases was monitored by im-
munoprecipitation with a monoclonal anti-p42/p44
antibody (Zymed Z033; Zymed Laboratories Inc., San
Francisco, USA) conjugated to protein G-Sepharose
4B beads, as described previously (Mitchell et al.,
1994b). In cytosolic extracts of «T3-1 cells treated
with either nothing, LHRH (100 nM, 10 min) or
phorbol 12,13-dibutyrate (PDBu, 300 nM, 8 min), 71
± 12, 74 + 10 and 67 + 9% of the recovered activity
was associated with the beads rather than the super¬
natant. Corresponding values using a control anti-)3-
tubulin monoclonal antibody of the same IgG sub¬
class (N 357, Amersham) were 12 ± 8, 4 + 8 and 23
± 13%, respectively (means + SEM, n = 3).
2.3. MAP kinase immunoblots
Phosphorylation of p42 and p44 MAP kinase was
determined by the electrophoretic mobility shift assay
(Alblas et al., 1993). aT3-l cells were grown in 12-well
plates and quiesced for 24 h before experiments.
Following incubation with agonists/antagonists, the
medium was aspirated, the cells washed in 1 ml ice-
cold Hanks balanced salt solution and scraped into
500 (jlI SDS buffer (50 mM Tris base, 5% EtSH, 2%
sodium dodecyl sulphate, pH 7.2), before heating to
100°C for 5 min and storage at -20°C. Four pi of
each sample was separated by electrophoresis on 20%
homogenous gels, and proteins were electroblotted to
polyvinylidene difluoride membrane (Immobilon-P,
Millipore) using a Phast-system apparatus (Pharmacia
Biotech). Non-specific binding was reduced by in¬
cubating the blots in 5% BSA/PBS overnight. MAP
kinases were then identified by incubating with mouse
monoclonal anti-MAP kinase antibody (Z033) (di¬
luted 1:1200), and then horseradish peroxidase conju-
gated-anti-mouse IgG (Scottish Antibody Production
Unit, Strathclyde), in 0.25% BSA/PBS/Tween 20
before visualisation using the Enhanced Chemi-
Luminescence (ECL) system (Amersham).
2.4. Inositol phosphate formation
aT3-l cells, cultured in 12-well plates, were in¬
cubated for 16 h under 95/5% 02/C02 in 0.5
ml/well Earle's Balanced Salt solution (EBSS) con¬
taining 10 mM glucose and 0.2% w/v BSA with
myo-[3H]inositol 2 /x.Ci/well. After washing, 10 mM
LiCl was added for 15 min before stimulation with
LHRH for 10 min. Incubations were stopped by aspi¬
ration and the addition of 700 q,l cold 1.34 M
trichloroacetic acid before assaying as described pre¬
viously (Mitchell et al., 1994a). In brief, following
centrifugation of cell homogenates at 12000 X g for
5 min (4°C) aliquots of supernatant were transferred
to tubes containing EDTA (pH 7.0) and 1:1 1,1,2-tri-
chloro-trifluoro-ethane:tri-V-octylamine for solvent
extraction of labelled phospholipids. After centrifuga¬
tion at 12000 X g for 5 min at 4°C aliquots of the
upper aqueous phase were adjusted to pH 8 and
hydrophilic inositol-containing compounds were sepa¬
rated on 1 ml columns of Dowex 1x8 (formate
form, mesh size 200-400). Inositol phosphates were
eluted in 1 M ammonium formate 0.1 M formic acid
(Mitchell et al., 1994a).
3. Results
3.1. LHRH-induced MAP kinase activation and inositol
phosphate formation
The potential activation of MAP kinase was investi¬
gated over a time course of 0-120 min with 100 nM
LHRH (Fig. la). MAP kinase activity increased
rapidly, reaching a peak by 10 min which represented
an increase to 245 ± 9% of basal (mean + SEM, n
= 6). This elevated activity was sustained for approxi-
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Fig. 1. Characteristics of LHRH-induced MAP kinase activation,
(a) Shows the specific [35S]thiophosphorylation of MAP kinase
substrate peptide after different times of incubation of aT3-l cells
with 100 nM LHRH (•) or 300 nM phorbol 12,13-dibutyrate;
PDBu (■). Each value is the mean + SEM from four to six
separate determinations, (b) Shows the concentration-dependence
of LHRH-induced MAP kinase activation (•) and [3H]inositol
phosphate formation (▲ ) after 10 min incubation. Each value is the
mean ± SEM from four to six determinations.
mately 40 min, and then gradually declined leaving a
significant residual activation at 120 min. The basal
(unstimulated) activity showed no detectable change
through an equivalent time course. The concentra¬
tion-dependence of LHRH-induced MAP kinase ac¬
tivity and of [3H]inositol phosphate formation were
closely concurrent, with both responses being nearly
maximal by 100 nM and showing comparable EC50
values (the concentration required for 50% of maxi¬
mal activation) of 3.4 + 0.4 and 2.8 ± 0.3 nM
respectively (Fig. lb).
3.2. Involvement of protein kinase C and a pertussis
toxin-sensitive component in MAP kinase activation
LHRH-induced MAP kinase activation appears to
depend on PKC since the response was inhibited by
GF109203X, a highly selective inhibitor of PKC
(Toullec et al., 1991) with an IC50 value of 1.8 + 0.2
giM (Fig. 2a), similar to its potency on a number of
well-characterized PKC-mediated cellular responses
(Toullec et al., 1991). At a concentration of 3 gM,
GF109203X had no detectable effect on basal MAP
kinase activity. In contrast to the MAP kinase re¬
sponse, LHRH-induced [3H]inositol phosphate pro¬
duction was unaffected by GF109203X at concentra¬
tions up to 5 giM. Furthermore, downregulation of
phorbol ester-sensitive PKC isoforms for 20 h with
300 nM PDBu caused 92 ± 10% inhibition of
LHRH-induced MAP kinase activation (means +
SEM, n = 4), with no change in basal activity.
Treatment with pertussis toxin (3-300 ng/ml for 18
h) showed no effect on [3H]inositol phosphate forma¬
tion in response to LHRH (Fig. 2b). In contrast,
pertussis toxin strongly inhibited LHRH-induced MAP
kinase activity (IC50 value, 32 + 4 ng/ml; 75% in¬
hibition by 300 ng/ml; Fig. 2b). Under similar condi¬
tions, treatment of aT3-l cells with either the inac¬
tive B-subunit of pertussis toxin (O'Neill et al., 1992)
or A-ethylmaleimide-inactivated holotoxin (Banga et
al., 1987) at a concentration of 100 ng/ml, had no
effect on LHRH-induced MAP kinase activity (104 +
10 and 85 + 13% of control LHRH responses, re¬
spectively (mean + SEM, n = 3) compared with an
inhibition to 38 + 8% of controls caused by 100
ng/ml holotoxin (mean + SEM, n = 6)). In order to
confirm these results with an independent technique,
the phosphorylation-induced gel mobility shift in im-
munoreactive p42 and p44 MAP kinases was moni¬
tored. Both p42 and (to a lesser extent) p44 species
displayed a component of reduced electrophoretic
mobility after LHRH stimulation for 10 min (Fig. 3a).
This effect was concentration-dependent (Fig. 3a) and,
in the case of p42 at least, was clearly inhibited by
either 3 gM GF 109203X or by preincubation with
100 ng/ml pertussis toxin (Fig. 3b).
3.3. Mastoparan- and phorbol ester-induced MAP kinase
activity
Mastoparan is an activator of G proteins with re¬
ported selectivity for Gj/G0 over other G proteins
(Gil et al., 1991). Exposure of aT3-l cells to masto¬
paran (5-15 giM) for 10 min resulted in a marked
increase in MAP kinase activity (Fig. 4a). The effect
was maximal at 10 giM where it represented an in¬
crease to 190 + 9% of basal activity (mean + SEM,
n = 6). No significant effect on [3H]inositol phos¬
phate production was noted at any concentration up
to 12.5 giM. Mastoparan-induced activation of MAP
kinase was substantially inhibited by pertussis toxin,
but not by GF 109203X (Fig. 4b), suggesting that the
PKC activation required for LHRH action was not
downstream of G;/G0 but probably a result of Gq/U-
mediated stimulation of phospholipase C. The PKC
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Fig. 2. Effects of the PKC inhibitor GF 109203X and pertussis
toxin on LHRH-induced MAP kinase activity and [3H]inositol
phosphate formation. The concentration-dependence of effects on
LHRH (100 nM)-induced MAP kinase substrate peptide
[35S]thiophosphorylation (•) and [3H]inositol phosphate formation
( a ) is shown in (a) for GF 109203X and in (b) for pertussis toxin.
Values are the means + SEM from four to six separate determina¬
tions. Inhibition of MAP kinase responses by > 0.5 (iM GF
109203X and by > 10 ng/ml pertussis toxin was statistically
significant (P < 0.05, Mann-Whitney 17-test).
activator 4/3-PDBu (300 nM) caused marked stimula¬
tion of MAP kinase activity (197 ± 13% of basal at 8
min; mean ± SEM, n = 6; Fig. la) which was not
mimicked by the inactive isomer 4a-PDBu (300 nM, 8
min; 110 ± 9% of basal, n = 4). The effect of PDBu
peaked slightly earlier than that of LHRH (at 8 min)
but had returned to the basal level by 1 h, at which
point there was still a significant residual activation by
LHRH (Fig. la). Ionomycin (10 p,M for 10 min)
caused no detectable activation of MAP kinase (106
+ 7% of control, mean + SEM, n = 4). PDBu-in-
duced MAP kinase activation was prevented by GF
109203X but was unaffected by pertussis toxin (Fig.
4b), excluding the possibility that the pertussis toxin-
Fig. 3. Anti-MAP kinase immunoblots showing LHRH-induced
mobility shifts. Anti-p42/p44 MAP kinase immunoblots were car¬
ried out after protein separation by electrophoresis, (a) Shows the
concentration-dependence of LHRH-induced reduction in mobility
of p42 (and to a lesser extent p44). Lanes 1, 2, 3, 4 and 5 show
results from 10-min incubations with 0, 1, 10 and 100 nM and 1 p.M
LHRH, respectively, (b) Shows the effects of GF 109203X and
pertussis toxin on the LHRH-induced mobility shift. Lanes 1, 2, 3
and 4 show control, 100 nM LHRH, 100 nM LHRH with 3 /rM GF
109203X, and 100 nM LHRH after 100 ng/ml pertussis toxin for 18
h, respectively. No other staining was detected in the lanes. Each
observation was replicated in the experiment and was typical of
three separate experiments.
sensitive component was operated downstream of PKC
(Katada et al., 1985) rather than by direct receptor
interaction. The combination of mastoparan and
PDBu caused greater MAP kinase activation than
either alone (Fig. 4b), but from the present experi¬
ments it is not possible to make any conclusions about
auditivity or synergy.
4. Discussion
It has recently become clear that MAP kinases can
be activated not only by growth factor and cytokine
receptors but also by a variety of G protein-coupled
receptors. These include receptors that interact pre¬
dominantly with Gq/11 such as M, and M3 mus¬
carinic, endothelin, angiotensin II, bombesin and TRH
receptors (Ely et al., 1990; Duff et al., 1992; Wang et
al., 1992; Offermans et al., 1993; Pang et al., 1993;
Crespo et al., 1994; Faure et al., 1994; Ohmichi et al.,
1994), those that interact predominantly with Gi/0
such as a2-ClO adrenergic, M2 muscarinic, D2 do¬
paminergic and A, adenosine receptors (Alblas et al.,
1993; Crespo et al., 1994; Faure et al., 1994) and those
that readily interact with both families of G proteins,
such as thrombin and lysophosphatidic acid (LPA)
receptors (Kahan et al., 1992; Hordijk et al., 1994).
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Fig. 4. Characteristics of mastoparan- and phorbol ester-induced
MAP kinase activation (a) Shows the concentration-dependence of
the effects of mastoparan (10 min incubation) on MAP kinase
substrate peptide [35S]thiophosphorylation (•) and [3H]inositol
phosphate formation (a). Values are the means + SEM from six
and four separate determinations, respectively, (b) Shows the acti¬
vation of MAP kinase induced by 10 min incubations with masto¬
paran (10 /iM), phorbol 12,14-dibutyrate (PDBu; 300 nM) and the
combination, as well as the effects thereon of GF 109203X (GF; 3
p.M) and pertussis toxin (Ptx; 100 ng/ml for 18 h). Values are the
means ± SEM from six to nine separate determinations. (*)
Indicates statistically significant inhibition of responses (P < 0.05,
Mann-Whitney C-test).
A partial PKC-dependence of M, muscarinic re¬
ceptor- and TRH receptor-mediated MAP kinase ac¬
tivation has been observed in both CCL 39 and COS
1 host cells and in GH3 cells, respectively (Kahan et
al., 1992; Qian et al., 1993; Ohmichi et al., 1994). In
contrast, the M3 receptor response in SH-SY5Y cells
and the bombesin receptor response in Swiss 3T3
cells were essentially prevented by PKC down-regu¬
lation or by PKC inhibitors (Offermans et al., 1993;
Pang et al., 1993). It is not yet clear whether the
different degrees of PKC dependence displayed by
these Gq-linked receptors reflect transducer prefer¬
ences of the receptors or cell-specific differences in
pathway components. However, activation of MAP
kinase by endothelin-1 was substantially inhibited by
PKC down-regulation and was unaffected by pertussis
toxin in a range of different cell types (Wang et al.,
1992; Bogoyevitch et al., 1993; Cazaubon et al., 1993).
Gi/0 receptor-mediated MAP kinase activation ap¬
pears not to be dependent on PKC, since the pertus¬
sis toxin-sensitive MAP kinase response to a2-C10
receptors in Rat-1 fibroblasts was unaccompanied by
any phosphoinositide hydrolysis and could not be reli¬
ably mimicked by phorbol esters (Alblas et al., 1993;
Hordijk et al., 1994). Furthermore, the response to
M2 but not to M, muscarinic receptors expressed in
COS 7 cells was inhibited by pertussis toxin, whereas
the converse effect was seen with PKC down-regu¬
lation (Crespo et al., 1994). Correspondingly, the acti¬
vation of MAP kinase by overexpression of a
GTPase-deficient mutant Gi2 a subunit (in Rat-1 but
not COS 7 cells) was unaltered by PKC down-regu¬
lation (Gupta et al., 1992; Qian et al., 1993). However,
recent evidence has suggested that (3y rather than a
subunits of G proteins may play the predominant role
in subsequent activation of MAP kinase by a variety
of G protein-linked receptors (Crespo et al., 1994;
Faure et al., 1994).
In the case of thrombin and LPA receptors, MAP
kinase activation is pertussis toxin-sensitive whilst
other responses such as phosphoinositide hydrolysis
and tyrosine phosphorylation are unaffected (Hung et
al., 1992; Kahan et al., 1992; Hordijk et al., 1994).
Interestingly, the MAP kinase activation caused by
LPA in Rat-1 cells cannot be robustly mimicked by
endothelin, despite the ability of endothelin to elicit
phosphoinositide hydrolysis and tyrosine phosphoryla¬
tion in these cells (Hordijk et al., 1994). As found with
the receptors signalling singly through Gi/0, MAP
kinase responses to LPA and thrombin do not display
a consistent dependence on PKC. In Rat-1 cells, the
MAP kinase response to LPA was not mimicked by
phorbol esters (although it was attenuated by a gen¬
eral kinase inhibitor staurosporine) (Hordijk et al.,
1994) and the response to thrombin was unaffected by
PKC down-regulation (Gupta et al., 1992). In umbili¬
cal vein endothelial cells or CCL 39 cells, however,
thrombin-evoked MAP kinase activation was attenu¬
ated by a selective PKC inhibitor, Ro 31-8220, or by
PKC down-regulation (Wheeler-Jones and Pearson,
1995; Kahan et al., 1992).
Where tested, both the Gq/11- and the Gi/0-linked
MAP kinase responses appear to be accompanied by
increased GTP loading of p21ras' (Ohmichi et al.,
1994; Hordijk et al., 1994; Alblas et al., 1993) and are
severely attenuated by the overexpression of domi-
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nant negative mutant ras (Crespo et al., 1994). This
suggests that the later stages of these responses are
predominantly mediated by a conventional ras-raf
cascade. In the case of the Gq/11-linked receptors, the
site at which PKC acts is not clear. PKC may inacti¬
vate the p21 ras GTPase-activating protein, GAP
(Downward et al., 1990) or phosphorylate the ras
target, raf (Kolch et al., 1993). Although TRH pro¬
motes both GTP loading of p21ras and phosphoryla¬
tion of raf-1, these effects are reported to be PKC-in¬
dependent but accompanied by tyrosine phosphoryla¬
tion of a potential regulator of ras activation, she
(Ohmichi et al., 1994). The precise role of PKC in
Gq/11-linked receptor activation of MAP kinase
therefore remains unclear.
The remarkable aspect of MAP kinase activation by
the LHRH receptor is that it depends strongly on
pathways characteristic of both Gq/11- and Gj/0-linked
receptors, in being both highly dependent on PKC
and sensitive to pertussis toxin (Fig. 2). From the data
with mastoparan and PDBu, it appears that either
Gi/0 or PKC can elicit MAP kinase activation. Al¬
though the precise way these signals integrate in
compiling the LHRH response is unclear, it is possi¬
ble that PKC may exert a facilitatory action on the
Gi/0-mediated signal either at the level of p21rax
GTP loading or at the level of raf.
Interestingly, until the present study, there has been
no clear evidence that the LHRH receptor can inter¬
act with any G protein other than Gq/11 (Fig. 2; Hsieh
and Martin, 1992; Shah and Milligan, 1994; Stojilkovic
et al., 1994). Only one isolated report has described
partial sensitivity to pertussis toxin of LHRH-induced
[3H]inositol phosphate production, but that was in the
absence of any corresponding change in gonadotropin
secretion (Hawes et al., 1993). However, pertussis
toxin can demonstrate anomalous effects, indepen¬
dent of the attenuation of Gi/0 activation. Both the
blockade of LHRH-induced MAP kinase activation
here and authentic ADP-ribosylation of Gi/0 are seen
only with pertussis holotoxin and not with A-ethyl-
maleimide-treated toxin or the toxin B oligomer
(Banga et al., 1987; O'Neill et al., 1992). In accor¬
dance with this new evidence for Gi/0 activation by
the LHRH receptor, we have recently observed per¬
tussis toxin-sensitive LHRH-induced suppression of
forskolin-stimulated cAMP formation in aT3-l cells
(MacKenzie, C., Johnson, M.S., Sim, P.J. and Mitchell,
R., unpublished observations).
The LHRH receptor is a member of the rhodopsin
family of G protein-linked receptors but contains a
number of non-canonical motifs and lacks a carboxyl
terminal tail (Tsutsumi et al., 1992). This presumably
accounts for its characteristic resistance to rapid ho¬
mologous densensitisation (Davidson et al., 1994)
which may in turn be a key factor in its ability to
maintain interaction not only with Gq/]1 but also with
Gj/0 and sustain a relatively long-lasting activation of
MAP kinase.
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UNCONVENTIONAL SIGNALLING BY THE LHRH RECEPTOR
R Mitchell. M S Johnson, J Simpson, P J Sim, W B Wolbers, M Fennell and A J Ison
MRC Brain Metabolism Unit, University Department of Pharmacology, 1 George
Square. Edinburgh EH8 9JZ, Scotland
~'ne LHRH receptor is a member of the famiiy of G protein-linked receotors couoiec to
nydrolysis of pnosDhoinosiiiaes [1], The aeoenaence of LHRH-inaucea gonaaotroonin
secretion upon phospnoiiDase C activity has however been Questioned [2], In view of tne
unique anility of the LHRH receptor to eiicit the pnenomenon of self-orimmg [3], we nave
sougnt to define unconventional signals emanating from this receptor that may no: oe
generated by other members of the receotcr famiiy.
The phenomenon of LHRH self-pnming is aeoenaent UDon an apparently nove! soecies of
-KC with a pituitary-selective distribution [4] that we have partially Durifiec ana
cnaractenseo [51. Amongst the cellular targets of a PKC with these procenies are PLA?
ana PLD.
Signalling by means of tyrosine kinase ana MAP kinase cascaaes is classically asscciatec
with growth factor receotcrs. Nevertheless we nave snown that sac.n of tnese is strcngiv
activated by LHRH both in normal pituitary tissue anc in the aT3-1 gcnacotroon cell line.
LHRH-inouced orocuction of phospnotyrosine-immunoreactive proteins is mimicked in cart
py onorpol esters out net ov ionomycin ana is essential for LHRH-inaucea PLD activation
anc LH secretion [61. LHRH-inauced MAP kinase activation correlates strongiv with the
aciiitv of gonacotroons to demonstrate self-oriming anc occurs througn a DKC-aeoencent
rather than Ca^-aeoenaent or tyrosine kinase-ceoenaent mechanism [71. Since MAP
kinase is invclvec in the regulation of transcriptional, transiational anc cytoskeletal
organisation, it is a strong canciGate for a central roie in the self-priming pnenomenon
wnic.o is reliant on the raDid inauction of protein synthesis ana cytoskeletai cnanges.
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PI4 THE EFFECTS OF PROTEIN KINASE C INHIBITORS ON CONSTITLTIVELY-ACTIVE MAP KINASE FROM
RAT HIPPOCAMPUS
R. Mitcnell. T. Leslie. P.J. Sim. M.S. Jonnson ana W.B. Wolbers. MRC 3rain MetaDolism Unit, University Department of
Pharmacology. 1 George Sauare. Edinburgh EH8 9JZ
The MAP kinases imitogen-activatea orotein kinases), otnerwise Known as ERKs (extracellular signai-reguiated kinasesi are a family
of serine/threonine kinases that are rabidly activated by mitogens (CodP era/. 1991). A consensus target motif for pnosDnoryiation
oy MAP kinases nas been aefined ana recogntsea within tne amino acia seauences of oytosKeietai Droteins. otner kinases and
transcription factors (Clark-Lewis era/. 1991). In hiooocamdai neurons, onosonoryiation ana increased activity of MAP kinase is
brougnt aoout Oy NMDA receotcr activation (Baaing & Greenoerg. 1991). MAP kinase is also activatec by onorcol esters,
presumably by means of their ability to promote protein kinase C (PKC) activity (Cobo er at. 1991).
in oraer to assess some of the pnarmacoiogy of MAP kinases, we nave examined the effects of a number of widely-usea protein
kinase inhibitors on MAP kinase activity trom hioDOcamous cytosol. Tissue was nomogenisea in ice-cold 20 mM Tris HCI oH 7A witn
12 mM EDTA. 50 mM B-mercantoetnanol. protease innibitors ana 2.5 mM soaium ortnovanaaate. 52.5 mM B-givceroonosDnate ana
200 nM okaaaic acid. Five m samoies of a crude cytosoiic fraction were assayed in 25 ul assavs also containing 16 mM Tris riC) oH
7.4. 40 mM B-mercantoethanol. 160 nM okaaaic acid anc 50 uM ATP fy-35S] isoecific activity 1285 Ci/mmol: 0.35 uCi/'tuDei. After 40
min at 30°C. with or witnout the selective oeotiae substrate APRTPGGRR (2 mM: ClarK-Lewis er a/. 1991), tne reaction was stoooea
witn ice-cold trichloroacetic acid ana the thioDnosonoryiatea oebtiae collected by sootting onto DnosDnocelluiose oaoer and extensive
wasning in 75 mM H3PO4. The constitutive kinase activity couia be immunoorecioitatec oy a protein G-seonarose couDiec
monoclonal antibody (Zymed Z033) to tne 044 ana o42 soecies of MAP kinase ana was innicited by pretreatment of the cytosoiic
extract with sweet potato acid pnosonatase (0.3 - 10U) in tne absence out not in tne oresence of 10 mM pyroDnosonate.
A number of orotein kinase innibitors snowed tne following IC50 vaiues (mean - s.e.mean. n = 6 - 9 seDarate determinations):
staurosoorine, 1.5— 1.2 uM: K252a. 5.8 ± 1.4 uM: Ro 31-8220 (Davis er a/, 1989), 3.8 r 0.9 pM: H7. 66 = 1 llM: HA 1004. 7.0 ± 2.5
jiM: cneierythrine. 69 r 5 uM. It is imponant to consider that higner concentrations of these comoounas used in some exoeriments
on cellular resoonses may well influence MAP kinase as well as PKC. Interestingly, the 10-fold greater potency of HA 1004 than H7
seen here nas not been observed for any of the other kinases investigated (Hiaaka er at. 1984).
Baaing, H. & Greenoerg, M.E. (1991) Science 253. 912-914.
Clark-Lewis. I.. Sangnera. U.S. & Peiech. S.L. (1991) J. 3iol. Chem. 266, 15180-15184.
Cobb. M.H., Boulton. T.G. & Robbins, D.J. (1991) Cell. Regul. 2. 965-978.
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QZ no EVIDENCE FOR A NOVEL H7-RESISTANT SPECIES OF
PROTEIN KINASE C IN PITUITARY GLAND THAT
LEADS TO ACTIVATION OF MAP KINASE. Rorv Mitcnc:!.
Angcia ison. Pauiine Sim. James Simpson. Mcianic Johnson. Roger
CIcgg" ma Kevin Connor", MRC Brain Metabolism Unit. I George
Suuarc. Edinourgn ma "Harmon Research Insutute. Ayr. U.K.
Moae:s or" :ne roie or" PKC in sumuius-secretion couDiing. in the
activauon or pnospnoiipases An ana D ana in the regulation or C--1"
manners in me anterior pituitary giana have pointea to tne oreser.ee of
a form or PKC whicr. is resistant to H7 but sensitive to GF I09203X
ana Ro 31-8220. Cytosoiic PKCs from anterior pituitary tissue were
partially punfiea on DEAE ceiiuiosc foiiowec bv fractionation on
hydroxyiapatite. revealing an unusual iate-eiuting uomoonent of
activity aoser.t from a range of omer tissues tested. Tms fraction
contamec a morooi-acuvatec. PS-dccendcnt histone Ills- or GS
pecuae-Unase activity wnim was Ca^-indcpendent ana resistant to
K7 but not to Ro 31-8223. All otner eiuune activity was H7-sensiuve.
Immunoreactivitv for PKC a. 3|, ;no -f), 5. £. (no n; ana 31 kDa 3
eiutea a: different aosmons from tne H7-reststant species. Oniy 38
kDa 3 immunorcacttvitv was oresent in tne same fraction. Althoum
ail bancs were ciocxed in tne areser.ee of the relevant pentice antigens,
me identity of the mgr. MWt 3 product is uncertain. [--Pjauio-
anosDnor.'iation experiments revealed an unusual hi ah MWt aroauct
!>i30 kDai predominantly in me H7-resistant fraction from pituitary
but not midbrain control, whereas otner fractions ail produced
autopnosanoryiation signals clustered around 90 - 95 kDa. Tr.e H7-
resista.at PKC may oe a novel SDecies. one of tne newiv-describec
species such as B. /. or u or a modified form of a known species sucr.
as 3. in me ctT3-i gonaaotropn ceil iinc. stimulation of the
anosonoinositide-hydroiysing LHRH receptor evokes activation of
MAP kinase as measurea by phosphorylation of a selective peatice
substrate m an assay incorporating immunoprecipitation with an anti-
ERK1/2 reagent. This activation is unaffected by tyrosine kinase
inhibitors sucr. as iaver.dustm A yet is sensitive to PKC inhibitors sucr.
as GF • 09203X but not H7. Tnis suggests that one of tne cellular roies
of mis H7-resistani PKC is in me G protein receotor-inaucea cascade
of MAP kinase activation involving either MEKK- or pernaps rar-
mediatec aatnwavs.
529
ASScSSMSNT Cr HE POTENTIAL .-'.CLE OF ~'H6 NCN-CANCNICAL
~M7 RESIDUE Aso3,a iN THE = CCMINENT ACTIVATION GF MAP
KINASE 3Y "HE GnfiH RECEFTCR fSUT NOT OTHER G,-LiNKED
fiECH?TCfiSi EXPRESSED IN CCS 7 CELLS. 3 "nr-°.i e =
I H -.nrr. ~l =.~U V n n g ~ MfiC OtZin
Metaconsm unit. I Guorca Sauare. Scincurqn E.H8 9JZUK ana "Fisnoerg
Centre tcr Neurccioiogy, Mount Sinai Scnoci o! Meaicne. New vorx, NY
1CQ29 USA
.Ve nave creviousiv snown tnat tne GnfiH receotor elicits a
prominent activation ot MAP kinase ,n gcnacotrcoes tnrouan a similar
concentration range to tnat tor ipertussis toxin-msensmvel (-H]inositoi
pncscnate generation. GnHH-maucea MAP kinase accvanon is relatively
long lasting ana is ceoencent on coin protein Kinase C ana a certussis
toxin-sensitive ccmoonent: an unusual orotila. otrterwise aescncea cniv tor
tne tnrcmcin receatcr lanotner merr.oer ct tne small grcuo ot recaotors i
witn a TM7 .Asa tar Asn sucstituucni. n CCS 7 ceils transtectaa witn ;
GnRH. c-HT,q cr mGiuRi receotors. accroariate agonists causea
concentration-aeaenaent [3H]inositai onosanate formation ana PKC
translocation to a similar extent, nut cniv tne GnfiH receotcr causea
cetectaaie accvanon or MAP kinase ia PKC-ceoencent ana certussis ;
toxin-sensitive resconsei. Mutanon ot Asoaia to Asn croaucea a GnfiH ;
receotor cisciaving similar cotencv to tne wna tvpe in ngana Dincing, 1
pHlinositci cnoscnate anc MAP Hnasa assavs. cut wnicn was excressea
at ratner tower leveis. Activation ot .'MP kinase ov me mutant was sail
pertussis toxin-sensitive, .naicanng tnat tne sceciai anility ot tne GnfiH
receotor to activate an auxiliary certussis toxin-sensitive G crotein ana ;




| ACTIVATION OF MAP KINASE 3Y THE GnRH RECEPTOR
! THROUGH A PKC - DEPENDENT PERTUSSIS TOXIN-SENSITIVE
; MECHANISM. D ~im ma P.. M'tcnoti MRC Brain Metaootism Unit
1 George Saunre. Bdinourgn EHS 9JZ. UK ;
Mitogen activatea protein (MAP') kinases are known to have a central
i roie in a inverse array or intracellular signalling patnways. Tnesc tnciuae
I ceil cycie regulation inaucea by growtn factors wuose receptors nave
i intnnsic tyrosine kinase activity ana aiso. as nas become increasingly
j apparent. :'n me tmnsaucaon or signals tnrougn G protein-iimcea receptors'.
| suggesting a roie for MAP kinases :a aon-proliferative signalling
! cascaaes. We have deveioDea an in niro assay basea on
j [-^Slthiophospnoryiation of a seiective peptide suostrnte to investigate
i potential activation of MAP kinase ov gonaaotropnin reieasing-aormone j
J (GnRH) ana tne mechanisms responsible. In tne au-l gonaaotropn ccii |line, sttmui uon of the GnRH receptor (.a pnosonomositide-nyaroiysmg
'
receptor, known to couple to Grji results in a marked ana sustained
i increase in MAP kinase activity. This resconse was cieariv protein kinase
i C 'PKC)-dependent as me increasea MAP kinase activity'was ootentiv
inhibited by tee selective PKC Inhibitors Ro 31-8230 ana G?i09203X ana
■less strongly by another. H7. Phorooi ester down regulation of PKCs i
completely preventea GaRH-inaucea MAR kinase activity. Interestingly \
this resDonse was aiso higniv sensitive to pertussis toxin ana could be
paruaiiv mimicked by mastooaran ia G-protem activator with reoonea i
selectivity for G;/'Go/ in a pemissis toxm-sensitive manner. These results
suggest tnat tne GoRH receptor mav interact with 2 or more G-proteins
and tnat activation of MAP kinase bv :nts receotor may require
involvement of more man one concurrent signalling patnwav.
Phasonolloasa C-deoenaant activation of ryroame
kinases ov LHRH In nT3-1 calls, ana lis role in LHRH
priming of Inositol pno3onata production
RCRY MITCHELL. SUSANNE K. McCCNNELL 3na
PAULINE SIM
MRC 3rain Metaooiism Unit. I George Sauare. Eoincurgn
EH8 9JZ. 'JK
The LHRH recaotor is a memoer of the suoerramuv of
7-Yansmemorane aomain recsotors couoiea bv G croteins
;a ine activation of pnosonoiioase C (PLC', [11. Because
this receptor has :ne unusual apiiitv to bring aoout an
uoreguiation of us own signal transduction in terms of
inositol onoscnate oroauction [2] we nave ceen excionng its
aoiiity to activate unconventional ceiluiar signalling
oatnwavs [3] wnicn mignt oanicioate in modifying signal
transauction oy the receptor. '.Ve creviausiv oroviceo the
first eviaence that the LHRH receptor in a~2-i ceils can
'aoialv elicit increases in the cellular oontenr or anti-
onosonotyrcsine immunoreactive oroteins ana that this
oatnway s of functional importance in teaaing to the
activation or pnosonoiioase 0 [4j.
n crcer to cistinguisn the alternative hypotheses of a
'eguiation or tyrosine kinases or tyrosine cnosonatases
oeing resocnsioie. .ve carnea out the tallowing excenments
to explore directly any alterations in enzymic activity o:
aT2-i cen tyrosine Kinases.
After ouiescinc tor 20 n anc stimulation n serum-tree
meoium. oaiis were ncmcgenisea in 350 ui or 50 mM "ris
HC! pH T.4.), t mM HDTA. 2 mM McCH, 0.2 mg/.mi
cenzamtcine. 3.2 mM 4-,'2-aminoetnyibenzene suiononyi-
fluoricsi HC,'. O.t mc/mi soycean trypsin innicitor anc
centrivugec at 250C0 g for 20 mm acC) twice, .vitn
-esusoension of fhe oeilet in fresn cuifer. "he oeilet was
soiuonisaa in 50 mM Tris HC! fpi-i 7.41, t mM EDTA. 2%
Ncniaet-PAO. t0% glycerol. 50 mM 2-mercaotoetnanoi with
oeotiaase inhibitors, by stirring on ,ce for ' n. After
centnfucaiion at 550C0 g for 45 mm |A°C), :ne suoernatant
was ioaaeo onto OEAE oailuiose columns anc wasneo witn
5 cciumn volumes of column eaunibration ourfer: 25 mM
HE?55 (pH 7.01, ;o% glycerol, t mM cithiothreitoi. ' mM
SDTA. 0.t% Nonicet-PAO ana oeoticase inhibitors, bstcre
eiuting in 2 column volumes of butter containing too nM
NaC,'. Samples were assavea by a metnoa moaifiea
considerably from that of Litwin et ai 1991 [5], Assays
(100 ul) contamea 50 mM Tris HCI (pri 7.4), 12.5 mM
MgCH, 50 uM sooium orthovanaoate. 7 mg/mi
p-nitroonenyipnosonate, 0.6 uC! ATP [y-33F], 20 ui samcie.
with or without 1.6 mg/mi ooiy(Glu-Tyr: i:t). After as mm at
20°C (linear rate), assays were auenc.nea v/itn 50 ui of 0.1
M EDTA. 0.1 M ATP ana aiicuots were soottea onto 2MM
oaoer sauares ana wasnea extensively in 12%
tncnioroacetic acia. 70 mM onosononc acia.
Suostrate-tree planks snowea no time-aeoencent
Change in [33o[ incorporation (-7000 oom oer assay;
.vnereas incubation of ceils with 100 nM LHRH for 20 mm
oausea an accroxirnateiv 2 fold increase in 'ate ot f33Pi
incorporation into the suostrate 1-11000 com oer as mm in
controls ana (-22000 com per as min with LHRH). The
greatest increase in tyrosine kinase activity was seen at
5 mm incuoation with LHRH, declining graauailv tnerearter.
This response was innibitea in a concentraticn-aeoenaent
manner by me PLC innibitor U 73122 (83 ±11% innibition at
25 uMl ana oniv siiqmiy -eaucoa oy :ne ess active
congener u 73A33 (26 r 8% mnioition at 25 uM).
in orcar to assess acaotive changes in LHRH rececicr-
naucad pHlinositoi pnosbnate (ormation, a memoa Casea
on mat ot Sleonens et ai 1988 [S] was employed. Cans
were laoeilea far 16 h witn 1 jiCi/mi pHlinositol in canes's
Baiancea Salt Solution witn iO mM glucose ana 0.2%
oovine serum albumin. After wasnmg, ceils to oe primea
were incuoatea witn 2 nM LHRH 'or 15 mm: all ceils
extensively wasnea. :hen arter a furtner 20 mm. 10 mM LiC!
was accea for 15 mm oetore stimulation with ',00 nM LHRH
for 20 mm. Assays were sxacoea Oy aspiration ana :he
aacition of 700 ui cold 1.24 M mcnioroacetic acia. Call
scrapings were centntugeo at 12000 g for 5 mm (a°C, ana
500 ui at suoernatant was iransterrea to luoes with 50 ul
0.1 M EDTA (pri 7.0) ana 500 ui 1:1 freonnn-N-octyiamme.
After extensive vortexing ana centnfugation at 12000 g for
5 mm (a°C), 200 ul ot the uooer aaueous onase was accea
:c 200 ui 1M NariCCs witn Universal Incicator (overall oh ot
aoDrcximateiv 3). Laoeilec inositol onosonates were
seDaratec on 1 .ml columns ot Oowex "x3 (formate rcrm.
mesn size 200-400). "he columns were wasnea
extensively with water oerore samoie acoiicaticn ana men
20 column volumes ot water. 5 column volumes or 50 mM
ammonium 'orrmate ana (0 column volumes of ' M
ammonium rormate. 0.1M formic ac:o were acDiieb to eiute
jnmccitiec inositol, giyceroonosonoinositcis anc nositoi
onoscnates resoectiveiv.
As m cituitary (21, .n a~2-i ceils cretreatea for :S in v/itn
' nM oestrogen, a crier exccsure to a ,ow cose or LHRH
2 .nM -or '5 mini greatly facnitateo me orocuction :t
[3Hiinositoi onosonates eiicnso oy a suosecuenf cnanenge
.vim "00 oM LHRH for 20 .mm -206 a '2% o: uncrimec
'ssDonsasi with no Change n jnstimuiateo casai
[3Hiincsitci pnosonate orocuction as a result or mis
oonaitionmg oremcuoation. "his augmentation was
oreventeo oy me :vrosme Kinase mnioitors gemstem
.10-100 uM) ana methyl 2.5-ainycrcxycmnamate (20 u.M)
ano reoucea Oy lavenoustm A (10 uM).
These results cemonsmaie mat me LHRH receotor can
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Activation of MAP kinase by trie L.HRH receptor
througn a PKC-daoondent pertussis toxin-sen3itlve
mecnanism
PAULINE 5iM ana RCRY MITCHELL
MBC 3rain Metabolism Unit. I George Sauare. Ecinourgn
EH8 9JZ. UK
Mitogen-activatea orotein (MAP) kinases, a iamily or
Ser/Thr protein kinases, are known to ce invoivea in a wiae
vanetv ot intracellular signal transauction oatnways initiated
by binding at a vanetv or agonists to tneir 'esoective ceil
surraca recebtors [11. MAP kinases nave most commonly
been associated with ceil cycle regulation mcucsa ov
growtn factors wnose receotors nave intnnsic tyrosine
kinase activity. However, it is becoming increasingly
evident tnat receotcrs belonging to tne suoerramiiy cr seven
transmembrane contain. G orotein-couciea receotcrs may
also activate MAF kinase ana conseauently MAP kinase
mav aiso oe nvoivea in nan-proiiferative signalling
cascaces [21.
T0 enable us to investigate stimuius-mcucsa MAP
kinase activanon we ceveiooea an in vitro assay measunng
;3SSjtnioonosonoryiation or a selective ceotice substrate
containing tne consensus target motif cnaracenstic ot MAP
kinases [31. "he centity ot tne enzymic activity as
auinennc MAP kinase was confirmed using a monoclone.;
anti-MAP kinase antibody (ZQ32. Zymea. arv.i-
p44.£=Kl/D42£nK2j |n tf,e a~3-i gonaaotroon csii line,
stimuiatidn ot the iuteinising hormone-reieasing normone
(LHRri) recentor (a onosonoinositioe-nyaroiysing receotor.
known tn couoie to Ga [a.51) results in increased MAP
kinase activity. This increased activity peaked by 10 mm at
a near maximal concentration of 100 nM LHRH anc was
partially mimicked by pncrcci 12.13-dibutyrate (PDEu) (6j.
We have used a number of onarmacoiogicai agents to
I'urtner investigate the upstream comconents of this
signalling cascade.
The LHRH-inducsd increase in MAP kinase activity was
potently innibiteo by two PKC innioitors. GPI0S203X and
Eo 31-3220 (snowing IC30 values of 1.34 - 0.14 uM and
0.64± o.OS uM resoectiveiv) but with extremely iow ootency
by another PKC inhibitor or a cifferent structural ciass. H7
(IC-50 163±12 uM). This onarmacoiogy is consistent with an
acoarently novel PKC isororm iouna selectively in antenor
pituitary [71. Pre-incuoation tor 18 h with PDBu (300 nM) to
down-'eguiate the pnorcol ester-sensitive PKC isotorms.
comoieteiy abolished LHRH-inauced MAP kinase activity.
The tyrosine kinase innibitor iavenaustin A haa no ertect on
LHRH-inaucea MAP kinase activity at concentrations uo to
10 llM. The role of G oroteins was also investigated.
Incubation ior 18 h with pertussis toxin in the range of
30-200 ng/mi revealed that this LHRH-inaucea MAP kinase
activity was nigniv sensitive to this toxin suggesting that the
G arotein involved mav ce Gi or Go.
The present results clearly demonstrate an involvement
ot PKC or a "PKC-iike* kinase uostraam ot MAP kinase in
this signalling cascade. Also tor the first time we have
snown that the LHRH receptor can couoie to muitioie
G protein species, .e Gi/Go in addition to Ga. Taken
together these results suggest that activation of MAP
kinase oy this recsotor mav reauire concurrent involvement
at more than one signalling patnwav. Activation ot MAP
kinases tnrougn a Gi- ana ras-aeoenaent route nas been
reported tor the iysoonosonatidic acid (LPA) receotor ana
ccs-CIO adrenergic receotor [8.91. However, the exact
mechanism remains unclear, in the case of the LPA
receptor, it has oeen nvpotnesisea tnat a gsnistein- ana
staurosoorine-sensitive kinase may oe involved
downstream ot Gi. pernacs at the ievei ot memorane-
associatea proteins regulating ras. Certain isoiorms of
PKC have also oeen reported to pnosoncrviate rat [10] so
mav potentially exert a co-activation rose runner
downstream in the MAP kinase activation cascade. ;
seems oossioie that the aciiity or certain G crctein-couciec
recactcrs to activate MAP kinase in a non-oroiiferative rcie
may ce ceterminea by tneir aciiitv to co-activate convergent
signalling patnwavs.
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